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Summary 
Loss-of-function genetic screens are a powerful approach to identify the genes involved in 
biological processes. For nearly a century, forward genetic screens in model organisms have 
provided enormous insight into many cellular processes. However, the difficulty in generating 
and recovering bi-allelic mutations in diploid cells severely hindered the performance of 
forward genetic screens in mammalian cells. The development of a retroviral gene-trap vector 
to mutagenise the human near-haploid KBM7 cell line transformed forward genetic screens 
in human cells. The re-purposing of the microbial CRISPR/Cas9 system now offers an effective 
method to generate gene knockouts in diploid cells. Here, I performed a head-to-head 
comparison of retroviral gene-trap mutagenesis screens and genome-wide CRISPR knockout 
screens in KBM7 cells. The two screening approaches were equally effective at identifying 
genes required for the endoplasmic reticulum (ER)-associated degradation of MHC class I 
molecules. 
The ER-resident enzyme HMG-CoA reductase (HMGCR) catalyses the rate-limiting step in the 
cholesterol biosynthesis pathway and is targeted therapeutically by statins. To maintain 
cholesterol homeostasis, the expression of HMGCR is tightly regulated by sterols 
transcriptionally and post-translationally. Sterols induce the association of HMGCR with Insig 
proteins, which recruit E3 ubiquitin ligase complexes to mediate degradation of HMGCR by 
the ubiquitin proteasome system. However, the identity of the E3 ligase(s) responsible for 
HMGCR ubiquitination is controversial. Here, I use a series of genome-wide CRISPR knockout 
screens using a fluorescently-tagged HMGCR exogenous reporter and an endogenous HMGCR 
knock-in as an unbiased approach to identify the E3 ligases and any additional components 
required for HMGCR degradation. The CRISPR screens identified a role for the poorly 
characterised ERAD E3 ligase RNF145. I found RNF145 to be functionally redundant with gp78, 
an E3 ligase previously implicated in HMGCR degradation, and the loss of both E3 ligases was 
required to significantly inhibit the sterol-induced degradation and ubiquitination of HMGCR. 
A focused E3 ligase CRISPR screen revealed that the combined loss of gp78, RNF145 and Hrd1 
was required to completely block the sterol-induced degradation of HMGCR. I present a 
model to account for this apparent complexity.
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Chapter 1: Introduction 
In the introduction, I will first describe endoplasmic reticulum-associated degradation (ERAD). 
I will then describe how cellular cholesterol homeostasis is regulated via transcriptional, post-
translational and endocytic mechanisms, with emphasis on the post-translational regulation 
of HMG-CoA Reductase by ERAD, which will be the major focus of this thesis. I will conclude 
by describing how forward genetic screens are used as a powerful tool to determine gene 
function. 
 
1.1 The Ubiquitin System 
Ubiquitin is a highly conserved 76-amino acid polypeptide. Proteins are post-translationally 
modified by ubiquitin conjugation (ubiquitination) to mediate a range of cellular processes 
(Hershko and Ciechanover 1998). The ubiquitin modification is detected by proteins that 
contain ubiquitin-binding motifs, such as the coupling of ubiquitin to ER degradation (CUE), 
ubiquitin-interaction motif (UIM) and ubiquitin-association domain (UBA) (Hicke, Schubert, 
and Hill 2005). This thesis will focus on the ubiquitin proteasome system (UPS) in which 
ubiquitination targets a protein for degradation by the 26S proteasome (Nandi et al. 2006). 
However, ubiquitination is also critical for a range of nonproteolytic cellular functions 
including cell cycle progression, DNA repair, apoptosis and receptor mediated endocytosis 
(Komander and Rape 2012). 
The ubiquitination process requires the sequential action of three enzymes. First, ubiquitin is 
activated by an E1 activating enzyme in an ATP-dependent reaction by forming a thioester 
bond between ubiquitin and the E1’s active cysteine residue (Ciechanover et al. 1981, Haas 
and Rose 1982). The activated ubiquitin molecule is then transferred onto a cysteine residue 
on an E2 ubiquitin conjugating enzyme. A E3 ubiquitin ligase catalyses the transfer of ubiquitin 
from the E2 conjugating enzyme onto the substrate. The C-terminal glycine of ubiquitin 
typically forms an isopeptide bond with a substrate lysine residue (Pickart 2001). Some 
ubiquitin ligating enzymes act as E4 ligases to elongate a polyubiquitin chain (Koegl et al. 
1999). 
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The ubiquitin modification can be added onto proteins to create a diverse range of ubiquitin 
structures. Monoubiquitination describes the attachment of a single ubiquitin molecule, 
however a protein can be monoubiquitinated on multiple residues. As ubiquitin contains 
seven lysine residues (residues 6, 11, 27, 29, 33, 48 and 63), ubiquitin molecules can be added 
onto other ubiquitin molecules to form a polyubiquitin chain (Kirisako et al. 2006). 
Polyubiquitin chains can be constructed entirely from the same linkage, i.e. all ubiquitin 
molecules are added onto the same lysine residue. Complex ubiquitin chains can be 
constructed that contain different linkages or ubiquitin-like molecules to create a diverse 
array of structures to mediate cell signalling (Boname et al. 2010, Kravtsova-Ivantsiv and 
Ciechanover 2012). A polyubiquitin chain of at least four Lysine-48 (K48) linked ubiquitin 
molecules is the canonical signal for proteasomal degradation (Thrower et al. 2000).  
Most ubiquitin modifications involve the conjugation of ubiquitin onto a lysine residue. 
However, serine, threonine and cysteine residues can also be ubiquitinated to mediate 
proteasomal degradation or other cellular functions (Cadwell and Coscoy 2005, Carvalho et 
al. 2007, Tait et al. 2007, Wang et al. 2007, Wang, Bian, et al. 2017). 
 
1.1.1 E2 ubiquitin conjugating enzymes 
E2 conjugating enzymes have an active role in defining the features of ubiquitination, such as 
chain length and linkage type. E2s have a core ubiquitin-conjugating (UBC) domain containing 
the active cysteine residue that accepts activated ubiquitin from the E1 (Ye and Rape 2009). 
E2s have overlapping binding sites for E1s and E3s, therefore E2s cannot be recharged with 
ubiquitin while bound to an E3 ligase (Eletr et al. 2005). The interaction between E2s and E3s 
is typically weak, so some E3s have additional E2 binding sites to increase the affinity of the 
E2-E3 interaction (Chen et al. 2006). The localisation and activity of E2 conjugating enzymes 
can be influenced by cofactors (Biederer, Volkwein, and Sommer 1997, VanDemark et al. 
2001, Kostova et al. 2009, Jo, Hartman, and DeBose-Boyd 2013). 
As there are significantly more E3s (830) than E2s (45), a single E2 can interact with multiple 
E3s to mediate substrate ubiquitination. Specific E2-E3 pairings ubiquitinate a limited set of 
substrates, however some E2 conjugating enzymes are by definition much more promiscuous  
(Ye and Rape 2009). 
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1.1.2 HECT and RING E3 ubiquitin ligases 
In eukaryotes, E3 ubiquitin ligases can be split into two groups by the presence of a HECT 
(homologous to E6 associated protein C-terminus) or RING (really interesting new gene) 
domain. RING E3 ligases can be further divided into groups based on the arrangement of 
cysteine and histidine residues in the RING domain (Deshaies and Joazeiro 2009). The cysteine 
and histidine residues coordinate two zinc ions to create a ‘cross-brace’ structure. For RING 
E3 ligases, the E2 conjugating enzyme interacts directly with the RING domain and the 
substrate is recruited via a separate binding site. RING E3 ligases are scaffold proteins; the 
ubiquitin molecule is transferred directly from a ubiquitin-charged E2 onto the substrate 
(Deshaies and Joazeiro 2009). In contrast, HECT E3 ligases have a catalytic cysteine residue 
that forms a ligase-ubiquitin intermediate before transferring ubiquitin onto the substrate 
(Metzger, Hristova, and Weissman 2012). 
 
1.1.3 ER-associated degradation (ERAD) 
The endoplasmic reticulum (ER) is a membrane-bound organelle that extends throughout the 
cytoplasm. The ER is the site of several metabolic pathways that are critical for lipid 
homeostasis as well as the entry point of the secretory pathway, where approximately one 
third of the eukaryotic proteome must fold correctly (Kanapin et al. 2003). The ER has 
developed a complex quality control system to monitor protein folding. However, protein 
folding is a complex process that can involve several intermediate states. Mutant 
polypeptides can arise from DNA mutations or errors in transcription and translation. Protein 
complexes require the correct stoichiometry of constituent polypeptides and the 
accumulation of unassembled polypeptides must be prevented. ERAD targets incorrectly-
folded, mutant and unassembled polypeptides for proteasomal degradation (Vembar and 
Brodsky 2008). ERAD is also responsible for regulating the expression of correctly folded 
proteins in the ER to maintain lipid homeostasis (Hampton and Garza 2009). 
Surprisingly, there are no E1 activating enzymes, E2 conjugating enzymes or proteasomes in 
the ER lumen. Therefore, ERAD substrates must be ubiquitinated on the cytosolic side of the 
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ER membrane and degraded in the cytosol (Hegde and Ploegh 2010, Christianson and Ye 
2014). The use of the yeast S. cerevisiae as a model organism gave significant insights into the 
ERAD pathway (Sommer and Jentsch 1993, Hampton, Gardner, and Rine 1996, Hiller et al. 
1996). Many underlying principles and components of ERAD are highly conserved from S. 
cerevisiae to mammalian cells. However, mammals have developed a more complex ERAD 
network, probably to accommodate a more diverse range of substrates (Christianson et al. 
2012). 
 
1.1.4 S. cerevisiae ERAD E3 ligase complexes 
The ERAD machinery is organised in multi-protein complexes around an integral membrane 
E3 ligase to coordinate the ERAD process. The yeast genome encodes 80 E3 ubiquitin ligases, 
two of these are ERAD E3 ligases, Hrd1p (HMG-CoA degradation 1) and Doa10p (degradation 
of Matα2-10 protein). It is generally thought that substrates recognised in the ER lumen 
(ERAD-L) or ER membrane (ERAD-M) are ubiquitinated by Hrd1p. Whereas Doa10p targets 
substrates on the cytosolic side of the ER membrane (ERAD-C) (Taxis et al. 2003, Vashist and 
Ng 2004, Huyer et al. 2004, Carvalho, Goder, and Rapoport 2006). However, this division of 
substrates is probably an over-simplification and complete stabilisation is not observed in the 
absence of either Hrd1p or Doa10p (Gnann, Riordan, and Wolf 2004, Nakatsukasa et al. 2008, 
Goeckeler and Brodsky 2010). 
S. cerevisiae Hrd1 complex 
A genetic screen to identify genes required for the degradation of HMG-CoA Reductase 
identified the HRD genes, Hrd1p (a polytopic RING E3 ligase), Hrd2p (a proteasome 
component) and Hrd3p (Hampton, Gardner, and Rine 1996). Hrd3p is a type I transmembrane 
domain with a large ER-luminal domain that interacts with Hrd1p and stabilises Hrd1p 
(Gardner et al. 2000). The E2 conjugating enzyme Ubc7p is recruited to Hrd1p by Cue1p 
(Biederer, Volkwein, and Sommer 1997, Bagola et al. 2013). The Cdc48p/Npl4p/Ufd1p 
complex is recruited to Hrd1p by Ubx2p (Schuberth and Buchberger 2005, Neuber et al. 2005). 
Hrd1p-mediated degradation of ERAD-L substrates also requires Der1p, which is recruited by 
Usa1p (Carvalho, Goder, and Rapoport 2006). The ER-luminal domain of Hrd3p associates 
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with Yos9p and Kar2p to assist substrate recognition (Gardner et al. 2000, Denic, Quan, and 
Weissman 2006, Gauss et al. 2006). 
S. cerevisiae Doa10 complex 
Doa10p is also a poytopic RING E3 ligase (Swanson, Locher, and Hochstrasser 2001). Like for 
Hrd1p, Ubx2 recruits Cdc58p/Npl4p/Ufd1p to Doa10p (Neuber et al. 2005, Schuberth and 
Buchberger 2005). It has been suggested that the E2 conjugating enzyme Ubc6p mediates 
monoubiquitination and that Ubc7p mediates ubiquitin chain extension (Weber et al. 2016). 
 
1.1.5 Mammalian ERAD E3 ligase complexes 
Many factors in the S. cerevisiae ERAD network are highly conserved, however the 
mammalian ERAD network is far more elaborate. The human genome is estimated to encode 
over 800 E3 ligases with at least 37 putative ERAD E3 ligases (Kaneko et al. 2016). There are 
two mammalian homologues of Hrd1p, Hrd1 and gp78, and only one mammalian Doa10 
homologue, MARCH6 (also called TEB4).  
Mammalian Hrd1 complex 
Human Hrd1 (also called synoviolin) shares 26% sequence identity with S. cerevisiae Hrd1p, 
but shares similar topology with a N-terminal transmembrane domain and C-terminal 
cytosolic RING-H2 domain (Nadav et al. 2003, Kikkert et al. 2004). The Hrd3p homologue 
SEL1L associates with Hrd1 and recruits factors required for substrate recognition to its ER-
luminal domain such as Yos9p homologues OS9 and XTP3B (Christianson et al. 2008, 
Hosokawa et al. 2008, Bernasconi et al. 2008), the mannosidases EDEM1 (ER-degradation 
enhancing α-mannosidase-like protein) and EDEM3 (Cormier et al. 2009, Saeed et al. 2011), 
the disulphide reductase ERDJ5 (Williams et al. 2013) and the chaperone BiP (Hosokawa et al. 
2008). Other components of the Hrd1 complex include the Derlin proteins, Derlin-1, -2 and -
3 (Der1p homologues), Herp (Usa1p homologue), UBXD8, UBE2J1 (Ubc6p) homologue, 
UBE2G2 (Ubc7p homologue) and AUP1 (Cue1p homologue) (Schulze et al. 2005, Hwang, 
Walczak, et al. 2017, Christianson et al. 2012). The Hrd1 complex associates with the 
p97/Npl4/Ufd1 complex, however it is not clear whether the p97 complex binds directly to 
Hrd1 or is recruited by the Derlin proteins, UBXD8 or VIMP (VCP interacting membrane 
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protein) (Ye et al. 2004, Ye et al. 2005, Lilley and Ploegh 2005, Yeung et al. 2008, Greenblatt, 
Olzmann, and Kopito 2011, Suzuki et al. 2012). 
The ERAD of HMG-CoA Reductase will be discussed in more detail (see 1.2.2.3), but Hrd1 has 
not yet been shown to be involved in the ERAD of human HMG-CoA Reductase (Kikkert et al. 
2004). However, HMG-CoA Reductase was identified as a high confidence interaction partner 
of Hrd1 by mass spectrometry, suggesting that Hrd1 could influence HMG-CoA Reductase in 
an unknown manner (Christianson et al. 2012). A range of Hrd1 substrates have been 
reported including unassembled T cell receptor alpha chain (Kikkert et al. 2004), unassembled 
CD147 (Tyler et al. 2012), CD3-δ (Kikkert et al. 2004), immunoglobulin κ light chain (Shimizu, 
Okuda-Shimizu, and Hendershot 2010), p53 (Yamasaki et al. 2007), amyloid precursor protein 
(Kaneko et al. 2010), the Z variant of alpha 1-antitrypsin (Wang, Li, et al. 2011), gp78 (Shmueli 
et al. 2009), CD95/Fas (Kong et al. 2016), as well as both folded and unassembled major 
histocompatibility complex-I (MHC-I) heavy chain (Burr et al. 2011, Burr et al. 2013). 
Mammalian gp78 complex 
Gp78 (also called autocrine mobility factor receptor, AMFR) shares 15% sequence identity 
with S. cerevisiae Hrd1p  (Fang et al. 2001). Gp78 contains a N-terminal transmembrane 
domain, a RING-H2 domain, a UBE2G2-binding region (G2BR), a Cue1p-like domain and a VCP-
interaction motif (VIM) (Chen et al. 2006, Ballar et al. 2006). The G2BR and Cue1p-like 
domains are essential for gp78 E3 ligase activity (Chen et al. 2006).  Like Hrd1, gp78 also 
interacts with the Derlin proteins and UBXD8 (Christianson et al. 2012). Whilst gp78 can 
recruit the p97 (VCP) complex directly, the VIM is dispensable for gp78-mediated ERAD  
(Ballar et al. 2006). UBA-domain containing protein 2 (UBAC2) recruits UBXD8 to gp78, UBXD8 
can then recruit the p97/Npl4/Ufd1 complex to gp78 (Christianson et al. 2012). 
Several proteins involved in cholesterol and lipid metabolism are gp78 substrates, making 
gp78 an important regulator of lipid homeostasis (see 1.2.2). (Lee, Song, et al. 2006, Fisher, 
Khanna, and McLeod 2011, Liu et al. 2012, Choi et al. 2014). 
MARCH6 (TEB4) 
MACH6 belongs to the membrane-associated RING-CH (MARCH) family of E3 ubiquitin ligases. 
MARCH6 is the likely homologue of S. cerevisiae Doa10p (Kreft, Wang, and Hochstrasser 
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2006). MARCH6 has a N-terminal RING-CH domain and either 13 or 14 transmembrane helices 
(Kreft, Wang, and Hochstrasser 2006). The molecular mechanisms underlying MARCH6 
function are far less characterised than Hrd1 and gp78. Like gp78, MARCH6 regulates 
cholesterol homeostasis (see 1.2.2.7) (Zelcer et al. 2014, Loregger et al. 2015). 
TRC8 (RNF139) 
TRC8 is a polytopic, ER-resident RING-H2 ligase (Stagg et al. 2009). Human cytomegalovirus 
(HCMV) hijacks TRC8 to downregulate MHC-I as a part of HCMV’s immune-evasion strategy. 
The virally encoded protein US2 recruits TRC8 to MHC-I in the ER resulting in the rapid 
proteasomal degradation of MHC-I (Stagg et al. 2009). It was later found that CMV encoded 
US2 also recruits other cell surface proteins, including 6 integrin α-chains, the anti-
coagulation factor thrombomodulin, IL-12 receptor β1 chain and the NK cell ligand CD112, to 
TRC8 (Hsu et al. 2015).  
TRC8 associates with the intramembrane cleaving aspartyl protease, signal peptide peptidase 
(SPP) (Boname et al. 2014). Tail anchor proteins are a class of type II orientated integral 
membrane proteins that are attached to the membrane by a single embedded C-terminal 
helix (Borgese, Colombo, and Pedrazzini 2003). SPP cleaves the signal sequence from tail 
anchored proteins, such as heme oxygenase-1 (HO-1), allowing the TRC8-dependent 
proteasomal degradation of HO-1 (Boname et al. 2014). In the absence of SPP, TRC8 targets 
the hepatitis C virus immature core protein for degradation (Aizawa et al. 2016). 
TRC8’s N-terminal transmembrane domain contains a sterol sensing domain (SSD) (Lee et al. 
2010). Sterol sensing domains are found in several proteins involved in cholesterol 
metabolism, such as HMG-CoA Reductase, Niemann-Pick type C1 and SREBP cleavage-
activating protein (SCAP) (Hua et al. 1996, Martín et al. 2001, Millard et al. 2005). A sterol 
sensing domain is a series of  five transmembrane helices that can bind to sterol molecules 
(Kuwabara and Labouesse 2002). The role of TRC8 in cholesterol homeostasis is controversial 
and is discussed in 1.2.2.6. 
Other ERAD E3 ligases 
TMEM129 is an ER-resident E3 ligase consisting of the N-terminal transmembrane helices and 
a C-terminal atypical RING domain (van den Boomen et al. 2014). TMEM129 is recruited to 
Chapter 1: Introduction 
 
26 
 
the HCMV protein US11 by Derlin-1 to target MHC-I for ubiquitination and proteasomal 
degradation (van den Boomen et al. 2014). Unusually, two E2 conjugating enzymes, UBE2J2 
and UBE2K, mediate the US11-induced downregulation of MHC-I (Flierman et al. 2006, van 
den Boomen et al. 2014).     
RNF5 (RMA1) and RNF185 are homologous E3 ligases with 70% shared sequence identity. 
Both RNF5 and RNF185 have a N-terminal RING domain and two transmembrane helices. 
These homologous E3 ligases demonstrate functional redundancy for the ubiquitination of 
the cystic fibrosis transmembrane regulator (CFTR) (El Khouri et al. 2013). RNF170 is a 
polytopic RING E3 ligase that ubiquitinates inositol 1,4,5-triphosphate receptor (Lu et al. 2011, 
Wright et al. 2015). RFP2/TRIM13 and Nixin/ZNRF4 are single transmembrane helix RING E3 
ligases that ubiquitinate L-type calcium channel components and calnexin respectively 
(Lerner et al. 2007, Altier et al. 2011, Neutzner et al. 2011). 
Several cytosolic E3 ligases can also ubiquitinate ERAD substrates, including CHIP (Meacham 
et al. 2001), Nrdp1 (Fry et al. 2011), Parkin (Imai et al. 2002), Skp1-Cullin1-Fbx2-Roc1 
(SCF(Fbx2)) (Yoshida et al. 2002), SCF(Fbx6) (Yoshida et al. 2003), Smurf1 (Guo et al. 2011). 
These E3 ligases must cooperate with integral ER membrane factors to ubiquitinate ER-
localised substrates. 
 
1.1.6 ERAD substrate recognition 
To ensure protein homeostasis, ERAD must be able to target an enormous number of 
structurally diverse substrates. 
1.1.6.1 Glycan dependent recognition 
Most proteins that are co-translated into the ER are subject to the carbohydrate modification 
N-linked glycosylation. A glycan moiety is co-translationally attached onto asparagine 
residues in the consensus sequence N-X-T/S by the ER oligosaccharide transferase (OST) 
complex (Mohorko, Glockshuber, and Aebi 2011). The glycan moiety is modified extensively 
through the ER and Golgi to create a wide range of structures that influence protein structure 
and activity (Bieberich 2014).  
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The glycan structure is rapidly trimmed in the ER and binds to the chaperones calnexin and 
calreticulin (Hebert, Garman, and Molinari 2005). Cleavage of the final glucose residue in the 
glycan moiety by Glucosidase II releases the protein from calnexin or calreticulin. If the 
protein has not achieved its native folded state, the glycan is glucosylated by UDP 
glucose:glucose glucosyl-transferase 1 (UGT1). The reglucosylated protein can now re-
associate with calnexin or calreticulin (Hebert, Foellmer, and Helenius 1995, Sousa and Parodi 
1995). Proteins that are unable to exit the calnexin-calreticulin cycle are likely to be terminally 
misfolded and must therefore be targeted for ERAD. During each round of the calnexin-
calreticulin cycle, the glycan moiety is trimmed by ER α1,2-mannosidase I (ERManI) and ER 
degradation-enhancing 1,2-mannosidase-like proteins -1, -2 and -3 (EDEM1, EDEM2 and 
EDEM3) (Oda et al. 2003, Hirao et al. 2006, Olivari and Molinari 2007).  
The ER-resident lectins, OS9 and XPT3-B, recognise trimmed glycan structures with exposed 
mannose α1,6-linkages (Quan et al. 2008, Hosokawa et al. 2009, Yamaguchi et al. 2010). The 
functional relationship between OS9 and XPT3-B is unclear. Some studies show functional 
redundancy between OS9 and XPT3-B (Bernasconi et al. 2010, Burr et al. 2013). Whereas, 
other studies show that the loss of either OS9 or XPT3-B is sufficient to impair ERAD (Chen et 
al. 2011). SEL1L interacts with OS9, XPT3-B and the EDEM proteins and acts as a ‘gate-keeper’ 
to facilitate the transfer of substrates to Hrd1 (Denic, Quan, and Weissman 2006, Christianson 
et al. 2008). 
 
1.1.6.2 Recognition of non-glycosylated substrates 
Misfolded non-glycosylated proteins are also efficiently targeted by ERAD (Okuda-Shimizu 
and Hendershot 2007, Sekijima, Kelly, and Ikeda 2008). Chaperones, such as BiP,  recognise 
features of unfolded proteins, such as hydrophobic amino acid residues that are normally 
sequestered within a protein’s core (Otero, Lizák, and Hendershot 2010). 
 
1.1.6.3 Specialised scaffold proteins 
The ERAD of specific correctly-folded proteins can be induced by recruiting E3 ubiquitin ligase 
complexes to substrates by using a scaffold protein. HMCV uses two virally encoded proteins, 
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US2 and US11, to recruit MHC-I to E3 ubiquitin ligases to downregulated MHC-I (Stagg et al. 
2009, van den Boomen et al. 2014). The ERAD of HMG-CoA Reductase is induced by the sterol-
dependent interaction with the Insig proteins, which recruit an E3 ligase complex (Sever, 
Song, et al. 2003). 
 
1.1.7 Oxidoreductases 
Disulphide bonds formed by the oxidation of two thiol groups in cysteine residues help 
stabilise the structure of many proteins. The ER contains a large family of protein disulphide 
isomerase (PDI) enzymes that catalyse disulphide bond oxidation and reduction (Appenzeller-
Herzog and Ellgaard 2008). The oxidoreductases of the ER must ensure the stability of folded 
proteins but also reduce disulphide bonds in misfolded proteins to allow extraction from the 
ER and proteasomal degradation. Erdj5, a PDI family member, interacts with EDEM1 and BiP 
and is required for the ERAD of glycosylated and non-glycosylated substrates (Ushioda et al. 
2008, Dong et al. 2008, Hagiwara et al. 2011). 
 
1.1.8 Retrotranslocation and membrane extraction 
For ERAD substrates in the ER lumen to be ubiquitinated they must first be, at least partially, 
translocated across the ER membrane before they can be ubiquitinated and then released 
into the cytoplasm for degradation. This process is referred to as dislocation or  
retrotranslocation (Wiertz et al. 1996). For integral membrane ERAD substrates to be 
degraded by the cytosolic proteasome, they must be extracted from the ER membrane.  
1.1.8.1 The dislocon 
It is most likely that proteins are retronslocated across the ER through a protein channel, 
however the identity of this channel has yet to be conclusively determined. A candidate for 
the dislocon is the Sec61 complex, which facilitates the translocation of proteins into the ER 
(Johnson and van Waes 1999). However, the degradation of several ERAD ER-luminal 
substrates was independent of Sec61 (Sato and Hampton 2006, Wahlman et al. 2007, Garza, 
Sato, and Hampton 2009). A nascent polypeptide chain can fit through the Sec61 channel, 
however most glycosylated polypeptides are probably too bulky to fit through the pore 
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(Hebert, Bernasconi, and Molinari 2010). The Sec61 complex is therefore unlikely to provide 
the sole route for ER exit. 
The Derlin proteins (Derlin-1, -2 and -3) are the S. cerevisiae Der1p homologues. The Derlin 
proteins are small, polytopic, non-catalytic rhomboid-like proteins  that can oligomerise in the 
ER membrane (Lilley and Ploegh 2005, Lemberg 2013). Whilst several reports have shown a 
requirement for the Derlin proteins for retrotranslocation, it is not yet clear whether the 
Derlin proteins form part of a protein-conducting channel or enable retrotranslocation via 
another mechanism  (Ye et al. 2004, Lilley and Ploegh 2005, Greenblatt, Olzmann, and Kopito 
2011). 
The ERAD E3 ligase Hrd1 has also been proposed to form an important component of the 
protein-conducting channel (Carvalho, Stanley, and Rapoport 2010, Stanley, Carvalho, and 
Rapoport 2011, Baldridge and Rapoport 2016). A recent structure of S. cerevisiae Hrd1p in 
complex with Hrd3p revealed that five of Hrd1p’s eight transmembrane helices create an 
aqueous pore that through the ER membrane (Schoebel et al. 2017). Hrd1p forms a dimer in 
the ER membrane and a lateral seal for the potential Hrd1p channel is provided by the other 
Hrd1 molecule (Schoebel et al. 2017). Whilst these studies provide evidence for Hrd1’s 
involvement in retrotranslocation, the transmembrane domain of S. cerevisiae Hrd1 has also 
been shown to be dispensable for retrotanslocation (Garza, Sato, and Hampton 2009). 
The conflicting requirements for retrotranslocation and the failure to identify a universal 
protein-conducting channel most likely means that there is not a single route for ER 
extraction. The mechanism of retrotranslocation is probably substrate dependent and a single 
substrate might be able to follow multiple ER exit routes. 
 
1.1.8.2 The VCP (p97) AAA-ATPase 
The AAA-ATPase p97 (also called VCP, Cdc48p in S. cerevisiae) is essential for membrane 
extraction and retrotranslocation of ERAD substrates (Ye, Meyer, and Rapoport 2001, 
Rabinovich et al. 2002). Each p97 monomer contains two ATPase domains. P97 hexamers are 
organised as two stacked rings (D1 and D2) with a central pore (Zhang et al. 2000). The Npl4-
Ufd1 heterodimer interacts with the p97 hexamer to form a complex that can engage with 
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ERAD substrates. The association of p97 with Ufd1 and polyubiquitinated substrates activates 
p97’s ATPase activity (Bays et al. 2001, Jarosch et al. 2002, Meyer, Wang, and Warren 2002, 
Ye, Meyer, and Rapoport 2003, Flierman et al. 2003). ATP hydrolysis by p97 could drive the 
extraction process either by directly pulling on the ubiquitinated substrate or by perturbing 
the transmembrane component of the dislocon (Nakatsukasa and Brodsky 2008, Brodsky 
2012). 
 
1.1.9 Degradation by the proteasome 
Retrotranslocated or membrane-extracted ERAD substrates must be delivered to the 
proteasome for degradation rapidly to prevent the aggregation of exposed hydrophobic 
regions. Degradation is tightly coupled to retrotranslocation by a poorly defined mechanism. 
The p97 complex does not form stable interactions with the proteasome (Isakov and Stanhill 
2011, Verma et al. 2000). In S. cerevisiae, the UBL-UBA proteins Rad23p and Dskp promote 
the delivery of retrotranslocated ERAD substrates to the proteasome (Medicherla et al. 2004). 
In mammalian cells, the Bag6 complex and ubiuqilin have been implicated as chaperones for 
ubiquitinated retrotranslocated substrates (Ko et al. 2004, Lee and Ye 2013). 
The 26S proteasome consists of a 20S cylindrical core, in which proteolysis occurs, and two 
19S regulatory caps. Polyubiquitinated substrates bind to high affinity ubiquitin receptors, 
Rpn10 and Rpn13, in the 19S complex (Peth, Uchiki, and Goldberg 2010, Schreiner et al. 2008, 
Husnjak et al. 2008). The bound substrate is deubiquitinated by the 26S-associated 
deubiquitinating enzymes (DUBs), Usp14, Uch37 or Rpn11, unfolded and translocated into 
the 20S core (Smith et al. 2007, Finley 2009, Peth, Besche, and Goldberg 2009, Smith et al. 
2011). 
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1.2 Cholesterol Homeostasis 
Cholesterol and other lipids are critical molecules for cells and are essential for life. However, 
at very high concentrations, cholesterol is toxic to cells. Intricate regulatory mechanisms 
therefore maintain intracellular cholesterol homeostasis. This requires balancing the uptake 
of exogenous cholesterol and the endogenous production of cholesterol. The cholesterol 
biosynthesis pathway is tightly regulated at the level of transcription and degradation. I will 
emphasise the sterol-dependent regulation of HMG-CoA Reductase as the sterol-induced 
degradation of HMG-CoA Reductase will be a major topic of this thesis. 
 
1.2.1 Transcriptional control of cholesterol homeostasis 
1.2.1.1 The SREBP pathway 
Mammalian cells encode three closely related sterol regulatory binding element protein 
(SREBP), called SREBP-1a, SREBP-1c and SREBP2 (Brown and Goldstein 1997). SREBP-1a and 
SREBP-1c are encoded by the same gene, but are the products of different promoters and 
alternative splicing. SREBP-2 is the predominant SREBP isoform in the liver and induces the 
expression of cholesterogenic proteins, such as HMG-CoA Reductase and the LDL Receptor. 
SREBP-1c induces the expression of fatty acid biosynthesis pathway enzymes, whereas, 
SREBP-1a regulates both the cholesterol and fatty acid biosynthesis pathways (Goldstein, 
Rawson, and Brown 2002). 
All three SREBP proteins are synthesised as integral membrane proteins into the ER 
membrane, resulting in a hairpin orientation with the N-terminal transcription factor domain 
and C-terminal regulatory domain positioned in the cytosol (Figure 1.1). The C-terminal 
regulatory domain of all three SREBPs constitutively associates with SREBP cleavage-
activating protein (SCAP) (Sakai et al. 1997).  
SCAP has an N-terminal transmembrane domain, with eight transmembrane helices, and C-
terminal WD repeats, which interact with the SREBPs (Nohturfft, Brown, and Goldstein 
1998b). Transmembrane helices two-to-six constitute a sterol sensing domain (SSD) (Hua et 
al. 1996, Nohturfft, Brown, and Goldstein 1998a). At low cholesterol levels, SCAP is recruited 
by the COPII coat component Sec24 (Sun et al. 2005). The SCAP-SREBP heterodimer is 
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therefore transported to the Golgi (Sun et al. 2007). The mature SREBP transcription factor is 
liberated by sequential proteolytic cleavage in the Golgi. Firstly, Site-1 protease cleaves SREBP 
within the luminal loop (Duncan et al. 1997, Sakai et al. 1998). The Site-2 protease then 
cleaves within the transmembrane helix to release the N-terminal domain of SREBP (Duncan 
et al. 1998). The mature SREBP transcription factor can now migrate to the nucleus to interact 
with sterol response elements and induce target gene expression. 
When the ER membrane cholesterol content exceeds 5% of ER membrane lipids, cholesterol 
binds to SCAP’s SSD and SCAP now binds to the Insig proteins (Adams, Goldstein, and Brown 
2003, Adams et al. 2004). SCAP can no longer be recruited to the COPII coat when it is bound 
to an Insig protein. Therefore, the SCAP-SREBP heterodimer is retained in the ER (Sun et al. 
2005). The Brown and Goldstein laboratories identified three mutations in SCAPS’s SSD 
(D443N, Y298C and L315F) that rendered SCAP unable to associate with Insig and therefore 
unable to prevent SREBP processing despite high levels of cholesterol (Hua et al. 1996, 
Nohturfft, Brown, and Goldstein 1998a, Yabe et al. 2002, Yang et al. 2002, Adams, Goldstein, 
and Brown 2003). The over-expression of either Insig protein lowered the cholesterol 
concentration required to induce conformational changes in SCAP’s SSD (Adams, Goldstein, 
and Brown 2003). This allows the expression level of Insigs to regulate SREBP processing and 
therefore SREBP-target gene expression. 
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Figure 1.1 Mammalian SREBP pathway. At high cholesterol/sterol levels, immature SREBP-
SCAP dimer is retained in the ER by Insig. At low cholesterol/sterol levels, SCAP is recruited by 
the COPII coat complex and the immature SREBP-SCAP complex is transported to the Golgi. 
Proteolytic cleavage of immature SREBP by Site-1 protease (S1P) and Site-2 protease (S2P) 
releases the mature SREBP transcription factor, which migrates to the nucleus to upregulate 
target gene expression. From (Bien 2010) 
 
 
 
1.2.1.2 The Insig proteins 
The human genome encodes two Insig isoforms, Insig1 and Insig2. Both Insig proteins are ER-
resident glycoproteins containing six transmembrane helices (Feramisco, Goldstein, and 
Brown 2004). The two Insigs share 59% sequence identity. The main differences between the 
Insigs are in the hydrophilic N- and C-terminal regions as the transmembrane domains share 
85% sequence identity (Goldstein, DeBose-Boyd, and Brown 2006). The Insigs are not 
predicted to contain a sterol sensing domain, however the Insig proteins can bind oxysterols 
such as 25-hydroxycholesterol (Radhakrishnan et al. 2007).  
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There is a significant overlap in the function of Insig1 and Insig2, for example both Insigs can 
retain SCAP-SREBP in the ER (Yang et al. 2002, Yabe, Brown, and Goldstein 2002). However, 
the Insigs are subject to differential regulation. Insig1 is a SREBP target gene, whereas Insig2 
expression is independent of the SREBP pathway (Janowski 2002, Horton, Goldstein, and 
Brown 2002). The hypoxia-inducible factor 1α upregulates Insig2 during oxygen deprivation 
to limit cholesterol synthesis, an oxygen-demanding process (Hwang, Nguyen, et al. 2017).  
The liver expresses an organ-specific Insig2 isoform, named Insig2a (Yabe et al. 2003). The 
Insig2a transcript is transcribed from an upstream promoter and contains an extra non-coding 
5’ exon that is removed by splicing. Therefore, Insig2a and Insig2b encode the same protein 
but are differentially regulated. Insulin strongly suppresses Insig2a expression, which is 
otherwise very highly expressed in the liver. Whereas Insig2b is expressed at a low level (Yabe 
et al. 2003). 
 
1.2.1.3 Liver-X receptors 
Liver-X receptors (LXRs) are a second family of cholesterol-regulating transcription factors. 
Unlike SREBPs, LXRs are activated at high cellular sterol levels and induce a suite of genes to 
reduce cellular cholesterol (Zelcer and Tontonoz 2006). LXRs are activated by binding ligands 
such as cholesterol biosynthesis intermediates and oxysterols (Janowski et al. 1996, Yang et 
al. 2006, Spann et al. 2012). LXR target genes aim to reduce the cellular cholesterol level 
through several mechanisms, such as promoting cholesterol efflux (Venkateswaran et al. 
2000, Chawla et al. 2001, Kennedy et al. 2001), limiting cholesterol uptake (Zelcer et al. 2009) 
and reducing cholesterol biosynthesis (Sallam et al. 2016). 
 
 
 
 
 
 
Chapter 1: Introduction 
 
35 
 
1.2.2 Regulation of cholesterol homeostasis by ERAD 
ERAD is responsible for the regulated turnover of correctly folded enzymes in the ER, as well 
as being a critical component of ER protein quality control. The sterol-regulated degradation 
of key enzymes in the cholesterol biosynthesis pathway ensures that cholesterol production 
can be rapidly and significantly decreased. 
 
1.2.2.1 HMG-CoA Reductase (HMGCR) 
HMGCR is an 888 amino acid ER-resident protein that catalyses the major rate-limiting step 
of the cholesterol biosynthesis pathway, the reduction of HMG-CoA to mevalonate (Figure 
1.2) (Goldstein and Brown 1990). Statins therapeutically target HMGCR to lower plasma 
cholesterol levels and reduce the risk of atherosclerosis by competitive inhibition of HMGCR’s 
catalytic domain (Steinberg 2006). Mevalonate is also a precursor for many non-sterol 
isoprenoid molecules such as ubiquinone and haem A (Figure 1.2). 
HMGCR has an N-terminal transmembrane domain containing eight helices, with helices two-
to-six constituting a sterol sensing domain. The C-terminal cytoplasmic domain mediates 
HMGCR’s catalytic activity (Roitelman et al. 1992, Liscum et al. 1985). As HMG-CoA and 
mevalonate are both water soluble molecules, membrane attachment is to enable regulation 
of HMGCR abundance. HMGCR expression is regulated by sterols at the transcriptional level 
as a SREBP-2 target gene. HMGCR protein is also rapidly degraded at high cellular sterol levels 
by ERAD (Gil et al. 1985). 
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Figure 1.2 Mammalian cholesterol biosynthesis pathway. A series of cytosolic and integral 
ER membrane enzymes catalyse the biosynthesis of cholesterol from acetyl-CoA and 
acetoacetyl-CoA. HMG-CoA reductase (red) catalyses the major rate-limiting step of the 
cholesterol biosynthesis pathway, the conversion of HMG-CoA to mevalonate.  Non-sterol 
isoprenoid products are derived from farnesyl pyrophosphate. 
 
 
1.2.2.2 HMG2p degradation in S. cerevisiae 
S. cerevisiae encodes two HMGCR orthologs, Hmg1p and Hmg2p. Whilst Hmg1p is a stable 
protein, Hmg2p is rapidly degraded in response to non-sterol isoprenoids by ERAD mediated 
by the Hrd1p E3 ubiquitin ligase (Hampton, Gardner, and Rine 1996, Gardner and Hampton 
1999, Garza, Tran, and Hampton 2009). Farnesyl pyrophosphate binding to the SSD domain 
of Hmg2p altered the tryptic digest of Hmg2p and caused a greater tendency for aggregation 
(Shearer and Hampton 2005). Shearer and Hampton concluded that farnesyl pyrophosphate 
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binding induces a reversible conformational change in the SSD to a less ordered state and that 
this partially misfolded state is recognised by the HRD quality control pathway. 
Lanosterol induces Nsg1p, the Insig ortholog, to associate with Hmg2p’s transmembrane 
domain. The interaction with Nsg1p prevents the Hrd1p-mediated degradation of Hmg2p 
even in the presence of non-sterol isoprenoids (Flury et al. 2005, Theesfeld and Hampton 
2013). 
 
1.2.2.3 Sterol-induced degradation of HMGCR in mammalian cells 
The ubiquitin proteasome system is responsible for the rapid sterol-dependent degradation 
of mammalian HMGCR. Treating cells with proteasome inhibitors stabilised HMGCR and 
resulted in an accumulation of ubiquitinated HMGCR (Ravid et al. 2000). The N-terminal 
transmembrane domain of HMGCR is entirely responsible for the sterol-induced degradation 
of HMGCR (Gil et al. 1985). At low cholesterol/sterol levels, HMGCR is a stable protein. 
However, the degradation of HMGCR can be rapidly induced by cholesterol and mevalonate-
derived metabolites (Faust et al. 1982, Edwards, Lan, and Fogelman 1983, Nakanishi, 
Goldstein, and Brown 1988, Song, Javitt, and DeBose-Boyd 2005). 
The presence of sterols induces the association of Insig1 and Insig2 with the SSD in HMGCR’s 
transmembrane domain (Figure 1.3) (Sever, Yang, et al. 2003, Sever, Song, et al. 2003). The 
sterol-induced binding of Insigs to HMGCR is dependent on a YIYF motif in HMGCR’s SSD 
(Sever, Song, et al. 2003). The first tyrosine in the YIYF motif is equivalent to Y286 in SCAP, 
which is required for the sterol-dependent interaction between Insigs and SCAP (Nohturfft, 
Brown, and Goldstein 1998a, Adams, Goldstein, and Brown 2003). In stark contrast to S. 
cerevisiae, it is thought that the Insig proteins act as scaffolds to recruit E3 ubiquitin ligase 
complexes to HMGCR (Jo and Debose-Boyd 2010, Jo et al. 2011). Ubiquitinated HMGCR is 
extracted from the ER membrane by the p97 complex and degraded by the 26S proteasome 
(Cao et al. 2007, Morris et al. 2014). 
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Figure 1.3 Sterol-induced degradation of HMGCR. High sterol levels induce the recruitment 
of the Insig proteins to HMGCR’s transmembrane domain. The Insig proteins recruit ubiquitin 
E3 ligase complexes containing the E2 conjugating enzyme UBE2G2 (G2) and the p97 complex. 
HMGCR is ubiquitinated, extracted from the membrane and degraded by the proteasome. 
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1.2.2.4 The identity of the ubiquitin E3 ligase for HMGCR is controversial 
The ubiquitin E2 conjugating enzyme UBE2G2 mediates the sterol-induced ubiquitination of 
HMGCR (Miao et al. 2010). However, the identity of the E3 ubiquitin ligase responsible for 
HMGCR ubiquitination is controversial. The S. cerevisiae Hrd1p E3 ligase has two mammalian 
orthologues, Hrd1 and gp78. Whilst, the loss of Hrd1 caused an increased steady-state 
expression level of HMGCR, a role for Hrd1 in sterol-induced HMGCR degradation was quickly 
dismissed (Kikkert et al. 2004). 
The Debose Boyd laboratory suggested that gp78 was responsible for the sterol-induced 
degradation of HMGCR based on several observations (Song, Sever, and DeBose-Boyd 2005). 
They found gp78 to associate with Insig1 in the presence or absence of sterols and that Insig1 
mediates a sterol-dependent gp78 and HMGCR interaction. The over-expression of the gp78’s 
transmembrane domain had a dominant negative effect on HMGCR degradation. Depletion 
of gp78 by siRNA resulted in decreased sterol-induced degradation and ubiquitination of 
HMGCR (Song, Sever, and DeBose-Boyd 2005).  
A few years later, the Debose Boyd laboratory suggested that the sterol-induced degradation 
of HMGCR was mediated by two partially redundant E3 ligases, gp78 and TRC8 (Jo et al. 2011). 
The depletion of either gp78 or TRC8 in the human fibroblast cell line SV-589 resulted in a 
partial decrease in sterol-induced HMGCR degradation. The simultaneous depletion of gp78 
and TRC8 appeared to cause a nearly complete block in sterol-induced HMGCR degradation 
(Jo et al. 2011). Furthermore, hepatocytes from a liver-specific gp78-knockout mouse had an 
elevated level of steady state HMGR and a significant decrease in sterol-induced HMGCR 
degradation and ubiquitination (Liu et al. 2012). 
In an independent study by Allan Weissman’s laboratory, who first identified gp78 as an ERAD 
E3 ligase (Fang et al. 2001), mouse embryonic fibroblasts (MEFs) derived from gp78-knockout 
embryos showed no evidence of a role for gp78 in the sterol-induced degradation of HMGCR 
(Tsai et al. 2012). The Weissman laboratory addressed this discrepancy by depleting gp78 and 
TRC8 in the human fibroblast cell line (SV-589) used by the Debose Boyd laboratory (Song, 
Sever, and DeBose-Boyd 2005, Jo et al. 2011). These experiments showed no effect of the loss 
of gp78 and TRC8 on HMGCR degradation. The Weissman laboratory used a total siRNA 
concentration of 20 nM to deplete gp78 and TRC8, whereas the Debose Boyd laboratory used 
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a total siRNA concentration of 200 nM. When the Weissman laboratory repeated the 
experiment using 200 nM siRNA they observed a significant reduction in the sterol-induced 
degradation of HMGCR. However, the expression of an siRNA-resistant gp78 transgene could 
not restore HMGCR degradation (Tsai et al. 2012). Critically, the re-expression of gp78 could 
restore the expression of another gp78 substrate, CD82/KAI11 (Tsai et al. 2007). This strongly 
suggests that the phenotype observed by the Debose Boyd laboratory is the result of ‘off-
target’ effects. 
The identity of the E3 ubiquitin ligase responsible for the sterol-induced ubiquitination and 
degradation of HMGCR is therefore controversial. A major aim of this thesis will be to identify 
this ligase. 
In S. cerevisiae, geranylgeranyl pyrophosphate induces the Hrd1-mediated ubiquitination of 
Hmg2 (Garza, Tran, and Hampton 2009). In mammalian cells, geranylgeraniol, the alcohol 
derivative of geranylgeranyl pyrophosphate, enhances the sterol-induced degradation of 
HMGCR by promoting the membrane extraction and dislocation of ubiquitinated HMGCR 
(Sever, Song, et al. 2003, Schumacher et al. 2015). 
 
1.2.2.4 Cholesterol-regulated ERAD of the Insig proteins 
Whilst the ability for gp78 to ubiquitinate HMGCR is controversial, independent laboratories 
have observed the sterol-regulated ubiquitination of Insig1 by gp78 (Lee, Song, et al. 2006, 
Tsai et al. 2012). In sterol depleted cells, Insig1 is ubiquitinated by gp78 and has a half-life of 
less than 30 minutes. In the presence of cholesterol, Insig1 interacts with SCAP and is 
protected from gp78-mediated ubiquitination. In the absence of SCAP, the addition of 
cholesterol does not stabilise Insig1 (Lee, Song, et al. 2006).  
Insig1 is differentially regulated by sterols at the level of transcription and degradation. At low 
cholesterol levels, the Insig proteins dissociate from SCAP and so the SCAP-SREBP complex is 
transported to the Golgi for SREBP maturation. This results in SREBP-mediated upregulation 
of Insig1 transcription (Janowski 2002, Horton, Goldstein, and Brown 2002). Newly 
synthesised Insig1 will be degraded following gp78-mediated ubiquitination until the 
cholesterol level has increased sufficiently to induce the conformational change in SCAP to 
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allow Insig1 binding (Lee, Song, et al. 2006). At higher cholesterol levels, the Insig1-SCAP 
interaction retains SREBP in the ER, thereby inhibiting SREBP processing and Insig1 
transcription, as well as stabilising the Insig1 protein (Gong et al. 2006). 
Following ubiquitination, Insig1 must be extracted from the ER membrane before it can be 
degraded by cytosolic 26S proteasomes. UBXD8 recruits the p97 complex to gp78 to enable 
the membrane extraction of ubiquitinated Insig1. Unsaturated fatty acids block Insig1 ERAD 
by preventing the recruitment of the p97 complex to gp78 by UBXD8 (Lee et al. 2008). 
In cultured cell lines, Insig2 is significantly more stable than Insig1 and is not degraded in a 
sterol-dependent manner (Lee and Ye 2004, Lee, Song, et al. 2006). Surprisingly, gp78-
knockout murine primary hepatocytes had a dramatic increase in Insig2 expression and only 
a modest increase in Insig1 (Liu et al. 2012). Furthermore, a cycloheximide chase experiment 
also showed a significant decrease in Insig2 turnover in the gp78-knockout murine primary 
hepatocytes. This suggests that Insig2 might only be a gp78 substrate in hepatic cells (Liu et 
al. 2012). 
 
1.2.2.5 Other gp78 substrates 
Acyl-CoA:cholesterol acyltransferase 2 (ACAT2) catalyses the conversion of cholesterol and 
fatty acids to cholesteryl esters (Chang, Chang, and Cheng 1997). ACAT2 is ubiquitinated on 
cysteine 277 by gp78 in an Insig dependent manner (Wang, Bian, et al. 2017). High cellular 
cholesterol and lipid levels leads to the generation of reactive oxygen species (ROS) (Boden 
2011). Cysteine 277 is oxidised by ROS, preventing ubiquitination and degradation (Wang, 
Bian, et al. 2017). ACAT2 is therefore stabilised at high cholesterol levels to increase the 
conversion of cholesterol to cholesteryl esters to reduce cellular lipid overload. 
Diacylglycerol acyltransferase 2 (DGAT2) is one of the enzymes that catalyses the final step in 
triacylglycerol biosynthesis (McFie et al. 2011). Triacylglycerol is the dominant form of lipid 
storage in eukaryotes and so the regulation of DGAT2 is critical for lipid metabolism. Gp78 
has been suggested to mediate the ubiquitination of DGAT2, however the stimulus and 
requirements for DGAT2 ERAD are yet to be defined (Choi et al. 2014) 
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Apolipoprotein B-100 (ApoB) is an essential member of the very low density lipoprotein 
(VLDL) and LDL complexes and is therefore required for plasma cholesterol transport (Fisher 
and Ginsberg 2002). When the lipids transported by the VLDL and LDL complexes are limited, 
ApoB is ubiquitinated by gp78, dislocated by the p97 complex and degraded by the 26S 
proteasome (Liang et al. 2003, Fisher, Khanna, and McLeod 2011). 
 
1.2.2.6 TRC8 and cholesterol homeostasis 
TRC8 is an ER resident, polytopic, RING-H2 E3 ligase that mediates the HCMV US2-induced 
degradation of cell surface receptors such as MHC-I and SPP-dependent degradation of tail-
anchor proteins (Stagg et al. 2009, Boname et al. 2014, Hsu et al. 2015). TRC8 is the second 
E3 ubiquitin ligase implicated in HMGCR ERAD by the Debose Boyd laboratory but dismissed 
by the Weissman laboratory (Jo et al. 2011, Tsai et al. 2012). Both the Debose Boyd and 
Gemmill laboratories observed the co-precipitation of Insig1 and Insig2 with exogenous TRC8 
(Lee et al. 2010, Jo et al. 2011). TRC8 has been reported to inhibit SREBP-2 processing by 
hindering the recruitment of SCAP to Sec24 (Irisawa et al. 2009). The transmembrane domain 
of TRC8 contains a sterol sensing domain (Irisawa et al. 2009). These observations suggest 
that TRC8 could contribute to the regulation of cholesterol homeostasis. 
 
1.2.2.7 MARCH6 and cholesterol homeostasis 
Squalene monooxygenase catalyses the oxygenation of squalene into monooxidosqualene 
and is considered a key, frequently over-looked, rate-limiting step down-stream of HMGCR in 
cholesterol biosynthesis (Sharpe and Brown 2013). Squalene monooxygenase is after the 
isoprenoid (farnesyl pyrophosphate) branch of the mevalonate pathway and so committed to 
cholesterol production. Two independent studies reported the cholesterol-dependent 
degradation of squalene monooxygenase by the ER-resident E3 membrane-associated RING 
Finger 6, MARCH6 (Foresti et al. 2013, Zelcer et al. 2014). Zelcer et al. noticed that MARCH6 
influenced HMGCR expression. They observed an increase in the basal level of HMGCR when 
MARCH6 was depleted by siRNA, but could not see a definitive effect of MARCH6 depletion 
on the sterol-induced degradation of HMGCR (Zelcer et al. 2014).  
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The Zelcer laboratory published a later paper showing that MARCH6 acts as a negative 
regulator of SREBP-2 in hepatic cells, although no difference in SREBP-2 abundance or 
processing was detected (Loregger et al. 2015). The loss of MARCH6 also increased expression 
of the E3 ligase inducible degrader of LDLR (IDOL) in a wide range cell lines (Loregger et al. 
2015). IDOL is the E3 ubiquitin ligase that targets LDLR for degradation (Zelcer et al. 2009). 
There is therefore a significant decrease in LDLR protein abundance and LDL uptake following 
MARCH6 depletion (Loregger et al. 2015).  
 
1.2.3 Cholesterol Uptake 
To maintain cholesterol homeostasis, cells must balance the uptake of exogenous cholesterol 
as well as the endogenous production of cholesterol. Cholesterol is transported in low density 
lipoprotein (LDL) particles as cholesterol esters. LDL particles bind to the LDLR, which is 
internalised by clathrin-mediated endocytosis (Brown and Goldstein 1986). LDL particles 
dissociate from the LDLR as the pH of endosomes decreases. The LDLR is recycled back to the 
plasma membrane, whereas the LDL particles continue through the endosomal pathway to 
lysosomes (Brown, Anderson, and Goldstein 1983). Lysosomal acid hydrolases hydrolyse the 
LDL bound cholesteryl esters to release cholesterol from LDL particles (Sugii et al. 2003). The 
Niemann-Pick type C (NPC) proteins then facilitate cholesterol exit from lysosomes. 
Unesterified cholesterol first binds to NPC2, a small lysosomal protein. NPC2 bound 
cholesterol is transferred to NPC1, a large membrane spanning protein, and inserted into the 
membrane (Infante et al. 2008, Kwon et al. 2009, Wang et al. 2010). Cholesterol can then be 
transported to other cellular membranes (Chang et al. 2006, Urano et al. 2008). Loss-of-
function mutations in the NPC genes cause a dramatic accumulation of cholesterol in 
lysosomes, particularly in the liver, brain, and lungs, leading to death during childhood (Vanier 
and Millat 2003). 
The expression of the LDLR is tightly regulated transcriptionally and post-transcriptionally to 
control cholesterol uptake. The LDLR is a SREBP target gene (Horton, Goldstein, and Brown 
2002). Therefore, at low cellular cholesterol levels, LDLR expression is upregulated to increase 
cholesterol uptake.  
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Two distinct mechanisms target the LDLR for degradation. Proprotein convertase 
subtilisin/kexin type 9 (PCSK9) is a secreted protein that binds to the LDLR. In the presence of 
the autosomal recessive hypercholesterolaemia (ARH) adapter, the PCSK9/LDLR complex is 
internalised (Lagace et al. 2006). Whilst the lower pH in endosomes promotes the dissociation 
of LDL from the LDLR, PCSK9 has a higher affinity for the LDLR in the more acidic environment. 
The PCSK9-bound LDLR cannot be recycled back to the plasma membrane, instead the 
complex is degraded in lysosomes (Horton, Cohen, and Hobbs 2007).  
Activation of the transcription factor LXR by ligands, such as oxysterols, upregulates the 
expression of the ubiquitin E3 ligase IDOL. IDOL contains a C-terminal RING domain that 
mediates the ubiquitination of the LDLR, targeting the LDLR for lysosomal, rather than 
proteasomal, degradation (Zelcer et al. 2009). 
 
1.3 Forward genetic screens 
The genomic era, in which we now have a detailed description of an organism’s genetic 
content, has been enabled by next generation sequencing. The task is now to understand the 
function of the sequence of nucleotides. In 2007, it was estimated that two-fifths of the 
human genome remained uncharacterised (Reichardt 2007). Forward genetic screens are 
used to determine gene function, are a powerful tool in providing insight into the cellular 
pathways genes are involved in and can be used to implicate genes in pathological processes. 
Forward genetic screens can be performed in a remarkable range of cell types or model 
organisms using a variety of techniques. All forward genetic screens share the same 
underlying concept: select a process of interest, predict the phenotype that mutants unable 
to carry out this process will present, select the mutants with that phenotype and determine 
the sites of mutations to identify the affected genes (Forsburg 2001).  
 
1.3.1 Forward genetic screens in model organisms 
Hermann Müller pioneered the concept of forward genetic screens by studying the effect of 
X-ray induced mutations in Drosophila melanogaster (Muller 1927). Since this early work a 
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diverse repertoire of techniques has made D. melanogaster one of the most tractable 
organisms for geneticists  (Rubin and Lewis 2000, Venken and Bellen 2014). D. melanogaster 
forward genetic screens have provided significant insight into fundamental biological 
processes (Nüsslein-Volhard and Wieschaus 1980, St Johnston 2002, Housden et al. 2017). 
The budding yeast S. cerevisiae has been used extensively as a model organism to study a 
diverse range of biochemical processes (Hartwell, Culotti, and Reid 1970, Novick, Field, and 
Schekman 1980, Hampton, Gardner, and Rine 1996). The ability to maintain S. cerevisiae in a 
haploid state is extremely useful for geneticists (Nasmyth and Shore 1987). A haploid genome 
enables forward genetic screens, because the disruption of a gene cannot be compensated 
for by a second allele and so results in the loss of gene expression.  
In S. cerevisiae based screens, chemical or insertional mutagenesis is typically used to 
generate a population of mutants. Chemical mutagenesis involves treating cells with a 
chemical mutagen to create point and frame-shift mutations. Whereas, insertional 
mutagenesis involves the integration of a construct into a gene. Whilst chemical mutagenesis 
can induce a wider range of mutations, insertional mutagenesis is generally favoured as it is 
considerably easier to identify insertion sites than to identify chemically induced mutations. 
While the results from model organisms are insightful, the phylogenetic distance from 
mammals often renders the extrapolation of results into mammalian cell biology 
inappropriate (Grimm 2004). It is therefore important to interrogate mammalian biological 
processes using genetic screens in mammalian cells. 
 
1.3.2 Forward genetic screens in human cells 
1.3.3.1 Gene silencing by RNA interference 
The application of forward genetic screens in mammalian systems was hindered by the 
difficulty of generating and recovering bi-allelic mutations in diploid cells. Initial efforts to 
perform genome-wide loss of function screens used RNA-interference (RNAi) to silence gene 
expression by targeting mRNA.  
RNA interference refers to a gene silencing mechanism that was discovered in C. elegans (Fire 
et al. 1998). Long double-strand RNAs (dsRNAs) are processed by a Dicer ribonuclease to 
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create ~21 nucleotide dsRNAs (Bernstein et al. 2001). The processed dsRNAs are loaded into 
the RNA-induced silencing complex (RISC), which is then targeted to and degrades the 
cognate mRNA (Song et al. 2004). This mechanism can be exploited by transfecting cells with 
small interfering RNA (siRNA) duplexes that can be loaded onto RISC and therefore silence a 
gene of interest. Alternatively, short hairpin RNAs (shRNAs) can be stably expressed to 
mediate gene silencing. The RNaseIII enzyme Drosha initially processes shRNAs in the nucleus 
before further processing by Dicer in the cytosol to generate dsRNAs that can be loaded onto 
the RISC complex (Hutvágner et al. 2001, Lee et al. 2003). 
1.3.3.2 Genome-wide RNAi screens 
By targeting mRNA to silence a gene, RNAi circumvents the problem presented by multiple 
alleles. Genome-wide siRNA screens can be performed by transfecting cells with siRNAs 
targeting every gene in the genome. This method has successfully identified genes involved 
in lipid droplet formation (Guo et al. 2008), influenza virus replication (Karlas et al. 2010) and 
embryonic stem cell identity (Chia et al. 2010). However, RNAi usually only results in a partial 
knockdown of gene expression, which is not always sufficient to induce a phenotype. Off-
target effects of siRNAs are also a major problem, where siRNAs target a non-cognate mRNA 
(Jackson et al. 2003, Jackson et al. 2006, Sudbery et al. 2010). Another significant drawback 
of genome-wide siRNA screens is that they are very labour-intensive and expensive. Each 
gene is individually targeted in a separate pool of cells, therefore analysing approximately 
20,000 genes with multiple independent siRNAs for each gene requires an extraordinary 
number of individual experiments. 
An alternative approach to siRNA libraries was to use shRNA libraries, which offered several 
advantages (Bernards, Brummelkamp, and Beijersbergen 2006, Chang, Elledge, and Hannon 
2006, Moffat et al. 2006, Root et al. 2006, Bassik et al. 2009). As shRNAs can be stably 
expressed from a viral vector, they provide a longer period for gene knockdown to occur. A 
shRNA screen can be performed as a pooled experiment, instead of thousands of individual 
knockdowns. The shRNAs in the selected cells can be identified by amplifying and barcode 
from the shRNA vector by a conventional PCR reaction and deep sequencing (Bernards, 
Brummelkamp, and Beijersbergen 2006). Whilst genome-wide shRNA screens have provided 
useful insights, partial knockdown of gene expression and off-target effects still hamper 
shRNA screens. 
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1.3.4 Retroviral gene-trap mutagenesis screens in near-haploid human cells  
The Brummelkamp laboratory reported a major breakthrough using the near-haploid human 
KBM7 cell line (Figure 1.4) (Carette et al. 2009). The KBM7 cell line was derived from a patient 
with chronic myeloid leukaemia and has a haploid karyotype except for chromosome 8 and 
the sex chromosomes (Andersson et al. 1987, Kotecki, Reddy, and Cochran 1999). Carette et 
al. developed a retroviral gene-trap vector to randomly mutate a population of KBM7 cells 
(Carette et al. 2009). The gene-trap vector contains a strong adenoviral splice acceptor site 
upstream of a promoterless reporter gene (mCherry in this thesis) and an SV40 
polyadenylation signal. Following integration into the sense-strand of a gene, the strong splice 
acceptor site will accept splicing from the upstream exon, thereby producing a mCherry-
fusion transcript terminating at the polyadenylation signal. As KBM7 cells only have a single 
allele of most genes, insertion of the retroviral gene-trap vector into a gene results in its 
inactivation. Carette et al. demonstrated that the retroviral gene-trap vector integrates into 
98% of all expressed genes, 90% of marginally expressed genes and 65% of non-expressed 
genes (Carette, Guimaraes, et al. 2011). Brummelkamp and collaborators have used this 
forward genetic screen system to identify host genes required for the toxic effects of the 
cytolethal distending toxins (Carette, Guimaraes, et al. 2011), the binary actin-ADP 
ribosylating toxin Clostridium difficile transferase (Papatheodorou et al. 2011), tunicamycin 
(Reiling et al. 2011), cholera toxin (Guimaraes et al. 2011), Ebola virus (Carette, Raaben, et al. 
2011), Chlamydia trachomatis (Rosmarin et al. 2012), 3-bromopyruvate (3-BrPA) (Birsoy et al. 
2013), Lassa virus (Jae et al. 2013), Andes virus (Kleinfelter et al. 2015) and Rift Valley fever 
virus (Riblett et al. 2015). This approach has proven to be extremely powerful and successful 
when screening for resistance to a lethal phenotype. 
The Lehner laboratory has developed this technique to use a fluorescence-based phenotypic 
selection. This allows the investigation of a diverse range of cellular processes as we are no 
longer restricted to a lethal phenotype (Duncan et al. 2012, Timms et al. 2013, van den 
Boomen et al. 2014, Tchasovnikarova et al. 2015). At the start of my thesis, retroviral gene-
trap mutagenesis screens in near-haploid cells represented the gold standard for forward 
genetic screens in human cells. 
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Figure 1.4 Retroviral gene-trap mutagenesis screens in the near-haploid KBM7 cell line. The 
KBM7 cell line has a haploid karyotype except for chromosome 8 and the sex chromosomes. 
Mutagenesis of the KBM7 cell line using the gene-trap retrovirus creates a library of knockout 
cells. A selection can be performed to identify knockouts that display a phenotype of interest. 
Mapping the integration sites of the gene-trap retrovirus in the selected cells reveals the 
identity of the disrupted genes whose loss resulted in the phenotype of interest. 
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1.3.5 Genome-wide CRISPR/Cas9 knockout screens 
Precise genome editing using programmable nucleases are a transformative technology for 
cell biology research. Custom nucleases that can be designed to target a specific locus have 
been used for several years, including zinc-finger nucleases (ZFNs) (Carroll 2011) and 
transcription activator-like effector nucleases (TALENs) (Joung and Sander 2013). However, 
the microbial Type-II Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/ 
associated (Cas9) system is an exciting advance with a wide range of applications (Hsu, 
Lander, and Zhang 2014). A short guide RNA (gRNA), typically 20 bp, targets the Cas9 nuclease 
to a specific locus where the two nuclease domains of Cas9, HNH and RuvC, create a double 
strand break (DSB) in the DNA (Figure 1.5A) (Nishimasu et al. 2014, Sternberg et al. 2014). In 
most cases, the DSB will be repaired by the non-homologous end joining (NHEJ), an error-
prone process that frequently results in small insertions or deletions (Chiruvella, Liang, and 
Wilson 2013). If the inserted or deleted sequence disrupts the coding sequence that allele will 
be knocked-out (Figure 1.5B). Alternatively, if a donor template is provided, the double strand 
break can be repaired precisely by homologous recombination (HR). Sequences can be 
introduced to endogenous loci by inserting the desired sequence into the donor template 
(Figure 1.5B). The simplicity of the CRISPR/Cas9 system enables cheap and rapid genome 
editing. 
By using a large library of gRNAs to target the Cas9 nuclease to all annotated genes, 
CRISPR/Cas9 can be used to perform genome-wide forward genetic screens. At the start of 
my thesis project, four independent laboratories had reported proof-of-principle genome-
wide CRISPR knockout screens (Shalem et al. 2014, Wang et al. 2014, Zhou et al. 2014, Koike-
Yusa et al. 2014). These studies opened the exciting potential of performing genome-wide 
CRISPR/Cas9 screens in any cell type, as the CRISPR/Cas9 system is not restricted to a haploid 
karyotype.  
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Figure 1.5 The CRISPR/Cas9 system (A) Schematic view of CRISPR/Cas9-mediated DNA 
cleavage. A gRNA targets the Cas9 nuclease to its complementary sequence. The HNH and 
RuvC nuclease domains cleave the DNA resulting in a double strand break. (B) A CRISPR/Cas9-
mediated double strand break can be repaired by non-homologous end joining (NHEJ) or 
homologous recombination (HR). NHEJ is an error-prone process that results in small 
insertions or deletions. HR uses a template to precisely repair a double strand break. 
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1.4 Aims of this thesis 
1. Forward genetic screens are a powerful tool to elucidate gene function. At the beginning 
of my thesis project, the gold standard in forward genetic screens in cultured human cells 
were retroviral gene-trap mutagenesis screens in the near-haploid KBM7 cell line. The advent 
of CRISPR/Cas9 technology offers a method to generate bi-allelic mutations and therefore 
gene knockouts. The first proof-of-principle studies demonstrated that large gRNA libraries 
could be used to target the Cas9 nuclease to all annotated genes and thereby perform 
genome-wide CRISPR knockout screens. The major aim of the first part of my thesis project 
was to compare gene-trap mutagenesis haploid screens to CRISPR screens to determine 
which technology is more effective. This is described in Chapter 4. 
 
2. The sterol-induced degradation of HMGCR, the enzyme that catalyses the rate-limiting step 
in cholesterol biosynthesis, is a critical mechanism used by cells to regulate cholesterol 
homeostasis. At high cholesterol/sterol levels, HMGCR is rapidly degraded by the ubiquitin 
proteasome system. The Debose-Boyd laboratory has reported that gp78 and TRC8 are 
responsible for the sterol-induced ubiquitination of HMGCR (Song, Sever, and DeBose-Boyd 
2005, Jo et al. 2011). However, an independent study by the Weissman laboratory did not 
observe a requirement for gp78 or TRC8 in HMGCR degradation (Tsai et al. 2012). I therefore 
wanted to use forward genetic screens as an unbiased approach to identify the E3 ubiquitin 
ligase(s) responsible for HMGCR ubiquitination. I would then aim to biochemically 
characterise the E3 ubiquitin ligases identified by the forward genetic screens. These data are 
described in Chapters 5, 6 and 7.
Chapter 2: Materials and Methods 
 
52 
 
Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Buffers 
Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCL, 10 mM Na2NPO4, 2 mM KH2PO4, 
pH 7.4 
TRIS-buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4 
Luria-Bertani (LB) medium: 1% (w/V) Bacto-trptone, 0.5% (w/v) Bacto-yeast extract, 1% (w/v) 
NaCl, 0.1% (w/v) glucose 
SOC medium: 2% tryptone, 0.5% w/v yeast abstract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4 and 20 mM glucose 
6X SDS Loading Buffer: 60% glycerol, 300 mM Tris pH 6.8, 6% (w/v) SDS, 9% (w/v) DTT, 0.03% 
(w/v) bromophenol blue 
Bind and wash (B&W) buffer: 5 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1 M NaCl 
 
2.1.2 Enzymes, Reagents and Inhibitors 
Enzymes for manipulation of DNA were purchased from New England Biolabs (NEB). Reagents 
and inhibitors were purchased from Sigma unless otherwise stated. 
 
2.1.3 Antibodies 
Primary antibodies used were as follows: mAb W6/32 (recognises conformational MHC-I), 
rabbit α-TXNDC11 (Abcam, ab188329), rabbit α-FLAG (Sigma-Aldrich, F7425), mouse M1 α-
FLAG (Sigma-Aldrich, F3040), mouse α-B-Actin (Sigma-Aldrich, A5316), rabbit α-GANAB 
(GeneTex, GTX102237), rabbit α-EDEM2 (Sigma-Aldrich, E1728), rabbit α-EDEM3 (Sigma-
Aldrich E0409), rabbit α-PDI (Cell Signaling, #2446), SEL1L (Santa Cruz, sc-48080), GLU2B, 
mouse α-calnexin (AF8, a kind gift from M. Brenner, Harvard Medical School), Calreticulin, 
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mouse α-HMGCR (Santa Cruz, sc-27195), rabbit α-HMGCR (Abcam, ab174830), rabbit α-gp78 
(ProteinTech, 16675-1-AP), rabbit α-RNF145 (ProteinTech, 24524-I-AP), mouse α-V5 (Abcam, 
ab27671), mouse VU-1 α-ubiquitin (Life Sensors, VU101), rabbit α-myc (Cell Signalling, 2278), 
mouse α-UBE2G2 (Santa Cruz, sc-100613), mouse α-mCherry (Novus Biologicals, NBP1-
96752), rabbit α-UROD (Novus Biologicals, NBP2-20818). 
HRP-conjugated goat α-mouse and goat α-rabbit (Jackson). Alexa Fluor 647-conjugated α-
mouse (Life Technologies). 
 
2.2 Molecular biology 
2.2.1 Polymerase chain reaction 
Oligonucleotide primers were purchased from Sigma-Aldrich. For DNA template, typically 
used 10 ng of plasmid DNA, 60 ng of cDNA library or 100 ng of genomic DNA in a total volume 
of 50 µl using Phusion DNA polymerase (NEB). Standard conditions were: 
 10 µl  5x Phusion-HF Buffer (NEB) 
 X ng   DNA template 
 1 µl   10 mM dNTP mix 
 0.25 µl  Primer 1 (100 µM) 
 0.25 µl  Primer 2 (100 µM) 
 0.5 µl   Phusion polymerase 
 To 50 µl ddH2O 
Typical cycling parameters were: 
 95oC  30 s 
 95oC  10 s 
 55-68oC 20 s   x 30 cycles 
 72oC  20 s per kb 
 72oC  5 min 
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2.2.2 Fluorescent PCR to identify CRISPR-induced frame-shift mutations 
Genomic DNA was extracted from wild type HeLa cells and RNF145 CRISPR clones using the 
Quick-gDNA MicroPrep kit (Zymo Research). Oligonucleotides were ordered from Sigma-
Aldrich. To ensure a clean product, a nested PCR was performed. One of each primer pair for 
the second PCR was modified with 6FAM at its 5’ end. For gRNA #5 PCR1_Forward: 
GATTACAGGCGTGAGCCACCG, PCR1_Reverse: GTCTTTCTCCAGGAGCTTGTG, PCR2_Forward: 
CATAACCTGCCATCTAACTCC and PCR2_Reverse: GAAACACTTCCGTGCTGTAAGC. For gRNA #8 
PCR1_Forward: CAGAATGCTCACTAGAAGATTAG, PCR1_Reverse: 
GTAGTATACGTTCTCACATAG, PCR2_Forward: GTGATGTAGACACTCACCTAC and 
PCR2_Reverse GTGACAACCTATTAGATTCGTG. The size of the PCR product from the genomic 
DNA from wild type HeLa cells and each RNF145 CRISPR clone was resolved using an ABI 
3730xl DNA Analyser. 
 
2.2.3 DNA Cloning 
2.2.3.1 Gibson assembly 
Recombinant DNA plasmids were constructed using standard ligation or the Gibson assembly 
method (Gibson et al. 2009). Plasmid vectors were digested for 4 h with restriction enzymes 
at the appropriate temperature, typically 37oC, and then run out on an agarose gel. Bands 
were excised and purifired using the QIAquick gel extraction kit (Qiagen). PCR was used to 
amplify inserts with 20-30 bp overhangs with the desired vector. PCR products were also run 
out on an agarose gel and purified using the QIAquick gel extraction kit. The DNA 
concentration of inserts and vectors were measured using a NanoDrop spectrophotometer. 
Typically, 50 ng of vector and a 2-3 fold molar excess of inserts were mixed with and equal 
volume of 2x Gibson Assembly Maser Mix (NEB) and incubated for 1 h at 50oC. Two microliters 
of the mix was used to transform 5-alpha Competent E. coli (NEB) which were then spread on 
agar plates, containing ampicillin or kanamycin, and incubated overnight at 37oC. Individual 
colonies were picked into 3 ml LB medium containing ampicillin or kanamycin and cultured at 
37oC for 16 h with shaking.  
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The E. coli were pelleted by centrifugation and plasmid DNA was isolated using the QIAprep 
Spin miniprep kit (Qiagen). A sample of the plasmid DNA from each colony was digested and 
resolved on an agarose gel to ensure the insert was the correct size. Constructs were verified 
by Sanger sequencing (SourceBioscience). 
2.2.3.2 DNA ligation cloning 
Plasmid vectors were digested for 4 hr with restriction enzymes, run out on a gel and the 
desired bands were purified using the QIAquick gel extraction kit. Inserts were cut from 
plasmid DNA or amplified by PCR. PCR products were digested with restriction enzymes for 
at least 6 h, run out on a gel and purified using the QIAquick gel extraction kit. The DNA 
concentration of digested vectors and inserts was measured using a NanoDrop 
spectrophotometer. The vector and insert were mixed in a 1:4 molar ratio with T4 DNA Ligase 
(NEB) and incubated at room temperature for 1 h. Two microliters of the ligation mix were 
used to transform DH5α E. coli (Bioline) which were spread on selective agar plates and 
incubated overnight at 37oC. Individual colonies were selected into 3ml of LB medium 
containing ampicillin or kanamycin and cultured at 37oC for 16 h with shaking. Plasmid DNA 
was then isolated using the QIAprep spin miniprep kit. Constructs were verified by Sanger 
sequencing (SourceBioscience). 
2.2.3.3 gRNA cloning 
For CRISPR-mediated gene disruption, gRNAs were cloned as recommended by the Zhang 
laboratory (Ran et al. 2013). Oligonucleotides were ordered from Sigma-Aldrich, annealed, 
and cloned into the dual Cas9 and gRNA expression vector pSpCas9(BB)-2A-Puro (Addgene 
#48139, deposited by Dr. Feng Zhang) or the lentiviral gRNA expression vector pKLV-
U6gRNA(BbSI)-PGKpuro2ABFP (Addgene #50946, deposited by Dr. Kosuke Yusa).  
 
2.3 Constructs 
2.3.1 Lentiviral vectors 
The pHRSIN lentiviral system was used for the expression of exogenous genes (Demaison et 
al. 2002). These vectors contain the cis-acting HIV1 viral elements, the long terminal repeats 
(LTRs), the ψ packaging signal, the rev response element (RRE) and the central polypurine 
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tract (cPPT), with an internal spleen-focus forming virus (SFFV) promoter to drive expression 
of the gene of interest, followed by the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE) to increase the stability of the transcribed mRNA. A downstream 
promoter drives the expression either a fluorescent protein or a selectable marker. 
 
2.3.2 Lentiviral expression of exogenous genes 
The lentiviral vectors pHRSIN-PSFFV-GFP-PPGK-BlasticidinR, pHRSIN-PSFFV-GFP-PPGK-HygromycinR 
and pHRSIN-PSFFV-GFP-PPGK-PuromycinR were used for exogenous expression, with the gene 
of interest cloned in place of GFP. 
pHRSIN GFP-HLA-A2 was a kind gift from Dr. Louise Boyle. TXNDC11 coding sequence was 
ordered as a series of gBlocks (IDT) and assembled using the Gibson Assembly method by 
Richard Timms. TXNDC11 mutants were cloned by Richard Timms using site directed 
mutagenesis. 
The transmembrane domain of HMGCR and mCherry encoding sequences were amplified by 
PCR from plasmid vectors (HMGCR construct was a kind gift from Dr Joseph Roitelman) and 
assembled into pHRSIN using the Gibson Assembly method. 
RNF145 and Insig1 IMAGE clones were purchased from Geneservice by Dick van den Boomen. 
The open reading frames were amplified by PCR and cloned into pHRSIN vectors. RING and 
sterol sensing domain mutations were created by amplifying the RNF145 coding sequence by 
PCR in fragments so that mutations could be introduced in the primers. The PCR fragments 
were assembled into pHRSIN using the Gibson Assembly method. The coding sequence for 
Insig2 was amplified from HeLa cDNA and cloned into pHRSIN using the Gibson Assembly 
method. The nuclease Cas9 was cloned from the lenti-Blast vector (Addgene #49535, kindly 
deposited by Feng Zhang) into pHRSIN using BamHI and NotI. 
 
2.3.3 Donor template vector for CRISPR-mediated knock-in 
A donor template for creating a HMGCR-Clover knock-in was created by modifying the pDonor 
loxP Ub-Puro vector (a generous gift from Prof Ron Kopito). Homology arms of approximately 
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1 kb were amplified from HeLa genomic DNA by PCR, and assembled with the loxP-Ub-Puro 
cassette from pDonor loxP Ub-Puro and the backbone from pMAX-GFP (Amaxa) digested with 
NsiI and PciI using the Gibson Assembly method. 
 
2.3.4 Lentiviral expression of shRNAs 
For expression of shRNAs, the pHR-SIREN vector was used. Oligonucleotides were ordered 
from Sigma-Aldrich, annealed, cloned into the pHR-SIREN vector using BamHI and EcoRI, and 
sequence verified. Hairpins were designed using Clontech’s RNAi target sequence selector. 
Oligonucleotide sequences in Appendix 1. 
 
2.4 Cell culture 
2.4.1 Tissue culture 
KBM7 cells were maintained in IMDM supplemented with 10% fetal calf serum and 
penicillin/streptomycin. HeLa and 293T cells were maintained in DMEM supplemented with 
10% fetal calf serum and penicillin/streptomycin. Single cell HeLa cells were seeded into flat-
bottomed 96-well plates. 
 
2.4.2 Sterol depletion 
HeLa cells were seeded prior to sterol depletion. Attached, approximately 50% confluent, 
HeLa cells were washed five times with PBS. Washed cells were then cultured overnight in 
DMEM supplemented with 10% lipoprotein-depleted fetal calf serum (a kind gift from Prof 
David Savage then purchased from Biosera) plus 10 µM Mevastatin (Source Bioscience) and 
penicillin/streptomycin. Final concentrations of 2 µg/ml 25-hydroxycholesterol (Sigma-
Aldrich) and 20 µg/ml cholesterol (Sigma-Aldrich) were added to sterol depleted cultures to 
analyse sterol-induced protein degradation. 
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2.4.3 Transfection of HeLa cells 
HeLa cells were transfected using the TransIT-HeLaMONSTER kit (Mirus) according to the 
manufacturer’s instructions. Cells were seeded at a confluency of 20-30% in 12-well plates 
and transfected with 1 µg DNA, 3 µl TransIT-HeLa reagent and 2 µl MONSTER reagent in 
OptiMEM (Gibco). When HeLa cells were transfected with pools of gRNAs, the 1 µg was split 
evenly between the individual gRNA-expressing constructs. 
 
2.4.4 Transfection of siRNAs 
HeLa cells were transfected at 20-30% confluency in 6-well plates. 10 µl of Oligofectamine 
(Invitrogen) as mixed with 20 µl of OptiMEM (Gibco) and incubated at room temperature for 
5 min. In a separate tube, siRNA was diluted in OptiMEM (total volume 170 µl), combined 
with the oligofectamine/OptiMEM mixture and incubated at room temperature for a further 
20 min. The medium was removed from the cells and replaced with antibiotic-free DMEM 
supplemented with 20% FCS. The siRNA/oligofectamine mixture was diluted further with 800 
µl of OptiMEM before being added to the cells. Control samples were transfected MISSION 
siRNA Universal Negative Control (Sigma-Aldrich). Gene-targeting siRNA sequences are in 
Appendix 1. 
 
2.4.5 Lentivirus production 
Lentivirus was generated by triple transfection of HEK 293T cells with the pHRSIN lentiviral 
vector plus the packaging vectors pCMVΔR8.91 and pMD.G. For a standard transection in a 6-
well plate, HEK 293T cells seeded at 70% confluency in antibiotic free medium were 
transfected with 2 µg total DNA (comprising 1 µg pHRSIN vector, 0.7 µg pCMVΔR8.91 and 0.3 
µg pMD.G) using TransIT-293 (Mirus) as recommended by the manufacturer. After 48 h the 
supernatant was harvested, filtered through a 0.45 µm filter and added to target cells, which 
were then centrifuged at 1800 rpm for 45 min. Transgene expression was typically assessed 
48 h post-transduction. Drug selection typically started 24 h post-transduction. 
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2.4.6 Flow cytometry 
Cells were washed with PBS and resuspended in cold PBS. Samples were analysed using a 
FACSCalibur (BD) or a LSRFortessa (BD). Flow cytometry data was analysed using FlowJo 
software. 
 
2.4.7 Fluorescence-activated cell sorting (FACS) 
Cells were harvested, washed with PBS, resuspended in sort solution (PBS containing 10 mM 
HEPES and 2% FCS) and filtered through a 50 µm filter. Samples were sorted on an Influx 
machine (BD). 
 
2.5 Haploid Genetic Screen 
2.5.1 Retroviral gene-trap mutagenesis 
Gene-trap retrovirus was produced by triple transfection of HEK 293T cells with the gene-trap 
retrpviral vector plus the packaging vectors pMD.GagPol and pMD.G in a ratio of 10:7:3. Gene-
trap retrovirus was produced in 14 cm plates. The viral supernatant was harvested 48 h post-
transfection and directly applied to KBM7 cells for a screen to ensure maximise the viral titer. 
Transduction of 100 million KBM7 cells was performed in 24-well plates with 500 µl of viral 
supernatant added to 1x106 KBM7 cells per well with 10 µg/ml polybrene. The plates were 
spun for at 1800 rpm for 1 h. Three hours later, the cells were pooled, spun down and 
resuspended in fresh IMDM. The transduction efficiency was determined 48 h post-
transduction by assessing mCherry (marker on the retrovirus) by flow cytometry. 
2.5.2 Iterative FACS selection 
Mutagenised KBM7 cells were cultured for eight days before being sorted by FACS. Typically, 
the highest 0.6% of GFP-expressing cells are selected in the first round of FACS. The selected 
cells were expanded in culture before a second round of FACS was performed to purify the 
GFPhigh population. 
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2.5.3 Mapping retroviral integration sites 
Genome DNA was isolated from 5 million selected KBM7 cells and 5 million unselected 
mutagenised KBM7 cells using the Gentra Puregene kit (Qiagen). The genomic DNA was 
digested overnight with either NlaIII or MseI. The digested DNA was then purified using the 
Qiagen PCR purification kit. Annealed adaptors (sequences in Appendix 2) were ligated onto 
the genomic DNA fragments using T4 DNA Ligase (NEB) overnight at 4oC. Another column 
clean-up was performed using the Qiagen PCR purification kit followed by a further clean up 
with 0.75x Ampure XP beads (Agencourt). The adapter annealed-DNA was then used as the 
template for a linear PCR (Accuprime Taq HiFi, Invitrogen; 250 cycles) with a biotinylated 
primer binding just upstream of the 5’LTR of the integrated retrovirus. The product was then 
annealed to 5 µl streptavidin dynabeads (M-280 Invitrogen, blocked for 20 min with 0.5% BSA) 
for 2 h at room temperature in binding and wash (B&W) buffer plus 0.1% Tween-20 with 
orbital shaking at 1100 rpm. After washing, the beads were used as the template for an 
exponentrial PCR (18 cycles) with a P5-adapted primer binding to the viral 5’ LTR and a 
barcoded and P7-adapted primer binding the 3’ adaptor. After a final column clean-up the 
PCR product was sequenced using the Illumina HiSeq platform using a custom primer binding 
to the extreme end of the viral 5’ LTR.  
2.5.4 Analysis of sequencing data to identify retroviral integration sites 
Illumina HiSeq data as analysed through a custom analysis pipeline developed by Richard 
Timms. Using the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) the raw cram files 
were converted into fastq files and bases with low quality scores and adaptor sequence were 
trimmed from the 3’ end of the reads. Reads less than 20 bp long were then discarded, and 
identical sequences amoung the remaining reased were collapsed into a single fasta file. 
These reads were then mapped to the human genome (hg19) using Bowtie (Langmead et al. 
2009). Reads that mapped uniquely to the human genome were imported into SeqMonk 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/), converted into a set of 
inique integration sites and quantified using the gene-trap analysis pipeline. For the bubble 
plot presented in Figure 3.2C, the degree of enrichment of each gene in the selected 
population compared to the unselected cells was calculated using a Bonferroni-corrected 
one-sided Fisher’s exact test. All genes found to contain gene-trap integrations are listed 
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alphabetically on the x-axis; bubble size is proportional to the number of gene-trap 
integrations predicted to inactivate gene expression (in parentheses). 
 
2.6 CRISPR knockout screens 
2.6.1 gRNA libraries 
For the genome-wide CRISPR knockout screens in Figure 3.3D, Figure 4.2E and Figure 4.6E, 
the Genome-Scale CRISPR Knock-out (GeCKO v2) library was used (addgene #1000000049, 
deposited by Feng Zhang) (Sanjana, Shalem, and Zhang 2014). For the genome-wide CRISPR 
knockout screens in Figure 5.3D and Figure 5.5E the Bassik gRNA library was used (a kind gift 
from Dr Michael Bassik, Stanford). The ubiquitome gRNA library used in Figure 7.3B and 
Figure 7.6 is the product of a collaboration between the Lehner and Nathan laboratories. 
2.6.2 gRNA library lentivirus 
Lentivirus was produced using the standard protocol in 14 cm plates of HEK 293T cells by the 
triple transfection of the gRNA library plasmid pool and the packaging vectors pCMVΔR8.91 
and pMD.G in a ratio of 10:7:3. The viral supernatant was harvested 48 h post-transfection, 
filtered through a 45 µm filter and immediately frozen in aliquots of 5 ml and 1 ml to be stored 
at -80oC. 
To determine the viral titer of the gRNA library viral supernatant, a 1ml aliquot of the frozen 
supernatant was thawed and a range of volumes were added wells containing 1 million cells 
to be used in the screen. Plates were spun at 1800 rpm for 1 h. The transduction efficiency 
was determined 48 h post transduction. For the GeCKO v2 library, the percentage of 
puromycin resistant cells was determined. For the Bassik and ubiquitiome gRNA libraries, 
transduction efficiency was measured by assessing the percentage of cells expressing the 
mCherry and BFP markers respectively. The volume of viral supernatant required to achieve 
a multiplicity of infection (m.o.i.) of approximately 0.3 was noted for use in forward genetic 
screens. 
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2.6.3 Fluorescence based CRISPR screens 
For the CRISPR screen with the GeCKO library in Figure 3.2 1x108 KBM7 cells were transduced 
at an m.o.i. of 0.3. For the CRISPR screens with the GeCKO library in Figure 4.2 and Figure 4.6 
5 x 107 HeLa cells were transduced at an m.o.i. of 0.3. For the CRISPR screens with the Bassik 
library in Figure 5.3 and Figure 5.5 1 x 108 HeLa cells were transduced at an m.o.i of 0.3. For 
the ubiquitome library screens in Figure 7.3 and Figure 7.6 1 x 107 HeLa cells were transduced 
at an m.o.i. of 0.3. 
The cell line chosen to use in a CRISPR screen was transduced with pHRSIN-PSFFV-Cas9-PPGK-
HygromycinR. Transduced cells were selected with hygromycin treatment. To confirm Cas9 
activity in the screen cell line, the Cas9-expressing cells were transduced the pKLV vector 
encoding a β-2-microglobulin (B2M)-targeting gRNA. Transduced cells were selected with 
puromycin. MHC-I surface expression was assessed five days post-transduction by flow 
cytometry. B2M knockout results in the loss of MHC-I surface expression. The B2M gRNA 
typically results in >90% population with low MHC-I surface expression, although there is 
some variation between cell types. 
For KBM7 cells, transductions were performed in 24-well plates with 1x106 cells per well. For 
HeLa cells, transductions were performed in 6-well plates with 1x106 cells per well. All plates 
were spun for 1 h at 1800 rpm. Transduced cells were selected with 1 µg/ml puromycin 24 
hours post-transduction. The puromycin concentration was increased to 2 µg/ml 48 hours 
post-transduction. Puromycin treatment was maintained until the first FACS selection as 
recommended by the Zhang laboratory (Shalem et al. 2014) 
A first FACS selection was performed on day 8 post-transduction to select gene knockouts 
with altered expression of the fluorescent reporter. Typically, 1x108 cells were processed by 
the FACS machine to select the top 0.6% reporter-expressing cells. For the ubiquitome screens 
in Figure 7.3 and Figure 7.6 2x105 selected cells were pelleted and genomic DNA extracted 
immediately after sorting, using the Quick-gDNA MicroPrep kit (Zymo Research). For the 
genome-wide screens, the selected cells were expanded in culture, typically for eight days, 
before a second FACS selection was performed to purify the population of mutants. The cells 
selected in the second sort were expanded in culture until 5x106 cells could be harvested for 
genomic DNA extraction using the Gentra Puregene kit (Qiagen). 
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2.6.4 DNA preparation and sequencing 
To amplify the gRNA sequences from extracted genomic DNA, two PCR steps were performed. 
The first PCR amplified the gRNAs using 50 separate 100 µl reactions with 4 µg genomic DNA 
in each reaction using Q5 High-Fidelity DNA Polymerase (NEB). Primer sequences in appendix 
2. For each sample, the PCR products were pooled. A tenth was taken and purified by 
QIAquick PCR Purification (Qiagen). A second PCR was performed to attach Illumina adaptors 
to barcode the samples. This was done with a single 100 µl reaction for each sample using 1 
ng of prodct from PCR 1. Amplification was carried out using 12, 16 or 20 cycles. The products 
from PCR 2 were purified using Ampure XP beads (Agencourt). The sample with the smallest, 
clearly defined peak on a Agilent Bioanalyser DNA1000 Chip (Agilent) was selected for 
sequencing. Samples from genome-wide CRISPR screens were sequenced on the Illumina 
HiSeq platform; samples from the ubiquitome CRISPR screens were sequenced on the 
Illumina MiniSeq platform. 
2.6.5 CRISPR screen data analysis 
Illumina HiSeq data as analysed through a custom analysis pipeline developed by Richard 
Timms. Using the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) the raw cram files 
were converted into fastq files. The 3’ end of the resulting reads were trimmed to the leave 
the gRNA sequences, and then mapped to an index of the gRNA sequences in the relevant 
gRNA library using Bowtie 2 (Langmead et al. 2009). The resulting gRNA counts were analysed 
using the RSA algorithm using the default settings (König et al. 2007). 
 
2.7 Biochemistry 
2.7.1 Cell Lysis 
For α-UBE2G2 and α-UROD immunoblots, cells were lysed in 1% SDS plus 1:100 Benzonase 
(Sigma-Aldrich) in TBS for 30 min at room temperature. The lysates were then heated to 70oC 
in SDS sample buffer for 10 min. 
For all other immunoblots and immunoprecipitations, cells were lysed in 1% digitonin plus 10 
mM iodoacetate (IAA), 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and Roche complete 
protease inhibitor, as well as 10 mM N-ethylmaleimide for ubiquitination assays, for 30 min 
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at 4oC. Lysates were spun for 10 min at 13000 xg to remove insoluble material. The 
supernantant was then processed for immunoblot or immunoprecipitation. 
2.7.2 Immunoprecipitation 
Post-nuclear supernatants where made up to 1 ml with 0.5% digitonin and then precleared 
with IgG Sepharose for 1 h on a rotator at 4oC. HMGCR was immunoprecipitated using rabbit 
α-HMGCR (Abcam, ab174830) and protein A-sepharose overnight at 4oC on a rotator. 
RNF145-V5 was immunoprecipitated using mouse α-V5 (Abcam, ab27671) and protein A-
sepharose overnight at 4oC on a rotator. Endogenous RNF145 was immunoprecipitated using 
rabbit α-RNF145 (ProteinTech, 24524-I-AP) and protein A-sepharose for 4 h at 4oC on a 
rotator. 
After one wash with 0.5% digitonin and at least five washes with 0.1% digitonin, samples were 
eluted by heating in 2x SDS sample buffer. HMGCR and RNF145 immuno-precipitations were 
eluted by heating at 50oC for 15 min, whereas RNF145-V5 immunoprecipitations were eluted 
by heating at 65oC for 15 min. 
2.7.3 SDS-PAGE 
Lysates and immunoprecipitates were separated by SDS-PAGE. Tris-glycine acrylamide gels 
were made using the following recipe: 
Resolving gel    Stacking gel 
0.375 mM Tris-HCl pH 8.8  0.125 mM Tris-HCl pH 6.8 
0.1% SDS    0.1% SDS 
0.1% APS    0.1% APS 
6-12% acrylamide   1.8% acrylamide 
 
2.7.4 Immunoblotting 
Polyvinylidene fluoride (PVDF) membranes (Millipore) were incubated in methanol before 
soaking in transfer buffer. Proteins separated by SDS-PAGE were transferred onto PVDF 
membrane at 20V for 1 h using a Bio-Rad Semi-Drey Transfer Cell. Membranes were blocked 
with 5% milk in PBS-T (PBS plus 0.2% Tween-20) for 1 h at room temperature and probed with 
primary antibody in 5% milk in PBS-T overnight at 4oC. After three washes of 5 min in PBS-T, 
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membranes were probed with secondary goat anti-mouse or anti-rabbit horseradish 
peroxidase (HRP) secondary antibody (Jackson) in 5% milk in PBS-T for 1 h at room 
temperature. Membranes were washed at least 5 times for 5 min with PBS-T before 
visualising reactive bands with ECL, West Pico or West Dura (Thermo Fisher Scientific). 
To visualise ubiquitinated HMGCR with VU-1 antibody, after protein transfer onto a PVDF 
membrane, the PVDF membrane is treated with 0.5% glutaraldehyde/PBS for 20 min, washed 
with PBS and then blocked in 5% mile in 0.1% Tween-20 in PBS. 
 
2.8 Mass spectrometry 
2.8.1 Gel-based sample preparation 
Eluates from RNF145-V5 immunoprecipitations (Table 6.1) were run approximately 1 cm into 
a polyacrylamide gel (NuPage, Invitrogen). Subsequently the gel pieces containing samples 
were excised and cut into small pieces. Gel pieces were washed by dehydration in 100% ACN 
and rehydration with 50 mM TEAB 3x. To reduce and alkylate, gel pieces were rehydrated in 
10 mM TCEP and 20 mM IAA and incubated at room temperature in the dark for 30 min, 
followed by an additional wash. Gel pieces were finally dehydrated in 100% ACN followed by 
a short additional drying step in a vacuum centrifuge before rehydration in a solution of 50 
mM TEAB and 10 ng/μl Trypsin and incubation on ice for 30 min. Excess trypsin solution was 
removed and replaced with 50 mM TEAB before digestion overnight at 37oC.  
2.8.2 Bead-based sample preparation 
To 100 μl eluates from endogenous RNF145 immunoprecipitation (Figure 6.9) 10 μl “SP3 
beads” were added and the samples were processed similarly to Hughes et al (PMID: 
25358341) with minor modification. First, eluate were reduced and alkylated by adding 
TCEP/IAA (Tris(2-carboxyethyl)phosphine hydrochloride / Iodoacetamide) to a final 
concentration of 10 mM and 20 mM respectively and incubated at RT in the dark for 30 min 
shaking at 1000 rpm. Following alkylation 10 μl formic acid (FA) and 110 μl Acetonitrile (ACN) 
were added and incubated at RT for 10 min. Then after standing on a magnetic rack for 2mins 
supernatant was removed and the beads washed vigorously with the following solvents, 
waiting for beads to collect on the magnet after each wash: 180 µl ACN, 70% EtOH X2, ACN. 
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The final acetonitrile wash was removed and the tubes briefly centrifuged and the replaced 
on the magnetic rack, the final few microliters of ACN were then removed.  SP3 beads were 
then suspended in 30 µl of 50mM HEPES pH 8.5/0.1% Sodium Deoxycholate (SDC) containing 
250 ng of trypsin. Beads were then incubated for 16 h at 37oC in a Thermomixer with a heated 
lid, shaking at 1200 rpm. Digests were then made up to 100uL with 50mM HEPES and acidified 
with 3 ul 10% TFA to precipitate SDC. SDC precipitates were removed by two phase 
partitioning by adding 500 µL Ethyl Acetate, thorough vortexing, centrifugation (15’000 g, 5 
min) and removal of the lower phase. Cleaned up samples were dried in a vacuum centrifuge 
and resuspended in 10 µl 5% DMSO/1% TFA for LC-MS analysis. 
2.8.3 LC-MS/Data Analysis 
LC-MS analysis was performed by a revered phase nano-chromatography system interfaced 
via an electrospray ionization source with an Orbitrap Fusion spectrometer in a 1 h analysis 
per sample. Raw data were searched against the Uniprot Human reference proteome by an 
implementation of MASCOT within Proteome Discover ver 2.1 (PD). A peptide and protein 
FDR threshold of <0.01 was set and peptides were grouped into protein according to the 
minimum parsimony principle. Proteins were quantified using the PD node “precursor ions 
quantifier” which is an implementation of the Hi3 method of label free quantification. 
 
 
Unless otherwise stated, experiments were performed once.
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3.0 Results summary 
The layout of my thesis is described below: 
Chapter 3, I demonstrate that gene-trap mutagenesis and genome-wide CRISPR knockout 
screens are equally effective at identifying factors required for MHC-I ERAD in KBM7 cells. The 
parallel forward genetic screens both identify a requirement for TXNDC11 in glycoprotein 
ERAD. To complete the story, I include work performed by collaborators who found TXNDC11 
to be an ER-localised disulphide reductase that acts on a component of the ERAD machinery. 
Chapters 4 and 5, I performed a series of genome-wide CRISPR screens using a fluorescently-
tagged exogenous HMG-CoA Reductase (HMGCR) reporter and then an endogenous HMGCR-
Clover knock-in to identify the E3 ubiquitin ligase for HMGCR. These screens identified the 
poorly characterised ERAD E3 ligase RNF145. The loss of RNF145 resulted in a partial loss of 
HMGCR reporter degradation, however I did not detect a difference in the degradation of 
endogenous, untagged HMGCR. 
Chapter 6, I show that the E3 ligases gp78 and RNF145 are functionally redundant in HMGCR 
degradation. The combined loss of gp78 and RNF145 results in a pronounced block in the 
sterol-induced degradation and ubiquitination of HMGCR. However, the presence of either 
E3 ligase is sufficient for efficient HMGCR degradation. I demonstrate that RNF145 interacts 
with both Insig proteins independent of the sterol environment and I observed an interaction 
between RNF145 and HMGCR by mass spectrometry that is enhanced by sterols and 
proteasome inhibition. 
Chapter 7, I use a focused E3 ligase CRISPR screen to identify a role for Hrd1 in HMGCR 
degradation. The combined loss of all three ligases (gp78, RNF145 and Hrd1) is required to 
completely block the sterol-induced degradation of HMGCR. However, the loss of Hrd1 alone 
or in combination with either gp78 or RNF145 does not inhibit the sterol-induced degradation 
of HMGCR.  
I present a model for the sterol-induced degradation of HMGCR in which gp78 and RNF145 
are partially redundant, primary E3 ubiquitin ligases for HMGCR that are recruited to HMGCR 
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by the Insig proteins at high sterol levels. In the absence of both gp78 and RNF145, Hrd1 acts 
as a secondary E3 ubiquitin ligase to mediate HMGCR degradation. 
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Chapter 3: A genetic dissection of 
mammalian ERAD through comparative 
haploid and CRISPR forward genetic screens 
 
3.1 Introduction 
Forward genetic screens in human cells have been significantly hindered by the difficulty in 
recovering bi-allelic knockouts. A major advance by the laboratory of Thijn Brummelkamp 
used a retroviral gene-trap vector in the near-haploid KBM7 cell line (Carette et al. 2009). The 
Lehner laboratory has adapted this technology to perform fluorescence-based forward 
genetic screens to investigate a range of cellular processes (Duncan et al. 2012, Timms et al. 
2013, van den Boomen et al. 2014, Tchasovnikarova et al. 2015). At the start of my PhD 
project, gene-trap mutagenesis screens in the near-haploid KBM7 cell line were the gold 
standard in forward genetic screens in human cells. 
Precise genome editing using programmable nucleases is a transformative technology for cell 
biology research (Kim and Kim 2014). CRISPR/Cas9 technology is a major advance with a wide 
range of applications (Hsu, Lander, and Zhang 2014). The CRISPR/Cas9 system offers a rapid 
and efficient method to generate bi-allelic mutations and therefore gene knockouts. By using 
a large library of gRNAs to target the Cas9 nuclease to all annotated genes, CRISPR/Cas9 
technology can be used to perform genome-wide forward genetic screens (Shalem et al. 2014, 
Wang et al. 2014, Koike-Yusa et al. 2014). 
A major aim of the first part of my thesis project was to directly compare the effectiveness of 
genome-wide CRISPR knockout screens against retroviral gene-trap mutagenesis screens.  
Previous work in the Lehner laboratory has shown that the MHC-I allele HLA-A2 is degraded 
by ERAD via the canonical glycoprotein control pathway (Burr et al. 2011, Burr et al. 2013). I 
chose to perform my forward genetic screens on MHC-I ERAD because I wanted to use a 
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system that was familiar to the Lehner laboratory with multiple known components to act as 
positive controls in my screens. 
 
3.2 Results 1 
3.2.1 A fluorescent reporter system to monitor MHC-I ERAD 
I first set out to perform a gene-trap mutagenesis screen to identify factors required for the 
ERAD of MHC-1. To enable a fluorescence-based phenotypic selection, KBM7 cells were 
transduced with a lentiviral construct encoding a green fluorescent protein (GFP)-tagged 
MHC-I allele (HLA-A2) (Figure 3.1A). The transduced population was single cell cloned and a 
clone was identified with low GFP-HLA-A2 expression. Depletion of SEL1L, a known 
component required for MHC-1 ERAD, by RNA interference showed a significant increase in 
GFP fluorescence, demonstrating that GFP-HLA-A2 was being degraded by ERAD in this clone 
(Figure 3.1B). 
 
Figure 3.1 Establishing a fluorescent reporter for MHC-I ERAD. (A) A Schematic of the lentiviral 
construct encoding the GFP-HLA-A2 fusion protein. Expression is driven by the powerful spleen focus-
forming virus (SFFV) promoter. (LTR, long-terminal repeat; WPRE, Woodchuck hepatitis virus 
posttranscriptional regulatory element). (B) Identifying a KBM7 clone expressing GFP-HLA-A2 that is 
degraded by ERAD. The KBM7 clone was transduced with a lentiviral construct expressing a non-
targeting or SEL1L-targeting shRNA. Transduced cells were selected with puromycin treatment and 
GFP fluorescence was measured by flow cytometry.  
 
Chapter 3: A genetic dissection of mammalian ERAD through comparative haploid and CRISPR 
forward genetic screens 
 
71 
 
3.2.2 A haploid gene-trap mutagenesis screen for MHC-I ERAD 
To perform the gene-trap mutagenesis screen, 108 GFP-HLA-A2 KBM7 cells were transduced 
with a gene-trap retrovirus carrying a mCherry marker. I cultured the library to allow the 
generation of gene knockouts. A minimum of 108 cells were kept in culture to ensure that 
representation of the library was maintained. After 8 days, I performed a first round of 
selection by FACS to isolate mCherrypositive (retroviral gene-trap transduced) GFPhigh cells. The 
frequency of gene knockouts that results in the loss of MHC-I ERAD is very low in a library of 
KBM7 cells mutagenised by a retroviral gene-trap vector. It is extremely difficult to see a 
distinct population of cells with the desired phenotype during a first sort and so the 0.6-0.8% 
of cells with highest GFP expression are typically selected. The selected cells were expanded 
for 7 days before a second round of FACS. The resultant population contained a significant 
enrichment for GFPhigh cells (Figure 3.2B).  
Genomic DNA was extracted from the selected GFPhigh cells and a library of the original 
mutagenised cells that had not been selected and had grown for the same amount of time. 
The retroviral integration sites in each population were identified by linear amplification-
mediated PCR (LAM-PCR) and sequencing on the Illumina HiSeq platform. Retroviral gene-
trap integration sites were analysed for their ability to inactivate the gene into which they 
had integrated. Analysing the enrichment of inactivating insertions in the FACS selected cells 
compared to the unselected library identified a suite of candidate genes (Figure 3.2C).  
The screen was very successful in identifying many hits that could be grouped into several 
functional classes. The largest group contains genes previously shown to be required for 
ERAD, including the mannosidases EDEM1 and EDEM2, the E3 ubiquitin ligase Hrd1 (gene 
name is SYVN1), the Hrd1 binding partners SEL1L and DERLIN2, and the E2 conjugating 
enzymes UBE2J1 and UBE2G2 (Figure 3.2C) (Burr et al. 2011, Burr et al. 2013). The second 
functional group of candidate genes contained factors required for N-glycosylation. This 
group included all three members of the dolichol-phosphate-mannose (DPM) synthase 
complex (DPM1, DPM2 and DPM3), the complex required to generate mannosyl donors 
(Maeda et al. 2000). The mannosyltransferase enzymes, ALG3 and ALG9 were also identified. 
The ERAD of glycoproteins is initiated by the trimming of mannose residues on N-glycans 
(Ninagawa et al. 2014). The loss of the mannosyltransferases identified in the gene-trap 
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mutagenesis screen will result in a glycan moiety that does not enter the mannose-trimming 
cycle and so preventing the recognition of GFP-HLA-A2 as a glycoprotein ERAD substrate. The 
third class of candidate genes consists of known components of the non-sense mediated 
decay pathway (Figure 3.2C). The identification of these genes suggests that the GFP-HLA-A2 
mRNA is also being targeted for degradation. 
The screen also identified two uncharacterised genes, PRR7-AS1 and TXNDC11. TXNDC11 is 
an uncharacterised protein disulphide isomerase (PDI) family member, also known as EFP1, 
and was originally identified as a binding partner of dual oxidase 1 (DUOX1), a hydrogen 
peroxide-generating enzyme (Wang et al. 2005). Richard Timms later validated TXNDC11 and 
a selection of other hits using CRISPR-mediated gene disruption (Figure 3.2D). For each gene, 
a population of GFPhigh cells could be seen by flow cytometry following CRISPR-mediated 
gene-disruption (Figure 3.2D). The use of a single gRNA against a gene results in a mixed 
population of knockouts cells and cells expressing a functional protein because in some cases 
non-homologous end joining will result in an insertion or deletion that does not result in a 
frameshift mutation.  
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Figure 3.2 A haploid gene-trap mutagenesis forward genetic screen identifies genes required for 
glycoprotein ERAD. (A) A schematic overview of the gene-trap mutagenesis screen. (B) GFP-HLA-A2 
KBM7 cells were transduced with a retroviral gene-trap vector carrying a mCherry marker, GFP
high
 cells 
were isolated by two rounds of FACS. (C) Bubble plot illustrating hits from the screen. Bubble size is 
proportional to the number of independent inactivating gene-trap integrations (number in 
parentheses). (D) CRISPR knockout validation of candidate genes. GFP-HLA-A2 cells were transduced 
with Cas9 and gRNA targeting a candidate gene. Increased GFP-HLA-A2 was detected by flow 
cytometry (Richard Timms). 
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3.2.3 A parallel genome-wide CRISPR knockout screen for MHC-I ERAD 
The GFP-HLA-A2 KBM7 clone identified in Figure 3.2A had proven to be an extremely powerful 
tool. I identified many candidate genes when I used this clone in a gene-trap mutagenesis 
screen, providing a benchmark against which I could compare a genome-wide CRISPR 
knockout screen. I transduced the GFP-HLA-A2 clone with a lentiviral reporter encoding the 
nuclease Cas9 and selected transduced cells. Before performing the screen, I wanted to 
ensure that the Cas9 expressed in the clone could efficiently generate gene knockouts. A 
gRNA targeting β2-microglobulin (B2M) was transduced into the Cas9-expressing GFP-HLA-
A2 KBM7 cells. Cell surface MHC-I expression was analysed 5 days post-transduction by flow 
cytometry, demonstrating efficient CRISPR-mediated gene disruption of B2M. 
The GeCKO v2 library, from Feng Zhang’s laboratory, was one of the first genome-wide CRISPR 
libraries made available via Addgene (Sanjana, Shalem, and Zhang 2014). The GeCKO v2 
library contains 123,411 gRNAs targeting 19,050 genes. Each gene is targeted by 6 gRNAs and 
the library also includes non-targeting controls (Sanjana, Shalem, and Zhang 2014). Lentivirus 
was produced by transfecting HEK293T cells with the pooled gRNA plasmids and standard 
lentivirus packaging vectors. The viral supernatant was titrated onto GFP-HLA-A2 Cas9 cells 
to determine the volume of supernatant required to infect 30% of the cells. The gRNA 
expression plasmid encodes a puromycin resistance gene enabling the multiplicity of infection 
(M.O.I.) to be determined by calculating the percentage of cells that survive puromycin 
treatment. A M.O.I. of 0.3 is desirable to ensure that each cell only receives a single gRNA. 
To perform the genome-wide CRISPR knockout screen, 108 GFP-HLA-A2 cells were transduced 
at a M.O.I. of 0.3. This means that 3x107 cells were transduced with gRNA library virus. As the 
library contains 123,411 gRNAs, the coverage of the screen was 243 cells/gRNA. The library 
was treated with puromycin to select transduced cells. Puromycin selection was maintained 
until the first sort (on day 8) following the advice of the Zhang laboratory (Shalem et al. 2014). 
I enriched mutant GFPhigh cells using two sequential rounds of FACS as described for the gene-
trap mutagenesis screen. A significantly greater enrichment was observed after the first sort 
in the CRISPR screen compared to the gene-trap mutagenesis screen and a highly enriched 
population of GFPhigh cells was obtained from the second sort (Figure 3.3C). 
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Figure 3.3 A parallel genome wide CRISPR knockout screen identifies genes required for 
glycoprotein ERAD. (A) Cas9-expressing GFP-HLA-A2 KMB7 cells were transduced with a B2M-
targetting gRNA to confirm Cas9 activity. B2M knockout efficiency was determined by 
measuring MHC-I cell surface expression by flow cytometry five days post-transduction. B2M 
gRNA lentiviral construct also expressed BFP to allow selection of transduced cells. (B) 
Schematic overview of the CRISPR screen. (C) Cas9-expressing GFP-HLA-A2 KBM7 cells were 
transduced with the GeCKO v2 gRNA library. GFP
high
 cells were selected by two sequential 
rounds of FACS. (D) The RSA algorithm identified candidate genes that were significantly 
enriched in the selected cells. 
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Genomic DNA was extracted from the selected GFPhigh population together with the library of 
unselected mutagenised cells grown over the same time period. The gRNA sequences in each 
population were amplified by PCR using primers that bind to the integrated lentiviral 
construct. The abundance of the gRNAs in each population was determined by deep 
sequencing using the Illumina HiSeq platform. The RSA algorithm was then used to identify 
candidate genes (Figure 3.3D) (König et al. 2007). This revealed that the CRISPR screen was 
successful at identifying candidate genes that were grouped into the same functional 
classifications as the hits in the gene-trap screen. 
To determine whether a gene is a hit in this CRISPR screen, the degree of enrichment of each 
of the 6 gRNAs targeting that gene must be considered. The RSA algorithm first assigns each 
gRNA with an activity score based on the enrichment of the normalised count of the gRNA in 
the selected cells compared to the unselected library (Table 3.1). The activity scores for all 
gRNAs targeting a gene are then used to determine a p-value for the probability that the 
enrichment is statistically significant. Three example genes are given in Table 3.1. Three 
gRNAs targeting DPM3 are very highly enriched, their normalised count increased by two 
orders of magnitude following the two sorts, so these are assigned a high activity score 
(greater than 2). Two of the other gRNAs targeting DPM3 are modestly enriched, their 
normalised count increased by an order of magnitude, so these are assigned a high activity 
score (between 1 and 2). The last gRNA targeting DPM3 is only slightly enriched and so this is 
assigned a low activity score (less than 1). Therefore, there are 3 very active, 2 active and 1 
weakly active gRNAs targeting DPM3 and so DPM3 was assigned a very low p-value. In 
contrast, there are 2 very active, 2 weakly active and 2 inactive gRNAs targeting Derlin-2, 
which was therefore assigned a moderate p-value. If I consider the gRNAs targeting HMG-CoA 
Reductase, there is a single gRNA that is reasonably enriched, one diluted and the remaining 
four gRNAs are not detected in the selected cells. The inactivity of the other 5 gRNAs strongly 
suggests that an off-target effect is responsible for the enrichment of gRNA #21680 against 
HMG-CoA Reductase. HMG-CoA Reductase was therefore assigned a high, insignificant p-
value. 
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Table 3.1 CRISPR screen analysis. Break down of gRNA normalised count, RSA activity score 
and RSA p-value for DPM3, DERL2 and HMGCR from screen in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Library Sort
HGLibA_13862 1.29 7.44 0.76
HGLibA_13863 4.94 508.21 2.01
HGLibA_13864 1.45 39.63 1.44
HGLibB_13841 1.97 449.04 2.36
HGLibB_13842 3.72 576.94 2.19
HGLibB_13843 2.62 90.43 1.54
HGLibA_12997 24.21 4952.74 2.31
HGLibA_12998 2.04 0.00 0.00
HGLibA_12999 3.51 11.87 0.53
HGLibB_12979 7.12 1591.89 2.35
HGLibB_12980 8.97 27.53 0.49
HGLibB_12981 0.12 0.00 0.00
HGLibA_21707 1.26 0.00 0.00
HGLibA_21708 9.53 0.34 -1.45
HGLibA_21709 9.37 0.00 0.00
HGLibB_21679 2.18 0.00 0.00
HGLibB_21680 15.50 366.62 1.37
HGLibB_21681 1.83 0.00 0.00
1.3HMGCR
10.065DPM3
Normalised count
Gene gRNA_ID Activity Signifiicance (-logP)
5.047DERL2
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3.2.4. Gene-trap mutagenesis and genome-wide CRISPR knockout screens yield comparable 
results in KBM7 cells 
Both genome-wide screening methods identified 19 candidate genes, with 16 (>70%) shared 
hits and 3 hits unique to each (Figure 3.4A). This high concordance rate demonstrates that 
the two technologies are comparable and both are very effective at identifying candidate 
genes.  
CRISPR-mediated gene disruption was used to knockout four of the genes identified by a 
single screen. The loss of each component resulted in an increase in GFP-HLA-A2 expression 
(Figure 3.4B). This shows that SMG6 and UPF2 are false negatives in the CRISPR screen. All 6 
gRNAs against each gene were detected in the library, however they failed to be enriched by 
the iterative sorting process (Figure 3.4C). This strongly suggests that gRNAs in the library 
targeting SMG6 and UPF2 are inefficient at generating gene knockouts. At the same time, 
ALG12 and SMG7 are false negatives in the gene-trap mutagenesis screen. Inactivating gene-
trap integrations were not enriched in SMG7. There appears to be a small enrichment in 
inactivating gene-trap integrations in ALG12, however ALG12 falls below the cut-off for 
statistical significance (Figure 3.4D). The low number of total integrations into ALG12 suggests 
that ALG12 might lie in a relative ‘cold-spot’ for retroviral integration. Neither SMG7 or ALG12 
are located in a section of diploid chromosome in KBM7 cells. 
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Figure 3.4 Gene-trap mutagenesis and genome-wide CRISPR knockout screens yield comparable 
results in KBM7 cells. (A) Overlap of the screen hits from the gene-trap mutagenesis and CRISPR 
screens. (B) CRISPR validation of genes only identified in one screen. Cas9-expressing GFP-HLA-A2 cells 
were transduced with a lentiviral construct expressing a candidate gene targeting gRNA. GFP 
expression was determined by flow cytometry (Richard Timms). (C) Illumina sequencing data from the 
CRISPR screen relating to UPF2 and SMG6 shows all gRNAs were detected in the library but only one 
gRNA was enriched for each gene in the selected cells. (D) Illumina sequencing data from the gene-
trap mutagenesis screen relating to ALG12 and SMG7.  
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Despite yielding very similar results the mutagenic coverage of the two technologies was 
remarkably different (Figure 3.5). The CRISPR screen was limited to the 19,050 protein coding 
genes targeted by the gRNA, whereas the gene-trap mutagenesis screen could target 32,000 
open reading frames. The mutagenic coverage of the CRISPR screen appears to be much more 
even than the gene-trap screen. However, Figure 3.5 shows gRNA count and does not reveal 
any information regarding a gRNA’s effectiveness at generating a gene knockout and the 
integration of the retrovirus is biased towards actively expressed genes (Carette, Guimaraes, 
et al. 2011). 
 
 
 
Figure 3.5 GeCKO v2 RNA library provides more even mutagenic coverage than retroviral 
gene-trap mutagenesis. The number of unique inactivating integration sites in each open 
reading frame and the number of times each gRNA was detected by Ilumina sequencing. 
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3.3 Results 2 
The work presented in the section 3.3 is not my own work and is included to complete the 
TXNDC11 story. This section is from a collaboration between Richard Timms and Iva 
Tchasovnikarova from Paul Lehner’s laboratory and Lea Christensen from Lars Ellgaard’s 
laboratory at the University of Copenhagen, Denmark. 
 
3.3.1 TXNDC11 is an ER-resident thioredoxin domain protein 
TXNDC11, an uncharacterised PDI family member, was identified by both the gene-trap 
mutagenesis and CRISPR screens. TXNDC11 had been previously identified in a yeast two-
hybrid screen for dual oxidase 1 (DUOX1) binding partners (Wang et al. 2005). However, 
nothing was known about the function of TXNDC11.  
TXNDC11 is predicted to contain a single transmembrane domain, five thioredoxin-like (Trx) 
domains and a coiled-coil region (Figure 3.6A and 3.6B) (Webb and Sali 2014, Yang et al. 2015, 
Kelley et al. 2015). PDI-family proteins use two catalytic cysteine residues in a CXXC motif to 
catalyse the oxidation or reduction of disulphide bonds (Chivers, Laboissière, and Raines 
1996). Only Trx5 of TXNDC11 contains a CXXC (CGFC) motif, whereas Trx1 contains a CXXS 
(CGQS) motif and the remaining three Trx domains do not contain any active site cysteine 
residues. 
The localisation of TXNDC11 was investigated by immunofluorescence (Figure 3.6C). Co-
localisation of epitope-tagged TXNDC11 with the ER-resident protein Calnexin suggested an 
ER localisation for TXNDC11. This was supported by the sensitivity of endogenous TXNDC11 
to Endoglycosidase H (Endo H) digestion (Figure 3.6D).  
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Figure 3.6 TXNDC11 localises to the ER (A) Schematic of predicted TXNDC11 protein 
architecture. (B) Schematic depicting predicted domains of TXNDC11. (C) FLAG-tagged 
exogenous TXNDC11 co-localises with calnexin (ER) as assessed by immunofluorescence. (D) 
Endogenous TXNDC11 is sensitive to EndoH digestion confirming ER localisation. 
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3.3.2 Redox activity of TXNDC11 is required for GFP-HLA-A2 degradation 
TXNDC11 knockout clones were derived from the GFP-HLA-A2 KBM7 clone using CRISPR-
mediated gene disruption (Figure 3.7A). As expected, each TXNDC11 knockout clone had an 
elevated level of GFP-HLA-A2 expression (Figure 3.7B). Re-expression of wild type TXNDC11 
rescued GFP-HLA-A2 degradation (Figure 3.7C). To determine whether a redox function of 
TXNDC11 was required for GFP-HLA-A2 degradation, a TXNDC11 mutant was cloned in which 
Trx5’s catalytic cysteines were mutated to alanine (AXXA).  The Trx5 AXXA TXNDC11 mutant 
was unable to rescue GFP-HLA-A2 degradation (Figure 3.7C). Expression of Trx5 AXXA 
TXNDC11 was confirmed by immunoblot, therefore implicating a redox function for TXNDC11 
(Figure 3.7D). A Trx1 AXXA TXNDC11 mutant could rescue GFP-HLA-A2 degradation, 
confirming that Trx1 is not an active thioredoxin domain (Figure 3.7C). 
 
3.3.3 TXNDC11 is a disulphide reductase 
We next sought to determine whether TXNDC11 catalyses the oxidation or reduction of 
disulphide bonds. The Trx5 domain was expressed in E. coli and purified by Lea Christensen 
(Figure 3.8B). An AMS shift assay estimated a reduction potential of between -234 mV and -
242 mV for the Trx5 domain. Comparing this value to the reduction potential of other PDI-
family members indicates that TXNDC11 is a disulphide reductase  (Frickel et al. 2004, 
Chambers et al. 2010, Hagiwara et al. 2011). 
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Figure 3.7 TXNDC11 redox activity is required for efficient ERAD (A) TXNDC11 knockout 
clones from GFP-HLA-A2 KBM7 cells transduced with Cas9 and TXNDC11-targeting gRNA. 
Absence of TXNDC11 protein was confirmed by immunoblot (B) GFP-HLA-A2 expression in 
TXNDC11 knockout clones was assessed by flow cytometry. (C) Re-expression of TXNDC11 in 
TXNDC11 knockout cells. TXNDC11 knockout cells were transduced with a lentiviral construct 
encoding wild type, Trx1 (AXXA) or Trx5 (AXXA) TXNDC11. GFP-HLA-A2 expression was 
measured by flow cytometry. (D) Immunoblot analysis confirmed expression of Trx5 (AXXA) 
mutant TXNDX11. 
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Figure 3.8 TXNDC11 is a disulphide reductase. (A) A Ubiquitin (Ub)-HIS-Trx5 domain of TXNDC11 
fusion protein was expressed in E. coli. A non-active site cysteine was mutated (C743S) to prevent 
disulphide-mediated oligomerisation. (B) Trx5 domain was purified by Ni-NTA affinity 
chromatography, TEV protease cleavage and gel filtration (T, total protein after expression; P, pellet 
after lysis; S, supernatant after lysis; FT, flow-through; W, wash; E, elution. Numbers indicate different 
fractions). (C) Redox titration of Trx5 (C743) domain with lipoic acid (DHLA/LA). The alkylating agent 
4-acetamido-4’maleimidylstilbene-2,2’-disulfonic acid (AMS) reacts with free thiol groups, adding 490 
Da per thiol. The oxidised and reduced forms of Trx5 can therefore be resolved on a polyacrylamide 
gel. Lipoic acid (DHLA/LA; reduction potential -290 mV) was used to titrate reducing conditions (Lees 
and Whitesides 1993) 
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3.3.4 TXNDC11 is required for the degradation of other ERAD substrates 
A selection of ERAD substrates were selected to determine whether TXNDC11 was required 
for the ERAD of proteins other than HLA-GFP-A2. Depletion of TXNDC11 by shRNA rescued 
expression of unassembled CD3 delta chain (CD3δ), unassembled T cell receptor alpha chain 
(TCRα) and the Null-Hong Kong (NHK) variant of alpha 1-antitrypsin, implicating a 
requirement for TXNDC11 in the ERAD of a range of substrates (Figure 3.9A).  
To determine whether the reductase activity of TXNDC11 acts on the ERAD substrate itself or 
a component of the ERAD machinery, two NHK mutants were cloned. In the first mutant, NHK 
(QQQ), all N-gylcosylation sites were removed (asparagine to glutamine). In the second 
mutant, NHK (C/S), the single cysteine residue in NHK was mutated to serine to prevent 
disulphide-bonded dimer formation (Ushioda et al. 2008). TXNDC11 depletion had little effect 
on NHK (QQQ), providing more evidence to place TXNDC11 in glycoprotein-ERAD (Figure 
3.9B). However, TXNDC11 depletion impaired the degradation of cysteine-free NHK (C/S) 
(Figure 3.9B). This suggests that TXNDC11 acts on a component of the ERAD machinery rather 
than the ERAD substrate. 
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Figure 3.9 TXNDC11 depletion inhibits the degradation of other ERAD substrates. (A) KBM7 
cell lines stably-expressing mCherry-tagged CD3δ, TCRα or NHK were transduced with a 
lentiviral construct encoding a TXNDC11-targeting or control shRNA. ERAD substrate 
expression was measured by flow cytometry. (B) KBM7 cell lines stably-expressing 
fluorescently-tagged wild type, non-glycosylated (QQQ) or cysteine-free (C/S) NHK were 
transduced with a lentiviral construct encoding a TXNDC11-targeting or control shRNA. NHK-
mCherry expression was measured by flow cytometry. (C) Efficient depletion of TXNDC11 by 
shRNA was confirmed by immunoblot. 
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3.3.5 TXNDC11 interacts with glycoprotein ERAD machinery 
We next sought to identify TXNDC11 interaction partners to further elucidate its function. 
Immunoprecipitation of endogenous TXNDC11 was performed followed by mass 
spectrometry analysis, with an immunoprecipitation from a TXNDC11 knockout clone to 
control for non-specific binding to TXNDC11 antibody and Protein A Sepharose. This identified 
six TXNDC11 binding partners (Figure 3.10A): the mannosidases EDEM2 and EDEM3, the 
oxidoreductase PDI, TXNDC5 and both subunits of the alpha-glucosidase complex (GANAB 
and GLU2B) (D'Alessio, Caramelo, and Parodi 2010). The co-immunoprecipitation of TXNDC11 
with GANAB, EDEM2, EDEM3 and PDI was confirmed by immunoblot (Figure 3.10B). We also 
observed an increase in EDEM2 and EDEM3 protein abundance in the absence of TXNDC11 
(Figure 3.11). EDEM2 and PDI were hits in both forward genetic screens, indicating that the 
interactions between TXNDC11 and EDEM2 and PDI are crucial for glycoprotein ERAD. 
 
Figure 3.10 TXNDC11 interacts with glycoprotein ERAD machinery. (A) TXNDC11-interacting 
partners were identified by mass spectrometry analysis following an immunoprecipitation of 
endogenous TXNDC11. (B) TXNDC11-interacting partners were validated by immunoblot. 
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3.11 Loss of TXNDC11 increases EDEM2 and EDEM3 expression. Immunoblot analysis of 
TXNDC11-interacting partners in TXNDC11 knockout clones. 
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3.4 Discussion 
The first part of my thesis project has demonstrated that genome-wide CRISPR knockout 
screens are as effective at identifying candidate genes in KBM7 cells as the previous gold-
standard in human forward genetic screens. David Sabatini’s laboratory have also reported a 
strong similarity in results from gene-trap mutagenesis and genome-wide CRISPR knockout 
screens (Wang et al. 2015). However, they did not identify any hits from chromosome eight 
in the gene-trap screen (as this chromosome is diploid) whilst the CRISPR screen did. 
It was not surprising when two groups demonstrated that CRISPR knockout screens were 
more effective than shRNA screens, as RNA interference screens were not the previous gold 
standard screening method (Morgens et al. 2016, Evers et al. 2016). 
 
3.4.1 Mutagenic potential of retroviral gene-trap versus genome-wide CRISPR library 
A major advantage of the retroviral gene-trap vector is the ability to target all accessible 
chromatin, although there is a bias towards actively expressed genes (Carette, Guimaraes, et 
al. 2011). In contrast, a genome-wide CRISPR knockout screen is limited to the pre-
determined genes targeted by the gRNAs that make up the library. Although not pursued as 
a part of this project, the gene-trap mutagenesis screen identified the antisense RNA encoded 
by PRR7-AS1, which is not targeted by the GeCKO v2 library. The gene-trap mutagenesis 
method also has the potential to disrupt regulatory elements in promoter regions of genes. 
A genome-wide CRISPR knockout screen is immediately limited by the gRNA library. The 
GeCKO v2 library contains six gRNAs per gene and gRNAs were designed on the basis of 
minimising gRNA off-target effects (Sanjana, Shalem, and Zhang 2014). Other gRNA libraries 
contain more gRNAs per gene and place more emphasis on gRNA efficacy. The Bassik library, 
which is used later in this thesis, and Sabatini’s activity-optimised library contain 10 gRNAs 
per gene (Wang et al. 2015, Morgens et al. 2017). The presence of more gRNAs for each gene 
means that genes that have a couple of ineffective gRNAs are more likely to be identified by 
the screen. The later gRNA libraries were designed using algorithms that prioritise gRNA 
efficacy, but exclude gRNAs with high off-target predictions (Wang et al. 2015, Morgens et al. 
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2017). It is likely that gRNA libraries will evolve to be increasingly effective as our 
understanding of CRISPR-mediated gene disruption develops. 
 
3.4.2 Practical considerations of gene-trap mutagenesis versus CRISPR screens 
The most significant advantage offered by CRISPR screens is the potential to perform forward 
genetic screens in human non-haploid cells, such as poly-ploid cancer cell lines and primary 
cells. The genome-wide CRISPR knockout screen presented in this Chapter was carried out in 
a haploid KBM7 clone. From this data, I cannot comment on whether the effectiveness of a 
CRISPR screen will diminish in diploid cells. 
The mutagenesis is more straightforward in a haploid gene-trap screen as a CRISPR screen 
requires the construction and propagation of a genome-wide gRNA library. However, the 
amplification of gRNA sequences in a CRISPR screen is significantly easier than the large-scale 
mapping of retroviral integration sites using LAM-PCR in a gene-trap mutagenesis screen. 
I chose to use genome-wide CRISPR knockout screens for the next section of my thesis project 
because of the significant practical advantage in preparing a CRISPR screen for sequencing.  
 
3.5 Summary 
In this Chapter, I used complementary forward genetic screens to identify factors required for 
MHC-I ERAD. There was a significant overlap between the results from the gene-trap 
mutagenesis and genome-wide CRISPR knockout screens, demonstrating that CRISPR screens 
are as effective as the previous gold-standard genome-wide screening method. Both screens 
identified a novel requirement for TXNDC11 in MHC-I ERAD. My collaborators went on to 
show that TXNDC11 is an ER-localised disulphide reductase that acts on another component 
of the ERAD machinery. 
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Chapter 4: A series of genome-wide CRISPR 
knockout screens to identify the E3 
ubiquitin ligase(s) for HMG-CoA Reductase 
 
4.1 Introduction 
The expression level of HMGCR is tightly regulated by the intracellular sterol environment at 
the level of transcription and post-translation. At low sterol levels, SCAP does not associate 
with the ER-resident Insig proteins and so the SCAP-SREBP heterodimer can traffic to the Golgi 
(Figure 1.1) (Yabe, Brown, and Goldstein 2002, Yang et al. 2002). SREBP is cleaved in the Golgi 
to release the active form of SREBP, which migrates to the nucleus and up-regulates the 
expression of its target genes, including HMGCR (Goldstein, DeBose-Boyd, and Brown 2006). 
The loss of the cholesterol-dependent interaction with SCAP results in the degradation of 
Insig1 by gp78 (Lee, Song, et al. 2006). Additionally, at low sterol levels, the Insig proteins do 
not associate with HMGCR and so HMGCR is not targeted for ERAD (Figure 1.3) (Sever, Song, 
et al. 2003, Sever, Yang, et al. 2003). 
At high sterol levels, the Insig proteins bind to SCAP to retain the SCAP-SREBP complex in the 
ER, thereby decreasing SREBP target gene expression (Figure 1.1) (Yabe, Brown, and Goldstein 
2002, Yang et al. 2002). The Insig proteins also associate with the transmembrane domain of 
HMGCR and act as a sterol-sensitive scaffold to recruit an E3 ubiquitin ligase complexes to 
HMGCR (Figure 1.3) (Sever, Song, et al. 2003, Sever, Yang, et al. 2003). Cholesterol protects 
Insig1 form gp78-mediated degradation (Lee, Song, et al. 2006). Whilst the role of Insigs as a 
sterol-sensitive scaffold is widely accepted, the identity of the E3 ubiquitin ligase responsible 
for the sterol-induced degradation of HMGCR is controversial (Jo et al. 2011, Tsai et al. 2012). 
This controversy is described in 1.2.2.4 on page 39. 
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In the first section of my thesis project, I successfully used genome-wide forward genetic 
screens to identify many ERAD components, including the E3 ubiquitin ligase required for the 
degradation of MHC-I (Chapter 3). Other members of the Lehner laboratory have also used 
forward genetic screens to identify ERAD E3 ligases (Stagg et al. 2009, van den Boomen et al. 
2014). Therefore genome-wide CRISPR knockout screens seemed a useful and unbiased 
approach to identify the E3 ubiquitin ligase for HMGCR. 
 
 
4.2 Results 
4.2.1 Establishing a fluorescent HMGCR reporter in HeLa cells 
I needed to establish a fluorescent reporter for HMGCR expression as the basis for my 
fluorescence-based phenotypic selection. My first approach was to use a fluorescently-tagged 
HMGCR exogenous transgene. The post-translational sterol-dependent regulation of HMGCR 
only requires the transmembrane domain of HMGCR (Gil et al. 1985). By replacing the 
catalytic domain of HMGCR with mCherry I generated a fluorescent reporter for HMGCR 
expression without disrupting the cellular cholesterol homeostasis by over-expressing the 
catalytic domain of HMGCR (Figure 4.1A). Transcription of the HMG-mCherry fusion protein 
was driven by the powerful SFFV promoter and is therefore independent of the SREBP 
pathway (Figure 4.1B). This ensures that the HMG-mCherry fusion protein will only be subject 
to post-translational sterol-dependent regulation. 
HeLa cells were transduced with a lentiviral construct encoding the HMG-mCherry fusion-
protein and a single cell clone was obtained (Figure 4.1C). HMG-mCherry was stabilised 
following a 16-hour treatment with Bortezomib, a proteasome inhibitor, demonstrating that 
the HMG-mCherry fusion protein was constitutively degraded by the proteasome under 
normal, sterol-replete tissue culture conditions (Figure 4.1D).  
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Figure 4.1 Establishing a fluorescent HMGCR reporter in HeLa cells. (A) A schematic of HMGCR 
illustrating the transmembrane domain, containing a sterol sensing domain, and the cytosolic catalytic 
domain. The catalytic domain is replaced by mCherry in the HMG-mCherry construct. (B) A Schematic 
of the lentiviral construct encoding the HMG-mCherry fusion protein. Expression is driven by the 
powerful spleen focus-forming virus (SFFV) promoter. (LTR, long-terminal repeat; WPRE, Woodchuck 
hepatitis virus posttranscriptional regulatory element). (C) A single cell clone stably expressing HMG-
mCherrry was isolated. Steady state expression of HMG-mCherry was measured by flow cytometry. 
(D) The HMG-mCherry expressing clone was sterol depleted by culture in LPDS containing medium 
with 10µM mevastatin overnight or treated with 25nM Bortezomib for 16 hours. (E) The HMG-
mCherry clone was sterol depleted overnight then cultured for a further 3 hours in the presence or 
absence of sterols (2 µg/ml 25-hydroxycholesterol plus 20 µg/ml cholesterol) to demonstrate correct 
sterol dependent degradation of the reporter. (F) Wild type HeLa cells were treated with 25nM 
Bortezomib for 16 hours or sterol depleted overnight then cultured for 3 hours in the presence or 
absence of sterols. The cells were lysed and immunoblotted for endogenous HMGCR. 
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Cells can be sterol depleted by overnight culture in medium containing lipoprotein-depleted 
serum and 10µM mevastatin. Sterol depletion increases endogenous HMGCR expression by 
upregulating SREBP-dependent transcription and stabilises HMGCR protein by reducing 
sterol-dependent degradation. As HMG-mCherry transcription is independent of the SREBP 
pathway, the increase in HMG-mCherry following overnight sterol depletion is caused by 
decreased sterol-induced degradation (Figure 4.1D). The increase in HMG-mCherry 
expression was similar following proteasome inhibition and sterol depletion, suggesting that 
HMG-mCherry is predominantly degraded in a sterol-dependent manner. The degradation of 
HMG-mCherry could be induced by adding sterols (2 µg/ml 25-hydroxycholesterol plus 20 
µg/ml cholesterol) into the sterol-depleted culture (Figure 4.1E). This shows that HMG-
mCherry is subject to sterol-induced degradation and is therefore an appropriate tool to use 
in a forward genetic screen to identify the E3 ubiquitin ligase responsible for the sterol-
induced ubiquitination and degradation of HMGCR.  
Blocking the degradation of HMGCR in wild type HeLa cells with Bortezomib rescued HMGCR 
(Figure 4.1F). However, blocking the degradation of HMGCR and inducing SREBP-dependent 
transcription by overnight sterol depletion resulted in significantly higher expression of 
HMGCR. The addition of sterols induces the rapid degradation of HMGCR, as well as stopping 
SREBP-driven transcription. There is a marked difference in the effect of Bortezomib 
treatment and sterol depletion on HMG-mCherry and endogenous HMGCR, which highlights 
the pronounced effect that SREBP-dependent transcription has on HMGCR expression (Figure 
4.1D and Figure 4.1F). Therefore, a forward genetic screen for increased HMG-mCherry 
expression will focus on the post-translational regulation of HMGCR rather than SREBP-
dependent transcription. 
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4.2.2 A genome-wide CRISPR knockout screen to identify the E3 ubiquitin ligase of HMGCR 
I hypothesised that the loss of the E3 ubiquitin ligase responsible for targeting HMG-mCherry 
for degradation would result in the stabilisation of HMG-mCherry. I would then be able to 
enrich this HMG-mCherryhigh phenotype by FACS. 
I performed a genome-wide CRISPR knockout screen using the GeCKO v2 library as described 
in Chapter 3. Briefly, the HMG-mCherry clone was transduced with the Cas9 nuclease and 
Cas9 function was confirmed using the control B2M gRNA. The Cas9-expressing HMG-
mCherry clone was transduced with the GeCKO v2 library at a M.O.I. of 0.35 and HMG-
mCherryhigh cells were selected by two sequential rounds of FACS (Figure 4.2A). The resultant 
population had a modest enrichment of 30% mCherryhigh cells. However, when the selected 
cells were compared to the starting clone on a histogram plot, the majority of the population 
showed a notably higher level of HMG-mCherry expression.  
The selected cells and starting clone were then analysed for their ability to degrade HMG-
mCherry in response to sterols (Figure 4.2B). HMG-mCherry was still stabilised by sterol 
depletion and degraded in response to sterols in the selected population, indicating that I had 
not enriched a population of mutants with impaired sterol-induced HMG-mCherry 
degradation, despite the rescue at steady state. Immunoblot analysis of these cells showed a 
significant rescue of endogenous HMGCR in the selected cells at steady state compared to 
the starting clone (Figure 4.2C). This demonstrates that the rescue of HMG-mCherry in the 
selected cells was not an artefact of over-expression. However, there was no difference in the 
sterol-induced degradation of endogenous HMGCR.  
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Figure 4.2 A genome wide CRISPR knock-out screen to identify the E3 ubiquitin ligase for HMGCR 
identifies MARCH6 (A) The level of HMG-mCherry was determined by flow cytometry in the starting 
clone and the population from each round of FACS to measure the enrichment in HMG-mCherryhigh 
cells. (B) The un-mutagenised HMG-mCherry clone and the selected cells were sterol depleted 
overnight followed by a four-hour culture in the presence or absence of sterols to determine the 
enrichment of mutants unable to degrade HMG-mCherry in response to sterols (C) Cells from (C) were 
lysed and immunoblotted for endogenous HMGCR. (Un, untreated; 5nM B, treated with 5nM 
Bortezomib for 16 hours; SD, overnight sterol depletion; SD +, overnight sterol depletion plus 4 hours 
with sterols). (D) Identification of candidate genes using the RSA algorithm (König et al. 2007). 
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The gRNA abundance was quantified in the selected cells and an unselected library that had 
been grown for the same amount of time. The RSA algorithm was used to identify candidate 
genes (Figure 4.2D). The screen was successful in identifying multiple hits that could be readily 
grouped into several functional classifications listed below. 
 ERAD and UPS 
The largest group contains genes involved in ERAD and the UPS, including the E3 ubiquitin 
ligase MARCH6 (see 4.2.3). Two E2 conjugating enzymes, UBE2G2 and UBE2J2, were also 
identified. UBE2G2 is already known to be critical for the sterol-induced ubiquitination of 
HMGCR (Miao et al. 2010). Ancient Ubiquitous Protein 1 (AUP1) is an ERAD associated protein 
that recruits the soluble E2 conjugating enzyme UBE2G2 to membrane-bound E3 ubiquitin 
ligases and has been implicated in the sterol-dependent degradation of HMGCR (Jo, Hartman, 
and DeBose-Boyd 2013, Klemm, Spooner, and Ploegh 2011). The screen identified multiple 
components of the VCP/p97 ATPase complex, UBXD8 (FAF2), Npl4 (NPLOC4), UFD1L and p97 
(VCP) itself. The p97 complex is required to extract HMGCR from the ER membrane so that 
HMGCR can be degraded by the proteasome in the cytosol (Morris et al. 2014). The screen 
also identified components of the poorly characterised ER membrane complex (EMC), EMC3 
and EMC6, suggesting a role for the EMC in the ERAD of HMGCR (Christianson et al. 2012). 
 Insig 
The Insig proteins act as scaffolds to recruit the E3 ubiquitin ligase to HMGCR in a sterol-
dependent manner (Jo and Debose-Boyd 2010). This screen identified Insig2 but not Insig1 
suggesting that the screen was not saturating. 
 Cholesterol import and the endocytic pathway 
The low-density lipoprotein receptor (LDLR) and Niemann-Pick proteins (NPC1 and NPC2) are 
required for the import of cholesterol from the extracellular space (Brown and Goldstein 
1986, Infante et al. 2008, Kwon et al. 2009). The screen also identified components of the 
vacuolar ATPase (ATP6AP1 and ATP6V1G1) and endo-lysosome pathway (light green in Figure 
4.2D), which are required for the endocytosis and recycling of the LDLR (Brown and Goldstein 
1986). The loss of these genes will block the uptake of exogenous cholesterol and sterol 
deplete the cell leading to the stabilisation of HMG-mCherry. 
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 Haem biosynthesis and protein prenylation 
Unexpectedly, the screen identified uroporphyrinogen decarboxylase (UROD) as a candidate 
gene. UROD catalyses the decarboxylation of four acetate side chains of iroporphyrinogen in 
the haem biosynthetic pathway (Whitby et al. 1998). Haem A contains an isoprenoid side 
chain that is derived from farnesyl pyrophosphate, an intermediate in the cholesterol 
biosynthetic pathway downstream of HMGCR (Dhar, Koul, and Kaul 2013). The identification 
of UROD in the forward genetic screen raises the possibility that a feedback loop exists to 
increase mevalonate production (i.e. stabilise HMGCR) when haem biosynthesis is blocked. 
Farnesyl pyrophosphate derivatives are covalently attached to proteins in a process referred 
to as protein prenylation (Dhar, Koul, and Kaul 2013). The identification of protein 
prenyltransferase alpha subunit repeat-containing protein 1 (PTAR1) suggests that inhibiting 
protein prenylation stabilises HMGCR. Alternatively, the activity of an enzyme required for 
the degradation of HMGCR might be dependent on prenylation. 
 Other 
TXNDC15 is a poorly characterised PDI family member. C19orf43 is an uncharacterised protein 
consisting of 176 amino acids. Secondary structure and protein domain prediction programs 
did not identify any features shared between c19orf43 and other proteins and so it was not 
pursued for validation or investigation. MGA encodes a transcription factor that is routinely 
detected in screens and is likely to be an artefact of expression from the lentiviral construct. 
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4.2.3 MARCH6 and the cholesterol biosynthesis pathway 
The aim of the genome-wide CRISPR knockout screen was to identify the E3 ubiquitin ligase 
for HMGCR. The only candidate gene that encodes an E3 ubiquitin ligase is MARCH6. MARCH6 
plays an important role in regulating cholesterol biosynthesis pathway by targeting squalene 
monooxygenase for degradation in a cholesterol-dependent manner (Gill et al. 2011, Foresti 
et al. 2013, Zelcer et al. 2014). Nolan Zelcer’s paper describing the induction of IDOL and 
subsequent decrease in LDLR expression following MARCH6 depletion had not been 
published when I identified MARCH6 in the CRISPR screen (Loregger et al. 2015). 
Zelcer et al. observed an increase in the basal level of HMCGR when MARCH6 was depleted 
by siRNA but did not see a definitive effect of MARCH6 depletion of the sterol-induced 
degradation of HMGCR (Zelcer et al. 2014). To address the effect of MARCH6 on HMGCR I 
used siRNA to deplete MARCH6 in the HMG-mCherry HeLa clone. I observed an accumulation 
of HMG-mCherry in cells transfected with MARCH6 siRNA compared to those transfected with 
a control siRNA, validating the CRISPR screen (Figure 4.3A). These cells were sterol depleted 
overnight and then cultured in the presence or absence of sterols for a further four hours. In 
the absence of sterols, control cells stabilised HMG-mCherry leading to a 4.8-fold increase in 
MFI (green to blue in Figure 4.3A), whereas cells depleted of MARCH6 stabilised HMG-
mCherry by 3.9-fold. When sterols were added following sterol depletion, control cells 
decreased their MFI by 46% and MARCH6 knockdown cells decreased their MFI by 53% (blue 
to red in Figure 4.3A). This suggests that MARCH6 is not required for the sterol-induced 
degradation of HMG-mCherry. Immunoblot analysis of the cells in Figure 4.3A showed no 
rescue of endogenous HMGCR at steady state, in contrast to Zelcer et al., and no change in 
the sterol-induced degradation of HMGCR following MARCH6 depletion (Figure 4.3B) (Zelcer 
et al. 2014). 
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Figure 4.3 MARCH6 depletion does not inhibit the sterol-induced degradation of HMGCR. 
(A) The HMG-mCherry expressing HeLa clone was transfected with 90nM MARCH6 or control 
siRNA. Cells were sterol depleted 3 days post-transfection. On day 4 post-transfection, cells 
were cultured for a further 4 hours in the presence or absence of sterols. HMG-mCherry 
expression was determined by flow cytometry. (B) Cells from (A) were lysed and 
immunoblotted for endogenous HMGCR. (C) Immunoblot of untreated cells for HMGCR in 
wild type HeLa cells and a MARCH6 knockout HeLa clone. (D) Wild type HeLa cells and a 
MARCH6 knockout HeLa clone were sterol depleted overnight then in the presence or 
absence of sterols for a further 4 hours.  Cells were lysed and immunoblotted for endogenous 
HMGCR. 
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I did not determine the extent of the depletion of MARCH6 but it is likely that there is an 
incomplete knockdown due to the absence of a rescue of HMGCR at steady state. A MARCH6 
knockout HeLa clone (kindly provided by Sandra Stefanovic-Barrett (Nathan laboratory, 
Cambridge)), generated by CRISPR-mediated gene disruption, was employed to assess 
HMGCR degradation in a MARCH6 null background. The loss of MARCH6 had been confirmed 
by Sandra Stefanovic-Barrett by sequencing the locus targeted by the gRNA to confirm the 
presence of frameshift insertions or deletions in all alleles. The clone also exhibits a significant 
rescue of squalene monooxygenase, demonstrating a functional rescue due to the loss of 
MARCH6. Immunoblot analysis of the MARCH6 knockout clone and its parental HeLa line 
showed a significant increase in HMGCR at steady state (Figure 4.3C). Following sterol 
depletion more HMGCR was detected in the MARCH6 knockout clone than the parental HeLa 
cell line. Whilst there appears to be slightly more HMGCR in the MARCH6 knockout clone 
following the sterol-induced degradation of HMGCR, the higher starting point shows that 
there is no defect in HMGCR degradation in the absence of MARCH6 (Figure 4.3C). 
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4.2.4 HeLa cells are autofluorescent in the absence of UROD 
UROD was an unexpected high-confidence hit in the screen and suggested a potential 
feedback loop from the haem biosynthesis pathway to the cholesterol biosynthesis pathway 
(Figure 4.2E). I observed an apparent increase in HMG-mCherry expression following CRISPR-
mediated gene disruption of UROD (Figure 4.4A). However, the gMFI was increased in the 
channel (610nm) used to detect mCherry by flow cytometery from wild type HeLa cells (which 
do not express any exogenous transgene) following CRISPR-mediated gene disruption of 
UROD. Knockdown of UROD by shRNA in the HMG-mCherry HeLa clone also lead to an 
increase in fluorescence detected by the 610nm channel on the flow cytometer (Figure 4.4B). 
However, immunoblot analysis of these cells showed no increase in HMG-mCherry protein 
abundance (Figure 4.4C). Taken together these data show that the CRISPR screen correctly 
identified UROD as a gene whose loss leads to increased fluorescence detected by the 610nm 
channel. However, HMG-mCherry expressing HeLa cells become autofluorescent following 
UROD depletion, presumably due to the accumulation of a fluorescent intermediate in the 
haem biosynthesis pathway, not due to the stabilisation of HMGCR. 
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Figure 4.4 HeLa cells are autofluorescent following depletion of UROD. (A) Wild type HeLa 
cells and the HMG-mCherry expressing clone were transiently transfected with Cas9 and a 
control or UROD-targeting gRNA. Cells were analysed by flow cytometry 7 days post-
transfection. (B) The HMG-mCherry HeLa clone was transduced with a control or UROD 
shRNA. Cells were analysed by flow cytometry 7 days post-transduction. (C) Cells from (B) 
were lysed and immunoblotted to determine HMG-mCherry expression and UROD depletion. 
(Ctl, control; U, UROD) 
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4.2.5 UBE2G2 is critical for the sterol-induced degradation of HMG-mCherry 
Despite the success of the CRISPR screen in identifying many factors required for the 
regulation of HMGCR, the only E3 ligase identified was MARCH6. Whilst MACRH6 influences 
HMGCR expression, it does not target HMGCR (Figure 4.3). I next sought to examine the HMG-
mCherry system further and identify a method for adapting the CRISPR screen to identify the 
E3 ubiquitin ligase for HMGCR. 
UBE2G2 has been previously reported as an E2 conjugating enzyme required for the sterol-
induced ubiquitination of HMGCR (Miao et al. 2010). I generated UBE2G2 knockout clones by 
transiently transfecting the HMG-mCherry clone with Cas9 and a UBE2G2-targeting gRNA, 
selecting transfected cells with puromycin treatment and single cell cloning by serial dilution. 
UBE2G2 knockout clones were identified by immunoblot (Figure 4.5A). HMG-mCherry was 
strongly rescued at steady state in the UBE2G2 knockout clones (comparing green and grey 
in Figure 4.5B), showing a defect in the degradation of HMG-mCherry and validating the 
identification of UBE2G2 in the CRISPR screen. A small stabilisation of HMG-mCherry was 
observed when the UBE2G2 knockout clones were sterol-depleted overnight, but there was 
no decrease in HMG-mCherry when sterols were added to the sterol-depleted culture for four 
hours (Figure 4.5B). UBE2G2 is therefore an essential component required for the sterol-
induced degradation of HMG-mCherry. Immunoblot analysis confirmed a significant rescue 
of endogenous HMGCR at steady state and a significant block in the sterol-induced 
degradation of endogenous HMGCR in the UBE2G2 knockout clones (Figure 4.5C). 
It is possible that more than one E3 ligase might use UBE2G2 to ubiquitinate HMGCR, in a 
manner similar to the previously suggested model by Russel Debose-Boyd (Jo et al. 2011). If 
one of the E3 ligases responsible for ubiquitinating HMG-mCherry is lost, the rate of sterol-
induced HMG-mCherry degradation could be reduced and therefore selected by FACS in a 
screen. 
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Figure 4.5 UBE2G2 is critical for the sterol-induced degradation of HMG-mCherry. (A) HMG-
mCherry HeLa UBE2G2 knockout clones were identified by immunoblot. (B) The HMG-
mCherry HeLa clone and the UBE2G2 knockout clones were sterol depleted overnight then 
cultured for a further four hours in the presence or absence of sterols. HMG-mCherry 
expression was analysed by flow cytometry. (C) Untreated HMG-mCherry expressing wild 
type cells and UBE2G2 knockout clones were lysed and immunoblotted for endogenous 
HMGCR. (D) Cells from (B) were lysed and immunoblotted for endogenous HMGCR. (WT, wild 
type) 
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4.2.6 A genome-wide CRISPR knockout screen using sterol depletion to identify the E3 
ubiquitin ligase for HMGCR 
I performed a second genome-wide CRISPR knockout screen in the HMG-mCherry HeLa clone 
to identify the E3 ubiquitin ligase(s) for HMGCR. I changed the FACS strategy to further focus 
the screen on the sterol-induced degradation of HMGCR. The day before sorting, the 
mutagenised library was sterol depleted overnight to stabilise HMG-mCherry. Sterols were 
added to the culture for five hours and HMG-mCherryhigh cells were then selected by FACS 
(Figure 4.6A). A time course experiment showed the continuous degradation of HMG-
mCherry in response to sterols over five hours (Figure 4.6B). A five-hour incubation was the 
longest practical culture possible in the screen.  The aim of this FACS strategy was to select 
cells that could not degrade HMG-mCherry in response to sterols or had a slower rate of HMG-
mCherry degradation.  
The Cas9-expressing HMG-mCherry clone was transduced with the GeCKO v2 library at a 
M.O.I. of 0.3. I attempted to enrich mutants with a reduced rate of sterol-induced HMG-
mCherry by sequential rounds of FACS using the strategy illustrated in Figure 4.6A. Whilst the 
resultant population had a significant rescue of HMG-mCherry at steady state, the sterol 
depletion assay showed that HMG-mCherry was still stabilised by sterol depletion and 
degraded in response to sterols (Figure 4.6C). Immunoblotting demonstrated that the 
selected cells also expressed more endogenous HMGCR at steady state than the starting 
clone. However, the selected cells only showed a slight decrease in the sterol-induced 
degradation of endogenous HMGCR (Figure 4.6D). Together the flow cytometry and 
immunoblot analysis of the selected cells show that there was very little enrichment for cells 
that had a reduced ability to degrade HMGCR in response to sterols. 
Despite this, genomic DNA was extracted from the selected cells together with an unselected 
library that had grown for the same amount of time. The gRNA abundance was determined 
in the selected cells and the library by sequencing on the Illumina HiSeq platform. The RSA 
algorithm only identified a small number of candidate genes in this screen (Figure 4.6E) (König 
et al. 2007). It was reassuring to identify UBE2G2 as a high-confidence hit, proving that the 
screen was technically successful. UBE2J2 is also identified by the screen and is a common hit 
with the steady state HMG-mCherry screen (Figure 4.2E).  
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Figure 4.6 A genome wide CRISPR knockout screen using sterol depletion to identify the E3 ubiquitin 
ligase for HMGCR identifies RNF145. (A) The FACS strategy used in the CRISPR screen to identify 
factors required for the sterol induced degradation of HMG-mCherry. Cells with a reduced ability to 
degrade HMG-mCherry in response to sterols should be selected by FACS in the gate indicated. (B) 
The HMG-mCherry expressing HeLa clone was sterol depleted overnight and then cultured in the 
presence of sterols for the indicated time periods.  (C) The HMG-mCherry expressing clone and 
selected cells were sterol depleted and cultured for a further four hours in the presence or absence 
of sterols. HMG-mCherry expression was measured by flow cytometry. (D) Cells from (C) were lysed 
and immunoblotted for endogenous HMGCR (SC, starting clone; S2, sort 2; un, untreated; SD, sterol 
depleted; +, sterol depleted plus four hours sterols). (E) Candidate genes were identified using the RSA 
algorithm (König et al. 2007). 
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Other factors known to be required for the sterol-induced degradation of HMGCR (FAF2, 
INSIG1 and UFD1L) are identified as borderline hits (Sever, Yang, et al. 2003, Cao et al. 2007, 
Morris et al. 2014). The screen also identified the poorly characterised ERAD E3 ligase RNF145 
as a borderline hit (Graham et al. 2015, Kaneko et al. 2016). RNF145 is a homolog of TRC8, 
one of the E3 ligases suggested to ubiquitinate HMGCR (Jo et al. 2011). Alignment coverage 
against TRC8 was 94%, with 47% similarity and 27% shared sequence identity. I also identified 
a YLYF motif near the N-terminus of RNF145. A YIYF in the sterol-sensing domain (SSD) of SCAP 
and HMGCR is required for these proteins to interact with the Insig proteins (Yang et al. 2002, 
Sever, Song, et al. 2003). The presence of the YLYF motif suggested that RNF145 might contain 
a SSD and interact with the Insig proteins. RNF145 is therefore a highly promising candidate 
gene from this CRISPR screen. 
 
4.2.7 Loss of RNF145 partially inhibits the sterol-induced degradation of HMG-mCherry 
I sought to validate a role for RNF145 in the sterol-induced degradation of HMGCR by CRISPR-
mediated gene disruption using four independent gRNAs. In each case I observed an increase 
in HMG-mCherry expression at steady state, a decreased stabilisation of HMG-mCherry with 
sterol depletion (5-fold increase compared to 7.8-fold increase in control cells) and a slight 
decrease in the sterol-induced degradation of HMG-mCherry (49-51% decrease compared to 
54.5% decrease in control cells) (Figure 4.7A). These three observations show that the loss of 
RNF145 inhibits the sterol-induced degradation of HMG-mCherry. However, this partial 
phenotype could be the result of an indirect effect or redundancy at the level of the E3 ligase. 
When the cells from Figure 4.7A were immunoblotted for endogenous HMGCR, it was initially 
very promising to see an increase in HMGCR at steady state (Figure 4.7B). However, only 
RNF145 gRNA #4 appeared to show a slight decrease in the sterol-induced degradation of 
endogenous HMGCR. The consistent phenotype obtained with these four RNF145-targeting 
gRNAs was difficult to see against endogenous HMGCR. I therefore concluded that the loss of 
RNF145 alone did not result in a decrease in the sterol-induced degradation of endogenous 
HMGCR detectable by immunoblotting.  
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Figure 4.7 Loss of RNF145 partially inhibits the sterol-induced degradation of HMG-
mCherry. (A) The HMG-mCherry expressing clone was transfected with Cas9 and a control or 
RNF145-targeting gRNA. Transfected cells were selected by treatment with puromycin. Cells 
were sterol depleted overnight seven days post-transfection then cultured for a further four 
hours on day eight post-transfection in the presence or absence of sterols. HMG-mCherry 
expression was measured by flow cytometry. The geometric mean fluorescence intensity 
(gMFI) for each sample is given in the table. Sterol depletion (SD) fold increase was calculated 
by dividing sterol depleted gMFI by the untreated gMFI. The percent decrease in gMFI with 
the addition of sterols following sterol depletion was calculated by dividing the difference 
between sterol depleted gMFI and sterol depleted plus sterols gMFI by the sterol depleted 
gMFI then multiplying by 100. (B) The cells from (A) were lysed and immunoblotted for 
endogenous HMGCR. 
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4.3 Discussion 
4.3.1 Genome-wide CRISPR knockout screens in non-haploid cells 
Previously, I have shown that gene-trap mutagenesis and CRISPR knockout screens generate 
comparable results in KBM7 cells (Chapter 3). However, it was unknown whether the 
efficiency of CRISPR-mediated gene disruption might be reduced by the presence of multiple 
alleles if a CRISPR screen was performed in a non-haploid cell line. The CRISPR screens 
presented in this chapter were performed in HeLa cells.  I have not performed a direct 
comparison of CRISPR screens in KBM7 cells and HeLa cells, but the presence of multiple 
alleles does not appear to have hindered the efficacy of CRISPR screens as the screen for cells 
with increased HMG-mCherry at steady state identified a significant number of hits required 
to regulate HMGCR expression (Figure 4.2E).  
It is striking that the steady state HMG-mCherry screen identified components of the p97 
complex (Figure 4.2E) whereas neither the gene-trap mutagenesis nor CRISPR screen in KBM7 
cells identified any p97 complex components (Figure 3.2C and Figure 3.3D). It is likely that the 
loss of the p97 complex is lethal to a cell within the timeframe the KBM7 forward genetic 
screens (21 days). A potential advantage of genome-wide CRISPR knockout screens in non-
haploid cells could be the possibility of incomplete gene knockouts where a wild type allele 
of a gene remains. The single wild type allele might be able to express sufficient protein to 
maintain cell viability for the duration of the screen but the decreased protein abundance 
results in a phenotype that can be selected, i.e. haploinsufficiency. 
 
4.3.2 MARCH6 affects HMGCR expression 
The genome-wide CRISPR knockout screen for cells with increased HMG-mCherry expression 
identified the E3 ligase MARCH6 (Figure 4.2). At the time Zelcer et al. had already shown that 
MARCH6 depletion rescued HMGCR at steady state, although the role of MARCH6 in the 
sterol-induced degradation of HMGCR was unclear (Zelcer et al. 2014). My validation of 
MARCH6 in HMG-mCherry expressing HeLa cells using siRNA-mediated silencing and a 
MARCH6 knockout clone confirmed an increase in HMGCR expression at steady state in the 
absence of MARCH6 and I did not observe a requirement for MARCH6 in the sterol-induced 
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degradation of HMGCR (Figure 4.3). My results are consistent with those published by Zelcer 
et al and a personal communication from Pedro Carvalho (Zelcer et al. 2014). 
The Zelcer laboratory later reported that IDOL expression is induced when MARCH6 is 
depleted in a range of cell types, including those of non-hepatic origin (Loregger et al. 2015). 
Increased IDOL expression causes a decrease in LDLR protein abundance which results in 
reduced LDL uptake, thereby lowering the intracellular cholesterol concentration. Therefore 
SREBP-dependent transcription will be upregulated and HMGCR will be stabilised in the 
absence of MARCH6, accounting for the steady state phenotype observed by myself and the 
Brown laboratory (Figure 4.3) (Zelcer et al. 2014). 
 
4.3.3 UBE2G2 is essential for the sterol-induced degradation of HMG-mCherry 
The ubiquitin E2 conjugating enzyme UBE2G2 has previously been shown to contribute to the 
sterol-induced ubiquitination of HMGCR (Miao et al. 2010). In this chapter, I used CRISPR-
mediated gene disruption to generate UBE2G2 knockout clones from the HMG-mCherry 
expressing HeLa clonal cell line. I found that the loss of UBE2G2 completely blocked the sterol-
induced degradation of HMG-mCherry (Figure 4.5B). The UBE2G2 clones had a significantly 
decreased rate of sterol-induced degradation of endogenous HMGCR, however there was a 
decrease in HMGCR abundance after a four-hour sterol treatment of sterol depleted cells 
(Figure 4.5C). This decrease could be the result of preventing SREBP-dependent transcription 
or ERAD mediated by another E2 conjugating enzyme that cannot lead to the sterol-induced 
degradation of HMG-mCherry. 
If the loss of an E2 conjugating enzyme caused a complete block to the sterol-induced 
degradation of HMG-mCherry, there must be an E3 ligase or a combination of E3 ligases 
whose loss also causes this phenotype. For a gene to be identified as a hit in a forward genetic 
screen, the loss of a gene must not be lethal within the timeframe of the screen (typically 18-
21 days). Functional redundancy is another barrier to gene identification in forward genetic 
screens. A gene cannot be identified if the loss of that gene is compensated for by another 
factor. 
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Several studies have shown the action of multiple E3 ligases on a single ERAD substrate (Zhang 
et al. 2015, Younger et al. 2006, Morito et al. 2008). However, none of these studies report a 
completely redundant system in which no phenotype is observed if only one ligase is 
depleted. If there are multiple E3 ligases responsible for ubiquitinating HMGCR, the loss of 
one ligase might not result in an increase in HMG-mCherry at steady state because the other 
ligase(s) can compensate and maintain low HMG-mCherry expression. I hypothesised that the 
loss of one of the E3 ligases responsible for the sterol-induced ubiquitination of HMG-
mCherry would result in a decreased rate of HMG-mCherry degradation in response to 
sterols. To test this hypothesis, I performed a second genome-wide CRISPR knockout screen 
using sterol depletion to enrich mutants with a reduced rate of sterol-induced HMG-mCherry 
degradation. This second CRISPR screen identified the poorly characterised ERAD E3 ligase 
RNF145 as a borderline hit (Figure 4.6). 
 
4.3.4 Is RNF145 the ubiquitin E3 ligase for HMGCR? 
RNF145 was a poorly characterised E3 ligase at the time of its identification in the CRISPR 
screen. The Lehner laboratory was aware of RNF145 due to its strong homology with TRC8, 
an ERAD E3 ligase that the Lehner laboratory uncovered (Stagg et al. 2009). TRC8 is also one 
of the ERAD E3 ligases implicated in HMGCR ERAD by the Debose Boyd laboratory but has 
been dismissed by the Weissman laboratory (Jo et al. 2011, Tsai et al. 2012).  
An shRNA screen had identified RNF145 as a negative regulator of phagocytic oxidative burst 
in macrophages and demonstrated an ER localisation for RNF145 (Graham et al. 2015). A more 
recent study profiled 37 potential ERAD E3 ubiquitin ligases, including RNF145 (Kaneko et al. 
2016). This study identified RNF145 as a ubiquitously expressed, ER-localised E3 ligase with 
12 transmembrane helices and a C-terminal RING domain. 
A transcriptomics screen for LXR-regulated genes has recently identified RNF145 (Cook et al. 
2017). This study used the Constrained Consensus TOPology prediction server to predict 14 
transmembrane helices and a C-terminal cytoplasmic RING domain. It is also suggested that 
the first six transmembrane helices constitute a putative sterol sensing domain. They also 
reported the presence of the YLYF motif that I observed in the second predicted 
transmembrane helix, suggesting RNF145 could interact with the Insigs (Sever, Song, et al. 
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2003, Yang et al. 2002). An ER localisation for RNF145 was confirmed and E3 ligase activity 
was confirmed in an in vitro autoubiquitination assay (Cook et al. 2017). Taken together these 
studies provide evidence for RNF145 as an ERAD E3 ligase and make RNF145 a very promising 
candidate gene for the E3 ligase for HMGCR. 
The validation experiment of RNF145 in the HMG-mCherry HeLa clone showed a decrease in 
the sterol-induced degradation of HMG-mCherry in the absence of RNF145 (Figure 4.7A). This 
partial phenotype supports the model in which multiple E3 ligases are involved in HMGCR 
ERAD. Although, an indirect effect cannot be ruled out at this stage, the absence of a notable 
difference in the sterol-induced degradation of endogenous HMGCR in cells depleted of 
RNF145 might be too small a difference to be resolved by immunoblot. 
The genome-wide CRISPR knockout screen using sterol depletion did not identify many high-
confidence hits. This is probably due to the low enrichment of mutants with a reduced rate 
of sterol-induced HMGCR degradation (Figure 4.6C). The failure to achieve a significant 
enrichment is likely the result of the small assay window as there is considerable overlap on 
a FACS plot between the HMG-mCherry clone after sterol depletion and after a five-hour 
culture with sterols. It is significantly easier to enrich a population in a fluorescence-based 
forward genetic screen if the desired mutants form a distinct population compared with the 
starting cell line (i.e. a wide dynamic range). 
Consequently, the next aim of my thesis project was to create a more sensitive system with a 
wider dynamic range to perform a genome-wide CRISPR knockout screen to identify the 
ubiquitin E3 ligases responsible for the sterol-induced degradation of HMGCR. 
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4.4 Summary 
Genome-wide CRISPR knockout screens are a powerful approach to identify genes required 
for HMGCR regulation. I performed two genome-wide CRISPR knockout screens using a 
fluorescently tagged HMGCR reporter. The first screen selected cells with an increase in HMG-
mCherry expression at steady state whereas the second screen used sterol depletion to select 
cells with a reduced rate of sterol-induced HMG-mCherry degradation. The second CRISPR 
screen identified a poorly characterised ERAD E3 ubiquitin ligase, RNF145. I validated the 
involvement of RNF145 in the sterol-induced degradation of HMG-mCherry, however I could 
not detect a requirement for RNF145 in the sterol-induced degradation of endogenous 
HMGCR. 
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Chapter 5: Genome-wide CRISPR knockout 
screens using fluorescently-tagged 
endogenous HMGCR identify RNF145 
 
5.1 Introduction 
The aim of my thesis project is to identify the E3 ubiquitin ligase(s) responsible for HMGCR 
ERAD. The genome-wide CRISPR knockout screens described in Chapter 4 identified a role for 
RNF145, a poorly characterised E3 ligase, in the sterol-induced degradation of an ectopic, 
fluorescently-tagged HMGCR reporter. 
The genome-wide CRISPR screens discussed in Chapter 4 showed two major limitations: 
firstly, the low enrichment of mutants with a reduced rate of sterol-induced HMG-mCherry 
degradation, most likely caused by a modest difference in fluorescence following sterol 
depletion. Secondly, the small difference in sterol-induced degradation of HMG-mCherry and 
endogenous HMGCR in the absence of UBE2G2 suggested that HMG-mCherry was not 
targeted for ERAD by all the ERAD machinery that endogenous HMGCR is. 
In the previous chapters I have used CRISPR-mediated gene disruption to knockout genes to 
analyse a phenotype caused by their absence. CRISPR/Cas9 genome editing technology can 
also be used to insert desired sequences into the genome. If an oligonucleotide template is 
provided, the Cas9-mediated DNA double strand break can be repaired accurately by 
homologous recombination instead of NHEJ (Hsu, Lander, and Zhang 2014). Due to the 
aforementioned shortcomings of the screens based on HMG-mCHerry overexpression, I 
sought to create a knock-in cell line in which endogenous HMGCR was tagged with a 
fluorescent protein. I hypothesised that SREBP-dependent transcription would increase the 
fluorescent window between sterol depleted and sterol repleted cells, increasing the 
probability of enriching a population of mutants that cannot degrade HMGCR efficiently in 
response to sterols in a forward genetic screen. Analysing the endogenous protein expression 
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would also remove the concern that the HMG-mCherry protein was not targeted by all the 
ERAD machinery that mediate the ubiquitination of endogenous HMGCR. 
 
5.2 Results 
5.2.1 Using CRISPR/Cas9 technology to tag endogenous HMGCR 
To create a HMGCR knock-in cell line, I transfected HeLa cells with Cas9, a gRNA targeting 
immediately downstream of the HMGCR stop codon and a donor template encoding Clover, 
an enhanced GFP variant (Figure 5.1A). The donor template consists of two arms that are 
homologous to the one kilobase genomic DNA sequence on either side of the HMGCR stop 
codon (Figure 5.1B). The sequence between the homologous arms will be incorporated into 
the genome when the template is used in homologous recombination to repair the 
CRISPR/Cas9-induced double strand break. The sequence to be inserted contained a myc-tag 
and Clover sequence that would form a HMGCR-myc-Clover endogenous fusion protein, as 
well as a drug resistance gene with an exogenous promoter flanked by loxP sites (Figure 5.1B). 
I simultaneously transfected HeLa cells with three different donor templates, each encoding 
a different drug resistance marker enabling selection of cells that had incorporated the 
template into multiple alleles. The resulting population of drug-resistant cells was then 
transfected with Cre-recombinase to remove the resistance cassette. The Cre-recombinase 
plasmid expressed mCherry so that I could select transfected cells by FACS. Single cell clones 
were isolated and the loss of the resistance cassette was confirmed by loss of cell viability 
when cultured in selection medium. 
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Figure 5.1 Using CRISPR/Cas9 to tag endogenous HMGCR with Clover. (A) Schematic illustrating the 
production of a knock-in. HeLa cells are transiently transfected with Cas9, a gRNA and a donor 
template. (ORF, open reading frame; UTR, untranslated region). (B) Schematic of the donor template 
used to create HMGCR-Clover knock-in. Three donor templates were used. Each encoded a resistance 
gene for puromycin, hygromycin or blasticidin. (C) HMG-Clover expression could not be detected in 
an untreated HMGCR-Clover clone by flow cytometry. (D) HMGCR-Clover HeLa cells were treated 
overnight with 25nM Bortezomib, overnight with 10µM mevastatin or for 8 hours with 10µM NMS-
873 (a p97 inhibitor). (E) HMGCR-Clover HeLa cells were sterol depleted overnight then cultured for a 
further 2 hours in the presence or absence of sterols. HMG-Clover expression was measured by flow 
cytometry to show appropriate sterol dependent regulation of HMGCR-Clover. (F) HMGCR-Clover was 
induced by overnight sterol depletion. HMGCR-Clover co-localised with the KDEL marker in the ER as 
assessed by immunofluorescence (Dick van den Boomen). (G) Immunoblot analysis of sterol depleted 
wild type HeLa cells (WT) and the HMGCR-Clover (HC) clone shows the higher molecular weight 
HMGCR-Clover protein. 
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5.2.2 Chemical inhibitors and sterols correctly modulate HMGCR-Clover expression  
A HMGCR-Clover single-cell clone was selected for characterisation. The HMGCR-Clover clone 
was indistinguishable from wild type HeLa cells by flow cytometry, demonstrating the low 
level of HMGCR expression at steady state when grown in tissue culture medium (Figure 
5.1C). Chemical inhibitors were then used to show that HMGCR-Clover was constitutively 
degraded by the proteasome in a p97-dependent manner (Figure 5.1D). Inhibiting HMGCR, 
and therefore cholesterol biosynthesis, with overnight statin (mevastatin) treatment also lead 
to the stabilisation of HMGCR-Clover (Figure 5.1D). Treating wild type HeLa cells with these 
inhibitors did not cause any change in fluorescence. 
It was critical to ensure that sterols correctly regulated HMGCR-Clover expression. A 25-fold 
increase in HMGCR-Clover was detected by flow cytometry after overnight sterol depletion 
(grey to red in Figure 5.1E) because of increased SREBP-induced transcription and decreased 
sterol-induced degradation. Adding sterols into the sterol depleted culture caused the rapid 
degradation of HMGCR-Clover (80% decrease in 2 hr), demonstrating appropriate sterol-
dependent regulation of HMGCR-Clover (red to blue in Figure 5.1E). Immunofluorescence was 
used to confirm an ER-localisation for HMGCR-Clover to ensure that the addition of Clover to 
the C-terminus had not disrupted HMGCR localisation (Figure 5.1F). Immunoblot analysis of 
sterol depleted HMGCR-Clover cells and wild type HeLa cells showed a higher molecular 
weight band (below 150 kDa) corresponding to the HMGCR-Clover fusion protein (Figure 
5.1G). The HMGCR-Clover cells also contained a (approximately 100 kDa) band corresponding 
to wild type HMGCR protein indicating that an allele remained untagged. This was fortunate 
as it allows me to determine whether an enrichment of HMGCR-Clover in a forward genetic 
screen reflected an enrichment of wild type HMGCR. The locus was also sequenced to confirm 
the correct DNA sequence of HMGCR-Clover and the integrity of the wild type allele. 
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5.2.3 Genetic validation of the HMGCR-Clover clone 
To confirm that the HMGCR-Clover cell line was an appropriate tool to use in a forward 
genetic screen, I sought to validate the positive controls for the screen. UBE2G2 has 
previously been reported to be the E2 conjugating enzyme for the sterol-induced degradation 
of HMGCR (Miao et al. 2010). I first used three independent UBE2G2-targeting gRNAs to 
knockout UBE2G2 by CRISPR-mediated gene disruption. In each case, I observed a significant 
rescue of HMGCR at steady state (grey to green in Figure 5.2A) suggesting that the basal 
turnover of HMGCR was impaired. I also observed a significant block in the sterol-induced 
degradation of HMGCR-Clover (blue to red in Figure 5.2A). The loss of UBE2G2 did not result 
in a complete block in HMGCR-Clover degradation, which is addressed in Chapter 7. 
Additionally, pools of four gRNAs were employed to knockout Insig1, Insig2 or both Insig1 and 
Insig2 by CRISPR-mediated gene disruption. Insig proteins retain the SCAP-SREBP complex in 
the ER in the presence of sterols and recruit an E3 ubiquitin ligase complex to HMGCR in 
response to sterols (Yabe, Brown, and Goldstein 2002, Yang et al. 2002, Sever, Song, et al. 
2003). The loss of either Insig caused a small rescue of HMGCR-Clover at steady state (row 1 
Figure 5.2B). However, the concomitant loss of both Insigs caused an almost complete rescue 
of HMGCR-Clover expression at steady state to the same level as seen following sterol 
depletion. The loss of both Insigs and sterol depletion show a similar phenotype as in both 
cases the SREBP-SCAP complex is not retained in the ER, leading to constitutive SREBP-
mediated transcription of HMGCR-Clover irrespective of the sterol environment. The steady 
state phenotypes demonstrate the functional redundancy between the Insigs. 
Adding sterols into a sterol-depleted culture in the absence of Insig1 revealed a significant 
defect in sterol-induced HMGCR-Clover degradation. In contrast, only a very small decrease 
in sterol-induced HMGCR-Clover degradation was observed in the absence of Insig2 (Figure 
5.2B). Therefore, Insig1 is dominant over Insig2 in this system. These non-redundant 
phenotypes suggest the Insig proteins act in different pathways, for example with different 
components. Adding sterols to cells deficient of both Insigs did not decrease HMGCR-Clover 
expression because HMGCR-Clover could not be targeted for degradation. 
HMGCR-Clover is regulated appropriately by UBE2G2 and the Insig proteins. The HMGCR-
Clover cell line is therefore an appropriate tool to use in forward genetic screens. 
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Figure 5.2 HMGCR-Clover expression is regulated correctly by UBE2G2 and Insigs. (A) The HMGCR-
Clover HeLa clone was transiently transfected with Cas9 and a UBE2G2-targeting or a control gRNA. 
Transfected cells were selected by puromycin treatment. Sterol induced degradation of HMGCR-
Clover was assessed ten days post-transfection by sterol depleting cells overnight followed by a two-
hour culture in the presence or absence of sterols. (B) The HMGCR-Clover HeLa clone was transiently 
transfected with Cas9 and either a control gRNA, a pool of 4 gRNAs targeting Insig1, a pool of 4 gRNAs 
targeting Insig2, or a pool of 8 gRNAs with 4 gRNAs targeting each Insig. Transfected cells were 
selected with puromycin treatment. Sterol induced degradation of HMGCR-Clover was assessed 8 days 
post-transfection by sterol depletion followed by a further four-hour culture in the presence or 
absence of sterols. Representative of three independent experiments. 
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5.2.4 Genome-wide CRISPR knockout screen for increased HMGCR-Clover expression at 
steady state 
The first genome-wide CRISPR knockout screen performed in the HMGCR-Clover clone 
selected cells with increased HMGCR-Clover expression at steady state. The HMGCR-Clover 
clone was transduced with Cas9 nuclease as described in previous chapters. The library used 
in this screen was a kind gift from Michael Bassik (Stanford University). This library contains a 
total of 211,695 gRNAs, with 10 gRNAs targeting 19,930 genes and 12,395 control gRNAs 
(Morgens et al. 2017).  
The Cas9-expressing HMGCR-Clover clone was transduced with the Bassik library at an M.O.I 
of 0.3. HMGCR-Cloverhigh cells were selected by two sequential rounds of FACS. The resultant 
population contained a significant enrichment of HMGCR-Cloverhigh cells across a wide range 
of HMGCR-Clover expression levels, suggesting that multiple cellular pathways had been 
disrupted (Figure 5.3A). Despite the increased level of HMGCR-Clover expression at steady 
state, the majority of the enriched population did not appear to have a significant defect in 
the sterol-induced degradation of HMGCR-Clover (Figure 5.3B). Immunoblot analysis of the 
cells in Figure 5.3B showed that, at steady state, the expression of the wild type HMGCR allele 
(~100 kDa band in Figure 5.3C) in the enriched population was increased demonstrating that 
the enrichment of HMGCR-Clover was due to the loss of genes required to regulate HMGCR 
expression (Figure 5.3C). The wild type HMGCR allele in the enriched population did not 
demonstrate decreased sterol-induced degradation. 
The abundance of gRNAs in the enriched population was compared to an unselected library 
as described in Chapter 3. The RSA algorithm showed that the screen successfully identified 
many candidate genes (Figure 5.3D).  The screen identified the positive control UBE2G2 but 
neither of the Insig proteins suggesting that, despite the large number of candidate genes 
identified, the screen was not saturating.  
The significant hits (Figure 5.3D) can be separated into two functional groups: 
 Cholesterol biosynthesis 
The screen identified many genes that encode enzymes in the cholesterol biosynthesis 
pathway (yellow in Figure 5.3D). The loss of these genes will block the production of 
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cholesterol (like statin treatment in Figure 5.1D) leading to a decrease in intracellular 
cholesterol and therefore increased SREBP-dependent transcription and the stabilisation of 
HMGCR.  
 Cholesterol import 
The LDLR and the Niemann-Pick genes (NPC1 and NPC2) are required for cholesterol import 
(Brown and Goldstein 1986, Infante et al. 2008, Kwon et al. 2009). A large suite of genes was 
also identified that encode proteins involved in the endo-lysosome pathway. The vacuolar 
ATPase (components ATPV1B2 and ATP6V1A were identified) is required for endosomal 
acidification along the endo-lysosome pathway as well as the activity of lysosomal hydrolases 
(Maxson and Grinstein 2014). Acidification of endosomes is required for LDL release from 
LDLR (Rudenko et al. 2002). The GNPTAB gene encodes N-acetylglucosamine-1-
phospotransferase subunits alpha and beta, an enzyme required for the formation of 
mannose 6-phosphate (M6P) on mannose glycans in the Golgi, the marker that targets 
lysosomal hydrolases to the lysosome (Braulke and Bonifacino 2009, Qian et al. 2010). 
Lysosomal hydrolases release cholesterol esters from LDL that has been imported via the LDLR 
pathway (Brown and Goldstein 1986). Therefore, the loss of GNPTAB will block cholesterol 
uptake by preventing the release of cholesterol esters from LDL particles. Other hits such as 
ARF6 and members of the GARP complex (VPS54, VPS52, VPs45, VPS53, VPS51) are required 
for a functional endo-lysosomal pathway (Schweitzer, Sedgwick, and D'Souza-Schorey 2011, 
Fröhlich et al. 2015, Wei et al. 2017). The loss of a gene that inhibits cholesterol uptake via 
the LDLR and the endo-lysosomal pathway will lead to a decrease in intracellular cholesterol 
concentration that will in turn activate SREBP-dependent transcription and promote the 
stabilisation of HMGCR. 
The screen also identified two uncharacterised genes (c18orf8 and c19ord25). Secondary 
structure and domain prediction algorithms did not identify any features reminiscent of E3 
ligases and so they were not pursued as a part of this thesis project. 
 
 
 
Chapter 5: Genome-wide CRISPR knockout screens using fluorescently-tagged endogenous HMGCR 
identify RNF145 
 
125 
 
Figure 5.3 A genome-wide CRISPR knockout screen in the HMGCR-Clover knock-in clone to identify 
the E3 ubiquitin ligase for HMGCR. (A) The Cas9-expressing HMGCR-Clover clone was transduced with 
the Bassik gRNA library. HMGCR-Clover
high
 mutants were enriched by two rounds of FACS. (B) The 
sterol induced degradation of HMGCR-Clover was assessed in the selected cells by overnight sterol 
depletion followed by a two-hour culture in the presence or absence of sterols. (C) Cells from (B) were 
lysed and immunoblotted for HMGCR (SC, starting clone; S1, sort 1; S2, sort 2). (D) Candidate genes 
were identified using the RSA algorithm (König et al. 2007). 
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5.2.5 CRISPR validation of HMGCR-Clover steady state screen hits 
I selected five hits from the HMGCR-Clover steady state screen for CRISPR validation alongside 
Insig1, a false-negative in the CRISPR screen. In each case, I observed an increase in HMGCR-
Clover expression following CRISPR-mediated gene disruption (Figure 5.4). The increase in 
HMGCR-Clover expression seen here is small compared to the level of expression seen in the 
HMGCR-Cloverhigh cells enriched in the CRISPR screen (Figure 5.3B). It should be noted that 
the enriched cells in the screen were analysed by flow cytometry 20 days after gRNA library 
transduction, whereas the cells were analysed in the validation experiment (Figure 5.4) 7 days 
after gRNA transfection. It is possible that the level of HMGCR-Clover could increase if the 
validation experiment was continued beyond seven days. A higher HMGCR-Clover expression 
level might also be caused by the loss of a gene that was not selected for validation, i.e. a 
component of the cholesterol biosynthesis pathway. 
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Figure 5.4 Validation of candidate genes identified in steady state HMGCR-Clover genome-
wide CRISPR knockout screen. The HMGCR-Clover HeLa clone was transiently transfected 
with Cas9 and a candidate gene-targeting gRNA or control gRNA. Transfected cells were 
selected with puromycin treatment. HMGCR-Clover expression was measured by flow 
cytometry 7 days post-transfection. 
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5.2.6 A genome-wide CRISPR knockout screen using sterol depletion in the HMGCR-Clover 
clone identified RNF145 
Despite identifying a large suite of genes in the steady state HMGCR-Clover screen, the only 
hit reported to be involved in ERAD was UBE2G2. To identify genes required for HMGCR 
degradation, I re-focussed my screen and performed a second genome-wide CRISPR knockout 
screen using the HMGCR-Clover cell line. In this second screen, I took advantage of the 
significant increase in HMGCR-Clover expression induced by sterol depletion due to SREBP 
driven transcription and stabilisation of HMGR-Clover protein. I then added sterols into the 
sterol depleted culture and selected cells by FACS with a decreased rate of HMGCR 
degradation (Figure 5.5A). I found that a five-hour incubation with sterols following overnight 
sterol depletion provided the maximum decrease in HMGCR-Clover (Figure 5.5B). The 
difference in HMGCR-Clover expression between sterol depleted and sterol replete 
incubation is significantly larger than that in the ectopic HMG-mCherry HeLa cell line used in 
Chapter 4. This should enable the enrichment of mutant cells that have a decreased rate of 
sterol-induced HMGCR degradation. 
The Cas9-expressing HMGCR-Clover clone was transduced at a M.O.I. of 0.3 with the Bassik 
gRNA library. The mutagenised cells were sterol depleted overnight and sterols were added 
back into the culture for five hours the following day. Rare mutant cells with a reduced ability 
to degrade HMGCR-Clover were selected by two sequential rounds of FACS using the strategy 
illustrated in Figure 5.5A. The resultant population only contained a small population of cells 
with an increased steady state level of HMGCR-Clover expression (green in Figure 5.5C). 
However, when compared to the starting clone, the majority of the cells in the selected 
population had a reduced ability to degrade HMGCR-Clover in response to sterols following 
sterol depletion (comparing red to orange Figure 5.5C). The width of the red histogram in 
Figure 5.5C indicates that the enriched population contains a variety of mutants with different 
abilities to degrade HMGCR-Clover. Immunoblot analysis of cells shown in Figure 5.5C 
confirmed that the selected cells also had a decreased ability to degrade wild type HMGCR in 
response to sterols following sterol depletion (compare S2 to SC in right panel of Figure 5.5D). 
Together, the flow cytometry and immunoblot analysis demonstrate that I have now 
performed a forward genetic screen that has enriched a population of mutants showing 
significantly inhibited sterol-induced HMGCR degradation. 
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Figure 5.5 A genome-wide CRISPR knockout screen in the HMGCR-Clover knock-in clone using sterol 
depletion to identifies RNF145 (A) FACS strategy to select mutants with a decreased ability to degrade 
HMGCR-Clover in response to sterols. (B) A five-hour culture provides the maximum window for the 
sterol induced degradation of HMGCR-Clover. HMGCR-Clover cells were sterol depleted overnight 
followed by the presence or absence of sterols for the indicated time. (C) The selected cells from the 
screen showed a reduced rate of sterol induced HMGCR-Clover degradation. Cells were sterol 
depleted overnight then cultured in the presence or absence of sterols for a further two hours. (D) 
Cells from (C) were lysed and immunoblotted for HMGCR (SC: starting clone, S1: sort 1, S2: sort 2). (E) 
Candidate genes were identified using the RSA algorithm (König et al. 2007) 
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I quantified the gRNA abundance in the selected cells and an unselected library using the 
Illumina HiSeq platform. The RSA algorithm identified a focussed suite of genes required for 
the sterol-induced degradation of HMGCR (Figure 5.5E) (König et al. 2007). The screen 
identified UBE2G2, as well as its accessory factor AUP1 which is thought to recruit UBE2G2 to 
membrane E3 ubiquitin ligases (Klemm, Spooner, and Ploegh 2011, Jo, Hartman, and DeBose-
Boyd 2013). Both Insig proteins were also identified, which are known to be required for the 
sterol-induced degradation of HMGCR (as demonstrated in Figure 5.2B) (Yabe, Brown, and 
Goldstein 2002, Yang et al. 2002, Sever, Song, et al. 2003). Strikingly, the screen identified 
RNF145, the same E3 ubiquitin ligase identified in the sterol depletion ectopic HMG-mCherry 
screen (Figure 4.6E).  
Trans-2,3-enoyl CoA reductase (TECR) catalyses the final steps in the synthesis of very long-
chain fatty acids (Moon and Horton 2003). The accumulation of long-chain fatty acid 
intermediates in the absence of TECR could disrupt the signal inducing the degradation of 
HMGCR-Clover. Polypeptide N-acetylgalctosaminyltransferase 11 (GALNT11) is a hit in both 
CRISPR screens that used sterol depletion (Figure 4.6E and Figure 5.5E). GALNT11 initiates 
protein O-linked glycosylation, suggesting that a protein involved in the degradation of 
HMGCR requires O-linked glycosylation (Schwientek et al. 2002). 
I was surprised to identify the LDLR in this screen. The medium used for sterol depletion 
contains serum that has been depleted of lipoprotein, so the cholesterol and 25-
hydroxycholesterol added after sterol depletion should not be taken up via the LDLR pathway. 
EH domain-containing protein 1 (EHD1) is a hit in all four HMGCR CRISPR screens. EHD1 is 
required for the internalisation and recycling of several plasma membrane receptors, 
including the LDLR (Naslavsky et al. 2007, Naslavsky and Caplan 2011). No other genes 
required for cholesterol up-take or the LDLR pathway were identified by the screen. 
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5.2.7 The loss of RNF145 causes a small decrease in the sterol-induced degradation of 
HMGCR-Clover 
CRISPR-mediated gene disruption was used to validate additional hits from the genome-wide 
CRISPR knockout screen that used sterol depletion. The loss of EHD1 and LDLR resulted in a 
small decrease in the sterol-induced degradation of HMGCR-Clover, suggesting that there is 
a small amount of residual lipoprotein in the medium (Figure 5.6A). However, the loss of 
NPC1, which was not a hit, did not affect the sterol-induced degradation of HMGCR-Clover, 
despite the rescue of HMGCR-Clover at steady state indicating the loss of NPC1. Taken 
together, this suggests that the LDLR can influence cholesterol homeostasis independent of 
the Niemann-Pick proteins.  
The loss of TECR following CRISPR-mediated gene disruption resulted in an increase in 
HMGCR-Clover expression at steady state and inhibited the sterol-induced degradation of 
HMGCR-Clover (Figure 5.6A). I did not determine the efficiency of CRISPR-mediated gene 
disruption of GALNT11, I therefore cannot conclude from this data that GALNT11 is a false 
positive of the sterol depletion CRISPR screens. 
Throughout my thesis project, I consistently observed a pronounced block in the sterol-
induced degradation of HMGCR in the absence of UBE2G2. The phenotype at steady state in 
the absence of UBE2G2 is less consistent. The loss of UBE2G2 predominantly caused an 
increase in HMGCR-Clover expression, however Figure 5.6A shows an instance when this did 
not occur. This is most likely because transcription also controls the steady state expression 
of HMGCR-Clover. 
I previously identified RNF145 in a genome-wide CRISPR screen for factors required for the 
sterol-induced degradation of a fluorescently-tagged ectopic HMGCR reporter (Figure 4.6E). 
CRISPR-mediated gene disruption of RNF145 caused a small decrease in the sterol-induced 
degradation of HMG-mCherry, but I did not detect a convincing effect on endogenous HMGCR 
(Figure 4.7). The only E3 ligase identified in my genome-wide CRISPR knockout screen using 
an endogenous HMGCR-Clover knock-in was RNF145 (Figure 5.5E). I therefore used CRISPR-
mediated gene disruption to validate a requirement of RNF145 in the sterol-induced 
degradation of HMGCR-Clover. To knockout RNF145, four independent gRNAs targeting 
RNF145 were used individually or as a pool. In each case I observed no difference to control 
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cells at steady state or following sterol depletion (top and middle rows Figure 5.6B). However, 
there was a small but highly reproducible decrease in the sterol-induced degradation of 
HMGCR-Clover in the absence of RNF145 (bottom row Figure 5.6B). In comparison, the loss 
of Insig1 resulted in a significant decrease in the sterol-induced degradation of HMGCR-Clover 
(Figure 5.6B). Whilst it was encouraging to see a decrease in the sterol-induced degradation 
of endogenous HMGCR in the absence of RNF145, this difference might be too small to detect 
by immunoblot and explain why I did not detect a pronounced difference in the sterol-
induced degradation of wild type HMGCR in Figure 4.7E. 
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Figure 5.6 Loss of RNF145 causes a small decrease in the sterol-induced degradation of HMGCR-
Clover. (A) HMGCR-Clover cells were transiently transfected with Cas9 and either a control gRNA or a 
pool of four gRNAs targeting the indicated gene. Transfected cells were selected with puromycin 
treatment. The sterol-induced degradation of HMGCR-Clover was assessed nine days post-
transfection. Cells were sterol depleted overnight eight days post-transfection and cultured for a 
further two hours in the presence or absence of sterols on day nine post-transfection. (B) HMGCR-
Clover cells were transiently transfected with Cas9 and a control gRNA, an RNF145-targeting gRNA, a 
pool of four RNF145-targeting gRNAs or a pool of four Insig1-targeting gRNAs. The sterol induced 
degradation of HMGCR-Clover was assess nine days post-transfection as described in (A). (B) is 
representative of more than three independent experiments. 
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5.2.8 RNF145 knockout HeLa clones do not exhibit decreased sterol-induced HMGCR 
degradation  
I next generated RNF145 knockout clones derived from wild type HeLa cells to assess whether 
RNF145 influences the sterol-induced degradation of wild type endogenous HMGCR. Wild 
type HeLa cells were transfected with Cas9 and an RNF145-targetting gRNA, transfected cells 
were selected with puromycin and single cells isolated by serial dilution. At the time, 
antibodies against RNF145 were not commercially available. Therefore, clones were screened 
for CRISPR/Cas9-induced frameshift insertion or deletion mutations by genomic PCR across 
the gRNA target site using fluorescent primers. The size of the fluorescent PCR product was 
determined, to single base pair resolution, using an ABI 3730xl DNA Analyser (Figure 5.7A). 
The size of the PCR product across gRNA #8’s target site was 325bp. Clones were identified 
that did not have insertions or deletions of multiples of three base pairs. A representative 
example is given in Figure 5.7A, clone #20 from the gRNA #8 transfection has a single peak on 
the fluorescent trace at 314bp indicating that all alleles in clone #20 have an 11bp deletion. 
The PCR products were TOPO-cloned and frameshift insertion or deletions were confirmed 
by Sanger DNA sequencing (Figure 5.7A). When, an antibody against RNF145 became 
available, the loss of RNF145 protein in the selected clones was confirmed by immunoblot 
(Figure 5.7B). The RNF145 band is indicated above 50 kDa, below the background band. 
To further investigate the involvement of RNF145 in HMGCR degradation, I chose two RNF145 
knockout clones derived from gRNA #5 (5_7 and 5_26) and two more derived from gRNA #8 
(8_8 and 8_20). I observed no difference in the sterol-induced degradation of HMGCR in these 
RNF145 knockout clones with a four-hour sterol treatment following sterol depletion (Figure 
5.7C). I also carried out a time-course experiment to see if the clones had a decreased rate of 
HMGCR degradation in response to sterols over a shorter period (Figure 5.7D). Clone 5_7 
shows a small difference after a three-hour incubation with sterols, however no difference 
was observed between wild type HeLa cells and the RNF145 knockout clones at other time 
points, as was further confirmed by clone 8_20 (Figure 5.7D). These findings do not support 
a requirement for RNF145 in the sterol-induced degradation of wild type endogenous 
HMGCR. A possible explanation for this discrepancy could be that the minor effect seen on 
HMGCR-Clover was insufficient to be detected by immunoblot and is followed in Chapter 6. 
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Figure 5.7 RNF145 knockout HeLa clones do not have a decreased rate of sterol-induced HMGCR 
degradation (A) RNF145 knockout clones were screened by genomic PCR using fluorescent primers 
across the gRNA target site locus. The size of the fluorescent PCR products was determined to single 
base pair resolution to identify frameshift insertion or deletion mutations. Fluorescent trace of PCR 
products from wild type HeLa cells and clone 20 from gRNA 8 (8_20) are shown. Sanger DNA 
sequencing confirmed the presence of frameshift insertions or deletions. (B) Immunoblot of lysates 
from selected RNF145 knockout clones to confirm loss of RNF145 protein. (C) Wild type HeLa cells and 
RNF145 knockout HeLa clones were sterol depleted overnight then cultured for four hours in the 
presence or absence of sterols. Cells were lysed and immunoblotted for HMGCR to assess the sterol 
induced degradation of HMGCR. (D) Wild type HeLa cells and two RNF145 knockout clones derived 
from independent gRNAs (5_7 and 8_20) were sterol depleted overnight then cultured with sterols 
for the time indicated. Cells were harvested, lysed and immunoblotted for HMGCR to assess the sterol 
induced degradation of HMGCR in the absence of RNF145 over a four-hour period. 
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5.3 Discussion 
5.3.1 Tagging endogenous proteins using CRISPR/Cas9 genome editing technology 
CRISPR/Cas9 technology is an incredibly powerful tool for cell biology research. Not only does 
CRISPR-mediated gene disruption allow the rapid generation of gene knockouts, it can be 
used to create knock-in cell lines, in which endogenous proteins are tagged with markers such 
as fluorescent proteins. The ability to perform a fluorescence-based forward genetic screen 
on the endogenous protein allowing me to monitor cellular changes in real time is a major 
advantage over the artefact-prone over-expression of an exogenous transgene. Before the 
advent of CRISPR/Cas9 technology, a fluorescence-based screen could only be performed on 
the expression of an endogenous protein if a good antibody was available against the protein 
of interest. Moreover, iterative sorts were not possible if an intracellular stain was required. 
I started the search for the ubiquitin E3 ligase targeting HMGCR using a HMG-mCherry 
reporter. I originally thought that the use of an exogenous SREBP-independent promoter 
would focus the screen on the sterol-regulated degradation of HMGCR. However, both 
genome-wide CRISPR screens did not significantly enrich a population of mutants that showed 
significantly reduced sterol-induced HMGCR degradation. Tagging endogenous HMGCR with 
Clover using CRISPR/Cas9 genome editing technology allowed me to take advantage of the 
SREBP-dependent transcription to create a large window to screen for mutants with impaired 
sterol-induced HMGCR degradation. This approach enabled a significant enrichment of 
mutants that were unable to degrade HMGCR as efficiently as the starting clone in response 
to sterols. Consequently, the HMGCR-Clover screen using sterol depletion identified more 
candidate genes with higher confidence. 
 
5.3.2 Differential effects of Insig proteins on the sterol-induced degradation of HMGCR 
The human genome encodes two Insig isoforms, Insig1 and Insig2. Both proteins function as 
sterol-sensing domain (SSD) interacting proteins (Dong and Tang 2010). At high levels of 
cellular cholesterol, both Insigs can interact with SCAP’s SSD and retain the SCAP-SREBP 
complex in the ER to inhibit SREBP-dependent transcription (Yabe, Brown, and Goldstein 
2002, Yang et al. 2002). Both Insig proteins also enable the sterol-induced degradation of 
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HMGCR by associating with HMGCR’s SSD in a sterol-dependent manner (Sever, Yang, et al. 
2003, Sever, Song, et al. 2003). 
As a part of the characterisation of the HMGCR-Clover cell line, I knocked out the Insig genes 
using CRISPR-mediated gene disruption (Figure 5.2B).  In the absence of Insig1 I observed a 
significant block in the sterol-induced degradation of HMGCR-Clover, whereas in the absence 
of Insig2 there was only a small decrease in the sterol-induced degradation of HMGCR-Clover. 
These partially redundant phenotypes imply a more significant role for Insig1 in the sterol-
induced degradation of HMGCR in this cell line. Insig2 might have a comparatively low 
expression level in HeLa cells and might not be able to efficiently mediate the sterol-induced 
degradation of HMGCR. There are no commercially available antibodies against the Insig 
proteins, so I cannot readily compare the protein abundance of an Insig in the absence of the 
other. 
 
5.3.3 Statistical significance in a forward genetic screen does not correlate with the gene-
knockout phenotype 
As the loss of Insig2 alone only had a minor effect on the sterol-induced degradation of 
HMGCR-Clover (Figure 5.2B), it might be surprising that Insig2 is the most statistically 
significant gene in the CRISPR screen (Figure 5.5E). This example demonstrates the power of 
forward genetic screens to identify genes with small intermediate phenotypes. The statistical 
significance of a candidate gene is determined by the enrichment of the gRNAs that target 
that gene. The enrichment of a gRNA is not only dependent on the phenotype of the gene 
knockout, but also the efficiency of gene knockout and the growth disadvantage (or 
advantage) of the gene knockout. Therefore, the statistical significance of a gene as a 
candidate in a forward genetic screen does not provide insight into the strength of the 
phenotype caused by the loss of that gene, i.e. the phenotype caused by the loss of Insig1 is 
greater than that caused by the loss of Insig2 (Figure 5.2B). 
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5.3.4 RNF145 is required for the sterol-induced degradation of HMGCR-Clover 
In Chapter 4 I validated the involvement of RNF145 in the sterol-induced degradation of HMG-
mCherry, however I was unable to see a requirement for RNF145 on the sterol-induced 
degradation of endogenous HMGCR. In this chapter, I refined the forward genetic screen by 
using a knock-in cell line expressing Clover-tagged endogenous HMGCR. However, RNF145 
was still the only E3 ligase identified. Using a flow cytometry-based assay, I could now see a 
small decrease in the sterol-induced degradation of endogenous HMGCR in the absence of 
RNF145 (Figure 5.6A). This finding could indicate an indirect effect on HMGCR degradation in 
the absence of RNF145 or functional redundancy amongst multiple ubiquitin E3 ligases able 
to ubiquitinate HMGCR in response to sterols. The next aim of my thesis project was therefore 
to identify other E3 ubiquitin ligases that ubiquitinate HMGCR alongside RNF145. 
 
5.4 Summary 
In this chapter, I generated a knock-in cell line, in which endogenous HMGCR is tagged with 
the fluorescent protein Clover. I demonstrated the correct regulation of HMGCR-Clover 
expression using chemical inhibitors, modulating sterol conditions, and using CRISPR-
mediated gene disruption to knockout UBE2G2 and the Insigs. I went on to use the HMGCR-
Clover cell line in two genome-wide CRISPR knockout screens. The first screen identified a 
large suite of genes required to maintain basal expression of HMGCR. The second screen 
focussed on the sterol-induced degradation of HMGCR and identified known components of 
the ERAD machinery alongside the ERAD E3 ligase RNF145, which I had previously identified 
in Chapter 4. CRISPR validation of RNF145 revealed a small decrease in sterol-induced 
degradation of HMGCR-Clover in the absence of RNF145. 
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Chapter 6: Gp78 and RNF145 are required 
for the sterol-induced degradation of 
HMGCR 
 
6.1 Introduction 
I have presented a series of genome wide CRISPR knockout screens to identify the ubiquitin 
E3 ligase for HMGCR. The poorly characterised E3 ligase RNF145 was identified by two screens 
that used sterol depletion to focus on the degradation of HMGCR. However, the CRISPR 
validation of RNF145 only revealed a small but reproducible decrease in the degradation of 
HMGCR-Clover and I could not detect an effect on wild type HMGCR by immunoblot. The two 
most likely possibilities for the small decrease in HMGCR-Clover degradation in the absence 
of RNF145 are that RNF145 regulates HMGCR degradation indirectly or that another ubiquitin 
E3 ligase compensates for the loss of RNF145 and can ubiquitinate HMGCR as well.  
Several studies have previously found a requirement for multiple E3 ligases to efficiently 
target ERAD substrates for degradation (El Khouri et al. 2013, Zhang et al. 2015). The next aim 
of my thesis project was therefore to identify the E3 ligase that is functionally redundant with 
RNF145. 
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6.2 Results 
6.2.1 Depletion of gp78 suggests functional redundancy with RNF145  
I took a candidate gene approach to investigate whether RNF145 is redundant with other 
ubiquitin E3 ligases. As gp78 and TRC8 had previously been implicated in HMGCR ERAD, I 
started by testing the sterol-induced degradation of HMGCR-Clover following the depletion 
of gp78 and TRC8 in the presence and absence of RNF145 (Figure 6.1). I used CRISPR-
mediated gene disruption to produce a RNF145 null background in the HMGCR-Clover HeLa 
cell line. The loss of RNF145 caused a small decrease in the sterol-induced degradation of 
HMGCR-Clover, as described in Chapter 5.  
Depletion of gp78 in the gControl population resulted in a decrease in the sterol-induced 
degradation of HMGCR-Clover, implicating a role for gp78 in HMGCR degradation (Figure 6.1). 
When I depleted gp78 in the RNF145 null background, I observed a significant increase in 
HMGCR-Clover at steady state and a pronounced decrease in the sterol-induced degradation 
of HMGCR-Clover. This strongly suggests that there is redundancy between gp78 and RNF145 
in the sterol-induced degradation of HMGCR. 
There was no difference in sterol-induced HMGCR-Clover degradation between cells 
transfected with control siRNA or TRC8-targeting siRNA in the presence or absence of RNF145. 
I did not confirm TRC8 depletion by qPCR or immunoblot, however I used the laboratory 
protocol that results in the efficient depletion of TRC8 (Stagg et al. 2009). 
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Figure 6.1 Gp78 and TRC8 siRNA-mediated knockdown in the presence and absence of 
RNF145 HMGCR-Clover HeLa cells were transfected with Cas9 and either a control gRNA or a 
pool of four RNF145-targeting gRNAs. Transfected cells were selected with puromycin 
treatment. Selected cells were transfected with 100nM control siRNA on day 5 post gRNA 
transfection, 100nM gp78 siRNA on day 5 post gRNA transfection or 50nM TRC8 siRNA day 6 
post gRNA transfection. The cells were sterol depleted overnight eight days post gRNA 
transfection. On day 9 post gRNA transfection, cells were cultured for a further two hours in 
the presence or absence of sterols. HMGCR-Clover expression was assessed by flow 
cytometry. Representative of two independent experiments. 
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6.2.2 Gp78 and RNF145 are required for sterol-induced HMGCR-Clover degradation 
I sought to determine whether the decreased sterol-induced HMGCR-Clover degradation in 
gp78 siRNA-treated cells was caused by the loss of gp78 or an siRNA off-target effect. I used 
a pool of four gRNAs to knockout gp78 by CRISPR-mediated gene disruption. Here, I saw no 
difference in sterol-induced HMGCR-Clover degradation between gGp78 and gControl 
HMGCR-Clover cells (Figure 6.2A). Targeting RNF145 with a pool of four gRNAs, once again, 
resulted in a small decrease in sterol-induced HMGCR-Clover degradation. When I 
simultaneously targeted gp78 and RNF145 with a pool of four gRNAs against each ligase, I saw 
a marked increase in HMGCR-Clover at steady state and a pronounced decrease in the sterol-
induced degradation of HMGCR-Clover. The loss of both gp78 and RNF145 resulted in a 
phenotype reminiscent of the absence of UBE2G2. This provides strong evidence of the 
functional redundancy of gp78 and RNF145 and implies that both ligases are required for the 
sterol-induced degradation of HMGCR-Clover.  
When TRC8 was targeted by CRISPR-mediated gene disruption using a single gRNA, I did not 
observe functional redundancy between RNF145 and TRC8 in the degradation of HMGCR 
(Figure 6.2B). I confirmed the efficient generation of TRC8 knockout cells by analysing the 
TRC8-dependent degradation of MHC-I by the human cytomegalovirus protein US2 (Stagg et 
al. 2009). Transducing control cells with US2 resulted in the down-regulation of MHC-I at the 
cell surface (red line in Figure 6.2C). However, less than 30% of the gTRC8 population 
displayed a low MHC-I cell surface phenotype following US2 transduction (cells gated on CFP 
marker for US2 expression), demonstrating the efficient generation of TRC8 knockouts by 
CRISPR-mediated gene disruption. 
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Figure 6.2 CRISPR-mediated gene disruption of both gp78 and RNF145 causes a significant decrease 
in sterol-induced HMGCR-Clover degradation. (A) HMGCR-Clover HeLa cells were transiently 
transfected with Cas9 and either a control gRNA, a pool of three gRNAs targeting UBE2G2, a pool of 
four gRNAs targeting gp78, a pool of four gRNAs targeting RNF145, or a pool of eight gRNAs in which 
four target gp78 and four target RNF145. Transfected cells were selected with puromycin. Cells were 
sterol depleted overnight seven days post-transfection and then cultured for a further two hours in 
the presence or absence of sterols. (B) As (A) but a single gRNA targeted TRC8 instead of a pool of four 
gRNAs targeting gp78. (C) US2-mediated downregulation of MHC-I to confirm TRC8 knockout. HeLa 
cells were transfected with Cas9 and either a control or TRC8-targeting gRNA. Transfected cells were 
selected by puromycin treatment. Selected cells were transduced with a lentiviral construct encoding 
US2 and a CFP marker on day 5 post-transfection. MHC-I cell surface expression was measured by flow 
cytometry on day 10 post-transfection. Representative of more than three independent experiments. 
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6.2.3 Gp78 and RNF145 are required for the sterol-induced degradation of wild type HMGCR 
It was crucial to confirm that the loss of gp78 and RNF145 caused a significant decrease in the 
sterol-induced degradation of wild type HMGCR and that the Clover tag was not responsible 
for the double knockout phenotype. I generated gp78 and RNF145 double knockout HeLa 
clones by transfecting RNF145 knockout clones derived from gRNA #5 (5_7 and 5_26 from 
Figure 5.7) with gp78 gRNA #4 and by transfecting RNF145 knockout clone 8_20 (derived from 
gRNA #8) with gp78 gRNA #3.  I used different combinations of gRNAs to minimise the risk of 
pursuing a gRNA off-target effect. The loss of gp78 in clones derived from RN145 knockout 
cells was confirmed by Immunoblot (Figure 6.3A). 
Immunoblot analysis of the gp78 and RNF145 double knockout HeLa clones revealed a 
significant recue of HMGCR at steady state (Figure 6.3B). Whereas, the loss of RNF145 alone 
only caused a small increase in steady state HMGCR expression. The ability of the gp78 and 
RNF145 double knockout clones to degrade HMGCR in response to sterols was assessed by 
sterol depleting the clones overnight followed by a further four-hour culture in the presence 
or absence of sterols. Encouragingly in every case, the double knockout clones had a marked 
reduction in sterol-induced HMGCR degradation (Figure 6.4). In comparison, the RNF145 
knockout clones were indistinguishable from wild type HeLa cells. Thereby demonstrating the 
requirement of both gp78 and RNF145 to efficiently degrade endogenous wild-type HMGCR 
in response to sterols. 
 
 
 
 
 
 
 
 
 
Chapter 6: Gp78 and RNF145 are required for the sterol-induced degradation of HMGCR 
 
145 
 
 
Figure 6.3 Gp78 and RNF145 double knockout clones have increased HMGCR expression at 
steady state (A) Gp78 knockout clones were identified by immunoblot. Clones were derived 
using different combinations of gp78 and RNF145 gRNAs. (B) Steady state HMGCR expression 
was assessed by immunoblot in parental wild type HeLa cells, RNF145 knockout clones and 
gp78 and RNF145 double knockout clones.  
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Figure 6.4 Gp78 and RNF145 double knockout clones cannot degrade HMGCR efficiently in 
response to sterols. Wild type HeLa cells or knockout clones were sterol depleted overnight, 
then cultured for a further four hours in the presence or absence of sterols. Cells were then 
lysed and immunoblotted for HMGCR (WT, wild type). 
 
6.2.4 Generating a gp78 and RNF145 double knockout HMGCR-Clover HeLa cell line 
I used FACS to generate a gp78 and RNF145 double knockout HMGCR-Clover cell line. To this 
end, HMGCR-Clover cells were transiently transfected with Cas9, gp78 gRNA #4 and RNF145 
gRNA #8. Eight days after transfection and selection of puromycin-resistant cells, an overnight 
sterol depletion was performed. The following day, sterols were added to the sterol depleted 
culture for two hours. I then selected cells expressing high levels of HMGCR-Clover by FACS 
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(Figure 6.5A) and confirmed the successful enrichment of a population that had a significant 
block in the sterol-induced degradation of HMGCR-Clover. Immunoblot analysis of the 
selected population confirmed the absence of gp78 and RNF145 protein (Figure 6.5B). 
Figure 6.5 Generating a gp78 and RNF145 double knockout HMGCR-Clover HeLa cell line (A) 
HMGCR-Clover cells were transfected with gp78 gRNA #4 and gp78 gRNA #8.  Transfected 
cells were selected with puromycin. Cells were sterol depleted overnight 8 days post 
transfection and then cultured for a further two hours in the presence or absence of sterols. 
HMGCR-Cloverhigh cells were selected by FACS. (B) Immunoblot to confirm loss of gp78 and 
RNF145 protein in the FACS selected population. RNF145 knockout clone 5_7 was used to 
confirm the RNF145 band. 
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6.2.5 Sterol-induced degradation of HMGCR requires E3 ligase activity of RNF145 
To confirm a role for RNF145 in the sterol-induced degradation of HMGCR, I sought to restore 
HMGCR-Clover degradation in the gp78 and RNF145 double knockout line by genetic 
complementation. Wild type RNF145 cDNA expressed by lentiviral transduction in the gp78 
and RNF145 double knockout HMGCR-Clover cell line resulted in a near-complete rescue of 
sterol-induced HMGCR-Clover degradation (Figure 6.6A). The expression of a RING-mutant 
(C552A H554A) RNF145 in the gp78 and RNF145 double knockout HMGCR-Clover cell line 
could not rescue sterol-induced HMGCR-Clover degradation showing that the E3 ligase 
activity of RNF145 is required for HMGCR degradation. Immunoblotting revealed that 
mutating the RING domain increased the expression of RNF145 (Figure 6.6B). This is a 
common observation for ubiquitin E3 ligases owing to their intrinsic auto-ubiquitination 
activity (Deshaies and Joazeiro 2009).  
The first five transmembrane helices of RNF145 are predicted to constitute a sterol sensing 
domain (SSD) (Cook et al. 2017). The second helix contains a YLYF motif, which shares 
sequence homology with the YIYF motif in the SSDs of SCAP and HMGCR. Mutating the YIYF 
motif in SCAP prevents association with Insigs and therefore inhibits the retention of SREBP 
in the ER (Yang et al. 2002). Mutating the YIYF motif in HMGCR also prevents the association 
with Insigs and therefore blocks the sterol-induced degradation of HMGCR (Sever, Song, et al. 
2003). To determine whether RNF145’s YLYF motif is required for the sterol-induced 
degradation of HMGCR, I mutated the YLYF motif to ALAF and AAAA, the same mutations 
introduced to HMGCR by Sever et al. (Sever, Song, et al. 2003). Unfortunately, the ALAF and 
AAAA RNF145 mutants were poorly expressed (Figure 6.6B), barring a comparison of their 
ability to restore HMGCR degradation to wild type RNF145. A possible solution to this problem 
could be to mutate the tyrosine residues to another hydrophobic residue such as 
phenylalanine. This might disrupt Insig binding but maintain the structure of the helix in the 
ER membrane. 
It was not until later in the project that a RNF145 antibody became available. The RNF145 
cDNA constructs in Figure 6.4C and 6.4D were therefore tagged with V5 to allow detection by 
immunoblot. Once I had a RNF145 antibody I could compare the expression level of the 
exogenous to endogenous RNF145. This revealed that there was only a modest over-
expression of exogenous RNF145 (Figure 6.6C). 
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Figure 6.6 E3 ligase activity of RNF145 is required for HMGCR degradation (A) The gp78 and RNF145 
double knockout HMGCR-Clover cell line was transduced with a lentiviral construct encoding an 
RNF145 cDNA (wild type, RING-mutant, ALAF (SSD mutant) or AAAA (SSD mutant). Transduced cells 
were selected by hygromycin selection. Sterol-induced degradation was assessed 6 days post 
transduction. (B) Immunoblot analysis of the cells from (A) revealed lower expression of SSD mutants 
and increased expression of RING-mutant compared to wild type RNF145 cDNA. (C) RNF145 knockout 
clone 5_7 was transduced with a lentiviral construct encoding either untagged or V5-tagged wild type 
RNF145. Transduced cells were selected by hygromycin selection, then lysed and immunoblotted to 
compare the expression level of endogenous and exogenous RNF145. 
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6.2.6 Gp78 knockout HeLa clones do not have impaired sterol-induced HMGCR degradation 
To determine the effect that the loss of gp78 has on HMGCR ERAD and to create stable 
reagents for future assays, I generated gp78 knockout clones using CRISPR-mediated gene 
disruption. Gp78 knockout clones, derived from two independent gRNAs, were identified by 
immunoblot (Figure 6.7A).  
I used Insig1, a known gp78 substrate, to demonstrate a functional consequence for the loss 
of gp78 (Lee, Song, et al. 2006). I transduced the parental wild type HeLa cells and gp78 
knockout clones, at a low M.O.I., with a lentiviral construct encoding myc-tagged Insig1. 
Immunoblot analysis revealed a dramatically higher expression of Insig1 in the gp78 knockout 
clones than in wild type HeLa cells, demonstrating a functional consequence for the loss of 
gp78 (Figure 6.7B). 
The fact that gp78 targets Insig1 for degradation complicates the effect that the loss of gp78 
has on HMGCR. There are no human Insig antibodies available, so I could not determine the 
expression level of endogenous Insig1 in the gp78 knockout HeLa clones. Gp78 knockout 
mouse embryonic fibroblasts and hepatocytes exhibit increased Insig1 expression at steady 
state (Tsai et al. 2012, Liu et al. 2012). Increased Insig1 expression will promote SCAP-SREBP 
retention in the ER, decreasing transcription of SREBP target genes. The increase in Insig1 
could also promote the degradation of HMGCR (Song, Sever, and DeBose-Boyd 2005).  
Some of the gp78 knockout clones showed a minor increase in HMGCR expression at steady 
state (Figure 6.7A), potentially driven by the reduced metabolic flux through the cholesterol 
biosynthesis pathway as a result of increased Insig1 levels (Liu et al. 2012). Decreased 
cholesterol production will feedback to stabilise HMGCR. 
The gp78 knockout HeLa clones could degrade HMGCR in response to sterols as efficiently as 
the parental wild type HeLa cells (Figure 6.7C). This is consistent with the observation that 
gp78 knockout MEFs can degrade HMGCR as efficiently as wild type MEFs (Tsai et al. 2012). 
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Figure 6.7 Gp78 knockout clones to analyse HMGCR degradation (A) Wild type HeLa cells 
were transfected with Cas9 and either gp78 gRNA #3 or #4. Transfected cells were selected 
by puromycin treatment then single cell cloned by serial dilution. Clones were screened by 
immunoblot. The absence of gp78 in two clones derived from each gRNA (3_4 and 3_17 from 
gRNA #3, 4_2 and 4_4 from gRNA #4) was confirmed (WT, wild type). (B) Wild type HeLa cells 
and gp78 knockout clones were transduced an M.O.I. of 0.1 with a lentiviral vector encoding 
myc-tagged Insig1. Transduced cells were selected with puromycin treatment. The selected 
cells were harvested, lysed and immunoblotted to assess Insig1-myc expression. (C) Parent 
wild-type HeLa cells and gp78 knockout HeLa clones were sterol depleted overnight followed 
by a further four-hour culture in the presence or absence of sterols. Cells were harvested, 
lysed and immunoblotted for HMGCR. 
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6.2.7 UBE2G2 is required for the sterol-induced degradation of HMGCR 
Throughout this thesis project, I have used UBE2G2 as a positive control for a gene whose loss 
leads to a significant block in sterol-induced HMGCR degradation. Consequently, UBE2G2 
knockout HeLa clones were generated as a positive control to assess HMGCR ubiquitination. 
UBE2G2 knockout clones derived from two independent gRNAs were identified by 
immunoblot (Figure 6.8A). Consistent with other UBE2G2 knockout clones in my thesis 
project, I observed an increase in HMGCR steady state expression and a significant block in 
the sterol-induced degradation of HMGCR (Figure 6.8B and 6.8C). Clone C1 was selected as a 
knockout clone when I first screened the clones and was used in the experiments shown in 
Figure 6.6. However, a much longer exposure of the immunoblot revealed a small amount of 
UBE2G2 protein in the clone C1. I have not sequenced the locus targeted by gRNA #C in this 
clone, however it would appear that at least one of the alleles has been repaired in-frame but 
the mutation has resulted in a dramatic decrease in UBE2G2 protein abundance. It is striking 
that the residual UBE2G2 protein in clone C1 appears to be sufficient to mediate HMGCR 
degradation (Figure 6.8C). However, clone C1 acts as a useful control. 
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Figure 6.8 UBE2G2 is required for the sterol-induced degradation of HMGCR (A) Wild type 
HeLa cells were transfected with Cas9 and either UBE2G2 gRNA #A or #C. Transfected cells 
were selected by puromycin treatment then single cell cloned by serial dilution. UBE2G2 
knockout clones were identified by immunoblot. Two clones were selected that were derived 
from gRNA #A, A7 and A8, and another two clones were selected that were derived from 
gRNA #C, C1 and C2 (WT, wild type). (B) Parental wild-type HeLa cells and UBE2G2 knockout 
clones were lysed and immunoblotted for HMGCR to analyse steady state HMGCR expression. 
(C) Parental wild-type HeLa cells and UBE2G2 knockout clones were sterol depleted overnight 
and then cultured for a further four hours in the presence or absence of sterols. The cells 
were then harvested, lysed and immunoblotted for HMGCR. 
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6.2.8 Gp78 and RNF145 are required for the sterol-induced ubiquitination of HMGCR 
Before assessing HMGCR ubiquitination, I validated the HMGCR immunoprecipitation (Figure 
6.9A). I observed the efficient enrichment of HMGCR from sterol depleted cells, using 
untreated cells as a negative control. HMGCR was efficiently eluted from the antibody 
following a 15-minute incubation at 50oC. 
To assess the requirement of gp78 and RNF145 for the sterol-induced ubiquitination of 
HMGCR, single and double knockout clones were sterol depleted overnight. The cells were 
treated with 50µM MG132, a proteasome inhibitor, for 30 minutes before a one-hour culture 
in the presence or absence of sterols. Figure 6.9B suggests a small decrease in HMGCR 
ubiquitination in the absence of gp78 or RNF145, however this was not observed in RNF145 
knockout cells in Figure 6.9C. In contrast, the combined loss of gp78 and RNF145 caused an 
almost complete loss of sterol-induced HMGCR ubiquitination (Figure 6.9C). As robust sterol-
induced degradation of HMGCR was observed in the presence of either gp78 or RNF145, both 
gp78 and RNF145 can mediate the polyubiquitination of HMGCR. Consistent with previous 
studies, the loss of UBE2G2 resulted in a significant block to sterol-induced HMGCR 
ubiquitination (Figure 6.9B and Figure 6.9C) (Miao et al. 2010). 
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Figure 6.9 Gp78 and RNF145 are required for the sterol-induced ubiquitination of HMGCR 
(A) Wild type HeLa cells were left untreated or sterol depleted overnight to induce HMGCR 
expression. 106 cells were lysed and HMGCR was immunoprecipitated with Rb anti-HMGCR 
and Protein A Sepharose overnight at 4oC. The next day the immunoprecipitation was washed 
5 times before resuspending in 20 µl of 2x SDS sample loading buffer. The samples were first 
incubated at 50oC for 15 minutes. The samples were spun down, the supernatant removed 
and run out on a gel (50oC). Another 20 µl aliquot of 2x SDS sample loading buffer was added 
to the pellet followed by a 15-minute incubation at 65oC. The samples were spin down, the 
supernatant was removed and run out on a gel (65oC). (UN, untreated; SD, sterol depleted) 
(B) Parental wild-type HeLa cells or single knockout clones (gp78 knockout clone 4_2, RNF145 
knockout clone 5_7 and UBE2G2 knockout clone A7) were sterol depleted overnight. The 
following day, all sterol depleted cells were treated with 50µM MG132 for 30 minutes and 
then for one hour in the presence or absence of sterols. 4x106 cells from each condition were 
harvested and immunoprecipitated with anti-HMGCR, followed by immunoblot for ubiquitin. 
(C) sterol induced HMGCR ubiquitination was assessed in wild-type HeLa cells, RNF145 
knockout clone 5_7, gp78 and RNF145 double knockout clone 5_7 #7 and UBE2G2 knockout 
clone A7 as described in (B). 
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6.2.9 RNF145 constitutively associates with Insig1 and Insig2 
The model for the sterol-induced degradation of HMGCR revolves around the Insig proteins 
acting as sterol-sensitive scaffolds to recruit an E3 ubiquitin ligase complex to HMGCR 
(Goldstein, DeBose-Boyd, and Brown 2006). I therefore wanted to determine whether 
RNF145 interacts with the Insig proteins and whether this interaction is sensitive to the sterol 
environment. 
Due to the absence of antibodies against endogenous Insig1 and Insig2, epitope-tagged Insig 
cDNAs were used. To ensure that the exogenous Insig proteins restore HMGCR degradation 
in Insig knockout cells, Insig knockout HMGCR-Clover cells for each Insig were created by 
transiently transfecting Cas9 and a pool of four gRNAs. After a prolonged culture (8 days) the 
knockout cell lines were transduced with a lentiviral construct encoding an Insig. Transduced 
cells were selected and the sterol-induced degradation of HMGCR-Clover was assessed 
(Figure 6.10A). Re-expression of each myc-tagged Insig restored the steady state expression 
of HMGCR-Clover as well as the sterol-induced degradation of HMGCR-Clover. Epitope-tagged 
Insig transgenes are therefore appropriate tools to investigate the mechanism of HMGCR 
degradation. 
Next, I stably expressed myc-tagged Insig1 and myc-tagged Insig2 in the presence or absence 
of V5-tagged (C-terminus) RING-mutant RNF145 in a gp78 and RNF145 double knockout HeLa 
clone. Cells were sterol depleted overnight, then treated with 50nM Bortezomib for 30 
minutes before a further 2-hour culture in the presence or absence of sterols. Both Insig1 and 
Insig2 co-precipitated with RNF145 in the presence and absence of sterols (Figure 6.10B). The 
constitutive association of RNF145 with the Insigs should enable RNF145 to be recruited to 
HMGCR in response to sterols. 
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Figure 6.10 RNF145 constitutively associates with Insig1 and Insig2 (A) HMGCR-Clover cells were 
transiently transfected with Cas9 and a pool of four gRNAs targeting either Insig1 or Insig2. 
Transfected cells were selected by puromycin treatment. Eight days later, Insig knockout HMGCR-
Clover cells were transduced with a lentiviral construct encoding the (myc-tagged) Insig gene that had 
been disrupted. Transduced cells were selected by puromycin selection. Cells were sterol depleted 
overnight and then cultured for a further two hours in the presence or absence of sterols. HMGCR-
Clover expression was assessed by flow cytometry. (B) A gp78 and RNF145 double knockout HeLa 
clone was transduced with lentiviral constructs encoding either myc-tagged Insig1 or Insig2 with or 
without V5-tagged RING-mutant RNF145. Transduced cells were selected with puromycin (Insig) or 
hygromycin (RNF145). Selected cells were sterol depleted overnight. The following day, the sterol 
depleted samples were treated with 50nM Bortezomib for 30 minutes and then cultured for a further 
2 hours in the presence or absence of sterols. Cells were then lysed and RNF145-V5 was 
immunoprecipitated. Immunoprecipitates were resolved by SDS-PAGE and immunoblotted. 
Representative of two independent experiments. 
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6.2.10 Identifying RNF145 binding partners by mass spectrometry 
I sought to identify other RNF145 interacting factors by performing an immunoprecipitation 
followed by mass spectrometry analysis. I stably expressed V5-tagged wild type RNF145 in a 
RNF145 knockout HeLa clone (5_7). Whilst RNF145 is constitutively associated with the Insig 
proteins, I predicted that other interactions made with RNF145 would be sensitive to the 
cellular sterol environment. Three sets of RNF145-V5-expressing cells were sterol depleted 
overnight. The next day, one sample remained under sterol deplete conditions, one sample 
was treated with sterols for one hour and the last sample was treated with 50µM MG132 for 
30 minutes followed by 1 hour with sterols. I also performed an immunoprecipitation in the 
RNF145 knockout clone that did not express RNF145-V5 to control for non-specific binding to 
anti-V5 antibody or Protein A Sepharose beads. 
A selection of proteins identified from the RNF145-V5 immunoprecipitations are listed in 
Table 6.1 (full list in Appendix 3). It is surprising that HMGCR is identified in the sterol depleted 
sample (10 peptides). The Insig and HMGCR interaction is dependent on sterols and so it 
would be expected that the RNF145 and HMGCR interaction would also be sterol dependent 
(Sever, Song, et al. 2003). Treating sterol depleted cells with sterols for one hour did not 
increase the abundance of HMGCR in the RNF145-V5 immunoprecipitation and the number 
of unique peptides identified decreased (7 peptides). However, both the number of unique 
peptides (16 peptides) and the area (a measure of abundance) of HMGCR increased when the 
sterol depleted cells were treated with sterols and MG132. This suggests a sterol dependent 
interaction between HMGCR and RNF145 that is sensitive to proteasome inhibition. It was 
promising to detect an interaction between HMGCR and RNF145, however proteasome 
inhibition was not controlled for. It is therefore not possible to exclude a constitutive 
association between HMGCR and RNF145 that is protected by proteasome inhibition.  
Multiple ERAD components and proteasome subunits were identified by mass spectrometry. 
UBXD8 (FAF2) is a hit in both genome wide CRISPR knockout screens that used sterol 
depletion to focus on HMGCR degradation. UBXD8 helps to recruit the p97 ATPase complex 
to the ER membrane (Lee et al. 2008). UBAC2 recruits UBXD8 to gp78, therefore the mass 
spectrometry data suggests that UBAC2 might also recruit UBXD8 to RNF145 (Christianson et 
al. 2012). Erlin-2 and Derlin-1 are common interaction partners of ERAD E3 ubiquitin ligases 
(Christianson et al. 2012). Ubiquilin is proposed to assist delivery of poly-ubiquitinated 
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substrates to the proteasome (Ko et al. 2004). No E2 conjugating enzyme was identified in 
the RNF145 immunoprecipitation, however AUP1 was identified. AUP1 recruits UBE2G2 to 
TRC8 and assists the recruitment of UBE2G2 to gp78 (Jo, Hartman, and DeBose-Boyd 2013). 
It is therefore likely that AUP1 facilitates the recruitment of UBE2G2 to RNF145.  
A striking hit from the RNF145-V5 immunoprecipitation is gp78. The number of unique 
peptides identified and gp78 abundance is similar in the sterol depleted and sterol treated 
samples, with an increase in unique peptides and abundance in the sterol treated sample with 
MG132, a pattern resembling HMGCR.  This suggests that gp78 and RNF145 could oligomerise 
through a direct interaction. Perhaps more likely, gp78 and RNF145 might interact with the 
same Insig molecule through distinct binding sites. However, the over-expression of the 
transmembrane domain of gp78 inhibits HMGCR degradation. If correct this might imply that 
the E3 ubiquitin ligases have a shared binding site on the Insig proteins (Song, Sever, and 
DeBose-Boyd 2005). No other ERAD E3 ligases were identified in the mass spectrometry 
analysis. 
Several hits are SREBP-2 target genes in the cholesterol biosynthesis pathway, such as HMG-
CoA Synthase and 7-dehydrocholesterol reductase (Dooley, Millinder, and Osborne 1998, 
Prabhu, Sharpe, and Brown 2014). Importantly, the negative control for non-specific 
immunoprecipitation was not sterol depleted and the protein abundance might be too low 
without sterol depletion to detect these proteins as non-specific binding partners. 
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Table 6.1 Selected interaction partners of RNF145. Three sets of RNF145 knockout HeLa cells 
stably expressing RNF145-V5 were sterol depleted overnight. The next day, one sample 
remained sterol depleted, another was treated with sterols for one hour and the other sample 
was treated with 50µM MG132 for 30 minutes before a 1-hour culture with sterols. The 
RNF145 knockout clone without RNF145-V5 was used as a negative control. 1x107 cells from 
each condition were lysed and RNF145 was immunoprecipitated with anti-V5 antibody. 
Immunoprecipitates were analysed by mass spectrometry. Hits were excluded from RNF145-
V5 samples if they were detected in the negative control. Proteins are ranked based on the 
number of unique peptides in the MG132 and sterol treated sample. Area is a measure of 
abundance. Full list in Appendix 3. 
 
 
 
 
Peptides Area Peptides Area Peptides Area
Q8N766 ER membrane protein complex subunit 1 EMC1 15 1.99 13 2.40 19 3.35
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 10 1.41 7 1.41 16 7.65
Q96MT1 RING finger protein 145 RNF145 15 102.48 14 126.23 15 140.74
O14818 Proteasome subunit alpha type-7 PSMA7 7 2.98 4 2.57 9 8.04
P20618 Proteasome subunit beta type-1 PSMB1 3 0.78 3 0.93 9 3.82
Q14534 Squalene monooxygenase SQLE 5 1.08 5 1.40 8 2.77
P49720 Proteasome subunit beta type-3 PSMB3 2 1.02 2 0.81 7 3.84
P28074 Proteasome subunit beta type-5 PSMB5 5 0.97 2 0.55 7 4.05
A0A024RA52 Proteasome subunit alpha type-2 PSMA2 7 3.71
Q96CS3 FAS-associated factor 2 FAF2 3 1.53 5 1.98 6 4.70
Q9UKV5 E3 ubiquitin-protein ligase AMFR (gp78) AMFR 4 0.68 3 0.67 6 1.46
Q8NBM4 Ubiquitin-associated domain-containing protein 2 UBAC2 5 1.60 3 1.04 6 2.92
P28070 Proteasome subunit beta type-4 PSMB4 2 0.58 2 0.42 6 2.67
Q9UMX0 Ubiquilin-1 UBQLN1 2 1.27 6 1.68
Q16850 Lanosterol 14-alpha demethylase CYP51A1 2 0.58 6 1.21 5 1.31
Q9NPA0 ER membrane protein complex subunit 7 EMC7 2 0.85 2 0.73 5 1.31
O94905 Erlin-2 ERLIN2 2 0.70 4 0.65 5 1.21
Q15738 Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating NSDHL 1 1.86 1 2.13 4 1.47
P28066 Proteasome subunit alpha type-5 PSMA5 1 0.37 2 1.09 4 4.58
P28072 Proteasome subunit beta type-6 PSMB6 1 1.16 1 0.90 4 3.10
Q9UBV2 Protein sel-1 homolog 1 SEL1L 2 0.40 4 0.76
O14975 Very long-chain acyl-CoA synthetase SLC27A2 3 1.83 3 0.49 3 0.58
Q9P0I2 ER membrane protein complex subunit 3 EMC3 2 1.60 1 1.61 3 1.48
Q9Y679 Ancient ubiquitous protein 1 AUP1 1 0.43 1 0.17 3 1.12
Q9P035 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 HACD3 2 0.92 1 1.61 2 1.17
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic HMGCS1 4 0.87 4 1.89 2 0.68
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic ACAT2 3 0.78 3 1.33 2 1.04
Q99436 Proteasome subunit beta type-7 PSMB7 2 2.30
Q15006 ER membrane protein complex subunit 2 EMC2 2 0.28 1 1.12 2 1.36
Q9BUN8 Derlin-1 DERL1 2 0.40
Q9UBM7 7-dehydrocholesterol reductase DHCR7 1 1.00 2 0.79 1 1.18
Q9NR19 Acetyl-coenzyme A synthetase, cytoplasmic ACSS2 1 1.57 1 1.14
P37268 Squalene synthase FDFT1 2 0.73 3 0.67 1 1.25
O00767 Acyl-CoA desaturase SCD 1 2.63
SD + sterols +MG132
Accession Gene Name
Sterol depleted (SD) SD + sterols
Gene ID
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Immunoblot analysis demonstrated that the expression level of RNF145-V5 was only 
modestly higher than endogenous RNF145 (Figure 6.6C). It is therefore unlikely that the 
interaction partners identified in Table 6.1 are artefacts of protein over-expression. However, 
a recent analysis of Hrd1-interacting partners observed subtle differences between the 
immunoprecipitation of endogenous and over-expressed Hrd1 (Hwang, Walczak, et al. 2017). 
To further investigate potential RNF145-interacting partners, I immunoprecipitated 
endogenous RNF145 followed by mass spectrometry analysis. Four sets of wild type HeLa cells 
were sterol depleted overnight. The next day, one sample remained sterol depleted, and 
samples were treated with 50 nM Bortezomib for 1.5 hours, sterols for 1 hour or 50 nM 
Bortezomib for 30 minutes followed by a further hour with sterols. In addition, an RNF145 
knockout clone (8_20) was sterol depleted overnight and used as a negative control for non-
specific binding to anti-RNF145 antibody and Protein A Sepharose (Figure 6.11A). 
Of note, the number of unique peptides enriched with endogenous RNF145 was lower when 
compared with RNF145-V5 immunoprecipitation (full list in Appendix 4). An interpretation of 
this experiment is further complicated by the identification of RNF145 peptides in the 
immunoprecipitation from the RNF145 knockout clone (Figure 6.11B), presumably owing to 
the expression of a RNF145 truncated protein not detectable by immunoblot. The truncated 
protein might be able to associate with RNF145’s interaction partners rendering this 
particular RNF145 knockout clone an inadequate negative control.  
The immunoblot analysis of the total lysates and immunoprecipitates suggested there was an 
equivalent abundance of RNF145 in each sample (Figure 6.11A). However, the mass 
spectrometry identified a greater abundance of RNF145 peptides in Bortezomib treated 
samples (Figure 6.11B), consistent with a previous study (Cook et al. 2017).  
HMGCR was identified in each RNF145 immunoprecipitation (Figure 6.11B), however the 
abundance of HMGCR that co-precipitated with RNF145 increased significantly when the cells 
were treated with sterols in the presence of Bortezomib. This is consistent with the model in 
which sterols promote the recruitment of RNF145 to HMGCR and HMGCR is then degraded 
by the proteasome. As this project moves forward, it will be critical to determine whether the 
interaction between HMGCR and RNF145 is dependent on the Insig proteins. 
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I also tried to take advantage of the BioID system to identify RNF145 interaction partners 
(Roux et al. 2012). BirA is a biotin ligase from E. coli that becomes highly promiscuous when 
arginine 118 is mutated to glycine (R118G).  BirA R118G biotinylates proteins in close 
proximity, which can then be identified by a streptavidin immunoprecipitation and mass 
spectrometry (Roux et al. 2012). Unfortunately, the C-terminal BirA-tagged RNF145 fusion 
protein would not express in HeLa cells and the N-terminal BirA tagged RNF145 fusion protein 
was cleaved. I therefore could not pursue BioID as a method to identify RNF145 interaction 
partners. 
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Figure 6.11 Identification of HMGCR as an endogenous RNF145 interaction partner (A) Four sets of 
wild type HeLa cells were sterol depleted overnight. The following day, one sample remained sterol 
depleted, one sample was treated with 50nM Bortezomib for 1.5 hours, one sample was treated with 
sterols for 1 hour and the last sample was treated with 50nM Bortezomib for 30 minutes followed by 
a 1-hour culture with sterols. An RNF145 knockout clone (8_20) was also sterol depleted overnight. 
1x107 cells from each condition were lysed and endogenous RNF145 was immunoprecipitated with 
anti-RNF145 antibody. Five percent of the immunoprecipitates were resolved by SDS-PAGE to confirm 
the efficient enrichment of RNF145. The immunoprecipitates were analysed by mass spectrometry. 
Full list of proteins in Appendix 4. (B) The number of unique peptides and the abundance of RNF145 
and HMGCR in the immunoprecipitates described in (A) measured by mass spectrometry (SD, sterol 
depleted). 
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6.2.11 Gp78 might stabilise RNF145 during sterol-induced HMGCR ubiquitination 
The findings in this chapter suggest that gp78 and RNF145 are Insig-associated E3 ubiquitin 
ligases that ubiquitinate HMGCR. One of the current aims of the project is to determine 
whether gp78 and RNF145 influence each other’s expression or stability. In a preliminary 
experiment, the expression of RNF145 was analysed in the presence or absence of gp78, in 
different sterol conditions, with or without the proteasome inhibitor MG132 (Figure 6.12).  
In wild type HeLa cells, the expression of RNF145 initially appears to be induced by sterol 
depletion. This experiment has not been repeated and so I cannot rule out the inefficient 
transfer of RNF145 from the acrylamide gel to the PVDF membrane to account for the reduced 
RNF145 signal in the outer lanes of this immunoblot (Figure 6.12). 
In gp78 knockout cells, there is a marked increase in RNF145 expression in MG132-treated 
cells following the addition of sterols to a sterol-depleted culture (Figure 6.12). This suggests 
that RNF145 is co-degraded following sterol-induced HMGCR ubiquitination. The presence of 
gp78 might prevent the degradation of RNF145 by sharing the ubiquitination of HMGCR. 
Alternatively, given that gp78 was identified as a potential RNF145-interaction partner by 
mass spectrometry (Table 6.1), the association of RNF145 with gp78 might stabilise RNF145. 
This preliminary observation suggests that gp78 and RNF145 influence each other and 
understanding the relationship between the two E3 ligases is critical. This result (Figure 6.12) 
needs to be repeated and it will be interesting to see if gp78 is affected by the loss of RNF145. 
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Figure 6.12 RNF145 is degraded in the absence of gp78 by sterol repletion following sterol 
depletion. Wild type HeLa cells or gp78 knockout (clone 4_2) were sterol depleted overnight. 
The following day, sterols were added back into the sterol depleted culture for the indicated 
period. 50 µM MG132 was added to the indicated samples 30 min before the addition of 
sterols. Cells were lysed and analysed by immunoblot. 
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6.3 Discussion 
6.3.1 CRISPR-mediated gene disruption versus RNA interference 
Throughout this thesis project I have used CRISPR-mediated gene disruption to create 
knockout cell lines for loss-of-function analysis. Previously, projects relied on RNAi to deplete 
genes of interest. However, gene silencing with siRNA or shRNA is typically incomplete. The 
UBE2G2 CRISPR clone C1 (Figure 6.8A) is extraordinary as it is a heterozygous knockout with 
extremely low UBE2G2 protein abundance. The difference in UBE2G2 expression between 
clone C1 and the parental wild-type HeLa cells would represent a very efficient knockdown. 
However, residual UBE2G2 protein was sufficient to mediate the sterol-induced degradation 
of HMGCR (Figure 6.8C), emphasising the superiority of CRISPR-mediated gene disruption. 
A disadvantage of CRISPR-mediated gene disruption is that it takes longer to generate gene 
knockouts than for a gene to be depleted by RNAi. When I transfected control cells with gp78-
targeting siRNA, I observed a decrease in the sterol-induced degradation of HMGCR-Clover 
(Figure 6.1). Depleting gp78 in RNF145 knockout cells resulted in a greater decrease in the 
sterol-induced degradation of HMGCR-Clover. This raises the question, does the gp78 siRNA 
cause a phenotype due to the depletion of gp78 or an off-target effect of the siRNA? The 
Weissman laboratory made a convincing argument that the reduced rate of sterol-induced 
HMGCR degradation seen by the Debose Boyd laboratory following gp78 depletion is the 
result of siRNA off-target effects (Tsai et al. 2012). However, I used a different gp78 siRNA 
sequence to the Debose Boyd laboratory at a lower concentration and so it is unlikely that I 
observed the consequences of the same off-target effect. This raises the possibility that the 
acute loss of gp78 leads to a decreased rate of sterol-induced HMGCR degradation (Figure 
6.1), however over time the cell adapts so that the loss of gp78 does not impair the sterol-
induced degradation of HMGCR (Figure 6.2A).  
The depletion of a gene by RNAi can be readily determined by quantitative real-time (qPCR). 
The absence of a gene-specific antibody complicates determination of CRISPR-mediated gene 
knockout efficiency. Alternatively, gene knockouts can be confirmed by sequencing the gRNA-
targeted genomic locus to confirm frame-shift insertions or deletions in all alleles, as was 
initially done to identify RNF145 knockout clones in Chapter 5. However, this method cannot 
be applied to a heterogenous population.  
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6.3.2 Gp78 and RNF145 mediate the sterol-induced degradation of HMGCR 
Despite identification of RNF145 in two genome-wide CRISPR screens, only a small decrease 
in HMGCR reporter degradation was observed in CRISPR validation experiments. 
Consequently, I postulated the existence of an additional E3 ligase mediating the 
ubiquitination of HMGCR in the absence of RNF145. To test this hypothesis, I used CRISPR-
mediated gene disruption and RNA interference to abolish gp78 or TRC8 in the presence or 
absence of RNF145. I consistently saw a significant decrease in the sterol-induced degradation 
of HMGCR in the absence of both gp78 and RNF145 (Figure 6.1, 6.2, 6.3 and 6.4). The re-
expression of RING-mutant RNF145 could not restore HMGCR degradation in a gp78 and 
RNF145 double knockout cell line, indicating that the E3 ligase activity of RNF145 is required 
for HMGCR degradation (Figure 6.6A). A gp78 and RNF145 double knockout clone showed a 
significant reduction in sterol-induced HMGCR ubiquitination, whereas robust ubiquitination 
of HMGCR was observed in single gp78 or RNF145 knockout clones (Figure 6.9). This suggests 
that gp78 and RNF145 both ubiquitinate HMGCR and these two E3 ligases act in parallel, 
rather than sequentially. I did not observe any role for TRC8 in HMGCR degradation in HeLa 
cells (Figure 6.1 and Figure 6.2B). 
The sterol-induced degradation of HMGCR is dependent on the Insig proteins, which interact 
with HMGCR’s sterol sensing domain at high cellular cholesterol levels (Sever, Yang, et al. 
2003, Sever, Song, et al. 2003). The Debose Boyd laboratory have previously implicated gp78 
as the E3 ligase responsible for HMGCR degradation (Song, Sever, and DeBose-Boyd 2005, Jo 
et al. 2011). They observed the constitutive association of gp78 with Insig1 and a sterol 
dependent interaction between gp78 and HMGCR that was dependent on Insig1 (Song, Sever, 
and DeBose-Boyd 2005, Jo et al. 2011). The model for gp78-mediated ubiquitination of 
HMGCR therefore uses Insig1 as a sterol sensitive scaffold protein to recruit gp78 to HMGCR 
at high cholesterol levels. 
I observed RNF145 interacting with both Insig1 and Insig2 independent of sterols (Figure 
6.10B). This therefore places RNF145 in the position to be recruited to HMGCR by both Insig 
proteins in a sterol dependent manner. I identified HMGCR as a RNF145 interaction partner 
by mass spectrometry. This interaction was enhanced by sterols and proteasome inhibition 
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(Table 6.1 and Figure 6.11). Future work on this project will aim to determine whether the 
interaction between HMGCR and RNF145 is dependent on the Insig proteins. However, the 
evidence presented in this Chapter strongly suggests that RNF145, like gp78, is recruited to 
HMGCR by the Insig proteins to mediate HMGCR ubiquitination. 
 
6.3.3 ERAD pathways with multiple E3 ligases 
Previous reports have also implicated the action of multiple E3 ubiquitin ligases on ERAD 
substrates. Most cystic fibrosis patients carry the ΔF508 mutation in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) protein that inhibits protein folding and leads 
to the degradation of CFTRΔF508 by the UPS (Kopito 1999). RNF5 (RMA1) and CHIP 
ubiquitinate CFTRΔF508, however, they recognise different misfolded domains of CFTRΔF508 
at different protein quality control checkpoints (Younger et al. 2006).  
Gp78 has been shown to ubiquitinate CFTRΔF508 in cooperation with RNF5 in an ERAD 
pathway independent of CHIP (Morito et al. 2008). RNF5 initiates the degradative pathway by 
mono-ubiquitinating CFTRΔF508. Gp78 then binds to mono-ubiquitinated CFTRΔF508 via its 
CUE domain and mediates poly-ubiquitination. Accordingly, gp78 failed to ubiquitinate CFTR 
when RNF5 had been depleted by RNAi (Morito et al. 2008). It is unlikely that gp78 and 
RNF145 act sequentially on HMGCR because robust ubiquitination of HMGCR is seen in the 
single ligase knockout clones (Figure 6.9B). The significant block in HMGCR ubiquitination in 
the absence of both gp78 and RNF145 suggests that the ligases act on HMGCR in parallel. 
RNF5 and RNF185 share 70% sequence identity and are functionally redundant for CFTRΔF508 
degradation (El Khouri et al. 2013). The knockdown of either ligase caused a small increase in 
CFTRΔF508 expression, whereas the simultaneous knockdown of both ligases resulted in a 
dramatic increase in CFTRΔF508 expression and a significant decrease in its post-translational 
degradation (El Khouri et al. 2013). This ERAD pathway is reminiscent of the combined 
involvement of gp78 and RNF145 in HMGCR degradation. The loss of one ligase is 
compensated for by a second E3 ligase and concomitant only the loss of both ligases results 
in a marked decrease in degradation. 
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Co-operation between Hrd1 and gp78 has also been reported for the ERAD of model 
substrates MHC-147 and TCRα (Zhang et al. 2015). However, only Hrd1 depletion reduced 
ubiquitination of MHC-147 and TCRα. The authors propose that gp78 is required for the 
correct function of the BAG6 complex, which assists the delivery of aggregate-prone, 
retrotranslocated ERAD substrates to the proteasome (Wang, Liu, et al. 2011, Liu et al. 2014, 
Zhang et al. 2015). Given that the loss of RNF145 alone does not cause a significant loss of 
HMGCR ubiquitination, gp78 must be able to ubiquitinate HMGCR and is not primarily 
influencing HMGCR ERAD via the BAG6 complex. 
 
6.3.4 Why are multiple E3 ligases required for HMGCR degradation? 
My data and previously published data point towards a model in which gp78 and RNF145 are 
constitutively associated with the Insig proteins (Song, Sever, and DeBose-Boyd 2005). In the 
presence of sterols, the Insig proteins recruit gp78 and RNF145 to HMGCR leading to the 
ubiquitination and subsequent degradation of HMGCR. This mechanism is strikingly different 
from the ubiquitination of the yeast HMGCR ortholog, Hmg2, by Hrd1. A sterol intermediate, 
farnesyl pyrophosphate, induces a conformational change in Hmg2’s sterol sensing domain 
that is recognised by Hrd1p (Garza, Tran, and Hampton 2009, Shearer and Hampton 2005, 
Theesfeld and Hampton 2013). In stark contrast to human cells, the Insig ortholog, Nsg1, is 
stimulated by lanosterol to associate with Hmg2 to block the degradation of Hmg2 (Flury et 
al. 2005, Theesfeld and Hampton 2013). 
The re-purposing of the Insig proteins to act as scaffold factors to promote the sterol-induced 
degradation of HMGCR might allow the coordination of multiple E3 ubiquitin ligases to give 
finer control over HMGCR expression in different cell types that have different sterol 
requirements. All cell types must be able to maintain cholesterol homeostasis by balancing 
endogenous cholesterol biosynthesis and cholesterol uptake. However, the liver is a major 
organ for lipid biosynthesis and so hepatic cells might adapt the regulation of the cholesterol 
biosynthesis pathway to enable greater cholesterol production. Individual ligase knockout 
HeLa clones shown in this study demonstrate no decrease in sterol-induced degradation of 
HMGCR. This is consistent with gp78 knockout MEFs and gp78-depleted human fibroblasts 
(Tsai et al. 2012). In contrast to gp78 knockout MEFs, gp78 knockout mouse hepatocytes show 
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a significant decrease in sterol-induced HMGCR degradation (Liu et al. 2012). Another striking 
feature of the gp78 knockout mouse hepatocytes is their significant rescue of Insig2 at steady 
state and impaired degradation of Insig2 in a cycloheximide chase experiment. Previous 
studies saw no effect of sterols or gp78 depletion on exogenous Insig2 stability in Chinese 
Hamster Ovary (CHO) cells or human fibroblasts (Lee, Gong, et al. 2006, Lee, Song, et al. 2006). 
These observations show that there is a difference between how epithelial cells and 
hepatocytes regulate HMGCR and the Insig proteins. In this thesis project, I have only assessed 
HMGCR degradation in HeLa cells. As the project moves forward, it will be interesting to 
analyse how the relative contribution of gp78 and RNF145 to HMGCR degradation varies 
between cell types and how this correlates with differential cholesterol metabolism. 
In this thesis project, I have induced the degradation of HMGCR by adding cholesterol and 25-
hydroxycholesterol to cells that have been sterol depleted overnight. HMGCR degradation 
can also be induced by other sterol intermediates, such as mevalonate and 24,25-
dihydrolanosterol (Song, Javitt, and DeBose-Boyd 2005, Lange et al. 2008). It is possible that 
different stimuli favour the recruitment of different ubiquitin E3 ligases to HMGCR. 
 
6.4 Summary 
In this chapter, I used siRNA-mediated gene depletion and CRISPR-mediated gene disruption 
to identify gp78 and RNF145 as functionally redundant ubiquitin E3 ligases for the sterol-
induced degradation of HMGCR. In the absence of either E3 ligase there is little or no decrease 
in the sterol-induced ubiquitination and degradation of HMGCR. However, in the absence of 
both gp78 and RNF145 I observed a significant decrease in the sterol-induced ubiquitination 
and degradation of HMGCR. The Debose-Boyd laboratory has previously shown that gp78 is 
recruited to HMGCR by the Insig proteins in response to sterols (Sever, Yang, et al. 2003). Co-
precipitation experiments presented in this thesis demonstrate that RNF145 interacts with 
both Insig1 and Insig2 independent of the cellular sterol conditions. I also observed a sterol 
sensitive interaction between RNF145 and HMGCR that was enhanced by proteasome 
inhibition. Together these findings support a model in which both RNF145 and gp78 are 
recruited to HMGCR by the Insig proteins to mediate the ubiquitination of HMGCR. 
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Chapter 7: Hrd1-mediated degradation of 
HMGCR in the absence of gp78 and RNF145 
 
7.1 Introduction 
Whilst the loss of gp78 and RNF145 causes a significant block in the sterol-induced 
degradation of HMGCR, I always observed a lower abundance of HMGCR in cells that were 
cultured with sterols after sterol depletion compared to cells that remained under sterol 
deplete conditions. I also consistently observed less sterol-induced degradation of HMGCR in 
the absence of UBE2G2 than in the absence of both gp78 and RNF145. I hypothesised that 
there was at least one other ubiquitin E3 ligase that ubiquitinates HMGCR in response to 
sterols. The aim of this section of my thesis project was to identify more ubiquitin E3 ligases 
that mediate the sterol-induced degradation of HMGCR and to determine the redundancy 
with gp78 and RNF145. 
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7.2 Results 
7.2.1 The degradation of HMGCR is mediated by gp78, RNF145 and at least one more elusive 
E3 ligase 
So far, I have assumed that gp78 and RNF145 both use UBE2G2 as the E2 ubiquitin conjugating 
enzyme to mediate the ubiquitination of HMGCR. To confirm this assumption, I used CRISPR-
mediated gene disruption to knockout UBE2G2 in the gp78 and RNF145 double knockout 
HMGCR-Clover cell line. Surprisingly, this result gave me two significant results (i) a significant 
increase in HMGCR-Clover at steady state and (ii) a complete block in sterol-induced HMGCR-
Clover degradation (Figure 7.1A). If two genes are in the same pathway, the combined loss of 
the two genes will not have an additive effect. In contrast, if the combined loss of two genes 
has an additive effect, the genes act in at least two independent pathways. Critically, an 
additive effect does not rule out the possibility that both genes also act in the same pathway. 
Therefore, the additive effect at both steady state and following sterol depletion of losing 
UBE2G2 on top of the double ligase knockout leads to two important conclusions. Firstly, 
there is at least one more E3 ubiquitin ligase that uses UBE2G2 to mediate HMGCR 
ubiquitination. Secondly, either gp78 or RNF145 can use another E2 ubiquitin conjugating 
enzyme to mediate HMGCR ubiquitination. If both gp78 and RNF145 only used UBE2G2 to 
mediate HMGCR degradation, there would not be an additive effect of losing gp78 and 
RNF145 in combination with the loss of UBE2G2. 
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Figure 7.1 An elusive E3 ligase requires UBE2G2 and Insig1 to mediate HMGCR degradation 
in the absence of gp78 and RNF145. Wild type or gp78 and RNF145 double knockout HMGCR-
Clover HeLa cells were transiently transfected with Cas9 and either a control gRNA or a pool 
of three UBE2G2-targeting gRNAs. Transfected cells were selected by puromycin treatment. 
The cells were sterol depleted overnight eight days post transfection, then cultured for a 
further four hours in the presence or absence of sterols. HMGCR-Clover expression was 
assessed by flow cytometry. Representative of three independent experiments. 
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I next sought to determine which E3 ligase can use another E2 enzyme. The loss of UBE2G2 
and either gp78 or RNF145 resulted in a significant rescue of HMGCR-Clover at steady state 
(Figure 7.2A). However, only the loss of both gp78 and UBE2G2 resulted in a near-complete 
block in sterol-induced HMGCR-Clover degradation. Whilst this data does not mean that gp78 
does not use UBE2G2 to mediate HMGCR ubiquitination, it indicates that gp78 can use 
another E2 conjugating enzyme. 
The model for the sterol-induced degradation of HMGCR is dependent upon the Insig proteins 
acting as sterol sensitive scaffold factors (Sever, Song, et al. 2003). I next sought to determine 
whether the elusive E3 ligase is dependent on the Insig proteins to degrade HMGCR. I found 
that the loss of Insig1 in the gp78 and RNF145 double knockout HMGCR-Clover line lead to a 
near-complete block in sterol-induced HMGCR-Clover degradation (Figure 7.2B). In contrast, 
the loss of Insig2 in the gp78 and RNF145 double knockout line had no additional effect on 
the degradation of HMGCR-Clover. 
Since there is an additive effect of UBE2G2 and Insig1 in the combined absence of gp78 and 
RNF145, it is therefore likely that the elusive E3 ligase(s) uses UBE2G2 and Insig1 to mediate 
the sterol-induced ubiquitination of HMGCR in the absence of gp78 and RNF145. 
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Figure 7.2 The elusive E3 ligase requires UBE2G2 and Insig1 to mediate HMGCR degradation 
in the absence of gp78 and RNF145 (A) Wild type HMGCR-Clover HeLa cells were transfected 
with a control gRNA, a pool of three UBE2G2-targeting gRNAs, a pool of four gp78-targeting 
gRNAs, a pool of four RNF145-targeting gRNAs or a combination of these gRNA pools. 
Transfected cells were selected with puromycin treatment. Cell were sterol depleted 
overnight eight days post transfection, then cultured for a further two hours in the presence 
or absence of sterols. (B) Wild type or gp78 and RNF145 double knockout HMGCR-Clover HeLa 
cells were transiently transfected with a control gRNA, a pool of four Insig1-targeting gRNAs 
or a pool of four Insig2-targeting gRNAs. Transfected cells were selected with puromycin 
treatment and HMGCR-Clover degradation was assessed as in (A). Representative of two 
independent experiments. 
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7.2.2 TRC8 is not involved in the sterol-induced degradation of HMGCR 
The obvious candidate gene for the elusive E3 ligase was TRC8, which associates with Insig1 
and uses UBE2G2 to ubiquitinate substrates (Brauweiler et al. 2007, Lee et al. 2010). I have 
already tested TRC8 as a candidate gene for E3 ligases that might be redundant with RNF145 
and observed no requirement for TRC8 (Figure 6.1 and Figure 6.2B). I used the same gRNA 
from Figure 6.2C, which consistently results in a population of >70% TRC8 knockouts, to 
knockout TRC8 in the gp78 and RNF145 double knockout HMGCR-Clover cell line. The cells 
transfected with the TRC8-targeting gRNA were indistinguishable from control cells (Figure 
7.3A). TRC8 is therefore not the missing ubiquitin E3 ligase. 
To confirm that the loss of TRC8 similarly had no effect on wild type HMGCR, I transfected 
wild type HeLa cells, a gp78 knockout HeLa clone, a RNF145 knockout clone and a gp78 and 
RNF145 double knockout clone with the TRC8-targeting gRNA. The loss of TRC8 did not result 
in any difference in sterol-induced HMGCR degradation in any of these genetic backgrounds 
(Figure 7.2B). I have not observed a role for TRC8 in the sterol-induced degradation of HMGCR 
throughout this thesis project. The US2-mediated down-regulation of MHC-I demonstrated 
that TRC8 is expressed in HeLa cells (Figure 6.2C) (Stagg et al. 2009). 
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Figure 7.3 TRC8 is not required for the sterol-induced degradation of HMGCR (A) Gp78 and 
RNF145 double knockout HMGCR-Clover HeLa cells were transfected with Cas9 and either a 
control gRNA or TRC8-targeting gRNA. Transfected cells were selected with puromycin 
treatment. Cells were sterol depleted overnight eight days post transfection, then cultured 
for a further three hours in the presence or absence of sterols. HMGCR-Clover expression was 
assessed by flow cytometry. (B) Wild type HeLa cells, gp78 knockout clone 4_2, RNF145 
knockout clone 5_7 and gp78 and RNF145 double knockout clone 5_7 #7 were transiently 
transfected with Cas9 and either a control gRNA or TRC8-targeting gRNA. Transfected cells 
were sterol depleted overnight eight days post transfection, then cultured for a further three 
hours in the presence or absence of sterols. Cells were lysed and immunoblotted for HMGCR 
(WT, wild type; Ctl, control; KO, knockout). 
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7.2.3 A focused ubiquitin E3 ligase CRISPR knockout screen identifies Hrd1 and RNF185 as 
additional E3 ligases required for HMGCR-Clover degradation 
The Lehner laboratory, in collaboration with James Nathan’s laboratory, has created a gRNA 
library for ubiquitin-related genes. This library is made up of 6 sub-pools: E1s/E2s, E3 ligases, 
deubiquitinating enzymes, ubiquitin-binding/-like proteins, proteasome components and 
control gRNAs. I decided to use the E3 ligase sub-pool to perform a focused CRISPR screen in 
the gp78 and RNF145 double knockout HMGCR-Clover cell line to identify the elusive E3 ligase 
that can also mediate HMGCR ERAD. To focus the screen on the sterol-induced degradation 
of HMGCR, I used the same FACS strategy that identified RNF145 in Figure 5.5. This involved 
sterol depleting the mutagenised library overnight, then treating the culture with sterols for 
five hours before selecting HMGCR-Cloverhigh mutants by FACS.  
The gp78 and RNF145 double knockout HMGCR-Clover cell line was transduced with the 
nuclease Cas9 and Cas9 activity was confirmed with the control B2M gRNA. The Cas9-
expressing double knockout cell line was transduced at a M.O.I. of 0.3 with the E3 ligase gRNA 
library. Transduced cells were selected with puromycin and cells with a decreased rate of 
sterol-induced HMGCR degradation were selected by FACS on day 8 using the FACS strategy 
described above. Given that the size of the library was significantly smaller than the genome 
wide libraries (8300 gRNAs compared to 211,695 gRNAs in the Bassik genome wide library) I 
only carried out one round of FACS and subsequent DNA extraction. I expanded 20,000 cells 
so that I could test the enrichment from the sorting process. The selected population had a 
small enrichment, approximately 2%, of mutants that had a reduced ability to degrade 
HMGCR-Clover in response to sterols (Figure 7.4A). 
I quantified the gRNAs in the selected cells and unselected library using the Illumina MiniSeq 
platform. The RSA algorithm identified two significantly enriched genes, RNF185 and Hrd1 
(gene name SYVN1) (Figure 7.4B) (König et al. 2007). Although Hrd1 has previously been 
shown to be dispensable for HMGCR degradation, the identification of Hrd1 in this screen 
suggests that Hrd1 is functionally redundant with gp78 and RNF145 (Kikkert et al. 2004). 
RNF185 is an ER-localised E3 ubiquitin ligase that targets CFTRΔ508 for degradation and 
ubiquitinates cGAS to promote enzymatic activity (El Khouri et al. 2013, Wang, Huang, et al. 
2017). 
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Figure 7.4 E3 ligase CRISPR screen in the gp78 and RNF145 double knockout HMGCR-Clover HeLa 
cell line (A) Cas9 expressing gp78 and RNF145 double knockout HMGCR-Clover HeLa cells were 
transduced with the E3 ligase library at an M.O.I. of 0.3. Transduced cells were selected with 
puromycin treatment. The mutagenised library was sterol depleted overnight eight days post gRNA 
library transduction. The following day, sterols were added into the sterol depleted culture for five 
hours and HMGCR-Cloverhigh cells were selected by FACS. 200,000 cells were lysed for genomic DNA 
extraction and 20,000 cells were expanded in culture. The enrichment of the selected population was 
tested by sterol depleting wild type, the starting gp78 and RNF145 double knockout, the mutagenised 
library and the selected HMCR-Clover cells overnight, followed by a four-hour culture in the presence 
or absence of sterols. HMGCR-Clover expression was assessed by flow cytometry. (B) The RSA 
algorithm identified RNF185 and Hrd1 (König et al. 2007). 
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 7.2.4 Hrd1-mediated degradation of HMGCR in the absence of gp78 and RNF145 
I used CRISPR-mediated gene disruption to validate the requirement of Hrd1 and RNF185 in 
the degradation of HMGCR-Clover in the absence of gp78 and RNF145. The loss of Hrd1 in the 
gp78 and RNF145 double knockout HMGCR-Clover cell line resulted in a dramatic increase in 
HMGCR-Clover at steady state, resembling the loss of UBE2G2 in the double knockout line 
(Figure 7.5A). In contrast, the loss of RNF185 alone did not alter steady-state HMGCR-Clover 
expression. However, loss of either Hrd1 or RNF185 in the absence of gp78 and RNF145 
caused a complete block in sterol-dependent HMGCR-Clover degradation (Figure 7.5A).  
I next sought to confirm that both Hrd1 and RNF185 degraded wild type HMGCR by using 
CRISPR-mediated gene disruption to knockout Hrd1 or RNF185 in a gp78 and RNF145 double 
knockout HeLa clone (5_7 #7). The loss of either Hrd1 or RNF185 increased wild type HMGCR 
steady state expression, with a larger increase in the absence of Hrd1 (Figure 7.5B). The loss 
of Hrd1 in a gp78 and RNF145 double knockout clone resulted in a complete block in sterol-
induced HMGCR degradation (Figure 7.5C). However, the loss of RNF185 in a gp78 and 
RNF145 double knockout clone only had a minor effect on the sterol-induced degradation of 
HMGCR. The inconsistency between the effect of RNF185 on the degradation of HMGCR-
Clover and wild type HMGCR suggests that RNF185 is targeting the Clover tag, rather than 
endogenous HMGCR. 
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Figure 7.5 Hrd1-mediated degradation of HMGCR in the absence of gp78 and RNF145 (A) The gp78 
and RNF145 double knockout HMGCR-Clover cell line was transiently transfect with Cas9 and either a 
control gRNA, a pool of four Hrd1-targeting gRNAs or a pool of four RNF185-targeting gRNAs. 
Transfected cells were selected with puromycin treatment. The cells were sterol depleted overnight 
eight days post transfection then cultured for a further three hours in the presence or absence of 
sterols. HMGCR-Clover expression was assessed by flow cytometry. (B) Wild type HeLa cells were 
transiently transfected with Cas9 and a control gRNA. A gp78 and RNF145 double knockout HeLa clone 
(5_7 #7) was transiently transfected with Cas9 and either a control gRNA, a pool of four Hrd1-targeting 
gRNAs or a pool of four RNF185-targeting gRNAs. Transfected cells were selected with puromycin 
treatment. Steady state HMGCR expression was determine by immunoblot analysis. (WT, wild type) 
(C) Sterol induced HMGCR degradation was determined of the cells in (B) by overnight sterol depletion 
eight days post gRNA transfection followed by a four-hour culture in the presence or absence of 
sterols. Cells were lysed and immunoblotted for HMGCR. Representative of three independent 
experiments. 
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To determine the redundancy of Hrd1 with gp78 and RNF145, I knocked-out Hrd1 in 
combination with gp78 or RNF145. The loss of Hrd1 did not inhibit the degradation of HMGCR-
Clover in combination with the loss of gp78 or RNF145 (Figure 7.6). The only dual combination 
of ligases with a significant partial phenotype was the combination of gp78 and RNF145. There 
are two possibilities that could describe the partial redundancy of Hrd1 with gp78 and 
RNF145. Firstly, all three ligases can ubiquitinate HMGCR in a wild type cell, however Hrd1-
mediated ubiquitination of HMGCR is inefficient and gp78 or RNF145 can ubiquitinate HMGCR 
efficiently in the absence of Hrd1. Secondly, gp78 and RNF145 are the primary E3 ligases for 
HMGCR degradation and Hrd1 ubiquitinates HMGCR only in the absence of the primary E3 
ligases. 
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Figure 7.6 Hrd1 redundancy with gp78 and RNF145 in HMGCR-Clover degradation. Wild type 
HMGCR-Clover HeLa cells were transiently transfected with Cas9 and either a control gRNA 
or a pool of four gRNAs targeting the indicated gene. The sterol induced HMGCR-Clover 
degradation was assessed eight days post gRNA transfection. 
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7.2.5 Generating HMGCR-Clover UBE2G2 knockout clones 
I also sought to identify the E2 conjugating enzyme that gp78 can use in addition to UBE2G2 
to mediate the ubiquitination of HMGCR. I could have taken a candidate gene approach and 
knocked out the other E2 conjugating enzymes that have been implicated in ERAD so far, 
UBE2J1, UBE2J2 and UBE2K. However, I chose to use the E1 and E2 sub-pool of the Lehner 
and Nathan ubiquitome library in case another E2 was involved that had not previously been 
implicated in ERAD. 
To create a cell line to perform an E2 screen; I generated UBE2G2 knockout HMGCR-Clover 
clones from two independent gRNAs. The absence of UBE2G2 was confirmed by immunoblot 
(Figure 7.7A). Each UBE2G2 knockout clone showed a significant block in sterol-induced 
HMGCR-Clover degradation (Figure 7.7B).  
Chapter 7: Hrd1-mediated degradation of HMGCR in the absence of gp78 and RNF145 
 
185 
 
 
Figure 7.7 Isolating HMGCR-Clover UBE2G2 knockout clones (A) HMGCR-Clover HeLa cells 
were transiently transfected with Cas9 and a UBE2G2-targeting gRNA (either gRNA A or C). 
Transfected cells were selected with puromycin selection then single cell cloned by serial 
dilution. UBE2G2 knockout clones were identified by immunoblot. (WT, wild type) (B) 
Parental wild-type HMGCR-Clover HeLa cells and HMGCR-Clover UBE2G2 knockout clones 
were sterol depleted overnight then cultured for a further three hours in the presence or 
absence of sterols. HMGCR-Clover expression was assessed by flow cytometry. 
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7.2.6 A focused E2 conjugating enzyme CRISPR screen in a UBE2G2 knockout clone 
The UBE2G2 knockout clone C8 (Figure 7.7) was transduced with a lentiviral vector encoding 
the nuclease Cas9. The Cas9-expressing C8 clone was transduced at an M.O.I. of 0.3 with the 
E1 and E2 sub-pool of the Lehner/Nathan ubiquitome gRNA library. The mutagensied library 
was sterol depleted overnight eight days later. The next day sterols were added to the sterol 
depleted library for five hours and HMGCR-Cloverhigh cells were selected by FACS. Genomic 
DNA was extracted from approximately 200,000 cells and 20,000 cells were expanded in 
culture. The selected population’s ability to degrade HMGCR-Clover in response to sterols was 
tested, revealing a small enrichment of mutants with a reduced rate of sterol-induced 
HMGCR-Clover degradation (Figure 7.8A). 
The abundance of the gRNAs in the selected cells was compared to an unselected library using 
the RSA algorithm (König et al. 2007). The RSA algorithm assigned a significant number of E2 
enzymes a very high p-value (Figure 7.8B). However, this might be an artefact of using a small 
library with only 470 gRNAs. Encouragingly the highest ranking E2, UBE2K, has been 
implicated in ERAD as one of the E2 enzymes required for the downregulation of MHC-I by 
the human cytomegalovirus protein US11 and likely works with TMEM129 (Flierman et al. 
2006, van den Boomen et al. 2014). 
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Figure 7.8 E2 conjugating enzyme CRISPR screen in a UBE2G2 knockout clone (A) A focused E1/E2 
CRISPR screen was performed using a UBE2G2 knockout HMGCR-Clover clone that used sterol 
depletion to focus on the sterol induced degradation of HMGCR-Clover. To determine the enrichment 
in the screen, wild type HMGCR-Clover cells, the starting UBE2G2 knockout clone, the mutagensised 
library and the selected cells were sterol depleted overnight and then cultured for a further four hours 
in the presence or absence of sterols. HMGCR-Clover expression was assessed by flow cytometry. (B) 
Candidate genes were identified using the RSA algorithm (König et al. 2007). 
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7.2.7 UBE2K mediates the sterol-induced degradation of HMGCR-Clover inefficiently in the 
absence of UBE2G2 
I chose to knockout the second E2 from the screen, UBE2D2, using CRISPR-mediated gene 
disruption as well as the top hit, UBE2K (Figure 7.8B). The CRISPR validation was carried out 
in a different UBE2G2 knockout clone (A6) to the clone used in the screen. 
The loss of either UBE2D2 or UBE2K in a UBE2G2 knockout background resulted in an 
increased HMGCR-Clover expression level at steady state (Figure 7.9, compare green to grey). 
At steady state, the combined absence of UBE2K and UBE2G2 resulted in a significantly 
greater increase in HMGCR-Clover expression than the combined absence of UBE2D2 and 
UBE2G2 and is similar to the combined loss of gp78, RNF145 and Hrd1. Furthermore, the loss 
of UBE2K in the UBE2G2 knockout clone completely blocked the sterol-induced degradation 
of HMGCR-Clover, whereas the loss of UBE2D2 in the UBE2G2 knockout clone did not further 
impair the sterol-induced degradation of HMGCR-Clover. When UBE2K was knocked out in 
wild type HMGCR-Clover cells, there was no difference in steady state HMGCR-Clover 
expression or sterol-induced HMGCR-Clover degradation. The loss of UBE2D2 in wild type 
HMGCR-Clover cells caused a small increase in steady state HMGCR-Clover expression, but 
did not affect sterol-induced HMGCR-Clover degradation.  
Based on the data presented in Figure 7.2A and Figure 7.9, gp78 can mediate the 
ubiquitination of HMGCR with UBE2K in the absence of UBE2G2. Whilst UBE2D2 influences 
the steady state expression of HMGCR-Clover, I did not observe a requirement for UBE2D2 in 
the sterol-induced degradation of HMGCR-Clover (Figure 7.9). 
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Figure 7.9 CRISPR validation of UBE2D2 and UBE2K (A) Wild type or UBE2G2 knockout (clone 
A6) HMGCR-Clover cells were transiently transfected with Cas9 and either a control gRNA, a 
UBE2D2-targeting gRNA or a UBE2K-targeting gRNA. Transfected cells were selected with 
puromycin treatment. Selected cells were sterol depleted overnight eight days post 
transfection and then cultured for a further four hours in the presence or absence of sterols. 
HMGCR-Clover expression was assessed by flow cytometry. 
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7.3 Discussion 
7.3.1 TRC8 is not involved in HMGCR ERAD 
The Debose Boyd laboratory reported that TRC8 was required for the degradation of HMGCR 
(Jo et al. 2011). However, the Weissman laboratory could not reproduce this observation (Tsai 
et al. 2012). Throughout this thesis project, I have not seen a requirement for TRC8 in the 
degradation of HMGCR (Figure 6.1, 6.2B and 7.3). Even in the absence of gp78 and RNF145, 
TRC8 did not mediate the degradation of HMGCR. Independent laboratories have shown that 
exogenous TRC8 associates with both Insig proteins (Lee et al. 2010, Jo et al. 2011). Given the 
homology between TRC8 and RNF145 as well as TRC8’s constitutive binding to the Insig 
proteins, it is striking that TRC8 cannot ubiquitinate HMGCR, even in the absence of RNF145.  
 
7.3.2 CRISPR knockout screens using focused gRNA libraries 
The success of a CRISPR knockout screen is dependent on the ability to enrich mutants with 
the phenotype of interest. A high enrichment is more likely to be achieved if the phenotype 
of the mutants of interest is distinct from the starting population. The fluorescent window is 
small between gp78 and RNF145 double knockout HMGCR-Clover HeLa cells cultured in the 
presence or absence of sterols following sterol depletion, with a considerable overlap 
between the two populations on a FACS plot. The aim of the screen was to identify E3 
ubiquitin ligases and so I used a focused E3 ligase gRNA library. This ensured that other factors 
required for the sterol-induced degradation of HMGCR, such as proteasome components, p97 
complex components or UBE2G2, would not dilute the enrichment of E3 ligase knockouts. 
The ability to rapidly create focused gRNA libraries to sample a specific family of genes is an 
extremely powerful tool for cell biology research. Focused gRNA libraries are particularly 
useful if the aim of the screen is to identify a specific component. There are also practical 
advantages to performing screens with focused gRNA libraries. Focused CRISPR screens are 
less demanding on reagents and tissue culture time as fewer cells are required to maintain 
representation of the library. The lower complexity samples from focused gRNA libraries do 
not need to be sequenced as deeply as genome-wide libraries, therefore making sequencing 
cheaper and potentially more accessible. 
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It is worth remembering that all forward genetic screens performed with a library (CRISPR or 
RNA-interference based) are limited by the construction of the library. A focused library relies 
on the bioinformatic analysis used to identify all relevant genes. For example, TMEM129 
contains an atypical RING domain and so was not included in an siRNA E3 ligase library that 
was used to try to identify the E3 ligase responsible for US11-mediated MHC-I degradation 
(van den Boomen et al. 2014). Whereas, TMEM129 was identified by a genome wide library, 
as it is an annotated open reading frame, and in a retroviral mutagenesis haploid screen (van 
de Weijer et al. 2014, van den Boomen et al. 2014).  
 
7.3.3 Hrd1-mediated HMGCR degradation 
My focused E3 ligase CRISPR screen identified a role for Hrd1 as a ubiquitin E3 ligase that 
mediates the sterol-induced degradation of HMGCR in the absence of gp78 and RNF145. If 
either gp78 or RNF145 is present, the loss of Hrd1 had no effect on HMGCR degradation 
(Figure 7.6).  
As one of the orthologues of S cerevisiae Hrd1p, Hrd1 has already been assessed for its ability 
to target HMGCR for degradation. So far, there is no evidence to support a role for Hrd1 in 
the sterol-induced ubiquitination of HMGCR (Kikkert et al. 2004, Song, Sever, and DeBose-
Boyd 2005). Consistent with these studies, I did not see a decrease in sterol-induced HMGCR 
degradation in the absence of Hrd1 alone. 
The limited sterol-induced degradation of HMGCR-Clover in the gp78 and RNF145 double 
knockout HMGCR-Clover cell line could be abolished by the loss of UBE2G2, Insig1 or Hrd1 
(Figure 7.1, 7.2 and 7.5). This suggests that Hrd1 mediates the ubiquitination of HMGCR using 
UBE2G2 and Insig1. However, the Debose Boyd laboratory did not see co-precipitation of 
Hrd1 with the Insig proteins (Jo et al. 2011, Song, Sever, and DeBose-Boyd 2005). These 
experiments were performed by over-expressing epitope-tagged Hrd1 and Insigs in wild type 
CHO cells. It is possible that Hrd1 associates with Insig1 with a lower affinity than gp78 and 
RNF145. In the experiments presented by the Debose Boyd laboratory, endogenous gp78 and 
RNF145 might out-compete exogenous Hrd1 for Insig1 binding. It would therefore be 
interesting to see if Insig1 co-immunoprecipitates with Hrd1 in the absence of gp78 and 
RNF145. 
Chapter 7: Hrd1-mediated degradation of HMGCR in the absence of gp78 and RNF145 
 
192 
 
The current model for the sterol-induced degradation of HMGCR revolves around the Insig 
proteins acting as sterol dependent scaffold proteins to recruit E3 ligase complexes to HMGCR 
(Jo and Debose-Boyd 2010). HMGCR is reported to be a high confidence interaction partner 
of Hrd1 (Christianson et al. 2012). If Hrd1 is already bound to HMGCR, it is unlikely that Insig1 
is acting as a sterol sensitive Hrd1 recruitment factor. Instead, Hrd1 might only be able to 
ubiquitinate Insig1 bound HMGCR or Insig1 might recruit another factor required for Hrd1-
mediated HMGCR degradation.  
 
7.4 Summary 
In this chapter, I used a combinatorial gene knockout approach to demonstrate that the loss 
of UBE2G2 or Insig1 blocked the sterol-induced degradation of HMGCR-Clover in the absence 
of gp78 and RNF145. This suggested that there was another E3 ubiquitin ligase that could 
mediate sterol-induced HMGCR degradation using UBE2G2 and Insig1. I identified Hrd1 and 
RNF185 in a focused E3 ligase CRISPR screen in a gp78 and RNF145 double knockout HMGCR-
Clover cell line. Whilst the loss of either RNF185 or Hrd1 in the gp78 and RNF145 double 
knockout HMGCR-Clover cell line blocked the sterol-induced degradation of HMGCR-Clover, 
only the loss of Hrd1 in a gp78 and RNF145 double knockout HeLa clone blocked the sterol-
induced degradation of wild type HMGCR. The loss of Hrd1 only affects HMGCR degradation 
in the absence of both gp78 and RNF145. A focused E2 conjugating enzyme CRISPR screen in 
a UBE2G2 knockout HMGCR-Clover clone identified UBE2K. It is likely that gp78 can use UBE2K 
to ubiquitinate HMGCR in the absence of UBE2G2, all be it inefficiently.  
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Chapter 8: General Discussion 
8.1 Summary and model for HMGCR degradation 
Fluorescence-based forward genetic screens in human cells are a highly effective approach to 
identify genes required for a cellular process. The first major aim of my thesis project was to 
compare the efficacy of retroviral gene-trap mutagenesis haploid screens, the previous gold 
standard, to genome-wide CRISPR knockout screens. I found that, in KBM7 cells, the two 
screening methods produced highly concordant results (Figure 3.2 and Figure 3.3). Both 
screens identified a role for the uncharacterised gene TXNDC11 in glycoprotein ERAD. My 
collaborators went on to demonstrate that TXNDC11 is an ER-localised disulphide reductase 
that acts on a component of the ERAD machinery. 
HMGCR catalyses the rate-limiting step of the cholesterol biosynthesis pathway. To maintain 
cholesterol homeostasis, the expression of HMGCR is tightly regulated by transcriptional and 
post-transcriptional mechanisms. Cholesterol pathway intermediates stimulate the Insig 
proteins to recruit E3 ligase complexes to HMGCR to mediate ERAD (Sever, Song, et al. 2003, 
Sever, Yang, et al. 2003). However, the identity of the ERAD E3 ligases responsible for HMGCR 
ubiquitination was controversial (Tsai et al. 2012). I performed a series of fluorescence-based 
forward genetic screens as an unbiased approach to identify the E3 ligase responsible for the 
ubiquitination of HMGCR. My genome-wide CRISPR knockout screens identified a role for the 
poorly characterised ERAD E3 ligase RNF145 in the sterol-induced degradation of HMGCR 
(Figure 4.6 and Figure 5.5).  
The loss of RNF145 alone only resulted in a small reduction in the sterol-induced degradation 
of HMGCR-Clover (Figure 5.6A), however I could not detect a decrease in the sterol-induced 
degradation or ubiquitination of wild type HMGCR in the absence of RNF145 (Figure 5.7 and 
Figure 6.9B and 6.9C). The loss of gp78, an Insig-associated ERAD E3 ligase previously 
implicated in the sterol-induced degradation of HMGCR, did not result in a detectable 
decrease in the sterol-induced degradation or ubiquitination of HMGCR (Figure 6.7C and 
Figure 6.9B). However, the combined loss of both gp78 and RNF145 resulted in a pronounced 
decrease in the sterol-induced degradation and ubiquitination of HMGCR (Figure 6.4 and 
Figure 6.9C). This indicates that gp78 and RNF145 demonstrate partial functional redundancy 
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and act in parallel on HMGCR (Figure 8.1A). I proceeded to observe the constitutive 
association of RNF145 with both Insig proteins (Figure 6.10B) and a sterol-dependent 
interaction between RNF145 and HMGCR that was also enhanced by proteasome inhibition 
(Table 6.1 and Figure 6.11B). This supports a model in which the Insig proteins recruit both 
gp78 and RNF145 to HMGCR in a sterol-dependent manner (Figure 8.1A). 
In gp78 and RNF145 double knockout cells, I used a focused ubiquitin E3 ligase CRISPR screen 
to identify a role for Hrd1 in HMGCR degradation (Figure 7.4). The combined loss of gp78, 
RNF145 and Hrd1 completely blocks the sterol-induced degradation of HMGCR in HeLa cells 
(Figure 7.5C). Hrd1 is dispensable for sterol-induced HMGCR degradation (Kikkert et al. 2004). 
Consistent with previous studies, the loss of Hrd1 alone did not affect HMGCR degradation 
and a requirement for Hrd1 was only observed in the absence of both gp78 and RNF145 
(Figure 7.6). This suggests that Hrd1 acts as a back-up, secondary E3 ligase to mediate the 
degradation of HMGCR in the absence of gp78 and RNF145 (Figure 8.1B). No interaction 
between Hrd1 and the Insig proteins is reported (Song, Sever, and DeBose-Boyd 2005, Jo et 
al. 2011). It is possible that Hrd1 has a lower affinity for the Insig proteins and only interacts 
with the Insig in the absence of gp78 and RNF145 (Figure 8.1B). Alternatively, Hrd1 might not 
interact directly with the Insigs but recognises and ubiquitinates Insig-bound HMGCR (Figure 
8.1B). 
The loss of gp78 in UBE2G2 knockout cells resulted in a near-complete block in the sterol-
induced degradation of HMGCR-Clover, whereas the loss of RNF145 had no additional effect 
on sterol-induced HMGCR-Clover degradation in UBE2G2 knockout cells (Figure 7.2A). This 
suggests that gp78 can ubiquitinate HMGCR using another E2, in the absence of UBE2G2. A 
focused E2 screen identified the elusive E2 as UBE2K and the combined loss of both UBE2G2 
and UBE2K resulted in a near-complete block in sterol-induced HMGCR-Clover degradation 
(Figure 7.8 and Figure 7.9). It is therefore likely that gp78 ubiquitinates HMGCR using UBE2K 
in the absence of UBE2G2, however this process is inefficient (Figure 8.1A). 
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Figure 8.1 The sterol-induced degradation of HMGCR. (A) Insig proteins recruit gp78 and RNF145 to 
HMGCR in response to sterols. Gp78 and RNF145 mediate the ubiquitination of HMGCR using UBE2G2 
(G2). In the absence of UBE2G2, gp78 can use UBE2K (K). Gp78 and RNF145 are functionally 
redundant; they compensate for the loss of the other to maintain the cell’s ability to degrade HMGCR. 
Ubiquitinated HMGCR is extracted from the ER membrane in a p97 dependent manner and degraded 
by the proteasome. Ubiquitin is represented by black circles (B) HMGCR is degraded in a Hrd1-
dependent manner in the absence of gp78 and RNF145. The mechanism of Hrd1-mediated HMGCR 
degradation is yet to be determined. Hrd1 might interact with Insigs in the absence of gp78 and 
RNF145 so that it is recruited to HMGCR by the sterol-dependent association of Insigs with HMGCR. 
Alternatively, Hrd1 might interact directly with HMGCR, however Hrd1 might specifically ubiquitinate 
Insig-bound HMGCR. 
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8.2 Future work  
A major aim of this project, as it continues beyond my thesis, is to determine whether the 
RNF145-HMGCR interaction is dependent on the Insig proteins, i.e. similar to the gp78-
HMGCR interaction (Song, Sever, and DeBose-Boyd 2005, Jo et al. 2011). This will be tested 
by performing RNF145 immunoprecipitations in Insig knockout cell lines. 
It will be critical to understand the relationship between gp78 and RNF145 to elucidate the 
mechanism for HMGCR ubiquitination by multiple E3 ubiquitin ligases. The stability of gp78 
and RNF145 might be influenced by the loss of an interaction between the E3 ligases or 
differential Insig occupancy when one E3 ligase is absent. Preliminary data suggests that 
RNF145 is degraded by the proteasome by sterols in the absence of gp78 (Figure 6.12). This 
result needs to be repeated and it will be interesting to see if gp78 is affected by the loss of 
RNF145.  
CRISPR-mediated gene disruption in the gp78 and RNF145 knockout HMGCR-Clover cell line 
suggested that the residual degradation of HMGCR is dependent on Hrd1, Insig1 and UBE2G2 
(Figure 7.1, 7.2 and 7.5). It will be important to determine whether the loss of Hrd1 in 
combination with gp78 and RNF145 further reduces HMGCR ubiquitination. Hrd1 
immunoprecipitations should also be performed in wild type and gp78/RNF145 double 
knockout cells to determine whether Hrd1 interacts with HMGCR and the Insig proteins 
(Figure 8.1B).  
All the work presented in this thesis on HMGCR degradation was performed in HeLa cells. 
Whilst all cells need to regulate cholesterol homeostasis, different cells have different 
requirements for cholesterol. For example, hepatocytes are a major cholesterol-producing 
cell type. We will need to assess the requirement for gp78, RNF145 and Hrd1 in HMGCR 
degradation in different cells.   
 
8.3 RNF145 as an LXR target gene 
RNF145 was identified as a LXR target gene in a transcriptomics screen (Cook et al. 2017). The 
LXR genetic program aims to reduce cellular cholesterol through several mechanisms, such as 
inhibiting cholesterol biosynthesis (Sallam et al. 2016). It is plausible for the ubiquitin E3 ligase 
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responsible for HMGCR degradation to be an LXR target gene. However, if the model for 
HMGCR degradation is correct and the E3 ubiquitin ligases are recruited to HMGCR by the 
Insig proteins, it is likely that the Insig proteins are the rate limiting factors (Sever, Yang, et al. 
2003, Sever, Song, et al. 2003). Therefore, the upregulation of RNF145 alone is unlikely to 
affect HMGCR degradation. However, at high cholesterol levels, the Insig1 protein is stabilised 
(Lee, Song, et al. 2006). The increase in RNF145 transcription and decrease in Insig1 
degradation might be coordinated to increase HMGCR degradation. Alternatively, RNF145 
might be an LXR target gene to enhance the ubiquitination of a different RNF145 substrate to 
regulate lipid metabolism. 
The work in this thesis shows that RNF145-mediated ubiquitination of HMGCR is sterol-
regulated. Given that the transcription of RNF145 is controlled by sterol derivatives (as an LXR 
target gene), further characterisation of RNF145 should seek to determine whether RNF145 
turnover is sterol-regulated. If the expression of RNF145 is induced when the cell is seeking 
to reduce its cholesterol level, it follows that when the cholesterol level is restored to its 
desired level either RNF145 activity is stopped or RNF145 is degraded to decrease activity. 
 
8.4 Sterol sensing to induce HMGCR degradation 
Sterol sensing domains (SSDs) are a critical feature of proteins involved in maintaining 
cholesterol homeostasis (Goldstein, DeBose-Boyd, and Brown 2006). SCAP inhibits SREBP 
processing by associating with Insig proteins in the ER at high ER cholesterol levels (Yang et 
al. 2002, Yabe, Brown, and Goldstein 2002). The Brown and Goldstein laboratory observed 
the direct binding of cholesterol to SCAP in an in vitro binding assay (Radhakrishnan et al. 
2004). The Radhakrishnan laboratory went on to identify a significant cholesterol-induced 
conformational change in SCAP (Zhang et al. 2016, Gao et al. 2017). Co-precipitation and 
protease protection assays revealed that the binding of cholesterol to SCAP’s SSD induces the 
transition from a closed to open state, which enables binding to the Insig proteins (Zhang et 
al. 2016, Gao et al. 2017). The SCAP-Insig interaction can also be induced by the oxysterol 25-
hydroxycholesterol. However, in vitro binding assays revealed that 25-hydroxycholesterol 
binds specifically to Insig rather than SCAP (Sun et al. 2007, Radhakrishnan et al. 2007). 
Chapter 8: General Discussion 
 
198 
 
In contrast to SCAP, no-one has yet observed the direct binding of cholesterol or other sterols 
to the SSD of HMGCR (Goldstein, DeBose-Boyd, and Brown 2006). In this thesis project, I used 
a combination of cholesterol and 25-hydroxycholesterol to induce the degradation of 
HMGCR. It is tempting to speculate that 25-hydroxycholesterol-bound Insigs can also 
associate with HMGCR, in the same manner as they can with SCAP (Radhakrishnan et al. 
2007). It is yet to be determined how sterols induce the binding of Insigs to HMGCR to recruit 
E3 ligase complexes and enable the degradation of HMGCR. Sterols might bind to a currently 
unidentified protein that facilitates the Insig-HMGCR interaction. There are no candidate 
genes in the CRISPR screens presented in this thesis, however I always used cholesterol and 
25-hydroxycholesterol to induce HMGCR degradation. If 25-hydroxycholesterol-bound Insig 
can bind directly to HMGCR, in a similar way as to SCAP, then the addition of 25-
hydroxycholesterol might compensate for the loss of the sterol-binding protein. Using a single 
sterol to induce HMGCR degradation might enable the identification of the sterol-binding 
protein. 
 
8.5 CRISPR screen developments 
The CRISPR revolution has advanced spectacularly over the last few years. At the beginning 
of my thesis project, CRISPR technology was in its infancy with enormous potential for both 
cell biology research and therapeutics (Hsu, Lander, and Zhang 2014). Now, CRISPR 
technology has been reported to remove proviral HIV DNA from mice and to correct disease-
causing mutations in mouse models of conditions such as Duchenne muscular dystrophy and 
Huntington’s disease (Nelson et al. 2016, Yang et al. 2017, Yin et al. 2017). Controversially, 
Chinese and American laboratories have successfully used CRISPR-mediated genome editing 
in human embryos (Liang et al. 2015, Ma et al. 2017). However, both studies highlighted the 
necessity to reduce off-target effects of the Cas9 nuclease to ensure that no unwanted 
mutations are introduced into the germline.  
At the start of my thesis project, only a handful of proof-of-concept CRISPR screens had been 
reported (Wang et al. 2014, Shalem et al. 2014, Zhou et al. 2014, Koike-Yusa et al. 2014). Early 
on in this thesis project, I demonstrated that genome-wide CRISPR screens are as effective at 
identifying candidate genes as the previous gold standard method, retroviral gene-trap 
Chapter 8: General Discussion 
 
199 
 
mutagenesis haploid screens. An exciting attraction of CRISPR screens is the potential to 
perform forward genetic screens in any cell type, as CRISPR-mediated gene disruption is not 
restricted to a haploid karyotype. This potential has been realised, with CRISPR screens being 
reported that dissect a range of processes in physiologically relevant cell lines, including 
hepatic Huh7 cells (Marceau et al. 2016) and T cells (Park et al. 2017), as well as primary cells 
(Parnas et al. 2015).  
CRISPR/Cas9 technology can be readily adapted to alter gene expression by tagging a 
catalytically inactive Cas9 (dCas9) with effector domains. CRISPR interference (CRISPRi) refers 
to a system in which dCas9 is tagged with a repressive KRAB effector domain. A gene of 
interest can be efficiently silenced by targeting the dCas9-KRAB fusion protein to the 
promoter region of the gene (Gilbert et al. 2013). CRISPRi can be used to perform forward 
genetic screens using libraries of gRNAs that target the promoter region of all the desired 
open reading frames (Gilbert et al. 2014). Whilst CRISPRi results in a knockdown of gene 
expression rather than a gene knockout, there are some potential advantages to using 
CRISPRi. CRISPR knockout screens are limited to targeting protein-coding open reading frames 
because the loss of gene expression is dependent on the frame-shift mutations disrupting the 
amino acid sequence. Whereas, CRISPRi can silence expression of any open reading frame, 
including long non-coding RNA genes (Liu et al. 2017). 
A recent development aims to use the CRISPR/Cas9 system for precise ‘base editing’ (Komor 
et al. 2016). Cytidine deaminase enzymes convert cytidine to uridine, which results in a 
cytosine to thymidine or guanine to adenine mutation following DNA repair (Conticello 2008). 
Tagging dCas9 with a cytidine deaminase enzyme, such as activation-induced deaminase (AID) 
or APOBEC3G, efficiently and precisely creates point mutations (Komor et al. 2016). 
Therefore, using a tiled gRNA library across a gene-of-interest should be able to identify loss 
of function mutations and regions for gene function. 
The CRISPR/Cas9 system can also be adapted to upregulate target gene expression by tagging 
dCas9 with a transcription activator domain. All the Cas9 activation systems use VP64 as the 
activating effector domain alone or in combination with additional transcription-activating 
modules (Gilbert et al. 2013, Chavez et al. 2015, Joung, Konermann, et al. 2017). Genome-
wide gain-of-function screens can be performed by using a gRNA library that targets a Cas9-
activator fusion protein to the promoter of all annotated open reading frames (Gilbert et al. 
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2014, Joung, Engreitz, et al. 2017). Previously, gain-of-function screens were performed using 
the over-expression of cDNA libraries (Grimm 2004). However, gRNA libraries are significantly 
easier to work with because of the enormous variation in cDNA lengths and sequence features 
in a cDNA library.  
 
8.6 Concluding remarks 
The last decade has seen the extraordinary development of technologies to advance forward 
genetics in human cells. Retroviral gene-trap mutagenesis screens in near-haploid cells have 
made a significant contribution to our understanding of the biology of the cell. Custom 
genome editing with CRISPR/Cas9 technology is now transforming cell biology research. 
Geneticists can choose from a diverse range of cell types and CRISPR/Cas9 technologies to 
optimise their forward genetic screens for the cellular process they seek to interrogate.  
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Appendix 1: gRNA and RNAi sequences 
1. gRNA target sequences 
Target gene gRNA sequence 
EDEM2 TATCTGACCGGCTCTCCCAG 
PDI GCGGAAAAGCAACTTCGCGG 
ALG3 GGAGAAGAAACAGTAACCCA 
DPM3 GAGGACTTCCTGGCAGGACAA 
TXNDC11 #1 GTCAAGGACTGGAGACCTCA 
TXNDC11 #2 AAGAAGGTCAAATAACCAGG 
UPF2 GCTGGTGAAAGAGAGAGCAG 
SMG6 GCGGGTACTTCCAATGGGAG 
ALG12 TGACTGACTTACCTAAACAG 
SMG7 AGGTCCACTCACCATTGGAG 
UROD #1 GCACCAGCAAAGCCAATCAG 
UROD #2 ACACGTGCTGAAAAAGTCCT 
UBE2G2 #A CATGGGCTACGAGAGCAGCG 
UBE2G2 #C TTACCTGCTACAATTCCTTC 
UBE2G2 #D AGAATTAACACTGAATCCTC 
RNF145 #1 TGTTAAATGTGGCCCTG 
RNF145 #2 TTGGATGTCCTGTACAGAT 
RNF145 #3 GGAATTCAGAAAAGAGCCAG 
RNF145 #4 GGCTGCAAAGGAGAAACTGG 
RNF145 #5 TCATAGGCTTACCTGAAGAG 
RNF145 #8 AGTGTTAAATGTGGCCCTGA 
HMGCR C-terminus TCAGAACTGTCGGGCTATTC 
ATP6V1B2 #1 CTCCCGAGCTCCCACCGC 
ATP6V1B2 #2 GAGGAGACAAGATGGCGCTG 
EHD1 #1 TGCTGTACTGCCCCACG 
EHD1 #2 GCTCCGGCTCCTTCTTGCGG 
EHD1 #3 GAGAAGCAGCGGATCAGCAG 
EHD1 #4 GCAGAAGCTGCTACCCCTGG 
GNPTAB #1 GGTCAGAGAACAGATGGAGG 
GNPTAB #2 GTGGAGGTGGACACAAGGGA 
GALNT11 #1 ATCAAGAGTTGAGAGACTT 
GALNT11 #2 GGTGTGCCGGTCCTCACGGA 
GALNT11 #3 AGTGGCATGGATATCTGGGG 
GALNT11 #4 GGTCAGGAGGATCCCAGCAG 
LDLR #1 GAGGTGCGATGGCCAAG 
LDLR #2 GAATGCTTGGACAACAACGG 
LDLR #3 GAATGCTTGGACAACAACGG 
LDLR #4 GTGGCCCAGCGAAGATGCGA 
NPC #1 GTGCAGTTCGTGTTATA 
NPC #2 GGGCAGAACATGGTGTGCGG 
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NPC #3 GTAGCAGCAGGAGGAGGCCA 
NPC #4 AGATTTTCCAGTCCATGGGA 
Insig1 #1 CGTAGCTAGAAAAGCTA 
Insig1 #2 GCTGCTGTCCCGCAGCAGGG 
Insig1 #3 GCAGCCCCTACCCCAACACC 
Insig1 #4 TCAACCTGCTGCAGATCCAG 
Insig2 #1 AAGGAGAGACAGAGTCACCT 
Insig2 #2 CTAGATGTCTGTCAATGCAG 
Insig2 #3 GAATCATCAAGTTCACACTC 
Insig2 #4 AAAAGTCCACCACAGTCCAA 
TECR #1 CGCAAAGGCATAGTGCCAT 
TECR #2 GAGGTTCTTGATCTCCGCAA 
TECR #3 GTTCTGCAGAAGCTGCCCGT 
TECR #4 ATGAGTGACAGATGCAGGCG 
gp78 #1 GTTAGCTGGTCCGGCTCGCC 
gp78 #2 GCGGCGAGCCGGACCAGCTAA 
gp78 #3 GACTGGGCCACATCGCGGGCC 
gp78 #4 GTGAGGCCCGTGTAGGTGCGG 
TRC8 GGCGTCGATGATGTAAAGGC 
Control (B2M) GGCCGAGATGTCTCGCTCCG 
RNF185 #1 GGCGCTGGCGAGAGCGGA 
RNF185 #2 GGCTGATGACGGCATCCT 
RNF185 #3 GCTGGCGAGAGCGGAGGGC 
RNF185 #4 GATGCCGTCATCAGCCTGTG 
Hrd1 #1 GGTGTTCTTTGGGCAACTGA 
Hrd1 #2 GCACGGCAGTGATGATGG 
Hrd1 #3 GTCATCCCGAAAAACGGTGA 
Hrd1 #4 GACCAAGTCCAGCCCCAGCA 
UBE2D2 #1 CACCGGGCAAGCTACAATAATG 
UBE2D2 #2 GTTTGAAGGGGTAATCTGTT 
UBE2D2 #3 GTAGATCCGAGCAATCTC 
UBE2D2 #4 GTGTTCAGCAGGTCCTGT 
UBE2K #1 GAATTAAGAGGAGAAATAGC 
UBE2K #2 GGATTAAATGGGTATGTTTC 
UBE2K #3 GTGACGGAACTAATATT 
UBE2K #4 GCTGTCTGTTTGAACATTTC 
 
2. siRNA target sequences 
Target gene siRNA sequence 
gp78 GACGGAUUCAAGUACCUUU 
MARCHVI UCAUAGAUCUCGUCGCUUA 
TRC8 GGGAGCCGCUUACAAGAAA 
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3. shRNA forward oligo sequences (5’-3’) 
Target gene Forward oligo sequence (5'-3') 
Control GATCCGGGTATCGACGATTACAAATTCAAGAGATTTGTAATCGTCGATACCCTTTTTTG 
TXNDC11 #1 GATCCGCGGCAATTGTTGACGTGAATTCAAGAGATTCACGTCAACAATTGCCGTTTTTTG 
TXNDC11 #2 GATCCGTGGCTAACTCTCCTACCAATTCAAGAGATTGGTAGGAGAGTTAGCCATTTTTTG 
UROD #1 GATCCGGTCCGATCATGTGATCTTCTTCAAGAGAGAAGATCACATGATCGGACTTTTTTG 
UROD #2 GATCCGCTCCGACATCCTTGTTGTATTCAAGAGATACAACAAGGATGTCGGAGTTTTTTG 
UROD #3 GATCCGCCCAGAGCCATTAAGAGAATTCAAGAGATTCTCTTAATGGCTCTGGGTTTTTTG 
UROD #4 GATCCGCATGGACCCTGATGACATATTCAAGAGATATGTCATCAGGGTCCATGTTTTTTG 
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Appendix 2: Oligonucleotides for screen 
preparation 
 
Retroviral LAM-PCR 
 
 
Sequence 5'-3' 
Digested gDNA adaptor CCTATAGTGAGTCGTATTATATGAGTAGTACCATGGGAAC 
Digested gDNA adaptor GTTCCCATGGTACTACTCATATAATACGACTCACTATAGG 
Linear PCR primer [Biotin]-GGTCTCCAAATCTCGGTGGAAC 
P5-VirusZ AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCTCTATACGAAGTTATGGGCCCTAGCTC 
P7-Index5-Ad1 CAAGCAGAAGACGGCATACGAGAnnnnnnnTGACTGGAGTTCAGACGTGTGC
TCTTCCGATCTGTTCCCATGGTACTACTCATATAATACG 
Illumina sequencing 
primer 
AGCTCAGTACAAACCTACAGGTGGGGTCTTTCA 
  
CRISPR screen analysis 
 
GeCKO library 
 
 
Sequence 5'-3' 
sgRNA_outer_F GCTTACCGTAACTTGAAAGTATTTCG 
sgRNA_outer_R GTCTGTTGCTATTATGTCTACTATTCTTTCC 
P5-sgRNA_inner_F AATGATACGGCGACCACCGAGATCTACACTCTCTTGTGGAAAGGACGAAACA
CCG 
P7-index-
sgRNA_inner_R 
CAAGCAGAAGACGGCATACGAGAnnnnnnnGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
Illumina sequencing 
primer 
ACACTCTCTTGTGGAAAGGACGAAACACCG 
  
Bassik library 
 
 
Sequence 5'-3' 
sgRNA_outer_F AGGCTTGGATTTCTATAACTTCGTATAGCATACATTATAC 
sgRNA_outer_R ACATGCATGGCGGTAATACGGTTATC 
P5-sgRNA_inner_F AATGATACGGCGACCACCGAGATCTACACGCACAAAAGGAAACTCACCCT 
P7-index-
sgRNA_inner_R 
CAAGCAGAAGACGGCATACGAGATnnnnnnnGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCCGACTCGGTGCCACTTTTTC 
Illumina sequencing 
primer 
AGACTATAAGTATCCCTTGGAGAACCACCTTGTTGG 
  
Ubiquitome library 
 
 
Sequence 5'-3' 
sgRNA_outer_F GCTTACCGTAACTTGAAAGTATTTCG 
sgRNA_outer_R CGAGACTAGTGAGACGTGCTAC 
P5-sgRNA_inner_F AATGATACGGCGACCACCGAGATCTACACTCTCTTGTGGAAAGGACGAAACA
CCG 
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Appendix 2. Primer and adapter sequences used to prepare samples from forward genetic 
screens for Illumina sequencing 
 
P7-index-
sgRNA_inner_R 
CAAGCAGAAGACGGCATACGAGATnnnnnnnGTGACTGGAGTTCAGACGTGT
GCTCTTCCGATCT CCATTTGTCACGTCCTGCACG 
Illumina sequencing 
primer 
CTTGTGGAAAGGACGAAACACCG 
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Appendix 3: RNF145-V5 immunoprecipitation 
SD: sterol depleted, sterols: sterol depleted + 1 hr sterols, sterols + MG132: sterol depleted + 30 min 50 µM 
MG132 treatment followed by 1 hr sterols. 
#: number of unique peptides, A: Area 
Accession Gene name Gene ID 
SD sterols sterols + MG132 
# A # A # A 
Q8N766 ER membrane protein complex subunit 1 EMC1 15 1.99 13.00 2.40 19.00 3.35 
O75955 Flotillin-1 FLOT1 17 3.90 19.00 7.35 16.00 3.54 
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 10 1.41 7.00 1.41 16.00 7.65 
Q96MT1 RING finger protein 145 RNF145 15 102.48 14.00 126.23 15.00 140.74 
P32004 Neural cell adhesion molecule L1 L1CAM 13 4.64 19.00 13.80 14.00 5.85 
O15031 Plexin-B2 PLXNB2 12 1.50 21.00 3.61 14.00 1.42 
P00533 Epidermal growth factor receptor EGFR 14 2.54 17.00 5.63 13.00 2.10 
O96005 Cleft lip and palate transmembrane protein 1 CLPTM1 6 2.40 7.00 2.44 11.00 4.24 
Q86VI3 Ras GTPase-activating-like protein IQGAP3 IQGAP3 3 0.54 3.00 0.52 11.00 1.32 
Q12907 Vesicular integral-membrane protein VIP36 LMAN2 10 5.36 7.00 3.63 10.00 5.70 
P04844 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
RPN2 5 1.52 9.00 2.07 10.00 2.25 
O14980 Exportin-1 XPO1 9 1.78 14.00 2.59 10.00 1.26 
O14818 Proteasome subunit alpha type-7 PSMA7 7 2.98 4.00 2.57 9.00 8.04 
Q9UNQ0 ATP-binding cassette sub-family G member 2 ABCG2 10 3.16 10.00 6.11 9.00 3.53 
Q6YHK3 CD109 antigen CD109 9 1.82 17.00 3.84 9.00 1.34 
P20618 Proteasome subunit beta type-1 PSMB1 3 0.78 3.00 0.93 9.00 3.82 
P20020 Plasma membrane calcium-transporting ATPase 1 ATP2B1 5 1.23 9.00 2.56 9.00 1.01 
P10586 Receptor-type tyrosine-protein phosphatase F PTPRF 9 0.87 19.00 2.60 9.00 0.74 
Q9UJS0 Calcium-binding mitochondrial carrier protein Aralar2 SLC25A13 7 0.98 12.00 1.35 9.00 0.77 
Q7L576 Cytoplasmic FMR1-interacting protein 1 CYFIP1 3 0.96 9.00 1.19 9.00 0.68 
Q92621 Nuclear pore complex protein Nup205 NUP205 5 0.63 13.00 1.13 9.00 0.74 
Q14677 Clathrin interactor 1 CLINT1 5 0.49 7.00 0.52 9.00 0.86 
Q96AD5 Patatin-like phospholipase domain-containing protein 2 PNPLA2 6 2.95 7.00 4.35 8.00 2.32 
Q14534 Squalene monooxygenase SQLE 5 1.08 5.00 1.40 8.00 2.77 
P49720 Proteasome subunit beta type-3 PSMB3 2 1.02 2.00 0.81 7.00 3.84 
P28074 Proteasome subunit beta type-5 PSMB5 5 0.97 2.00 0.55 7.00 4.05 
Q9UKS6 Protein kinase C and casein kinase substrate in neurons 
protein 3 
PACSIN3 5 1.13 7.00 2.41 7.00 1.16 
A0A024RA52 Proteasome subunit alpha type PSMA2 
    
7.00 3.71 
Q5T5U3 Rho GTPase-activating protein 21 ARHGAP21 1 0.20 5.00 0.20 7.00 0.42 
Q96CS3 FAS-associated factor 2 FAF2 3 1.53 5.00 1.98 6.00 4.70 
Q14254 Flotillin-2 FLOT2 7 1.84 12.00 4.58 6.00 1.74 
Q8NBM4 Ubiquitin-associated domain-containing protein 2 UBAC2 5 1.60 3.00 1.04 6.00 2.92 
Q6DD88 Atlastin-3 ATL3 3 0.65 7.00 2.23 6.00 2.04 
P28070 Proteasome subunit beta type-4 PSMB4 2 0.58 2.00 0.42 6.00 2.67 
Q9UMX0 Ubiquilin-1 UBQLN1 2 1.27 
  
6.00 1.68 
O60237 Protein phosphatase 1 regulatory subunit 12B PPP1R12B 1 0.81 2.00 1.16 6.00 0.90 
Q9UKV5 E3 ubiquitin-protein ligase AMFR AMFR 4 0.68 3.00 0.67 6.00 1.46 
Q6P2E9 Enhancer of mRNA-decapping protein 4 EDC4 3 0.46 6.00 1.10 6.00 0.78 
Q9Y2L1 Exosome complex exonuclease RRP44 DIS3 5 0.56 6.00 0.85 6.00 0.53 
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F1T0I1 Protein transport protein Sec16A SEC16A 7 21.71 7.00 14.12 5.00 13.74 
P16070 CD44 antigen CD44 4 6.60 6.00 16.10 5.00 7.36 
Q15758 Neutral amino acid transporter B(0) SLC1A5 5 3.75 8.00 8.48 5.00 4.72 
Q9H9B4 Sideroflexin-1 SFXN1 9 1.67 10.00 2.45 5.00 2.07 
Q9NR30 Nucleolar RNA helicase 2 DDX21 3 0.82 8.00 2.98 5.00 1.48 
Q96SB3 Neurabin-2 PPP1R9B 9 1.92 7.00 2.01 5.00 0.80 
O14964 Hepatocyte growth factor-regulated tyrosine kinase 
substrate 
HGS 1 1.43 1.00 2.21 5.00 1.08 
P51648 Fatty aldehyde dehydrogenase ALDH3A2 3 0.95 3.00 0.86 5.00 2.29 
P01130 Low-density lipoprotein receptor LDLR 4 1.00 8.00 1.83 5.00 1.05 
Q14160 Protein scribble homolog SCRIB 2 0.48 9.00 2.06 5.00 0.57 
Q16850 Lanosterol 14-alpha demethylase CYP51A1 2 0.58 6.00 1.21 5.00 1.31 
Q9NPA0 ER membrane protein complex subunit 7 EMC7 2 0.85 2.00 0.73 5.00 1.31 
P52789 Hexokinase-2 HK2 7 0.57 10.00 1.38 5.00 0.87 
Q96FS4 Signal-induced proliferation-associated protein 1 SIPA1 3 0.69 5.00 0.86 5.00 1.22 
O94905 Erlin-2 ERLIN2 2 0.70 4.00 0.65 5.00 1.21 
Q7L014 Probable ATP-dependent RNA helicase DDX46 DDX46 1 0.72 2.00 0.63 5.00 0.53 
P78346 Ribonuclease P protein subunit p30 RPP30 1 0.57 3.00 0.36 5.00 0.71 
O00231 26S proteasome non-ATPase regulatory subunit 11 PSMD11 1 0.38 5.00 0.59 5.00 0.30 
Q6P4F7 Rho GTPase-activating protein 11A ARHGAP11
A 
  
2.00 0.44 5.00 0.47 
Q13769 THO complex subunit 5 homolog THOC5 
  
3.00 0.33 5.00 0.24 
P39656 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
DDOST 3 0.42 4.00 5.82 4.00 3.10 
P43121 Cell surface glycoprotein MUC18 MCAM 8 1.92 10.00 5.66 4.00 1.46 
P28066 Proteasome subunit alpha type-5 PSMA5 1 0.37 2.00 1.09 4.00 4.58 
Q15738 Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating 
NSDHL 1 1.86 1.00 2.13 4.00 1.47 
P28072 Proteasome subunit beta type-6 PSMB6 1 1.16 1.00 0.90 4.00 3.10 
Q14152 Eukaryotic translation initiation factor 3 subunit A EIF3A 4 0.39 14.00 3.17 4.00 0.86 
P25788 Proteasome subunit alpha type-3 PSMA3 3 0.86 3.00 0.82 4.00 2.54 
Q9NXW2 DnaJ homolog subfamily B member 12 DNAJB12 3 0.89 3.00 0.61 4.00 1.68 
Q6PJ61 F-box only protein 46 FBXO46 2 0.25 5.00 0.80 4.00 1.09 
Q9NRG9 Aladin AAAS 2 0.34 4.00 1.10 4.00 0.66 
O14579 Coatomer subunit epsilon COPE 2 0.50 1.00 0.50 4.00 0.85 
Q7L5D6 Golgi to ER traffic protein 4 homolog GET4 
    
4.00 1.75 
P00387 NADH-cytochrome b5 reductase 3 CYB5R3 1 0.19 4.00 0.60 4.00 0.77 
P57678 Gem-associated protein 4 GEMIN4 2 0.41 6.00 0.62 4.00 0.51 
Q7Z478 ATP-dependent RNA helicase DHX29 DHX29 1 0.50 4.00 0.52 4.00 0.46 
Q9UBV2 Protein sel-1 homolog 1 SEL1L 
  
2.00 0.40 4.00 0.76 
P09884 DNA polymerase alpha catalytic subunit POLA1 2 0.52 1.00 0.17 4.00 0.38 
O75128 Protein cordon-bleu COBL 4 0.25 6.00 0.33 4.00 0.23 
P80723 Brain acid soluble protein 1 BASP1 3 1.87 2.00 6.99 3.00 1.08 
Q15149-3 Isoform 3 of Plectin PLEC 
  
4.00 4.12 3.00 5.74 
P53985 Monocarboxylate transporter 1 SLC16A1 4 1.76 6.00 5.03 3.00 1.60 
O00560 Syntenin-1 SDCBP 4 1.34 4.00 2.97 3.00 1.80 
P83731 60S ribosomal protein L24 RPL24 2 1.38 2.00 2.33 3.00 1.93 
P63000 Ras-related C3 botulinum toxin substrate 1 RAC1 6 1.82 5.00 2.37 3.00 1.22 
P40692 DNA mismatch repair protein Mlh1 MLH1 2 1.39 1.00 3.50 3.00 0.26 
Q9Y6M5 Zinc transporter 1 SLC30A1 2 0.99 3.00 2.56 3.00 1.49 
Q9Y320 Thioredoxin-related transmembrane protein 2 TMX2 4 3.35 4.00 0.72 3.00 0.87 
P32969 60S ribosomal protein L9 RPL9 3 0.95 4.00 2.45 3.00 1.49 
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Q9P0I2 ER membrane protein complex subunit 3 EMC3 2 1.60 1.00 1.61 3.00 1.48 
Q14118 Dystroglycan DAG1 1 1.77 6.00 2.17 3.00 0.69 
P06756 Integrin alpha-V ITGAV 5 0.94 10.00 2.24 3.00 0.95 
O75396 Vesicle-trafficking protein SEC22b SEC22B 2 1.06 3.00 1.14 3.00 1.60 
Q8TC12 Retinol dehydrogenase 11 RDH11 1 1.50 2.00 1.47 3.00 0.68 
P53007 Tricarboxylate transport protein, mitochondrial SLC25A1 3 1.38 4.00 1.56 3.00 0.71 
P62070 Ras-related protein R-Ras2 RRAS2 3 1.09 4.00 1.84 3.00 0.69 
P13073 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1 2 1.42 3.00 1.15 3.00 0.74 
Q02543 60S ribosomal protein L18a RPL18A 2 0.71 4.00 1.54 3.00 1.01 
O95297 Myelin protein zero-like protein 1 MPZL1 2 0.65 3.00 1.53 3.00 0.75 
O14975 Very long-chain acyl-CoA synthetase SLC27A2 3 1.83 3.00 0.49 3.00 0.58 
Q96A33 Coiled-coil domain-containing protein 47 CCDC47 1 0.94 2.00 0.83 3.00 1.03 
P08574 Cytochrome c1, heme protein, mitochondrial CYC1 2 1.60 3.00 0.61 3.00 0.58 
Q92542 Nicastrin NCSTN 3 0.43 6.00 1.68 3.00 0.55 
Q9NR12 PDZ and LIM domain protein 7 PDLIM7 1 0.64 2.00 0.44 3.00 1.48 
P46777 60S ribosomal protein L5 RPL5 2 0.74 3.00 1.20 3.00 0.53 
Q9UBX3 Mitochondrial dicarboxylate carrier SLC25A10 2 0.88 3.00 0.84 3.00 0.59 
P55263 Adenosine kinase ADK 5 0.74 2.00 0.72 3.00 0.62 
P46977 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
STT3A 1 0.58 1.00 0.81 3.00 0.66 
O15381 Nuclear valosin-containing protein-like NVL 1 0.84 2.00 0.76 3.00 0.42 
Q14558 Phosphoribosyl pyrophosphate synthase-associated protein 
1 
PRPSAP1 2 0.45 3.00 0.66 3.00 0.85 
Q5ZPR3 CD276 antigen CD276 2 0.43 3.00 1.01 3.00 0.49 
P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-1 
GNB1 
    
3.00 1.89 
P51812 Ribosomal protein S6 kinase alpha-3 RPS6KA3 4 0.99 3.00 0.42 3.00 0.42 
P46060 Ran GTPase-activating protein 1 RANGAP1 3 0.50 5.00 0.77 3.00 0.50 
Q9Y679 Ancient ubiquitous protein 1 AUP1 1 0.43 1.00 0.17 3.00 1.12 
Q7L2E3 Putative ATP-dependent RNA helicase DHX30 DHX30 1 0.60 2.00 0.70 3.00 0.37 
Q86YQ8 Copine-8 CPNE8 1 0.29 4.00 0.75 3.00 0.53 
Q9Y5Y2 Cytosolic Fe-S cluster assembly factor NUBP2 NUBP2 1 0.47 2.00 0.39 3.00 0.54 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial IARS2 3 0.39 2.00 0.38 3.00 0.63 
Q9HC35 Echinoderm microtubule-associated protein-like 4 EML4 4 0.41 4.00 0.53 3.00 0.44 
Q15149-4 Isoform 4 of Plectin PLEC 
    
3.00 1.24 
Q14643 Inositol 1,4,5-trisphosphate receptor type 1 ITPR1 2 0.23 4.00 0.55 3.00 0.40 
Q9Y4P3 Transducin beta-like protein 2 TBL2 1 0.30 4.00 0.39 3.00 0.47 
P18031 Tyrosine-protein phosphatase non-receptor type 1 PTPN1 1 0.37 2.00 0.18 3.00 0.43 
O95347 Structural maintenance of chromosomes protein 2 SMC2 3 0.31 2.00 0.21 3.00 0.47 
P55061 Bax inhibitor 1 TMBIM6 
    
3.00 0.90 
Q96RT1 Erbin ERBIN 1 
 
2.00 0.55 3.00 0.30 
Q96KA5 Cleft lip and palate transmembrane protein 1-like protein CLPTM1L 1 0.27 2.00 0.13 3.00 0.44 
Q86TM6 E3 ubiquitin-protein ligase synoviolin SYVN1 
  
1.00 0.34 3.00 0.50 
A5YKK6 CCR4-NOT transcription complex subunit 1 CNOT1 1 0.26 4.00 0.34 3.00 0.21 
Q9UN37 Vacuolar protein sorting-associated protein 4A VPS4A 
    
3.00 0.74 
Q92620 Pre-mRNA-splicing factor ATP-dependent RNA helicase 
PRP16 
DHX38 
  
3.00 0.35 3.00 0.33 
Q9NX61 Transmembrane protein 161A TMEM161A 
    
3.00 0.63 
Q13619 Cullin-4A CUL4A 
  
2.00 0.32 3.00 0.25 
O60826 Coiled-coil domain-containing protein 22 CCDC22 1 0.22 1.00 
 
3.00 0.21 
Q14839 Chromodomain-helicase-DNA-binding protein 4 CHD4 
    
3.00 0.33 
O75150 E3 ubiquitin-protein ligase BRE1B RNF40 1 
 
1.00 
 
3.00 0.24 
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Q96CW5 Gamma-tubulin complex component 3 TUBGCP3 
    
3.00 0.16 
Q9NRZ9 Lymphoid-specific helicase HELLS 
    
3.00 0.14 
P12270 Nucleoprotein TPR TPR 1 
   
3.00 
 
A0A087WW8
9 
Protein IGHV3-72 IGHV3-72 3 54.95 2.00 63.66 2.00 32.52 
Q9NQC3 Reticulon-4 RTN4 1 2.38 4.00 5.23 2.00 2.32 
Q10589 Bone marrow stromal antigen 2 BST2 1 2.77 1.00 3.93 2.00 1.62 
P11233 Ras-related protein Ral-A RALA 5 1.93 6.00 3.41 2.00 2.15 
P22695 Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 4 1.26 8.00 4.68 2.00 1.01 
Q8WTV0 Scavenger receptor class B member 1 SCARB1 1 2.14 3.00 1.80 2.00 1.44 
Q9H2H9 Sodium-coupled neutral amino acid transporter 1 SLC38A1 2 1.78 3.00 2.06 2.00 1.34 
Q14126 Desmoglein-2 DSG2 4 0.51 11.00 4.07 2.00 0.58 
P07947 Tyrosine-protein kinase Yes YES1 3 1.21 4.00 2.24 2.00 1.01 
Q8NBI5 Solute carrier family 43 member 3 SLC43A3 2 1.70 3.00 0.91 2.00 1.68 
Q9NRR5 Ubiquilin-4 UBQLN4 
  
1.00 2.32 2.00 1.74 
Q99808 Equilibrative nucleoside transporter 1 SLC29A1 2 0.78 2.00 2.47 2.00 0.80 
O14828 Secretory carrier-associated membrane protein 3 SCAMP3 2 1.36 3.00 1.24 2.00 1.42 
P20645 Cation-dependent mannose-6-phosphate receptor M6PR 2 0.78 1.00 1.92 2.00 1.29 
P36897 TGF-beta receptor type-1 TGFBR1 2 0.93 3.00 2.10 2.00 0.87 
Q9P035 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 HACD3 2 0.92 1.00 1.61 2.00 1.17 
P06241 Tyrosine-protein kinase Fyn FYN 3 1.12 5.00 1.36 2.00 1.20 
P35268 60S ribosomal protein L22 RPL22 
    
2.00 3.66 
Q6NUK1 Calcium-binding mitochondrial carrier protein SCaMC-1 SLC25A24 4 0.97 7.00 2.08 2.00 0.54 
P39023 60S ribosomal protein L3 RPL3 
  
4.00 2.21 2.00 1.37 
P11166 Solute carrier family 2, facilitated glucose transporter 
member 1 
SLC2A1 2 0.31 3.00 1.83 2.00 1.34 
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic HMGCS1 4 0.87 4.00 1.89 2.00 0.68 
P01111 GTPase NRas NRAS 1 0.97 1.00 1.67 2.00 0.64 
O75695 Protein XRP2 RP2 1 0.82 1.00 1.76 2.00 0.69 
O00592 Podocalyxin PODXL 1 
 
2.00 1.96 2.00 1.23 
P61254 60S ribosomal protein L26 RPL26 2 1.45 2.00 0.98 2.00 0.73 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic ACAT2 3 0.78 3.00 1.33 2.00 1.04 
Q8NBM8 Prenylcysteine oxidase-like PCYOX1L 1 1.06 2.00 0.63 2.00 1.07 
Q15006 ER membrane protein complex subunit 2 EMC2 2 0.28 1.00 1.12 2.00 1.36 
Q9Y4W6 AFG3-like protein 2 AFG3L2 2 1.64 3.00 0.56 2.00 0.54 
P51114 Fragile X mental retardation syndrome-related protein 1 FXR1 2 0.82 3.00 1.28 2.00 0.60 
H3BQK9 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 MACF1 1 1.16 1.00 0.21 2.00 1.27 
P02794 Ferritin heavy chain FTH1 3 0.78 4.00 1.21 2.00 0.62 
P12277 Creatine kinase B-type CKB 2 1.15 2.00 0.67 2.00 0.77 
P07948 Tyrosine-protein kinase Lyn LYN 2 0.30 5.00 1.37 2.00 0.88 
P62995 Transformer-2 protein homolog beta TRA2B 1 0.72 3.00 0.85 2.00 0.78 
Q96N66 Lysophospholipid acyltransferase 7 MBOAT7 
  
2.00 1.22 2.00 1.10 
Q99436 Proteasome subunit beta type-7 PSMB7 
    
2.00 2.30 
Q6PJ69 Tripartite motif-containing protein 65 TRIM65 
  
1.00 1.33 2.00 0.87 
O75915 PRA1 family protein 3 ARL6IP5 1 0.44 1.00 0.97 2.00 0.67 
Q04721 Neurogenic locus notch homolog protein 2 NOTCH2 3 0.59 8.00 1.23 2.00 0.25 
Q8IX12 Cell division cycle and apoptosis regulator protein 1 CCAR1 1 0.73 1.00 0.73 2.00 0.46 
Q14240 Eukaryotic initiation factor 4A-II EIF4A2 1 0.08 2.00 0.84 2.00 0.98 
Q9Y3E0 Vesicle transport protein GOT1B GOLT1B 
  
2.00 1.21 2.00 0.68 
Q9HCE1 Putative helicase MOV-10 MOV10 2 0.53 4.00 0.79 2.00 0.51 
Q01780 Exosome component 10 EXOSC10 1 0.64 2.00 0.86 2.00 0.30 
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Q00341 Vigilin HDLBP 3 0.25 7.00 0.94 2.00 0.61 
P43007 Neutral amino acid transporter A SLC1A4 1 0.30 2.00 1.09 2.00 0.37 
Q9BXS9 Solute carrier family 26 member 6 SLC26A6 1 0.32 1.00 0.86 2.00 0.51 
Q5T0V7 Dystonin (Fragment) DST 
  
1.00 0.73 2.00 0.88 
Q9BZH6 WD repeat-containing protein 11 WDR11 2 0.52 2.00 0.57 2.00 0.52 
Q9H0U4 Ras-related protein Rab-1B RAB1B 
  
1.00 0.08 2.00 1.53 
Q9Y2A7 Nck-associated protein 1 NCKAP1 1 0.29 1.00 1.08 2.00 0.23 
Q93052 Lipoma-preferred partner LPP 4 0.52 4.00 0.68 2.00 0.34 
Q86TC9 Myopalladin MYPN 2 0.56 3.00 0.53 2.00 0.44 
Q9P2B2 Prostaglandin F2 receptor negative regulator PTGFRN 2 0.16 3.00 0.96 2.00 0.36 
Q15717 ELAV-like protein 1 ELAVL1 3 0.80 
  
2.00 0.68 
Q9BTW9 Tubulin-specific chaperone D TBCD 2 0.24 5.00 0.80 2.00 0.42 
Q9P0L0 Vesicle-associated membrane protein-associated protein A VAPA 
  
1.00 0.90 2.00 0.55 
P29317 Ephrin type-A receptor 2 EPHA2 
  
4.00 1.02 2.00 0.41 
Q15021 Condensin complex subunit 1 NCAPD2 
  
3.00 0.95 2.00 0.42 
Q99459 Cell division cycle 5-like protein CDC5L 1 0.34 3.00 0.53 2.00 0.48 
P82650 28S ribosomal protein S22, mitochondrial MRPS22 1 0.18 2.00 0.73 2.00 0.42 
Q86UP2 Kinectin KTN1 1 0.33 1.00 0.65 2.00 0.34 
P35658 Nuclear pore complex protein Nup214 NUP214 1 0.45 1.00 0.43 2.00 0.43 
Q15036 Sorting nexin-17 SNX17 
  
2.00 0.87 2.00 0.44 
Q08345 Epithelial discoidin domain-containing receptor 1 DDR1 
  
1.00 0.73 2.00 0.58 
P46087 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase NOP2 2 0.39 4.00 0.62 2.00 0.29 
Q9P2R3 Rabankyrin-5 ANKFY1 1 0.33 1.00 0.38 2.00 0.57 
Q14108 Lysosome membrane protein 2 SCARB2 
  
4.00 0.96 2.00 0.31 
Q9HAV4 Exportin-5 XPO5 2 0.45 4.00 0.50 2.00 0.25 
A1L0T0 Acetolactate synthase-like protein ILVBL 3 0.20 3.00 0.62 2.00 0.35 
P04183 Thymidine kinase, cytosolic TK1 
  
1.00 0.54 2.00 0.61 
Q92615 La-related protein 4B LARP4B 
  
1.00 0.68 2.00 0.45 
O60610 Protein diaphanous homolog 1 DIAPH1 3 0.19 5.00 0.64 2.00 0.30 
Q9H0D6 5'-3' exoribonuclease 2 XRN2 
  
1.00 0.57 2.00 0.51 
Q8N7H5 RNA polymerase II-associated factor 1 homolog PAF1 
  
3.00 0.49 2.00 0.60 
Q08752 Peptidyl-prolyl cis-trans isomerase D PPID 3 0.38 3.00 0.40 2.00 0.25 
Q96J02 E3 ubiquitin-protein ligase Itchy homolog ITCH 
  
6.00 0.70 2.00 0.33 
Q9UNN8 Endothelial protein C receptor PROCR 1 0.54 
  
2.00 0.48 
Q96DG6 Carboxymethylenebutenolidase homolog CMBL 1 0.11 1.00 0.56 2.00 0.32 
P49755 Transmembrane emp24 domain-containing protein 10 TMED10 1 0.47 
  
2.00 0.51 
Q14738 Serine/threonine-protein phosphatase 2A 56 kDa regulatory 
subunit delta isoform 
PPP2R5D 1 0.30 1.00 0.32 2.00 0.33 
Q8NHH9 Atlastin-2 ATL2 
  
4.00 0.58 2.00 0.36 
P50402 Emerin EMD 1 0.46 
  
2.00 0.45 
P37198 Nuclear pore glycoprotein p62 NUP62 1 0.32 2.00 0.25 2.00 0.32 
P11182 Lipoamide acyltransferase component of branched-chain 
alpha-keto acid dehydrogenase complex, mitochondrial 
DBT 
  
3.00 0.41 2.00 0.42 
Q8N4V1 Membrane magnesium transporter 1 MMGT1 
  
1.00 0.17 2.00 0.64 
Q92692 Nectin-2 NECTIN2 
  
2.00 0.60 2.00 0.21 
P18858 DNA ligase 1 LIG1 1 0.46 2.00 0.15 2.00 0.21 
P11908 Ribose-phosphate pyrophosphokinase 2 PRPS2 
    
2.00 0.80 
Q96PE2 Rho guanine nucleotide exchange factor 17 ARHGEF17 1 0.15 1.00 0.29 2.00 0.35 
Q9H0S4 Probable ATP-dependent RNA helicase DDX47 DDX47 1 
 
3.00 0.46 2.00 0.31 
Q12972 Nuclear inhibitor of protein phosphatase 1 PPP1R8 
  
2.00 0.23 2.00 0.46 
Q92556 Engulfment and cell motility protein 1 ELMO1 
    
2.00 0.68 
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Q96DZ1 Endoplasmic reticulum lectin 1 ERLEC1 
    
2.00 0.65 
Q8TEX9 Importin-4 IPO4 2 0.11 3.00 0.31 2.00 0.20 
Q5SRD1 Putative mitochondrial import inner membrane translocase 
subunit Tim23B 
TIMM23B 
    
2.00 0.63 
A0FGR8 Extended synaptotagmin-2 ESYT2 
  
2.00 0.27 2.00 0.35 
Q9NQW6 Anillin ANLN 
  
1.00 0.13 2.00 0.48 
Q13614 Myotubularin-related protein 2 MTMR2 
  
1.00 0.36 2.00 0.24 
A3KMH1 von Willebrand factor A domain-containing protein 8 VWA8 
  
1.00 0.28 2.00 0.32 
Q9P2R7 Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial 
SUCLA2 1 0.19 1.00 0.19 2.00 0.21 
O15127 Secretory carrier-associated membrane protein 2 SCAMP2 
  
1.00 0.21 2.00 0.37 
O15294 UDP-N-acetylglucosamine--peptide N-
acetylglucosaminyltransferase 110 kDa subunit 
OGT 1 0.24 1.00 0.14 2.00 0.16 
Q86V48 Leucine zipper protein 1 LUZP1 
  
1.00 
 
2.00 0.51 
Q9UDY2 Tight junction protein ZO-2 TJP2 1 
 
2.00 0.20 2.00 0.28 
O15118 Niemann-Pick C1 protein NPC1 
    
2.00 0.47 
Q5GLZ8 Probable E3 ubiquitin-protein ligase HERC4 HERC4 
    
2.00 0.46 
Q07157 Tight junction protein ZO-1 TJP1 
  
2.00 0.35 2.00 0.09 
Q14678 KN motif and ankyrin repeat domain-containing protein 1 KANK1 
    
2.00 0.44 
Q9BUN8 Derlin-1 DERL1 
    
2.00 0.40 
Q8NEZ5 F-box only protein 22 FBXO22 
    
2.00 0.35 
Q8IZH2 5'-3' exoribonuclease 1 XRN1 
    
2.00 0.34 
Q8N6R0 Methyltransferase-like protein 13 METTL13 
    
2.00 0.30 
Q10570 Cleavage and polyadenylation specificity factor subunit 1 CPSF1 
    
2.00 0.29 
Q9UBN7 Histone deacetylase 6 HDAC6 
    
2.00 0.23 
Q96JH7 Deubiquitinating protein VCIP135 VCPIP1 
    
2.00 0.16 
A0A075B7B8 Protein IGHV3OR16-12 (Fragment) IGHV3OR16
-12 
1 24.24 1.00 21.64 1.00 6.94 
A0A075B6R9 Protein IGKV2D-24 (Fragment) IGKV2D-24 2 17.18 1.00 17.11 1.00 13.71 
Q13576 Ras GTPase-activating-like protein IQGAP2 IQGAP2 
    
1.00 21.35 
A0A0B4J2D9 Protein IGKV1D-13 (Fragment) IGKV1D-13 1 8.95 1.00 6.86 1.00 2.96 
Q86YR7 Probable guanine nucleotide exchange factor MCF2L2 MCF2L2 
    
1.00 12.59 
H7C144 Alpha-actinin-4 (Fragment) ACTN4 
  
1.00 5.67 1.00 6.72 
P04211 Immunoglobulin lambda variable 7-43 IGLV7-43 1 5.37 1.00 3.68 1.00 1.95 
P21926 CD9 antigen CD9 2 2.36 2.00 4.51 1.00 2.86 
Q16563 Synaptophysin-like protein 1 SYPL1 1 2.48 1.00 4.27 1.00 2.94 
P01704 Immunoglobulin lambda variable 2-14 IGLV2-14 1 4.20 1.00 3.10 1.00 1.91 
P01817 Immunoglobulin heavy variable 2-5 IGHV2-5 1 3.63 1.00 3.60 1.00 1.15 
G8JLA2 Myosin light polypeptide 6 MYL6 
    
1.00 6.67 
P46776 60S ribosomal protein L27a RPL27A 1 0.19 2.00 3.89 1.00 2.58 
Q86Y46 Keratin, type II cytoskeletal 73 KRT73 
    
1.00 6.42 
P05556 Integrin beta-1 ITGB1 1 1.71 3.00 2.95 1.00 1.26 
P01601 Immunoglobulin kappa variable 1D-16 (Fragment) IGKV1D-16 1 3.04 1.00 1.94 1.00 0.94 
P01891 HLA class I histocompatibility antigen, A-68 alpha chain HLA-A 3 1.08 4.00 2.54 1.00 2.21 
P46778 60S ribosomal protein L21 RPL21 1 0.94 1.00 2.76 1.00 1.99 
Q9P2E9 Ribosome-binding protein 1 RRBP1 3 0.82 2.00 1.43 1.00 2.95 
P04899 Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 1 1.79 2.00 1.78 1.00 1.43 
Q96S97 Myeloid-associated differentiation marker MYADM 1 1.05 1.00 2.56 1.00 1.31 
Q8NFJ5 Retinoic acid-induced protein 3 GPRC5A 1 1.32 3.00 2.47 1.00 1.11 
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 HNRNPUL2 1 2.17 2.00 0.95 1.00 1.47 
A0A087WSZ0 Protein IGKV1D-8 (Fragment) IGKV1D-8 1 2.10 1.00 1.48 1.00 0.78 
P01764 Immunoglobulin heavy variable 3-23 IGHV3-23 1 1.89 1.00 1.79 1.00 0.66 
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P09496-2 Isoform Non-brain of Clathrin light chain A CLTA 1 2.02 
  
1.00 1.96 
P09382 Galectin-1 LGALS1 1 1.20 2.00 1.41 1.00 1.34 
Q6IWH7 Anoctamin-7 ANO7 
    
1.00 3.74 
P14174 Macrophage migration inhibitory factor MIF 
  
1.00 1.93 1.00 1.68 
Q04941 Proteolipid protein 2 PLP2 1 1.03 1.00 1.88 1.00 0.66 
Q03135 Caveolin-1 CAV1 1 2.02 2.00 1.40 1.00 0.11 
Q8TDN6 Ribosome biogenesis protein BRX1 homolog BRIX1 1 0.14 
  
1.00 3.39 
Q9NQC3-2 Isoform 2 of Reticulon-4 RTN4 
  
1.00 2.15 1.00 1.08 
Q9BUP3 Oxidoreductase HTATIP2 HTATIP2 
    
1.00 3.20 
Q9UBM7 7-dehydrocholesterol reductase DHCR7 1 1.00 2.00 0.79 1.00 1.18 
P10155 60 kDa SS-A/Ro ribonucleoprotein TROVE2 4 0.69 4.00 1.23 1.00 1.01 
Q9UHD9 Ubiquilin-2 UBQLN2 
    
1.00 2.75 
Q9NR19 Acetyl-coenzyme A synthetase, cytoplasmic ACSS2 
  
1.00 1.57 1.00 1.14 
H7BZJ3 Protein disulfide-isomerase A3 (Fragment) PDIA3 
  
1.00 1.92 1.00 0.75 
P37268 Squalene synthase FDFT1 2 0.73 3.00 0.67 1.00 1.25 
O00767 Acyl-CoA desaturase SCD 
    
1.00 2.63 
A0A0B4J1V2 Immunoglobulin heavy variable 2-26 IGHV2-26 2 1.22 2.00 0.97 1.00 0.43 
Q969X1 Protein lifeguard 3 TMBIM1 1 0.82 1.00 1.36 1.00 0.44 
P62899 60S ribosomal protein L31 RPL31 1 0.28 2.00 1.96 1.00 0.28 
Q96KR1 Zinc finger RNA-binding protein ZFR 2 0.30 3.00 0.74 1.00 1.46 
P15529 Membrane cofactor protein CD46 1 0.41 1.00 1.38 1.00 0.67 
P61026 Ras-related protein Rab-10 RAB10 1 0.84 2.00 0.76 1.00 0.85 
Q9BT67 NEDD4 family-interacting protein 1 NDFIP1 
  
1.00 1.89 1.00 0.55 
O60759 Cytohesin-interacting protein CYTIP 
    
1.00 2.42 
P29992 Guanine nucleotide-binding protein subunit alpha-11 GNA11 2 0.59 3.00 1.05 1.00 0.77 
P15151 Poliovirus receptor PVR 1 0.51 2.00 1.26 1.00 0.53 
Q9NXE4 Sphingomyelin phosphodiesterase 4 SMPD4 1 0.77 1.00 0.98 1.00 0.47 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog VAT1 1 0.91 5.00 0.99 1.00 0.30 
O43653 Prostate stem cell antigen PSCA 
  
1.00 1.62 1.00 0.50 
Q99595 Mitochondrial import inner membrane translocase subunit 
Tim17-A 
TIMM17A 1 0.75 1.00 0.55 1.00 0.81 
Q8NFW8 N-acylneuraminate cytidylyltransferase CMAS 
  
1.00 0.61 1.00 1.44 
Q07955 Serine/arginine-rich splicing factor 1 SRSF1 2 0.59 1.00 0.96 1.00 0.49 
Q8WYA6 Beta-catenin-like protein 1 CTNNBL1 1 0.55 2.00 0.65 1.00 0.84 
P62753 40S ribosomal protein S6 RPS6 
  
1.00 1.26 1.00 0.76 
Q14181 DNA polymerase alpha subunit B POLA2 1 0.40 1.00 0.86 1.00 0.73 
Q9BPX3 Condensin complex subunit 3 NCAPG 2 0.73 3.00 0.95 1.00 0.29 
P30825 High affinity cationic amino acid transporter 1 SLC7A1 
  
2.00 1.30 1.00 0.66 
Q8IWR0 Zinc finger CCCH domain-containing protein 7A ZC3H7A 
    
1.00 1.93 
O75781 Paralemmin-1 PALM 2 0.62 3.00 1.01 1.00 0.29 
Q92783 Signal transducing adapter molecule 1 STAM 
  
1.00 1.10 1.00 0.82 
P05362 Intercellular adhesion molecule 1 ICAM1 2 0.47 5.00 1.11 1.00 0.32 
Q5JWF2 Guanine nucleotide-binding protein G(s) subunit alpha 
isoforms XLas 
GNAS 2 0.46 5.00 0.90 1.00 0.52 
P63027 Vesicle-associated membrane protein 2 VAMP2 
  
1.00 1.09 1.00 0.76 
P31942 Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 2 0.78 1.00 0.45 1.00 0.61 
Q9GZT3 SRA stem-loop-interacting RNA-binding protein, 
mitochondrial 
SLIRP 2 0.51 2.00 0.65 1.00 0.68 
Q6P1M3 Lethal(2) giant larvae protein homolog 2 LLGL2 1 0.16 2.00 0.16 1.00 1.49 
P23634 Plasma membrane calcium-transporting ATPase 4 ATP2B4 3 0.49 4.00 1.08 1.00 0.24 
Q9UI26 Importin-11 IPO11 1 0.44 1.00 0.93 1.00 0.44 
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P62258 14-3-3 protein epsilon YWHAE 2 0.40 2.00 1.09 1.00 0.30 
P14649 Myosin light chain 6B MYL6B 2 0.57 1.00 0.44 1.00 0.76 
Q687X5 Metalloreductase STEAP4 STEAP4 2 0.42 2.00 0.64 1.00 0.70 
Q9Y639 Neuroplastin NPTN 1 0.27 3.00 1.10 1.00 0.38 
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial HADH 1 0.55 1.00 0.52 1.00 0.68 
Q9P287 BRCA2 and CDKN1A-interacting protein BCCIP 
  
2.00 0.75 1.00 0.97 
P31946 14-3-3 protein beta/alpha YWHAB 1 1.01 1.00 0.30 1.00 0.41 
Q9Y3L5 Ras-related protein Rap-2c RAP2C 3 0.48 2.00 0.72 1.00 0.51 
Q6NUM9 All-trans-retinol 13,14-reductase RETSAT 1 0.44 2.00 0.45 1.00 0.80 
O95671 N-acetylserotonin O-methyltransferase-like protein ASMTL 
  
1.00 0.92 1.00 0.77 
P11216 Glycogen phosphorylase, brain form PYGB 2 0.39 2.00 0.69 1.00 0.61 
P17252 Protein kinase C alpha type PRKCA 
  
3.00 0.66 1.00 0.99 
Q8TEM1 Nuclear pore membrane glycoprotein 210 NUP210 1 0.51 4.00 0.98 1.00 0.16 
Q96EK6 Glucosamine 6-phosphate N-acetyltransferase GNPNAT1 1 0.44 1.00 0.60 1.00 0.61 
Q9UH65 Switch-associated protein 70 SWAP70 1 0.62 2.00 0.47 1.00 0.55 
Q92544 Transmembrane 9 superfamily member 4 TM9SF4 
    
1.00 1.63 
P48651 Phosphatidylserine synthase 1 PTDSS1 
  
1.00 0.90 1.00 0.72 
Q9Y450 HBS1-like protein HBS1L 1 0.21 4.00 0.76 1.00 0.65 
P52594 Arf-GAP domain and FG repeat-containing protein 1 AGFG1 
  
2.00 0.42 1.00 1.19 
P61289 Proteasome activator complex subunit 3 PSME3 1 0.65 1.00 0.49 1.00 0.45 
O60888 Protein CutA CUTA 2 0.64 1.00 0.60 1.00 0.33 
P20674 Cytochrome c oxidase subunit 5A, mitochondrial COX5A 1 0.49 2.00 0.75 1.00 0.32 
Q15043 Zinc transporter ZIP14 SLC39A14 1 0.52 3.00 0.79 1.00 0.23 
Q5JPE7 Nodal modulator 2 NOMO2 2 0.45 2.00 0.58 1.00 0.50 
O75717 WD repeat and HMG-box DNA-binding protein 1 WDHD1 1 0.43 1.00 0.74 1.00 0.33 
Q8NF37 Lysophosphatidylcholine acyltransferase 1 LPCAT1 1 0.27 1.00 0.73 1.00 0.50 
P08240 Signal recognition particle receptor subunit alpha SRPRA 1 0.26 2.00 0.50 1.00 0.73 
P51571 Translocon-associated protein subunit delta SSR4 1 0.92 
  
1.00 0.55 
O15260 Surfeit locus protein 4 SURF4 1 0.29 2.00 0.52 1.00 0.66 
Q13123 Protein Red IK 1 0.61 2.00 0.27 1.00 0.59 
P13798 Acylamino-acid-releasing enzyme APEH 1 0.45 1.00 0.39 1.00 0.62 
P07954 Fumarate hydratase, mitochondrial FH 2 0.73 4.00 0.63 1.00 0.09 
P20700 Lamin-B1 LMNB1 5 0.75 5.00 0.52 1.00 0.16 
P19256 Lymphocyte function-associated antigen 3 CD58 
  
1.00 1.17 1.00 0.25 
Q8WY22 BRI3-binding protein BRI3BP 
    
1.00 1.42 
E9PLY5 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 
(Fragment) 
MACF1 
    
1.00 1.40 
Q92890 Ubiquitin fusion degradation protein 1 homolog UFD1L 
  
1.00 0.68 1.00 0.72 
Q9H2P9 Diphthine methyl ester synthase DPH5 2 0.45 1.00 0.38 1.00 0.57 
P19971 Thymidine phosphorylase TYMP 1 0.23 1.00 0.74 1.00 0.42 
Q02809 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 PLOD1 2 0.52 1.00 0.71 1.00 0.15 
Q08722 Leukocyte surface antigen CD47 CD47 1 0.74 
  
1.00 0.63 
Q9ULV4 Coronin-1C CORO1C 
  
1.00 0.93 1.00 0.44 
Q13509 Tubulin beta-3 chain TUBB3 2 0.60 3.00 0.77 1.00 
 
Q9H6S0 Probable ATP-dependent RNA helicase YTHDC2 YTHDC2 2 0.18 3.00 0.97 1.00 0.21 
O43760 Synaptogyrin-2 SYNGR2 
    
1.00 1.34 
Q96C36 Pyrroline-5-carboxylate reductase 2 PYCR2 1 1.00 
  
1.00 0.30 
Q02978 Mitochondrial 2-oxoglutarate/malate carrier protein SLC25A11 1 0.42 4.00 0.58 1.00 0.30 
Q9ULC4 Malignant T-cell-amplified sequence 1 MCTS1 3 0.38 2.00 0.43 1.00 0.48 
O95834 Echinoderm microtubule-associated protein-like 2 EML2 1 0.16 1.00 1.00 1.00 0.13 
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Q9H8Y5 Ankyrin repeat and zinc finger domain-containing protein 1 ANKZF1 1 0.35 3.00 0.47 1.00 0.47 
Q14247 Src substrate cortactin CTTN 1 0.48 5.00 0.55 1.00 0.23 
P36404 ADP-ribosylation factor-like protein 2 ARL2 2 0.81 1.00 0.45 1.00 
 
Q9HB07 UPF0160 protein MYG1, mitochondrial C12orf10 
    
1.00 1.24 
Q9Y4W2 Ribosomal biogenesis protein LAS1L LAS1L 1 0.34 1.00 0.45 1.00 0.43 
P55039 Developmentally-regulated GTP-binding protein 2 DRG2 2 0.55 1.00 0.56 1.00 0.10 
Q9BTX1 Nucleoporin NDC1 NDC1 1 0.39 2.00 0.32 1.00 0.50 
Q8NFH3 Nucleoporin Nup43 NUP43 1 0.42 1.00 0.44 1.00 0.34 
Q5VYK3 Proteasome-associated protein ECM29 homolog ECM29 1 0.19 3.00 0.54 1.00 0.46 
Q8WWM7 Ataxin-2-like protein ATXN2L 1 0.28 1.00 0.36 1.00 0.55 
Q9BSH4 Translational activator of cytochrome c oxidase 1 TACO1 1 0.09 
  
1.00 1.08 
P00492 Hypoxanthine-guanine phosphoribosyltransferase HPRT1 1 0.62 
  
1.00 0.53 
Q9BT78 COP9 signalosome complex subunit 4 COPS4 1 0.78 
  
1.00 0.38 
Q96PY5 Formin-like protein 2 FMNL2 1 0.10 2.00 0.81 1.00 0.24 
P51553 Isocitrate dehydrogenase [NAD] subunit gamma, 
mitochondrial 
IDH3G 1 0.11 1.00 0.68 1.00 0.36 
O60216 Double-strand-break repair protein rad21 homolog RAD21 
    
1.00 1.14 
O60547 GDP-mannose 4,6 dehydratase GMDS 1 0.40 2.00 0.30 1.00 0.45 
P08581 Hepatocyte growth factor receptor MET 1 0.26 4.00 0.63 1.00 0.26 
Q9Y6M7 Sodium bicarbonate cotransporter 3 SLC4A7 
  
2.00 0.91 1.00 0.22 
O95470 Sphingosine-1-phosphate lyase 1 SGPL1 
  
1.00 0.60 1.00 0.52 
Q8NI27 THO complex subunit 2 THOC2 1 0.32 2.00 0.38 1.00 0.40 
P08582 Melanotransferrin MELTF 1 0.25 4.00 0.72 1.00 0.13 
O43688 Phospholipid phosphatase 2 PLPP2 
  
2.00 0.80 1.00 0.29 
Q8NCG7 Sn1-specific diacylglycerol lipase beta DAGLB 2 0.27 5.00 0.50 1.00 0.29 
P47755 F-actin-capping protein subunit alpha-2 CAPZA2 1 0.36 
  
1.00 0.71 
P61006 Ras-related protein Rab-8A RAB8A 
  
1.00 1.06 1.00 
 
Q96FC9 ATP-dependent DNA helicase DDX11 DDX11 1 0.27 1.00 0.63 1.00 0.16 
Q06136 3-ketodihydrosphingosine reductase KDSR 
    
1.00 1.05 
O43402 ER membrane protein complex subunit 8 EMC8 1 0.47 
  
1.00 0.58 
O75306 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial 
NDUFS2 
  
4.00 0.63 1.00 0.40 
O14639-5 Isoform 5 of Actin-binding LIM protein 1 ABLIM1 
    
1.00 1.02 
P42025 Beta-centractin ACTR1B 
  
1.00 0.79 1.00 0.23 
P21912 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, 
mitochondrial 
SDHB 2 0.55 
  
1.00 0.47 
Q8NE86 Calcium uniporter protein, mitochondrial MCU 1 0.51 
  
1.00 0.50 
Q96G46 tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like DUS3L 1 0.63 1.00 0.23 1.00 0.15 
P69905 Hemoglobin subunit alpha HBA1 
    
1.00 1.01 
Q00765 Receptor expression-enhancing protein 5 REEP5 1 0.13 1.00 0.53 1.00 0.35 
Q86X29 Lipolysis-stimulated lipoprotein receptor LSR 
  
1.00 0.68 1.00 0.31 
Q9Y315 Deoxyribose-phosphate aldolase DERA 
  
1.00 0.37 1.00 0.62 
Q8IZ69 tRNA (uracil-5-)-methyltransferase homolog A TRMT2A 
  
1.00 0.46 1.00 0.51 
P33897 ATP-binding cassette sub-family D member 1 ABCD1 1 0.34 
  
1.00 0.62 
Q5VZK9 F-actin-uncapping protein LRRC16A LRRC16A 
  
1.00 0.45 1.00 0.50 
Q8WU90 Zinc finger CCCH domain-containing protein 15 ZC3H15 
  
1.00 0.61 1.00 0.33 
P51665 26S proteasome non-ATPase regulatory subunit 7 PSMD7 
  
2.00 0.50 1.00 0.43 
O14763 Tumor necrosis factor receptor superfamily member 10B TNFRSF10B 
  
1.00 0.61 1.00 0.31 
O15084 Serine/threonine-protein phosphatase 6 regulatory ankyrin 
repeat subunit A 
ANKRD28 2 0.40 2.00 0.14 1.00 0.33 
Q96S52 GPI transamidase component PIG-S PIGS 1 0.26 1.00 0.23 1.00 0.35 
Q15813 Tubulin-specific chaperone E TBCE 
  
2.00 0.41 1.00 0.43 
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Q9BTU6 Phosphatidylinositol 4-kinase type 2-alpha PI4K2A 
  
3.00 0.53 1.00 0.30 
Q13618 Cullin-3 CUL3 1 0.25 3.00 0.33 1.00 0.24 
Q9Y613 FH1/FH2 domain-containing protein 1 FHOD1 
    
1.00 0.81 
Q05655 Protein kinase C delta type PRKCD 
    
1.00 0.81 
Q9HBL0 Tensin-1 TNS1 1 0.44 
  
1.00 0.36 
Q9NPQ8 Synembryn-A RIC8A 1 0.51 2.00 0.30 1.00 
 
P52788 Spermine synthase SMS 1 0.34 1.00 0.24 1.00 0.23 
A1X283 SH3 and PX domain-containing protein 2B SH3PXD2B 
  
2.00 0.40 1.00 0.41 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 PSMD13 
    
1.00 0.79 
Q9HCE7 E3 ubiquitin-protein ligase SMURF1 SMURF1 
    
1.00 0.79 
Q9P265 Disco-interacting protein 2 homolog B DIP2B 3 0.21 1.00 0.39 1.00 0.18 
Q8NC42 E3 ubiquitin-protein ligase RNF149 RNF149 
  
1.00 0.42 1.00 0.36 
Q9NQR4 Omega-amidase NIT2 NIT2 1 0.33 1.00 0.26 1.00 0.18 
P24043 Laminin subunit alpha-2 LAMA2 
    
1.00 0.75 
Q9BQI0 Allograft inflammatory factor 1-like AIF1L 1 0.27 1.00 
 
1.00 0.48 
Q5TA45 Integrator complex subunit 11 CPSF3L 1 0.18 1.00 0.25 1.00 0.31 
Q9C0H2 Protein tweety homolog 3 TTYH3 
  
1.00 0.53 1.00 0.20 
Q9P0J7 E3 ubiquitin-protein ligase KCMF1 KCMF1 1 0.20 1.00 0.35 1.00 0.18 
Q6NVY1 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial HIBCH 1 0.38 
  
1.00 0.34 
P51151 Ras-related protein Rab-9A RAB9A 1 0.46 
  
1.00 0.25 
P42224 Signal transducer and activator of transcription 1-alpha/beta STAT1 1 0.36 3.00 0.35 1.00 
 
P11717 Cation-independent mannose-6-phosphate receptor IGF2R 1 0.26 4.00 0.45 1.00 
 
P49589 Cysteine--tRNA ligase, cytoplasmic CARS 1 0.13 2.00 0.41 1.00 0.17 
P62424 60S ribosomal protein L7a RPL7A 1 
 
1.00 0.42 1.00 0.28 
Q8TAA9 Vang-like protein 1 VANGL1 
  
4.00 0.70 1.00 
 
P23975 Sodium-dependent noradrenaline transporter SLC6A2 
    
1.00 0.70 
P35251 Replication factor C subunit 1 RFC1 
  
1.00 0.35 1.00 0.34 
P30460 HLA class I histocompatibility antigen, B-8 alpha chain HLA-B 
    
1.00 0.69 
Q13283 Ras GTPase-activating protein-binding protein 1 G3BP1 1 0.22 3.00 0.30 1.00 0.15 
Q8WVC0 RNA polymerase-associated protein LEO1 LEO1 
  
1.00 0.09 1.00 0.57 
P68402 Platelet-activating factor acetylhydrolase IB subunit beta PAFAH1B2 1 0.20 1.00 0.27 1.00 0.19 
Q8WUY1 Protein THEM6 THEM6 
    
1.00 0.65 
P32970 CD70 antigen CD70 
  
1.00 0.48 1.00 0.16 
Q8N2G8 GH3 domain-containing protein GHDC 
  
1.00 0.18 1.00 0.44 
Q9P0K7 Ankycorbin RAI14 1 0.38 
  
1.00 0.25 
Q14764 Major vault protein MVP 1 0.17 2.00 0.46 1.00 
 
P04920 Anion exchange protein 2 SLC4A2 1 
 
1.00 0.45 1.00 0.16 
Q5SRE5 Nucleoporin NUP188 homolog NUP188 2 0.13 4.00 0.28 1.00 0.19 
Q9UNF0 Protein kinase C and casein kinase substrate in neurons 
protein 2 
PACSIN2 1 0.20 2.00 0.26 1.00 0.14 
P53350 Serine/threonine-protein kinase PLK1 PLK1 
  
1.00 0.29 1.00 0.31 
O00750 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-
containing subunit beta 
PIK3C2B 
  
1.00 0.31 1.00 0.27 
P06213 Insulin receptor INSR 
  
3.00 0.44 1.00 0.15 
P52732 Kinesin-like protein KIF11 KIF11 
  
2.00 0.31 1.00 0.25 
P98196 Probable phospholipid-transporting ATPase IH ATP11A 
    
1.00 0.56 
P38606 V-type proton ATPase catalytic subunit A ATP6V1A 1 0.16 2.00 0.23 1.00 0.16 
Q15477 Helicase SKI2W SKIV2L 
  
1.00 0.30 1.00 0.24 
Q9UP95 Solute carrier family 12 member 4 SLC12A4 1 0.10 2.00 0.31 1.00 0.12 
Q3MIP1 Inositol 1,4,5-trisphosphate receptor-interacting protein-like 
2 
ITPRIPL2 1 
 
1.00 0.09 1.00 0.44 
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Q9Y3T9 Nucleolar complex protein 2 homolog NOC2L 
  
1.00 0.31 1.00 0.22 
Q13610 Periodic tryptophan protein 1 homolog PWP1 
    
1.00 0.53 
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1 PRKAA1 
    
1.00 0.52 
Q7RTV0 PHD finger-like domain-containing protein 5A PHF5A 
    
1.00 0.52 
Q8IU81 Interferon regulatory factor 2-binding protein 1 IRF2BP1 
    
1.00 0.52 
O15397 Importin-8 IPO8 
  
2.00 0.30 1.00 0.22 
Q99447 Ethanolamine-phosphate cytidylyltransferase PCYT2 
    
1.00 0.51 
Q9Y5Q8 General transcription factor 3C polypeptide 5 GTF3C5 
    
1.00 0.51 
P11441 Ubiquitin-like protein 4A UBL4A 
    
1.00 0.50 
Q96ST3 Paired amphipathic helix protein Sin3a SIN3A 
  
2.00 0.24 1.00 0.26 
P10620 Microsomal glutathione S-transferase 1 MGST1 1 0.24 
  
1.00 0.26 
Q15063 Periostin POSTN 
    
1.00 0.49 
Q8N122 Regulatory-associated protein of mTOR RPTOR 
  
1.00 0.25 1.00 0.24 
Q9UM54-6 Isoform 6 of Unconventional myosin-VI MYO6 
    
1.00 0.47 
O94972 E3 ubiquitin-protein ligase TRIM37 TRIM37 
    
1.00 0.46 
Q09161 Nuclear cap-binding protein subunit 1 NCBP1 
  
1.00 0.20 1.00 0.26 
Q8TCJ2 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 
STT3B 1 0.09 1.00 0.16 1.00 0.21 
O60427 Fatty acid desaturase 1 FADS1 
    
1.00 0.46 
Q9H0A0 RNA cytidine acetyltransferase NAT10 
  
1.00 0.28 1.00 0.17 
Q13564 NEDD8-activating enzyme E1 regulatory subunit NAE1 
  
1.00 0.27 1.00 0.17 
Q9HCK5 Protein argonaute-4 AGO4 
    
1.00 0.43 
Q86X55 Histone-arginine methyltransferase CARM1 CARM1 1 0.18 1.00 0.17 1.00 0.08 
O15258 Protein RER1 RER1 1 0.09 1.00 0.18 1.00 0.16 
Q15773 Myeloid leukemia factor 2 MLF2 
    
1.00 0.42 
O14981 TATA-binding protein-associated factor 172 BTAF1 
  
1.00 0.37 1.00 0.05 
P50336 Protoporphyrinogen oxidase PPOX 
  
1.00 0.22 1.00 0.20 
P20585 DNA mismatch repair protein Msh3 MSH3 1 0.22 
  
1.00 0.19 
Q14573 Inositol 1,4,5-trisphosphate receptor type 3 ITPR3 1 0.26 
  
1.00 0.15 
Q8TEP8 Centrosomal protein of 192 kDa CEP192 
    
1.00 0.40 
Q14147 Probable ATP-dependent RNA helicase DHX34 DHX34 
  
1.00 0.18 1.00 0.22 
O15344 E3 ubiquitin-protein ligase Midline-1 MID1 
  
1.00 0.18 1.00 0.22 
Q7Z3C6 Autophagy-related protein 9A ATG9A 
  
2.00 0.25 1.00 0.15 
Q9UNL2 Translocon-associated protein subunit gamma SSR3 
    
1.00 0.40 
Q12899 Tripartite motif-containing protein 26 TRIM26 
    
1.00 0.38 
Q9NWT1 p21-activated protein kinase-interacting protein 1 PAK1IP1 
    
1.00 0.38 
Q6IA86 Elongator complex protein 2 ELP2 
  
1.00 0.38 1.00 
 
P11117 Lysosomal acid phosphatase ACP2 
  
1.00 0.23 1.00 0.14 
Q8WUD6 Cholinephosphotransferase 1 CHPT1 
    
1.00 0.37 
Q8NEY8 Periphilin-1 PPHLN1 
  
1.00 0.12 1.00 0.25 
Q92636 Protein FAN NSMAF 
    
1.00 0.37 
Q9NQX4 Unconventional myosin-Vc MYO5C 1 0.12 
  
1.00 0.25 
O15091 Mitochondrial ribonuclease P protein 3 KIAA0391 
  
1.00 0.16 1.00 0.20 
Q9Y6D9 Mitotic spindle assembly checkpoint protein MAD1 MAD1L1 
    
1.00 0.36 
Q8NC60 Nitric oxide-associated protein 1 NOA1 
    
1.00 0.36 
Q8TAQ2 SWI/SNF complex subunit SMARCC2 SMARCC2 
    
1.00 0.36 
Q9NVN8 Guanine nucleotide-binding protein-like 3-like protein GNL3L 
  
2.00 0.25 1.00 0.10 
Q4G176 Acyl-CoA synthetase family member 3, mitochondrial ACSF3 
    
1.00 0.35 
Q53G44 Interferon-induced protein 44-like IFI44L 
    
1.00 0.34 
P30626 Sorcin SRI 
    
1.00 0.34 
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P49137 MAP kinase-activated protein kinase 2 MAPKAPK2 
  
1.00 0.21 1.00 0.13 
Q15291 Retinoblastoma-binding protein 5 RBBP5 
  
1.00 0.20 1.00 0.13 
P02671 Fibrinogen alpha chain FGA 
    
1.00 0.33 
Q9Y6K5 2'-5'-oligoadenylate synthase 3 OAS3 
    
1.00 0.33 
P46019 Phosphorylase b kinase regulatory subunit alpha, liver 
isoform 
PHKA2 
    
1.00 0.33 
Q8N8S7 Protein enabled homolog ENAH 
  
1.00 0.19 1.00 0.13 
O43292 Glycosylphosphatidylinositol anchor attachment 1 protein GPAA1 
    
1.00 0.32 
O43592 Exportin-T XPOT 
    
1.00 0.31 
Q8NCW5 NAD(P)H-hydrate epimerase NAXE 
    
1.00 0.31 
A6NNE9 E3 ubiquitin-protein ligase MARCH11 MARCH11 
    
1.00 0.31 
P33981 Dual specificity protein kinase TTK TTK 
    
1.00 0.31 
Q8NBJ9 SID1 transmembrane family member 2 SIDT2 
    
1.00 0.31 
Q96FX7 tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit 
TRMT61A 
TRMT61A 1 0.17 
  
1.00 0.14 
Q9Y2R5 28S ribosomal protein S17, mitochondrial MRPS17 1 
   
1.00 0.29 
O15357 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 INPPL1 
  
1.00 0.16 1.00 0.13 
Q96HB5 Coiled-coil domain-containing protein 120 CCDC120 
    
1.00 0.29 
Q9BTE6 Alanyl-tRNA editing protein Aarsd1 AARSD1 
    
1.00 0.29 
Q13286 Battenin CLN3 
    
1.00 0.28 
Q9BTE3 Mini-chromosome maintenance complex-binding protein MCMBP 
    
1.00 0.28 
P61296 Heart- and neural crest derivatives-expressed protein 2 HAND2 
    
1.00 0.28 
P48556 26S proteasome non-ATPase regulatory subunit 8 PSMD8 2 0.28 
  
1.00 
 
Q8IY17 Neuropathy target esterase PNPLA6 
  
1.00 
 
1.00 0.27 
Q7Z5K2 Wings apart-like protein homolog WAPL 
    
1.00 0.27 
Q9H1A4 Anaphase-promoting complex subunit 1 ANAPC1 
  
1.00 0.12 1.00 0.15 
Q5SWA1 Protein phosphatase 1 regulatory subunit 15B PPP1R15B 
    
1.00 0.26 
O95996 Adenomatous polyposis coli protein 2 APC2 
    
1.00 0.26 
Q86WB0 Nuclear-interacting partner of ALK ZC3HC1 
    
1.00 0.25 
Q13724 Mannosyl-oligosaccharide glucosidase MOGS 
    
1.00 0.25 
Q9BUQ8 Probable ATP-dependent RNA helicase DDX23 DDX23 
  
1.00 0.16 1.00 0.08 
Q8NBU5 ATPase family AAA domain-containing protein 1 ATAD1 
    
1.00 0.23 
Q6Q0C0 E3 ubiquitin-protein ligase TRAF7 TRAF7 
    
1.00 0.23 
O76013 Keratin, type I cuticular Ha6 KRT36 
    
1.00 0.23 
Q9BVQ7 Spermatogenesis-associated protein 5-like protein 1 SPATA5L1 
    
1.00 0.23 
Q15334 Lethal(2) giant larvae protein homolog 1 LLGL1 
    
1.00 0.23 
Q9UPQ9 Trinucleotide repeat-containing gene 6B protein TNRC6B 
    
1.00 0.23 
Q96I99 Succinate--CoA ligase [GDP-forming] subunit beta, 
mitochondrial 
SUCLG2 
    
1.00 0.23 
Q9UBQ0 Vacuolar protein sorting-associated protein 29 VPS29 
    
1.00 0.22 
P11234 Ras-related protein Ral-B RALB 
    
1.00 0.22 
Q13671 Ras and Rab interactor 1 RIN1 
  
1.00 
 
1.00 0.22 
Q9UNY4 Transcription termination factor 2 TTF2 2 0.08 
  
1.00 0.13 
Q9ULH0 Kinase D-interacting substrate of 220 kDa KIDINS220 
  
1.00 0.08 1.00 0.13 
O75934 Pre-mRNA-splicing factor SPF27 BCAS2 1 0.15 1.00 
 
1.00 0.06 
Q5T9L3 Protein wntless homolog WLS 
    
1.00 0.21 
Q13438 Protein OS-9 OS9 
    
1.00 0.21 
Q6P3X3 Tetratricopeptide repeat protein 27 TTC27 
    
1.00 0.20 
P17480 Nucleolar transcription factor 1 UBTF 
  
1.00 
 
1.00 0.20 
Q92665 28S ribosomal protein S31, mitochondrial MRPS31 
    
1.00 0.20 
P20930 Filaggrin FLG 
    
1.00 0.20 
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P54852 Epithelial membrane protein 3 EMP3 
    
1.00 0.20 
Q96T51 RUN and FYVE domain-containing protein 1 RUFY1 
    
1.00 0.19 
Q5VT66 Mitochondrial amidoxime-reducing component 1 MARC1 
    
1.00 0.19 
Q12986 Transcriptional repressor NF-X1 NFX1 1 
 
1.00 0.09 1.00 0.09 
Q9BSV6 tRNA-splicing endonuclease subunit Sen34 TSEN34 
  
1.00 
 
1.00 0.18 
O15372 Eukaryotic translation initiation factor 3 subunit H EIF3H 
    
1.00 0.18 
Q9Y2F9 BTB/POZ domain-containing protein 3 BTBD3 
    
1.00 0.18 
O14976 Cyclin-G-associated kinase GAK 
    
1.00 0.17 
Q9NSI2 Protein FAM207A FAM207A 
    
1.00 0.17 
O75608 Acyl-protein thioesterase 1 LYPLA1 
    
1.00 0.17 
P61073 C-X-C chemokine receptor type 4 CXCR4 
  
1.00 0.10 1.00 0.06 
P61313 60S ribosomal protein L15 RPL15 1 0.04 1.00 0.09 1.00 0.03 
P53990 IST1 homolog IST1 
  
1.00 
 
1.00 0.15 
Q9BRX2 Protein pelota homolog PELO 
    
1.00 0.15 
Q05397 Focal adhesion kinase 1 PTK2 
    
1.00 0.14 
Q9H0J9 Poly [ADP-ribose] polymerase 12 PARP12 
    
1.00 0.14 
Q7RTP6 Protein-methionine sulfoxide oxidase MICAL3 MICAL3 
    
1.00 0.14 
Q9NTJ3 Structural maintenance of chromosomes protein 4 SMC4 
    
1.00 0.14 
Q9P253 Vacuolar protein sorting-associated protein 18 homolog VPS18 
    
1.00 0.13 
Q99653 Calcineurin B homologous protein 1 CHP1 1 0.13 
  
1.00 
 
Q6SPF0 Atherin SAMD1 
  
1.00 
 
1.00 0.12 
Q86X76 Nitrilase homolog 1 NIT1 
    
1.00 0.12 
P28370 Probable global transcription activator SNF2L1 SMARCA1 
    
1.00 0.12 
O95905 Protein ecdysoneless homolog ECD 
    
1.00 0.11 
P12955 Xaa-Pro dipeptidase PEPD 
    
1.00 0.09 
Q5T5X7 BEN domain-containing protein 3 BEND3 
    
1.00 0.09 
Q96GD0 Pyridoxal phosphate phosphatase PDXP 
    
1.00 0.08 
Q9H0M0 NEDD4-like E3 ubiquitin-protein ligase WWP1 WWP1 
    
1.00 0.07 
Q13188 Serine/threonine-protein kinase 3 STK3 
  
1.00 
 
1.00 0.06 
Q8TC07 TBC1 domain family member 15 TBC1D15 
    
1.00 0.06 
P10319 HLA class I histocompatibility antigen, B-58 alpha chain HLA-B 
    
1.00 0.01 
Q3SY69 Mitochondrial 10-formyltetrahydrofolate dehydrogenase ALDH1L2 
    
1.00 
 
Q96P48 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-
containing protein 1 
ARAP1 
    
1.00 
 
P21281 V-type proton ATPase subunit B, brain isoform ATP6V1B2 
    
1.00 
 
P02452 Collagen alpha-1(I) chain COL1A1 
  
1.00 
 
1.00 
 
Q9UQB3 Catenin delta-2 CTNND2 
    
1.00 
 
Q14999 Cullin-7 CUL7 
    
1.00 
 
Q5UCC4 ER membrane protein complex subunit 10 EMC10 
    
1.00 
 
Q99999 Galactosylceramide sulfotransferase GAL3ST1 
    
1.00 
 
Q01415 N-acetylgalactosamine kinase GALK2 
    
1.00 
 
Q2TB90 Putative hexokinase HKDC1 HKDC1 
    
1.00 
 
Q5JSJ4 Integrator complex subunit 6-like INTS6L 
    
1.00 
 
Q9Y6N6 Laminin subunit gamma-3 LAMC3 
    
1.00 
 
Q7L5Y9 Macrophage erythroblast attacher MAEA 
    
1.00 
 
Q14165 Malectin MLEC 1 
   
1.00 
 
Q6ZNB6 NF-X1-type zinc finger protein NFXL1 NFXL1 
    
1.00 
 
Q93100 Phosphorylase b kinase regulatory subunit beta PHKB 
    
1.00 
 
Q7Z3K3 Pogo transposable element with ZNF domain POGZ 
    
1.00 
 
Q9BY42 Protein RTF2 homolog RTFDC1 
    
1.00 
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Q92966 snRNA-activating protein complex subunit 3 SNAPC3 
    
1.00 
 
Q08170 Serine/arginine-rich splicing factor 4 SRSF4 
    
1.00 
 
Q5VSL9 Striatin-interacting protein 1 STRIP1 
    
1.00 
 
Q96IR7 4-hydroxyphenylpyruvate dioxygenase-like protein HPDL 
  
1.00 432.34 
  
A0A075B6S6 Immunoglobulin kappa variable 2D-30 IGKV2D-30 2 89.40 
    
A0M8Q6 Ig lambda-7 chain C region IGLC7 1 4.02 2.00 72.96 
  
P01597 Immunoglobulin kappa variable 1-39 IGKV1-39 1 8.62 2.00 30.54 
  
O95425-4 Isoform SV4 of Supervillin SVIL 1 15.80 1.00 20.62 
  
Q8NBR6 Ubiquitin carboxyl-terminal hydrolase MINDY-2 FAM63B 1 26.55 
    
A0A0B4J1V1 Immunoglobulin heavy variable 3-21 IGHV3-21 
  
2.00 17.49 
  
Q96JN8 Neuralized-like protein 4 NEURL4 
  
1.00 14.85 
  
Q8WWI1-3 Isoform 3 of LIM domain only protein 7 LMO7 4 5.46 3.00 6.25 
  
A0A075B7D0 Protein IGHV1OR15-1 (Fragment) IGHV1OR15
-1 
  
1.00 9.96 
  
Q8IZ13 Protein ZBED8 ZBED8 1 9.96 
    
A0A0C4DH35 Protein IGHV3-35 (Fragment) IGHV3-35 
  
1.00 9.60 
  
P08123 Collagen alpha-2(I) chain COL1A2 
  
1.00 9.11 
  
A0A075B6H7 Protein IGKV3-7 (Fragment) IGKV3-7 
  
1.00 8.67 
  
P04430 Immunoglobulin kappa variable 1-16 IGKV1-16 2 4.32 2.00 2.99 
  
P08865 40S ribosomal protein SA RPSA 3 1.58 6.00 5.47 
  
O15085 Rho guanine nucleotide exchange factor 11 ARHGEF11 
  
1.00 6.93 
  
P62879 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-2 
GNB2 4 2.41 4.00 2.58 
  
Q86UX2 Inter-alpha-trypsin inhibitor heavy chain H5 ITIH5 2 4.84 
    
Q15286 Ras-related protein Rab-35 RAB35 2 1.97 3.00 2.87 
  
Q8NF86 Serine protease 33 PRSS33 
  
1.00 4.79 
  
Q53H12 Acylglycerol kinase, mitochondrial AGK 1 2.28 2.00 2.35 
  
Q01469 Fatty acid-binding protein, epidermal FABP5 5 3.21 1.00 1.27 
  
P15814 Immunoglobulin lambda-like polypeptide 1 IGLL1 1 2.46 1.00 1.85 
  
A0A0B4J1Y8 Protein IGLV9-49 IGLV9-49 1 2.40 1.00 1.62 
  
Q5JST6 EF-hand domain-containing family member C2 EFHC2 
  
1.00 3.77 
  
Q7Z7M9 Polypeptide N-acetylgalactosaminyltransferase 5 GALNT5 
  
1.00 3.76 
  
A6NIK2 Leucine-rich repeat-containing protein 10B LRRC10B 1 2.48 1.00 1.10 
  
P62820 Ras-related protein Rab-1A RAB1A 2 0.95 1.00 2.56 
  
P61224 Ras-related protein Rap-1b RAP1B 1 1.16 2.00 2.18 
  
Q9Y226 Solute carrier family 22 member 13 SLC22A13 
  
1.00 3.23 
  
Q58FF6 Putative heat shock protein HSP 90-beta 4 HSP90AB4P 1 1.50 1.00 1.63 
  
Q9Y566 SH3 and multiple ankyrin repeat domains protein 1 SHANK1 1 3.13 
    
P48668 Keratin, type II cytoskeletal 6C KRT6C 1 3.03 
    
A0A0C4DH69 Protein IGKV1-9 (Fragment) IGKV1-9 1 3.00 
    
O00217 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
mitochondrial 
NDUFS8 1 2.15 2.00 0.84 
  
P18825 Alpha-2C adrenergic receptor ADRA2C 
  
1.00 2.96 
  
P49454 Centromere protein F CENPF 1 2.78 
    
A0A075B7E8 Protein IGHV3OR16-13 (Fragment) IGHV3OR16
-13 
1 1.41 1.00 1.33 
  
Q99613 Eukaryotic translation initiation factor 3 subunit C EIF3C 9 1.29 10.00 1.42 
  
P11279 Lysosome-associated membrane glycoprotein 1 LAMP1 3 1.03 3.00 1.67 
  
Q2Q1W2 E3 ubiquitin-protein ligase TRIM71 TRIM71 
  
1.00 2.64 
  
Q99497 Protein deglycase DJ-1 PARK7 2 1.54 2.00 1.07 
  
Q9NUU7 ATP-dependent RNA helicase DDX19A DDX19A 
  
4.00 2.60 
  
A0A0B4J1V0 Immunoglobulin heavy variable 3-15 IGHV3-15 1 2.60 
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A0A0B4J2H0 Protein IGHV1-69-2 (Fragment) IGHV1-69-2 
  
1.00 2.60 
  
P0CJ78 Zinc finger protein 865 ZNF865 
  
1.00 2.58 
  
Q86YR6 POTE ankyrin domain family member D POTED 
  
1.00 2.56 
  
E9PAV3 Nascent polypeptide-associated complex subunit alpha, 
muscle-specific form 
NACA 1 0.96 1.00 1.57 
  
Q8TDB8 Solute carrier family 2, facilitated glucose transporter 
member 14 
SLC2A14 1 0.42 2.00 2.08 
  
A0A0C4DH29 Protein IGHV1-3 (Fragment) IGHV1-3 1 2.48 
    
P63096 Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1 1 1.26 2.00 1.21 
  
P09496 Clathrin light chain A CLTA 2 1.31 1.00 1.15 
  
A0A075B6Q5 Immunoglobulin heavy variable 3-64 IGHV3-64 1 1.30 1.00 1.09 
  
P53384 Cytosolic Fe-S cluster assembly factor NUBP1 NUBP1 1 1.14 1.00 1.18 
  
P01762 Immunoglobulin heavy variable 3-11 IGHV3-11 1 2.30 
    
Q9H3K2 Growth hormone-inducible transmembrane protein GHITM 1 1.91 3.00 0.34 
  
P04908 Histone H2A type 1-B/E HIST1H2AB 
  
3.00 2.17 
  
Q9Y4R8 Telomere length regulation protein TEL2 homolog TELO2 1 1.61 2.00 0.55 
  
Q14318 Peptidyl-prolyl cis-trans isomerase FKBP8 FKBP8 1 0.83 1.00 1.31 
  
P78310 Coxsackievirus and adenovirus receptor CXADR 5 0.72 6.00 1.41 
  
Q8IZF6 Adhesion G-protein coupled receptor G4 ADGRG4 1 2.10 
    
K7EKE6 Lon protease homolog, mitochondrial LONP1 1 0.85 1.00 1.24 
  
Q5TD94 Radial spoke head protein 4 homolog A RSPH4A 1 2.08 
    
Q06945 Transcription factor SOX-4 SOX4 
  
1.00 1.97 
  
Q6ZUX3 Crescerin-2 FAM179A 1 1.94 
    
Q9P0J0 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 
NDUFA13 1 0.66 1.00 1.20 
  
Q8NCB2 CaM kinase-like vesicle-associated protein CAMKV 
  
1.00 1.81 
  
Q96GE9 Transmembrane protein 261 TMEM261 1 1.71 
    
O15126 Secretory carrier-associated membrane protein 1 SCAMP1 1 0.91 1.00 0.80 
  
P12111 Collagen alpha-3(VI) chain COL6A3 1 1.70 
    
P00505 Aspartate aminotransferase, mitochondrial GOT2 2 0.75 1.00 0.94 
  
P18084 Integrin beta-5 ITGB5 2 0.31 5.00 1.34 
  
Q9UDV7 Zinc finger protein 282 ZNF282 
  
1.00 1.62 
  
Q8NDY3 [Protein ADP-ribosylarginine] hydrolase-like protein 1 ADPRHL1 
  
1.00 1.61 
  
O14925 Mitochondrial import inner membrane translocase subunit 
Tim23 
TIMM23 2 0.57 2.00 1.03 
  
Q15125 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase EBP 1 0.77 1.00 0.82 
  
O94925 Glutaminase kidney isoform, mitochondrial GLS 1 0.72 3.00 0.88 
  
P56975 Pro-neuregulin-3, membrane-bound isoform NRG3 
  
1.00 1.57 
  
P30508 HLA class I histocompatibility antigen, Cw-12 alpha chain HLA-C 3 0.45 3.00 1.11 
  
Q9BVC6 Transmembrane protein 109 TMEM109 1 1.54 
    
A0A0U1RRN1 UDP-galactose translocator SLC35A2 
  
1.00 1.49 
  
P17813 Endoglin ENG 
  
1.00 1.48 
  
P49903 Selenide, water dikinase 1 SEPHS1 1 0.54 2.00 0.92 
  
O75351 Vacuolar protein sorting-associated protein 4B VPS4B 2 0.64 4.00 0.82 
  
Q9HCC9 Lateral signaling target protein 2 homolog ZFYVE28 
  
1.00 1.44 
  
Q5T2W1 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 PDZK1 
  
1.00 1.44 
  
Q96PU5 E3 ubiquitin-protein ligase NEDD4-like NEDD4L 
  
6.00 1.42 
  
P54577 Tyrosine--tRNA ligase, cytoplasmic YARS 1 0.45 2.00 0.96 
  
P50895 Basal cell adhesion molecule BCAM 2 0.36 5.00 1.03 
  
P27348 14-3-3 protein theta YWHAQ 1 1.05 1.00 0.30 
  
P43487 Ran-specific GTPase-activating protein RANBP1 2 1.32 
    
Q9NZL9 Methionine adenosyltransferase 2 subunit beta MAT2B 2 0.66 2.00 0.65 
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P53582 Methionine aminopeptidase 1 METAP1 1 0.54 1.00 0.78 
  
A6NDZ8 Putative methyl-CpG-binding domain protein 3-like 4 MBD3L4 1 1.30 
    
A0A0A0MS14 Immunoglobulin heavy variable 1-45 IGHV1-45 1 0.68 1.00 0.61 
  
O75147 Obscurin-like protein 1 OBSL1 1 
 
3.00 1.28 
  
P23468 Receptor-type tyrosine-protein phosphatase delta PTPRD 
  
2.00 1.27 
  
Q9Y266 Nuclear migration protein nudC NUDC 1 0.44 1.00 0.80 
  
O96000 NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 10 
NDUFB10 2 0.57 2.00 0.67 
  
P49748 Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
ACADVL 
  
3.00 1.23 
  
P35237 Serpin B6 SERPINB6 1 0.76 3.00 0.46 
  
Q8WUM9 Sodium-dependent phosphate transporter 1 SLC20A1 1 0.37 1.00 0.84 
  
P38159 RNA-binding motif protein, X chromosome RBMX 2 0.59 4.00 0.61 
  
P51398 28S ribosomal protein S29, mitochondrial DAP3 1 0.49 2.00 0.70 
  
O60664 Perilipin-3 PLIN3 1 0.40 2.00 0.77 
  
Q9Y295 Developmentally-regulated GTP-binding protein 1 DRG1 2 0.53 5.00 0.63 
  
P60033 CD81 antigen CD81 
  
1.00 1.16 
  
P62745 Rho-related GTP-binding protein RhoB RHOB 
  
2.00 1.15 
  
Q8WWL2 Protein spire homolog 2 SPIRE2 
  
1.00 1.13 
  
P40763 Signal transducer and activator of transcription 3 STAT3 1 0.40 1.00 0.72 
  
Q9P289 Serine/threonine-protein kinase 26 STK26 3 0.38 3.00 0.74 
  
O60443 Non-syndromic hearing impairment protein 5 DFNA5 
  
2.00 1.12 
  
Q6ZW76 Ankyrin repeat and SAM domain-containing protein 3 ANKS3 1 1.11 
    
Q9H845 Acyl-CoA dehydrogenase family member 9, mitochondrial ACAD9 1 0.35 2.00 0.75 
  
P30044 Peroxiredoxin-5, mitochondrial PRDX5 1 0.61 1.00 0.49 
  
P07910-2 Isoform C1 of Heterogeneous nuclear ribonucleoproteins 
C1/C2 
HNRNPC 
  
1.00 1.10 
  
Q6ZU35 Uncharacterized protein KIAA1211 KIAA1211 1 0.54 2.00 0.55 
  
Q9BSJ2 Gamma-tubulin complex component 2 TUBGCP2 1 0.55 1.00 0.54 
  
P49821 NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial 
NDUFV1 1 0.51 5.00 0.58 
  
O43169 Cytochrome b5 type B CYB5B 1 1.09 
    
P48067 Sodium- and chloride-dependent glycine transporter 1 SLC6A9 
  
2.00 1.08 
  
Q9BY32 Inosine triphosphate pyrophosphatase ITPA 
  
1.00 1.08 
  
Q71U36 Tubulin alpha-1A chain TUBA1A 
  
1.00 1.07 
  
Q04725 Transducin-like enhancer protein 2 TLE2 
  
2.00 1.05 
  
O75832 26S proteasome non-ATPase regulatory subunit 10 PSMD10 1 1.05 
    
Q8IWS0 PHD finger protein 6 PHF6 1 
 
1.00 1.04 
  
P23284 Peptidyl-prolyl cis-trans isomerase B PPIB 1 0.54 2.00 0.49 
  
O75533 Splicing factor 3B subunit 1 SF3B1 3 0.33 7.00 0.70 
  
P84550 SKI family transcriptional corepressor 1 SKOR1 
  
1.00 1.02 
  
P02788 Lactotransferrin LTF 1 0.99 
    
O95278 Laforin EPM2A 
  
1.00 0.98 
  
Q9Y4F1 FERM, RhoGEF and pleckstrin domain-containing protein 1 FARP1 1 0.16 5.00 0.81 
  
Q15643 Thyroid receptor-interacting protein 11 TRIP11 1 0.97 
    
P15328 Folate receptor alpha FOLR1 2 0.44 3.00 0.52 
  
O43681 ATPase ASNA1 ASNA1 1 0.36 1.00 0.60 
  
O94855 Protein transport protein Sec24D SEC24D 1 0.85 1.00 0.11 
  
Q9Y5M8 Signal recognition particle receptor subunit beta SRPRB 
  
2.00 0.96 
  
Q9Y3E5 Peptidyl-tRNA hydrolase 2, mitochondrial PTRH2 1 0.28 1.00 0.67 
  
P28838 Cytosol aminopeptidase LAP3 1 0.36 1.00 0.59 
  
Q92747 Actin-related protein 2/3 complex subunit 1A ARPC1A 4 0.43 4.00 0.51 
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Q12846 Syntaxin-4 STX4 1 0.36 1.00 0.58 
  
P19404 NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial 
NDUFV2 1 0.30 1.00 0.64 
  
Q8N142 Adenylosuccinate synthetase isozyme 1 ADSSL1 1 0.93 
    
P49642 DNA primase small subunit PRIM1 1 0.45 2.00 0.47 
  
Q01844 RNA-binding protein EWS EWSR1 2 0.21 2.00 0.71 
  
Q15008 26S proteasome non-ATPase regulatory subunit 6 PSMD6 1 0.39 1.00 0.52 
  
P25787 Proteasome subunit alpha type-2 PSMA2 1 0.91 
    
O43663 Protein regulator of cytokinesis 1 PRC1 1 0.90 
    
Q6XQN6 Nicotinate phosphoribosyltransferase NAPRT 1 0.43 1.00 0.46 
  
Q5RI15 Cytochrome c oxidase protein 20 homolog COX20 
  
1.00 0.89 
  
Q8NEM2 SHC SH2 domain-binding protein 1 SHCBP1 1 0.36 1.00 0.53 
  
Q8IZ81 ELMO domain-containing protein 2 ELMOD2 
  
1.00 0.89 
  
Q86VM9 Zinc finger CCCH domain-containing protein 18 ZC3H18 2 0.35 3.00 0.53 
  
Q9Y3D9 28S ribosomal protein S23, mitochondrial MRPS23 2 0.43 1.00 0.44 
  
Q13217 DnaJ homolog subfamily C member 3 DNAJC3 3 0.26 3.00 0.61 
  
Q6PD62 RNA polymerase-associated protein CTR9 homolog CTR9 
  
1.00 0.87 
  
P0DME0 Protein SETSIP SETSIP 
  
2.00 0.86 
  
O75947 ATP synthase subunit d, mitochondrial ATP5H 
  
1.00 0.86 
  
Q06265 Exosome complex component RRP45 EXOSC9 1 0.24 1.00 0.62 
  
Q9P0K9 DOMON domain-containing protein FRRS1L FRRS1L 
  
1.00 0.85 
  
Q9Y5Z0 Beta-secretase 2 BACE2 
  
1.00 0.84 
  
Q53EL6 Programmed cell death protein 4 PDCD4 
  
1.00 0.84 
  
O00308 NEDD4-like E3 ubiquitin-protein ligase WWP2 WWP2 
  
1.00 0.83 
  
P98194 Calcium-transporting ATPase type 2C member 1 ATP2C1 
  
1.00 0.83 
  
O75390 Citrate synthase, mitochondrial CS 1 0.83 
    
O43491 Band 4.1-like protein 2 EPB41L2 1 0.38 3.00 0.44 
  
Q6NZY4 Zinc finger CCHC domain-containing protein 8 ZCCHC8 
  
1.00 0.82 
  
Q05519 Serine/arginine-rich splicing factor 11 SRSF11 
  
1.00 0.81 
  
P61019 Ras-related protein Rab-2A RAB2A 
  
2.00 0.80 
  
Q16222 UDP-N-acetylhexosamine pyrophosphorylase UAP1 
  
1.00 0.80 
  
O75449 Katanin p60 ATPase-containing subunit A1 KATNA1 
  
1.00 0.79 
  
P09429 High mobility group protein B1 HMGB1 1 0.45 1.00 0.33 
  
P40925 Malate dehydrogenase, cytoplasmic MDH1 2 0.29 2.00 0.50 
  
P42167 Lamina-associated polypeptide 2, isoforms beta/gamma TMPO 
  
3.00 0.79 
  
Q6S8J3 POTE ankyrin domain family member E POTEE 1 0.78 
    
P61769 Beta-2-microglobulin B2M 1 0.78 
    
Q9P2I0 Cleavage and polyadenylation specificity factor subunit 2 CPSF2 
  
1.00 0.78 
  
P55854 Small ubiquitin-related modifier 3 SUMO3 
  
1.00 0.77 
  
P50395 Rab GDP dissociation inhibitor beta GDI2 
  
3.00 0.77 
  
Q99798 Aconitate hydratase, mitochondrial ACO2 1 0.32 1.00 0.45 
  
Q9H6B4 CXADR-like membrane protein CLMP 
  
2.00 0.76 
  
P50148 Guanine nucleotide-binding protein G(q) subunit alpha GNAQ 
  
2.00 0.75 
  
A4FU49 SH3 domain-containing protein 21 SH3D21 
  
1.00 0.75 
  
Q8TCT8 Signal peptide peptidase-like 2A SPPL2A 
  
2.00 0.75 
  
Q9UHG3 Prenylcysteine oxidase 1 PCYOX1 1 0.34 1.00 0.40 
  
A0A075B6S9 Protein IGKV1-37 (Fragment) IGKV1D-37 
  
1.00 0.75 
  
P11766 Alcohol dehydrogenase class-3 ADH5 1 0.43 2.00 0.32 
  
O43813 LanC-like protein 1 LANCL1 
  
1.00 0.74 
  
P36957 Dihydrolipoyllysine-residue succinyltransferase component 
of 2-oxoglutarate dehydrogenase complex, mitochondrial 
DLST 
  
4.00 0.74 
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Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial ECH1 1 0.37 2.00 0.37 
  
Q13617 Cullin-2 CUL2 2 0.19 3.00 0.54 
  
P08183 Multidrug resistance protein 1 ABCB1 1 0.18 1.00 0.55 
  
P02461 Collagen alpha-1(III) chain COL3A1 
  
1.00 0.73 
  
Q9H0X4 Protein FAM234A FAM234A 
  
3.00 0.72 
  
P42702 Leukemia inhibitory factor receptor LIFR 
  
1.00 0.72 
  
Q9UGP8 Translocation protein SEC63 homolog SEC63 
  
1.00 0.71 
  
E7EX90 Dynactin subunit 1 DCTN1 
  
1.00 0.70 
  
Q9Y570 Protein phosphatase methylesterase 1 PPME1 2 0.25 2.00 0.45 
  
Q7KZN9 Cytochrome c oxidase assembly protein COX15 homolog COX15 
  
1.00 0.70 
  
Q9HAB3 Solute carrier family 52, riboflavin transporter, member 2 SLC52A2 
  
1.00 0.70 
  
Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 
  
1.00 0.68 
  
Q969S3 Zinc finger protein 622 ZNF622 1 0.23 1.00 0.45 
  
A0A0B4J1U7 Protein IGHV6-1 (Fragment) IGHV6-1 
  
1.00 0.68 
  
Q3MHD2 Protein LSM12 homolog LSM12 
  
1.00 0.68 
  
Q5JTV8 Torsin-1A-interacting protein 1 TOR1AIP1 1 0.28 1.00 0.40 
  
P48960 CD97 antigen CD97 1 0.34 2.00 0.33 
  
Q68CZ2 Tensin-3 TNS3 
  
2.00 0.67 
  
P17301 Integrin alpha-2 ITGA2 
  
2.00 0.67 
  
P57737 Coronin-7 CORO7 1 
 
1.00 0.67 
  
Q13459 Unconventional myosin-IXb MYO9B 
  
1.00 0.66 
  
Q9Y224 UPF0568 protein C14orf166 C14orf166 1 0.35 1.00 0.31 
  
O60902-3 Isoform 3 of Short stature homeobox protein 2 SHOX2 
  
2.00 0.65 
  
Q9Y2G3 Probable phospholipid-transporting ATPase IF ATP11B 1 0.18 1.00 0.48 
  
P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial UQCRFS1 
  
3.00 0.65 
  
P12235 ADP/ATP translocase 1 SLC25A4 1 0.36 1.00 0.28 
  
Q2TAL8 Glutamine-rich protein 1 QRICH1 1 0.36 3.00 0.28 
  
Q9Y6M4 Casein kinase I isoform gamma-3 CSNK1G3 
  
3.00 0.64 
  
P01714 Immunoglobulin lambda variable 3-19 IGLV3-19 
  
1.00 0.64 
  
P07099 Epoxide hydrolase 1 EPHX1 
  
3.00 0.64 
  
P40429 60S ribosomal protein L13a RPL13A 1 0.25 1.00 0.38 
  
Q969E2 Secretory carrier-associated membrane protein 4 SCAMP4 
  
2.00 0.64 
  
Q13547 Histone deacetylase 1 HDAC1 
  
2.00 0.63 
  
P63165 Small ubiquitin-related modifier 1 SUMO1 1 0.27 1.00 0.37 
  
P21399 Cytoplasmic aconitate hydratase ACO1 
  
1.00 0.63 
  
O94925-3 Isoform 3 of Glutaminase kidney isoform, mitochondrial GLS 1 0.63 
    
Q14156 Protein EFR3 homolog A EFR3A 
  
2.00 0.63 
  
Q96T76 MMS19 nucleotide excision repair protein homolog MMS19 
  
1.00 0.62 
  
Q13595 Transformer-2 protein homolog alpha TRA2A 1 0.62 
    
Q9HDC9 Adipocyte plasma membrane-associated protein APMAP 1 0.24 1.00 0.38 
  
P23588 Eukaryotic translation initiation factor 4B EIF4B 1 0.19 1.00 0.43 
  
Q8IXT5 RNA-binding protein 12B RBM12B 2 0.62 
    
P62495 Eukaryotic peptide chain release factor subunit 1 ETF1 
  
3.00 0.62 
  
Q9H223 EH domain-containing protein 4 EHD4 
  
1.00 0.61 
  
P28702 Retinoic acid receptor RXR-beta RXRB 1 
 
1.00 0.60 
  
Q9Y3D7 Mitochondrial import inner membrane translocase subunit 
TIM16 
PAM16 1 0.59 
    
Q6ZVX7 F-box only protein 50 NCCRP1 2 0.58 
    
Q9GZP0 Platelet-derived growth factor D PDGFD 
  
1.00 0.58 
  
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 1 0.25 1.00 0.33 
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P56134 ATP synthase subunit f, mitochondrial ATP5J2 
  
1.00 0.57 
  
Q96MC5 Uncharacterized protein C16orf45 C16orf45 1 0.57 
    
Q15907 Ras-related protein Rab-11B RAB11B 1 0.26 1.00 0.31 
  
O43615 Mitochondrial import inner membrane translocase subunit 
TIM44 
TIMM44 1 0.13 1.00 0.43 
  
P15559 NAD(P)H dehydrogenase [quinone] 1 NQO1 1 0.28 3.00 0.28 
  
O75127 Pentatricopeptide repeat-containing protein 1, 
mitochondrial 
PTCD1 1 0.29 1.00 0.28 
  
Q8IWA5 Choline transporter-like protein 2 SLC44A2 
  
1.00 0.56 
  
O95208 Epsin-2 EPN2 
  
1.00 0.56 
  
Q8N3E9 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 
delta-3 
PLCD3 
  
1.00 0.55 
  
Q14344 Guanine nucleotide-binding protein subunit alpha-13 GNA13 
  
3.00 0.55 
  
O00232 26S proteasome non-ATPase regulatory subunit 12 PSMD12 
  
1.00 0.55 
  
O96008 Mitochondrial import receptor subunit TOM40 homolog TOMM40 1 0.36 1.00 0.19 
  
Q93050 V-type proton ATPase 116 kDa subunit a isoform 1 ATP6V0A1 1 0.13 3.00 0.41 
  
P22570 NADPH:adrenodoxin oxidoreductase, mitochondrial FDXR 1 0.24 3.00 0.30 
  
A0A0G2JR96 Cytoplasmic FMR1-interacting protein 1 (Fragment) CYFIP1 
  
1.00 0.54 
  
Q8WVM8 Sec1 family domain-containing protein 1 SCFD1 
  
1.00 0.54 
  
Q15287 RNA-binding protein with serine-rich domain 1 RNPS1 
  
1.00 0.54 
  
P26038 Moesin MSN 
  
3.00 0.53 
  
Q5JXC2 Migration and invasion-inhibitory protein MIIP 1 0.53 
    
P22681 E3 ubiquitin-protein ligase CBL CBL 
  
1.00 0.53 
  
P61964 WD repeat-containing protein 5 WDR5 1 0.31 1.00 0.22 
  
Q8WX92 Negative elongation factor B NELFB 1 0.21 1.00 0.32 
  
Q9H9T3 Elongator complex protein 3 ELP3 
  
1.00 0.52 
  
Q13098 COP9 signalosome complex subunit 1 GPS1 
  
1.00 0.52 
  
Q14966 Zinc finger protein 638 ZNF638 1 0.22 1.00 0.30 
  
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1 DYNC1LI1 
  
4.00 0.51 
  
Q9P2D1 Chromodomain-helicase-DNA-binding protein 7 CHD7 
  
1.00 0.51 
  
P49753 Acyl-coenzyme A thioesterase 2, mitochondrial ACOT2 
  
2.00 0.51 
  
Q96BM9 ADP-ribosylation factor-like protein 8A ARL8A 
  
1.00 0.51 
  
Q8NA72 Centrosomal protein POC5 POC5 1 0.51 
    
Q9Y6E2 Basic leucine zipper and W2 domain-containing protein 2 BZW2 2 0.20 1.00 0.31 
  
Q9BV40 Vesicle-associated membrane protein 8 VAMP8 1 0.18 1.00 0.33 
  
Q13554 Calcium/calmodulin-dependent protein kinase type II 
subunit beta 
CAMK2B 
  
3.00 0.50 
  
Q9NTK5 Obg-like ATPase 1 OLA1 
  
1.00 0.50 
  
P51809 Vesicle-associated membrane protein 7 VAMP7 
  
1.00 0.50 
  
Q96P70 Importin-9 IPO9 2 0.29 2.00 0.21 
  
Q13162 Peroxiredoxin-4 PRDX4 1 0.13 3.00 0.37 
  
P27695 DNA-(apurinic or apyrimidinic site) lyase APEX1 1 0.27 2.00 0.23 
  
Q9NX74 tRNA-dihydrouridine(20) synthase [NAD(P)+]-like DUS2 
  
1.00 0.50 
  
Q15691 Microtubule-associated protein RP/EB family member 1 MAPRE1 1 0.26 1.00 0.24 
  
P61604 10 kDa heat shock protein, mitochondrial HSPE1 
  
2.00 0.49 
  
P18206 Vinculin VCL 
  
2.00 0.49 
  
P67870 Casein kinase II subunit beta CSNK2B 2 0.22 1.00 0.27 
  
Q13363 C-terminal-binding protein 1 CTBP1 
  
1.00 0.48 
  
Q9Y289 Sodium-dependent multivitamin transporter SLC5A6 
  
2.00 0.48 
  
O94776 Metastasis-associated protein MTA2 MTA2 
  
1.00 0.48 
  
Q9P1D2 PRO2472 
   
1.00 0.47 
  
Q9Y276 Mitochondrial chaperone BCS1 BCS1L 1 0.47 
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O00268 Transcription initiation factor TFIID subunit 4 TAF4 
  
1.00 0.47 
  
Q6P4Q7 Metal transporter CNNM4 CNNM4 
  
2.00 0.47 
  
O14617 AP-3 complex subunit delta-1 AP3D1 
  
1.00 0.46 
  
Q9Y5Q9 General transcription factor 3C polypeptide 3 GTF3C3 
  
1.00 0.46 
  
P54762 Ephrin type-B receptor 1 EPHB1 
  
1.00 0.46 
  
O95251 Histone acetyltransferase KAT7 KAT7 2 0.45 
    
Q8IX29 F-box only protein 16 FBXO16 
  
1.00 0.45 
  
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 1 0.44 
    
P12268 Inosine-5'-monophosphate dehydrogenase 2 IMPDH2 
  
2.00 0.43 
  
Q9P258 Protein RCC2 RCC2 
  
3.00 0.43 
  
Q9H4A3 Serine/threonine-protein kinase WNK1 WNK1 1 0.24 2.00 0.19 
  
Q9ULX6 A-kinase anchor protein 8-like AKAP8L 1 0.43 
    
P52888 Thimet oligopeptidase THOP1 
  
1.00 0.43 
  
Q9NVE4 Coiled-coil domain-containing protein 87 CCDC87 
  
1.00 0.43 
  
O75190 DnaJ homolog subfamily B member 6 DNAJB6 
  
1.00 0.43 
  
Q9BRJ6 Uncharacterized protein C7orf50 C7orf50 
  
1.00 0.42 
  
Q6P1N0 Coiled-coil and C2 domain-containing protein 1A CC2D1A 1 0.22 2.00 0.20 
  
P50750-2 Isoform 2 of Cyclin-dependent kinase 9 CDK9 
  
1.00 0.42 
  
P16989 Y-box-binding protein 3 YBX3 1 0.41 
    
P55786 Puromycin-sensitive aminopeptidase NPEPPS 
  
3.00 0.41 
  
Q8N183 Mimitin, mitochondrial NDUFAF2 
  
2.00 0.41 
  
O95154 Aflatoxin B1 aldehyde reductase member 3 AKR7A3 
  
1.00 0.41 
  
Q96S21 Ras-related protein Rab-40C RAB40C 1 0.40 
    
O75165 DnaJ homolog subfamily C member 13 DNAJC13 
  
2.00 0.39 
  
Q9Y6C9 Mitochondrial carrier homolog 2 MTCH2 
  
3.00 0.39 
  
P40121 Macrophage-capping protein CAPG 1 0.23 1.00 0.16 
  
O60763 General vesicular transport factor p115 USO1 1 0.24 3.00 0.15 
  
O60502 Protein O-GlcNAcase MGEA5 
  
1.00 0.39 
  
Q29983 MHC class I polypeptide-related sequence A MICA 
  
1.00 0.39 
  
Q9Y490 Talin-1 TLN1 
  
3.00 0.38 
  
P48507 Glutamate--cysteine ligase regulatory subunit GCLM 
  
1.00 0.38 
  
O60266 Adenylate cyclase type 3 ADCY3 
  
1.00 0.38 
  
P08758 Annexin A5 ANXA5 
  
2.00 0.38 
  
P84098 60S ribosomal protein L19 RPL19 1 
 
1.00 0.38 
  
Q9UBS4 DnaJ homolog subfamily B member 11 DNAJB11 
  
1.00 0.38 
  
Q9BVC4 Target of rapamycin complex subunit LST8 MLST8 1 0.38 
    
P27144 Adenylate kinase 4, mitochondrial AK4 2 0.19 1.00 0.18 
  
A7KAX9 Rho GTPase-activating protein 32 ARHGAP32 
  
1.00 0.37 
  
Q9GZT9 Egl nine homolog 1 EGLN1 
  
2.00 0.37 
  
P61011 Signal recognition particle 54 kDa protein SRP54 
  
1.00 0.37 
  
Q6ZRR9 Doublecortin domain-containing protein 5 DCDC5 
  
1.00 0.37 
  
Q9UM54 Unconventional myosin-VI MYO6 
  
1.00 0.37 
  
P51858 Hepatoma-derived growth factor HDGF 
  
1.00 0.37 
  
Q9UBB4 Ataxin-10 ATXN10 
  
2.00 0.36 
  
Q5VST6 Protein ABHD17B ABHD17B 
  
1.00 0.36 
  
Q9BTT6 Leucine-rich repeat-containing protein 1 LRRC1 1 0.36 1.00 
   
Q9BTV4 Transmembrane protein 43 TMEM43 1 0.36 
    
O15162 Phospholipid scramblase 1 PLSCR1 1 0.11 1.00 0.25 
  
Q5R3I4 Tetratricopeptide repeat protein 38 TTC38 
  
1.00 0.35 
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O14802 DNA-directed RNA polymerase III subunit RPC1 POLR3A 
  
1.00 0.35 
  
O75419 Cell division control protein 45 homolog CDC45 
  
1.00 0.35 
  
Q93008 Probable ubiquitin carboxyl-terminal hydrolase FAF-X USP9X 1 
 
3.00 0.34 
  
A6NDG6 Glycerol-3-phosphate phosphatase PGP 1 0.34 
    
P35659 Protein DEK DEK 
  
1.00 0.34 
  
P49257 Protein ERGIC-53 LMAN1 
  
1.00 0.34 
  
O14773 Tripeptidyl-peptidase 1 TPP1 
  
2.00 0.34 
  
P41240 Tyrosine-protein kinase CSK CSK 2 0.34 
    
Q9H4L4 Sentrin-specific protease 3 SENP3 
  
1.00 0.34 
  
Q9Y6N7 Roundabout homolog 1 ROBO1 
  
3.00 0.34 
  
Q8IWV8 E3 ubiquitin-protein ligase UBR2 UBR2 
  
1.00 0.33 
  
Q9H6X2 Anthrax toxin receptor 1 ANTXR1 1 
 
3.00 0.33 
  
Q7Z417 Nuclear fragile X mental retardation-interacting protein 2 NUFIP2 1 0.33 
    
Q86Y56 Dynein assembly factor 5, axonemal DNAAF5 1 0.14 1.00 0.19 
  
P55011 Solute carrier family 12 member 2 SLC12A2 
  
1.00 0.33 
  
Q15434 RNA-binding motif, single-stranded-interacting protein 2 RBMS2 
  
1.00 0.32 
  
Q8NBS9 Thioredoxin domain-containing protein 5 TXNDC5 1 0.14 1.00 0.18 
  
P46736 Lys-63-specific deubiquitinase BRCC36 BRCC3 1 0.32 
    
P23368 NAD-dependent malic enzyme, mitochondrial ME2 
  
1.00 0.32 
  
P35270 Sepiapterin reductase SPR 
  
1.00 0.32 
  
Q9BYG5 Partitioning defective 6 homolog beta PARD6B 1 0.32 
    
P63208 S-phase kinase-associated protein 1 SKP1 1 0.32 
    
Q8TDI0 Chromodomain-helicase-DNA-binding protein 5 CHD5 
  
1.00 0.32 
  
Q96JG6 Syndetin VPS50 
  
1.00 0.32 
  
A0AV96 RNA-binding protein 47 RBM47 1 0.32 
    
Q9NX58 Cell growth-regulating nucleolar protein LYAR 
  
2.00 0.31 
  
P01766 Immunoglobulin heavy variable 3-13 IGHV3-13 1 0.31 
    
Q96BZ8 Leukocyte receptor cluster member 1 LENG1 
  
1.00 0.31 
  
Q96K21 Abscission/NoCut checkpoint regulator ZFYVE19 
  
1.00 0.31 
  
O75223 Gamma-glutamylcyclotransferase GGCT 1 0.30 
    
Q9NRY6 Phospholipid scramblase 3 PLSCR3 
  
1.00 0.30 
  
O75116 Rho-associated protein kinase 2 ROCK2 
  
1.00 0.30 
  
Q5T750 Skin-specific protein 32 XP32 1 0.30 
    
Q8NE01 Metal transporter CNNM3 CNNM3 1 0.08 3.00 0.22 
  
Q9Y4D8 Probable E3 ubiquitin-protein ligase HECTD4 HECTD4 1 0.29 
    
Q9NYK5 39S ribosomal protein L39, mitochondrial MRPL39 1 0.29 
    
P33947 ER lumen protein-retaining receptor 2 KDELR2 1 0.29 
    
Q96I59 Probable asparagine--tRNA ligase, mitochondrial NARS2 
  
2.00 0.29 
  
P15291 Beta-1,4-galactosyltransferase 1 B4GALT1 
  
1.00 0.29 
  
Q6RW13 Type-1 angiotensin II receptor-associated protein AGTRAP 
  
1.00 0.29 
  
P46934 E3 ubiquitin-protein ligase NEDD4 NEDD4 
  
2.00 0.28 
  
Q9UIW2 Plexin-A1 PLXNA1 
  
2.00 0.28 
  
Q92575 UBX domain-containing protein 4 UBXN4 
  
1.00 0.28 
  
Q15904 V-type proton ATPase subunit S1 ATP6AP1 
  
1.00 0.28 
  
O00139 Kinesin-like protein KIF2A KIF2A 1 
 
1.00 0.28 
  
P61106 Ras-related protein Rab-14 RAB14 1 0.28 
    
Q9P0S9 Transmembrane protein 14C TMEM14C 1 0.28 
    
Q96JM3 Chromosome alignment-maintaining phosphoprotein 1 CHAMP1 
  
1.00 0.28 
  
Q16698 2,4-dienoyl-CoA reductase, mitochondrial DECR1 
  
1.00 0.28 
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Q9H3S7 Tyrosine-protein phosphatase non-receptor type 23 PTPN23 
  
1.00 0.28 
  
Q14241 Transcription elongation factor B polypeptide 3 TCEB3 
  
1.00 0.27 
  
Q8NGU2 Olfactory receptor 9A4 OR9A4 1 0.26 
    
P01705 Immunoglobulin lambda variable 2-23 IGLV2-23 1 0.26 
    
O00203 AP-3 complex subunit beta-1 AP3B1 
  
1.00 0.26 
  
Q06124 Tyrosine-protein phosphatase non-receptor type 11 PTPN11 
  
2.00 0.26 
  
Q9NXF1 Testis-expressed sequence 10 protein TEX10 
  
1.00 0.25 
  
P53701 Cytochrome c-type heme lyase HCCS 
  
1.00 0.25 
  
Q9H0X9 Oxysterol-binding protein-related protein 5 OSBPL5 
  
1.00 0.25 
  
Q5VT25 Serine/threonine-protein kinase MRCK alpha CDC42BPA 
  
4.00 0.25 
  
O60264 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 5 
SMARCA5 
  
1.00 0.25 
  
Q6UWE0 E3 ubiquitin-protein ligase LRSAM1 LRSAM1 
  
1.00 0.24 
  
Q969N2 GPI transamidase component PIG-T PIGT 
  
1.00 0.24 
  
Q12834 Cell division cycle protein 20 homolog CDC20 
  
1.00 0.24 
  
Q9UBF2 Coatomer subunit gamma-2 COPG2 1 0.07 2.00 0.17 
  
Q07065 Cytoskeleton-associated protein 4 CKAP4 
  
1.00 0.24 
  
Q9Y5L0 Transportin-3 TNPO3 
  
2.00 0.24 
  
Q96FZ2 Embryonic stem cell-specific 5-hydroxymethylcytosine-
binding protein 
HMCES 1 0.24 
    
Q99816 Tumor susceptibility gene 101 protein TSG101 
  
1.00 0.24 
  
Q6PJT7 Zinc finger CCCH domain-containing protein 14 ZC3H14 
  
1.00 0.24 
  
O60341 Lysine-specific histone demethylase 1A KDM1A 
  
1.00 0.24 
  
O94906 Pre-mRNA-processing factor 6 PRPF6 
  
2.00 0.23 
  
Q99543 DnaJ homolog subfamily C member 2 DNAJC2 
  
1.00 0.23 
  
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein SERBP1 
  
2.00 0.23 
  
Q12800 Alpha-globin transcription factor CP2 TFCP2 
  
2.00 0.23 
  
P29966 Myristoylated alanine-rich C-kinase substrate MARCKS 
  
2.00 0.23 
  
Q6P1M0 Long-chain fatty acid transport protein 4 SLC27A4 
  
1.00 0.22 
  
P19387 DNA-directed RNA polymerase II subunit RPB3 POLR2C 
  
1.00 0.22 
  
P98175 RNA-binding protein 10 RBM10 
  
1.00 0.22 
  
P50552 Vasodilator-stimulated phosphoprotein VASP 
  
3.00 0.22 
  
Q9ULF5 Zinc transporter ZIP10 SLC39A10 
  
1.00 0.21 
  
O75143 Autophagy-related protein 13 ATG13 
  
1.00 0.21 
  
Q96TC7 Regulator of microtubule dynamics protein 3 RMDN3 1 0.21 
    
O95861 3'(2'),5'-bisphosphate nucleotidase 1 BPNT1 
  
1.00 0.21 
  
Q9UI10 Translation initiation factor eIF-2B subunit delta EIF2B4 
  
1.00 0.21 
  
P30086 Phosphatidylethanolamine-binding protein 1 PEBP1 1 0.21 
    
Q96IJ6 Mannose-1-phosphate guanyltransferase alpha GMPPA 2 0.20 
    
Q9NTJ5 Phosphatidylinositide phosphatase SAC1 SACM1L 1 0.06 1.00 0.14 
  
Q53H96 Pyrroline-5-carboxylate reductase 3 PYCRL 1 0.06 2.00 0.14 
  
Q9NP72 Ras-related protein Rab-18 RAB18 
  
1.00 0.20 
  
Q96GD4 Aurora kinase B AURKB 1 0.20 
    
P50570 Dynamin-2 DNM2 
  
2.00 0.20 
  
P25490 Transcriptional repressor protein YY1 YY1 1 0.20 
    
Q9Y287 Integral membrane protein 2B ITM2B 
  
1.00 0.20 
  
Q9NRW7 Vacuolar protein sorting-associated protein 45 VPS45 
  
1.00 0.20 
  
Q7Z2Z2 Elongation factor-like GTPase 1 EFL1 
  
1.00 0.19 
  
Q96A26 Protein FAM162A FAM162A 
  
1.00 0.19 
  
Q8N4T0 Carboxypeptidase A6 CPA6 1 0.19 
    
Q9NV96 Cell cycle control protein 50A TMEM30A 
  
1.00 0.19 
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Q13409 Cytoplasmic dynein 1 intermediate chain 2 DYNC1I2 
  
1.00 0.19 
  
P49756 RNA-binding protein 25 RBM25 
  
1.00 0.19 
  
P30048 Thioredoxin-dependent peroxide reductase, mitochondrial PRDX3 1 0.19 
    
P34741 Syndecan-2 SDC2 
  
1.00 0.18 
  
Q9NX00 Transmembrane protein 160 TMEM160 
  
1.00 0.18 
  
Q63ZY3 KN motif and ankyrin repeat domain-containing protein 2 KANK2 
  
1.00 0.18 
  
Q96Q06 Perilipin-4 PLIN4 
  
1.00 0.18 
  
O43395 U4/U6 small nuclear ribonucleoprotein Prp3 PRPF3 
  
1.00 0.18 
  
Q06323 Proteasome activator complex subunit 1 PSME1 
  
1.00 0.18 
  
Q969Z0 Protein TBRG4 TBRG4 
  
2.00 0.18 
  
Q9NUM4 Transmembrane protein 106B TMEM106B 
  
2.00 0.18 
  
Q9H444 Charged multivesicular body protein 4b CHMP4B 
  
1.00 0.18 
  
Q969X5 Endoplasmic reticulum-Golgi intermediate compartment 
protein 1 
ERGIC1 1 0.17 
    
P53597 Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, 
mitochondrial 
SUCLG1 
  
1.00 0.17 
  
O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 
  
2.00 0.17 
  
P43307 Translocon-associated protein subunit alpha SSR1 
  
1.00 0.17 
  
Q92995 Ubiquitin carboxyl-terminal hydrolase 13 USP13 
  
2.00 0.17 
  
Q5QGS0 Protein KIAA2022 KIAA2022 1 0.17 
    
Q5SSJ5 Heterochromatin protein 1-binding protein 3 HP1BP3 
  
1.00 0.17 
  
P03905 NADH-ubiquinone oxidoreductase chain 4 MT-ND4 
  
1.00 0.17 
  
Q9NPL8 Complex I assembly factor TIMMDC1, mitochondrial TIMMDC1 
  
1.00 0.16 
  
Q9NY91 Low affinity sodium-glucose cotransporter SLC5A4 1 0.16 
    
Q13228 Selenium-binding protein 1 SELENBP1 
  
1.00 0.16 
  
Q9Y4L1 Hypoxia up-regulated protein 1 HYOU1 1 
 
2.00 0.16 
  
Q9H0J4 Glutamine-rich protein 2 QRICH2 
  
1.00 0.16 
  
O00273 DNA fragmentation factor subunit alpha DFFA 3 0.16 
    
P53794 Sodium/myo-inositol cotransporter SLC5A3 
  
1.00 0.16 
  
Q5H9R7 Serine/threonine-protein phosphatase 6 regulatory subunit 
3 
PPP6R3 1 0.16 
    
P56199 Integrin alpha-1 ITGA1 
  
1.00 0.16 
  
O00505 Importin subunit alpha-4 KPNA3 1 0.16 1.00 
   
Q9Y6I3 Epsin-1 EPN1 
  
1.00 0.16 
  
Q92896 Golgi apparatus protein 1 GLG1 1 0.16 
    
Q9UFC0 Leucine-rich repeat and WD repeat-containing protein 1 LRWD1 
  
1.00 0.16 
  
A6NK53 Zinc finger protein 233 ZNF233 1 0.16 
    
Q9NVM9 Protein asunder homolog ASUN 
  
1.00 0.15 
  
Q86TI2 Dipeptidyl peptidase 9 DPP9 
  
1.00 0.15 
  
Q99569 Plakophilin-4 PKP4 
  
2.00 0.15 
  
O43929 Origin recognition complex subunit 4 ORC4 
  
1.00 0.15 
  
Q96FN4 Copine-2 CPNE2 1 0.15 
    
Q9UL03 Integrator complex subunit 6 INTS6 
  
1.00 0.15 
  
Q9NZ01 Very-long-chain enoyl-CoA reductase TECR 
  
1.00 0.15 
  
Q9H3Z4 DnaJ homolog subfamily C member 5 DNAJC5 
  
1.00 0.15 
  
O15194 CTD small phosphatase-like protein CTDSPL 
  
1.00 0.14 
  
O43379 WD repeat-containing protein 62 WDR62 
  
1.00 0.14 
  
Q96K76 Ubiquitin carboxyl-terminal hydrolase 47 USP47 
  
2.00 0.14 
  
Q6P996 Pyridoxal-dependent decarboxylase domain-containing 
protein 1 
PDXDC1 
  
1.00 0.14 
  
Q15149-8 Isoform 8 of Plectin PLEC 1 0.14 
    
P61619 Protein transport protein Sec61 subunit alpha isoform 1 SEC61A1 
  
1.00 0.14 
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P25098 Beta-adrenergic receptor kinase 1 GRK2 
  
1.00 0.14 
  
P40222 Alpha-taxilin TXLNA 
  
1.00 0.13 
  
Q9H6T0 Epithelial splicing regulatory protein 2 ESRP2 
  
1.00 0.13 
  
O95359 Transforming acidic coiled-coil-containing protein 2 TACC2 1 0.13 
    
P32121 Beta-arrestin-2 ARRB2 
  
1.00 0.13 
  
Q9P0U3 Sentrin-specific protease 1 SENP1 
  
1.00 0.12 
  
P47895 Aldehyde dehydrogenase family 1 member A3 ALDH1A3 
  
3.00 0.12 
  
Q7Z4F1 Low-density lipoprotein receptor-related protein 10 LRP10 
  
1.00 0.12 
  
Q96I51 RCC1-like G exchanging factor-like protein RCC1L 
  
1.00 0.12 
  
P25963 NF-kappa-B inhibitor alpha NFKBIA 
  
1.00 0.12 
  
Q00535 Cyclin-dependent-like kinase 5 CDK5 1 0.11 
    
Q9UMZ2 Synergin gamma SYNRG 
  
1.00 0.11 
  
P36941 Tumor necrosis factor receptor superfamily member 3 LTBR 
  
1.00 0.11 
  
Q16851 UTP--glucose-1-phosphate uridylyltransferase UGP2 
  
1.00 0.11 
  
Q9UPT9 Ubiquitin carboxyl-terminal hydrolase 22 USP22 
  
1.00 0.11 
  
Q9H8M5 Metal transporter CNNM2 CNNM2 
  
1.00 0.11 
  
Q8IVS2 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial MCAT 
  
1.00 0.11 
  
P54727 UV excision repair protein RAD23 homolog B RAD23B 
  
1.00 0.11 
  
Q9NPF5 DNA methyltransferase 1-associated protein 1 DMAP1 
  
1.00 0.11 
  
Q9NVD7 Alpha-parvin PARVA 
  
1.00 0.10 
  
Q9UKX7 Nuclear pore complex protein Nup50 NUP50 
  
2.00 0.10 
  
Q6IPR3 tRNA wybutosine-synthesizing protein 3 homolog TYW3 1 0.10 
    
Q9NNW5 WD repeat-containing protein 6 WDR6 1 0.10 
    
Q5TCZ1 SH3 and PX domain-containing protein 2A SH3PXD2A 1 0.10 
    
Q8IX18 Probable ATP-dependent RNA helicase DHX40 DHX40 
  
1.00 0.09 
  
Q9Y4B5 Microtubule cross-linking factor 1 MTCL1 
  
1.00 0.09 
  
Q5VW36 Focadhesin FOCAD 
  
1.00 0.09 
  
Q9BV44 THUMP domain-containing protein 3 THUMPD3 
  
1.00 0.09 
  
O15111 Inhibitor of nuclear factor kappa-B kinase subunit alpha CHUK 1 0.08 
    
P82675 28S ribosomal protein S5, mitochondrial MRPS5 
  
1.00 0.08 
  
P56937 3-keto-steroid reductase HSD17B7 1 0.08 
    
P36507 Dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 
  
1.00 0.08 
  
Q9UBH6 Xenotropic and polytropic retrovirus receptor 1 XPR1 
  
1.00 0.08 
  
Q53HL2 Borealin CDCA8 
  
1.00 0.08 
  
Q9H6R4 Nucleolar protein 6 NOL6 1 0.07 
    
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 
  
1.00 0.07 
  
O14684 Prostaglandin E synthase PTGES 1 0.07 
    
Q9BTZ2 Dehydrogenase/reductase SDR family member 4 DHRS4 
  
1.00 0.07 
  
Q12824 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily B member 1 
SMARCB1 
  
1.00 0.07 
  
Q9H788 SH2 domain-containing protein 4A SH2D4A 1 0.07 
    
Q9Y520 Protein PRRC2C PRRC2C 
  
1.00 0.07 
  
Q8IYB3 Serine/arginine repetitive matrix protein 1 SRRM1 
  
1.00 0.07 
  
P54760 Ephrin type-B receptor 4 EPHB4 
  
1.00 0.06 
  
Q30201 Hereditary hemochromatosis protein HFE 
  
1.00 0.06 
  
Q8WYL5 Protein phosphatase Slingshot homolog 1 SSH1 1 0.06 
    
P68400 Casein kinase II subunit alpha CSNK2A1 1 0.02 1.00 0.03 
  
Q86VI4 Lysosomal-associated transmembrane protein 4B LAPTM4B 1 0.06 
    
Q8IUR0 Trafficking protein particle complex subunit 5 TRAPPC5 
  
1.00 0.05 
  
Q9H2C0 Gigaxonin GAN 
  
1.00 0.05 
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Q9NX46 Poly(ADP-ribose) glycohydrolase ARH3 ADPRHL2 1 0.04 
    
P31947 14-3-3 protein sigma SFN 1 0.04 
    
Q9NX57 Ras-related protein Rab-20 RAB20 
  
1.00 0.02 
  
Q13443 Disintegrin and metalloproteinase domain-containing 
protein 9 
ADAM9 1 
     
O95622 Adenylate cyclase type 5 ADCY5 
  
1.00 
   
F8VVT9 Arf-GAP with GTPase, ANK repeat and PH domain-containing 
protein 2 
AGAP2 
  
1.00 
   
Q9BSE5 Agmatinase, mitochondrial AGMAT 1 
     
Q02252 Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial 
ALDH6A1 
  
1.00 
   
O75179 Ankyrin repeat domain-containing protein 17 ANKRD17 1 
     
Q13535 Serine/threonine-protein kinase ATR ATR 1 
     
Q8N8U9 BMP-binding endothelial regulator protein BMPER 
  
1.00 
   
Q8IYS8 Biorientation of chromosomes in cell division protein 1-like 2 BOD1L2 
  
1.00 
   
Q9HA77 Probable cysteine--tRNA ligase, mitochondrial CARS2 
  
1.00 
   
Q567U6 Coiled-coil domain-containing protein 93 CCDC93 
  
1.00 
   
O60583 Cyclin-T2 CCNT2 
  
1.00 
   
Q9H3R5 Centromere protein H CENPH 
  
1.00 
   
Q13112 Chromatin assembly factor 1 subunit B CHAF1B 1 
     
Q8WVB6 Chromosome transmission fidelity protein 18 homolog CHTF18 
  
1.00 
   
Q9Y696 Chloride intracellular channel protein 4 CLIC4 1 
     
P29400-2 Isoform 2 of Collagen alpha-5(IV) chain COL4A5 
  
1.00 
   
P14384 Carboxypeptidase M CPM 1 
     
O60231 Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX16 
DHX16 
  
2.00 
   
Q8WXX0 Dynein heavy chain 7, axonemal DNAH7 1 
     
Q16610 Extracellular matrix protein 1 ECM1 1 
     
Q6PJG2 ELM2 and SANT domain-containing protein 1 ELMSAN1 1 
     
Q15303 Receptor tyrosine-protein kinase erbB-4 ERBB4 
  
1.00 
   
Q7Z6J4 FYVE, RhoGEF and PH domain-containing protein 2 FGD2 
  
1.00 
   
Q9Y5Y0 Feline leukemia virus subgroup C receptor-related protein 1 FLVCR1 
  
1.00 
   
Q8TAX9 Gasdermin-B GSDMB 
  
1.00 
   
Q86YV9 Hermansky-Pudlak syndrome 6 protein HPS6 
  
1.00 
   
Q12906-5 Isoform 5 of Interleukin enhancer-binding factor 3 ILF3 
  
1.00 
   
Q96ST2 Protein IWS1 homolog IWS1 
  
1.00 
   
H0YBM7 La-related protein 1 (Fragment) LARP1 
  
1.00 
   
Q6ICC9 Protein LDOC1L LDOC1L 1 
     
P48449 Lanosterol synthase LSS 
  
1.00 
   
P20794 Serine/threonine-protein kinase MAK MAK 
  
1.00 
   
P27816 Microtubule-associated protein 4 MAP4 
  
1.00 
   
O60244 Mediator of RNA polymerase II transcription subunit 14 MED14 1 
     
Q86W50 Methyltransferase-like protein 16 METTL16 
  
1.00 
   
Q9BUA6 Myosin regulatory light chain 10 MYL10 
  
1.00 
   
Q8IVL1 Neuron navigator 2 NAV2 
  
1.00 
   
Q8NFP9 Neurobeachin NBEA 
  
1.00 
   
O75251 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, 
mitochondrial 
NDUFS7 1 
     
P04150 Glucocorticoid receptor NR3C1 
  
1.00 
   
O60890 Oligophrenin-1 OPHN1 1 
     
Q9H074 Polyadenylate-binding protein-interacting protein 1 PAIP1 1 
     
O95263 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic 
phosphodiesterase 8B 
PDE8B 
  
1.00 
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P13667 Protein disulfide-isomerase A4 PDIA4 
  
1.00 
   
O00443 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-
containing subunit alpha 
PIK3C2A 
  
2.00 
   
Q99959 Plakophilin-2 PKP2 
  
1.00 
   
O43157 Plexin-B1 PLXNB1 1 
     
Q7Z3J3 RanBP2-like and GRIP domain-containing protein 4 RGPD4 1 
     
Q6P3W7 SCY1-like protein 2 SCYL2 1 
     
Q15019 Septin-2 SEPT2 
  
1.00 
   
O75387 Large neutral amino acids transporter small subunit 3 SLC43A1 
  
1.00 
   
Q658P3 Metalloreductase STEAP3 STEAP3 
  
1.00 
   
Q8WVM0 Dimethyladenosine transferase 1, mitochondrial TFB1M 
  
1.00 
   
P19438 Tumor necrosis factor receptor superfamily member 1A TNFRSF1A 
  
1.00 
   
Q9NS69 Mitochondrial import receptor subunit TOM22 homolog TOMM22 1 
     
Q9P2K2 Thioredoxin domain-containing protein 16 TXNDC16 
  
1.00 
   
Q5T124 UBX domain-containing protein 11 UBXN11 
  
1.00 
   
O94874 E3 UFM1-protein ligase 1 UFL1 
  
1.00 
   
P52735 Guanine nucleotide exchange factor VAV2 VAV2 
  
1.00 
   
A6NGB9 WAS/WASL-interacting protein family member 3 WIPF3 1 
     
Q96S55 ATPase WRNIP1 WRNIP1 
  
1.00 
   
Q9Y2X9 Zinc finger protein 281 ZNF281 
  
1.00 
   
 
 
 
Appendix 4: Endogenous RNF145 immunoprecipitation 
 
263 
 
Appendix 4: Endogenous RNF145 
immunoprecipitation 
 
KO: knockout, SD: sterol depleted, SD + B: sterol depleted + 1.5 hr 50 nM Bortezomib, sterols: sterol depleted 
+ 1 hr sterols, sterols + B: sterol depleted + 30 min 50 nM Bortezomib treatment followed by 1 hr with sterols. 
#: number of unique peptides, A: Area 
 
Accession Gene name Gene ID 
KO SD SD + B Sterols Sterols + B 
# A # A # A # A # A 
Q9H2G2 STE20-like serine/threonine-protein kinase SLK 
  
1 7.26 1 0.31 1 5.44 1 4.56 
P09874 Poly [ADP-ribose] polymerase 1 PARP1 
    
1 0.33 4 0.74 10 3.34 
Q01813 ATP-dependent 6-phosphofructokinase, 
platelet type 
PFKP 
  
1 0.40 1 0.32 2 4.39 1 2.42 
P61254 60S ribosomal protein L26 RPL26 
    
1 0.11 1 0.68 1 0.70 
P35268 60S ribosomal protein L22 RPL22 
  
1 0.64 1 0.47 1 0.71 1 2.64 
P78527 DNA-dependent protein kinase catalytic 
subunit 
PRKDC 
    
1 0.34 4 0.96 7 1.86 
P05090 Apolipoprotein D APOD 1 0.53 
  
1 0.23 3 0.81 3 1.23 
P04035 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase 
HMGCR 
  
1 0.42 2 0.58 1 0.45 2 2.18 
P43490 Nicotinamide phosphoribosyltransferase NAMPT 
  
1 0.20 1 0.38 2 1.90 2 1.38 
Q96DR8 Mucin-like protein 1 MUCL1 1 3.56 1 2.51 1 0.98 1 1.86 1 3.51 
P17480 Nucleolar transcription factor 1 UBTF 
  
1 0.57 1 0.86 2 1.92 3 2.95 
P11387 DNA topoisomerase 1 TOP1 
  
1 0.68 3 0.72 3 2.01 4 2.41 
P41091 Eukaryotic translation initiation factor 2 
subunit 3 
EIF2S3 
    
1 0.59 
  
2 1.97 
P68363 Tubulin alpha-1B chain TUBA1B 2 1.58 3 1.40 4 1.83 6 5.91 10 5.65 
B9A064 Immunoglobulin lambda-like polypeptide 5 IGLL5 
  
1 0.21 1 0.20 1 0.29 1 0.59 
P02768 Serum albumin ALB 4 1.91 1 1.40 3 0.82 4 1.63 5 2.32 
P13489 Ribonuclease inhibitor RNH1 
  
1 0.43 1 0.35 1 0.83 1 0.98 
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-
like protein 1 
HNRNPUL1 
    
1 0.59 7 2.71 1 1.58 
P62280 40S ribosomal protein S11 RPS11 1 0.42 1 1.61 1 1.48 2 2.67 1 3.87 
P01834 Ig kappa chain C region IGKC 1 23.04 1 34.76 1 24.17 1 41.83 1 62.40 
P25786 Proteasome subunit alpha type-1 PSMA1 
    
2 1.62 
  
4 4.03 
P42357 Histidine ammonia-lyase HAL 1 0.64 3 1.03 3 0.43 5 1.73 6 1.07 
P42677 40S ribosomal protein S27 RPS27 1 0.46 1 1.16 1 0.97 1 2.41 1 2.38 
Q7Z2W4 Zinc finger CCCH-type antiviral protein 1 ZC3HAV1 1 0.39 
  
3 0.81 6 2.84 6 1.95 
P62263 40S ribosomal protein S14 RPS14 1 1.06 1 2.83 1 3.13 1 6.26 1 7.10 
P50502 Hsc70-interacting protein ST13 
    
2 0.53 2 0.95 1 1.20 
Q6UWP8 Suprabasin SBSN 2 0.29 2 0.35 2 0.18 1 0.23 2 0.40 
P57721 Poly(rC)-binding protein 3 PCBP3 1 0.50 1 0.57 2 1.37 
  
2 2.94 
P33993 DNA replication licensing factor MCM7 MCM7 
  
1 0.28 1 0.59 2 1.73 1 1.22 
Q93034 Cullin-5 CUL5 
  
1 0.77 3 0.62 3 0.88 4 1.23 
P61247 40S ribosomal protein S3a RPS3A 
    
1 2.79 1 5.26 1 5.50 
Q8WWI1 LIM domain only protein 7 LMO7 
  
5 0.90 12 2.27 21 10.86 16 4.40 
P42704 Leucine-rich PPR motif-containing protein, 
mitochondrial 
LRPPRC 
  
2 0.69 2 0.70 2 2.12 2 1.32 
P35579 Myosin-9 MYH9 11 2.14 23 11.41 27 14.55 67 94.38 36 27.23 
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P08575 Receptor-type tyrosine-protein phosphatase C PTPRC 1 1.49 1 2.15 1 0.84 1 1.13 1 1.52 
P35637 RNA-binding protein FUS FUS 
    
2 0.98 2 2.69 2 1.75 
P43686 26S protease regulatory subunit 6B PSMC4 
    
1 0.53 
  
1 0.94 
P49368 T-complex protein 1 subunit gamma CCT3 1 0.16 
  
1 0.38 2 0.93 2 0.67 
Q6Y7W6 PERQ amino acid-rich with GYF domain-
containing protein 2 
GIGYF2 
  
1 1.16 2 0.94 5 5.20 3 1.65 
Q15369 Transcription elongation factor B polypeptide 1 TCEB1 
  
2 0.21 1 0.22 
  
1 0.37 
P62805 Histone H4 HIST1H4A 4 2.10 4 0.92 3 0.99 5 1.96 2 1.68 
P61313 60S ribosomal protein L15 RPL15 
  
1 0.30 1 0.48 1 1.01 1 0.81 
P35232 Prohibitin PHB 1 0.68 2 1.78 4 2.23 7 12.22 4 3.72 
O14950 Myosin regulatory light chain 12B MYL12B 1 0.57 1 3.47 3 2.10 3 16.50 3 3.45 
Q9UBQ5 Eukaryotic translation initiation factor 3 
subunit K 
EIF3K 
    
1 0.48 1 0.66 1 0.78 
Q5D862 Filaggrin-2 FLG2 5 3.65 7 5.52 2 1.75 4 1.75 4 2.77 
Q9UHD9 Ubiquilin-2 UBQLN2 
    
1 1.31 
  
1 2.04 
Q96EY1 DnaJ homolog subfamily A member 3, 
mitochondrial 
DNAJA3 1 0.40 
  
2 0.72 2 1.21 1 1.11 
P18621 60S ribosomal protein L17 RPL17 
    
1 2.15 1 3.84 1 3.33 
P01903 HLA class II histocompatibility antigen, DR 
alpha chain 
HLA-DRA 1 1.63 1 2.01 1 0.96 
  
1 1.48 
P54727 UV excision repair protein RAD23 homolog B RAD23B 
    
1 0.83 
  
2 1.28 
Q14134 Tripartite motif-containing protein 29 TRIM29 
    
1 0.28 6 2.23 1 0.44 
P20618 Proteasome subunit beta type-1 PSMB1 
    
1 0.40 
  
1 0.62 
P31151 Protein S100-A7 S100A7 5 17.01 4 3.69 3 3.92 4 6.42 4 5.98 
P63104 14-3-3 protein zeta/delta YWHAZ 1 0.53 1 1.55 1 0.51 1 0.71 1 0.77 
P41252 Isoleucine--tRNA ligase, cytoplasmic IARS 
    
1 0.66 1 1.29 1 1.00 
Q9Y320 Thioredoxin-related transmembrane protein 2 TMX2 
  
1 0.93 1 1.45 2 0.99 1 2.19 
P14923 Junction plakoglobin JUP 2 1.01 5 1.85 2 0.71 1 0.71 1 1.07 
Q9UI42 Carboxypeptidase A4 CPA4 2 0.68 1 0.97 1 0.56 3 0.44 1 0.84 
Q9Y383 Putative RNA-binding protein Luc7-like 2 LUC7L2 2 0.50 1 1.63 1 1.86 1 4.27 1 2.78 
Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase NSUN2 
  
2 0.52 4 1.02 9 6.47 6 1.51 
Q9Y496 Kinesin-like protein KIF3A KIF3A 
    
3 0.32 2 0.30 2 0.47 
P61978 Heterogeneous nuclear ribonucleoprotein K HNRNPK 1 0.67 1 0.48 1 0.77 2 1.06 1 1.11 
P31943 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 
  
1 0.58 1 0.56 2 0.86 2 0.82 
Q02241 Kinesin-like protein KIF23 KIF23 
    
1 0.17 
  
1 0.24 
P50454 Serpin H1 SERPINH1 
  
1 0.57 1 1.45 3 1.21 1 1.98 
Q86YZ3 Hornerin HRNR 4 2.47 7 8.24 6 2.61 5 2.22 6 3.57 
P02786 Transferrin receptor protein 1 TFRC 2 1.18 3 0.98 2 1.75 2 2.19 1 2.36 
O60814 Histone H2B type 1-K HIST1H2BK 2 1.49 3 0.74 2 0.53 2 1.23 2 0.71 
A4UGR9 Xin actin-binding repeat-containing protein 2 XIRP2 
  
1 0.43 1 0.40 1 1.00 1 0.53 
P01860 Ig gamma-3 chain C region IGHG3 3 30.71 2 50.00 3 11.89 2 57.38 2 15.46 
P61981 14-3-3 protein gamma YWHAG 
  
1 0.69 1 0.70 1 1.19 1 0.90 
P39023 60S ribosomal protein L3 RPL3 1 1.03 1 2.10 2 1.76 2 2.39 2 2.28 
P60228 Eukaryotic translation initiation factor 3 
subunit E 
EIF3E 
  
1 0.23 1 0.36 1 0.28 2 0.45 
P19474 E3 ubiquitin-protein ligase TRIM21 TRIM21 4 2.62 4 3.74 3 5.14 4 5.52 5 6.52 
Q96P63 Serpin B12 SERPINB12 1 2.06 1 2.16 1 1.83 3 1.83 3 2.30 
Q8NBM8 Prenylcysteine oxidase-like PCYOX1L 
    
1 0.36 
  
1 0.45 
P78344 Eukaryotic translation initiation factor 4 
gamma 2 
EIF4G2 1 0.99 1 1.15 3 1.42 3 1.52 3 1.79 
O15381 Nuclear valosin-containing protein-like NVL 1 0.61 2 0.49 2 0.45 2 0.62 2 0.56 
P10599 Thioredoxin TXN 2 10.39 2 6.45 2 5.11 2 8.03 2 6.38 
P23396 40S ribosomal protein S3 RPS3 1 0.53 2 0.81 2 0.93 2 1.61 2 1.17 
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P07099 Epoxide hydrolase 1 EPHX1 
  
1 0.47 1 0.37 1 0.68 1 0.45 
O75400 Pre-mRNA-processing factor 40 homolog A PRPF40A 1 0.30 1 0.47 1 0.80 
  
1 0.98 
Q13200 26S proteasome non-ATPase regulatory 
subunit 2 
PSMD2 
    
1 1.10 
  
2 1.33 
Q9NSD9 Phenylalanine--tRNA ligase beta subunit FARSB 1 0.71 1 0.49 2 0.83 2 1.21 2 1.00 
P25311 Zinc-alpha-2-glycoprotein AZGP1 4 2.20 4 1.00 1 1.31 1 2.02 3 1.60 
Q14152 Eukaryotic translation initiation factor 3 
subunit A 
EIF3A 3 0.56 2 1.27 5 1.39 6 1.29 5 1.68 
Q15370 Transcription elongation factor B polypeptide 2 TCEB2 
  
1 0.57 2 1.05 1 1.09 2 1.26 
Q6DD88 Atlastin-3 ATL3 
    
2 0.53 
  
2 0.63 
P05387 60S acidic ribosomal protein P2 RPLP2 
  
2 4.14 5 5.23 4 6.20 2 6.14 
P27635 60S ribosomal protein L10 RPL10 
    
1 0.82 1 1.46 1 0.95 
P14618 Pyruvate kinase PKM PKM 2 1.89 4 2.29 6 3.76 9 6.57 8 4.36 
O15372 Eukaryotic translation initiation factor 3 
subunit H 
EIF3H 1 4.24 1 3.52 1 8.52 1 5.40 1 9.86 
P26373 60S ribosomal protein L13 RPL13 
    
1 0.36 1 0.59 1 0.41 
P0C0S5 Histone H2A.Z H2AFZ 
    
2 2.31 2 3.85 2 2.63 
Q99623 Prohibitin-2 PHB2 1 0.51 1 1.51 1 2.12 6 7.92 5 2.41 
P62269 40S ribosomal protein S18 RPS18 
    
1 1.19 2 1.97 1 1.35 
P46060 Ran GTPase-activating protein 1 RANGAP1 
    
1 0.29 2 1.00 2 0.33 
P31944 Caspase-14 CASP14 10 11.92 7 7.04 5 6.87 10 10.89 5 7.73 
P53999 Activated RNA polymerase II transcriptional 
coactivator p15 
SUB1 1 2.12 1 2.59 1 3.98 1 5.63 1 4.47 
Q02413 Desmoglein-1 DSG1 5 1.06 7 1.92 4 0.93 8 1.22 7 1.02 
Q96PE2 Rho guanine nucleotide exchange factor 17 ARHGEF17 
    
1 0.59 1 0.35 2 0.64 
P0DMV9 Heat shock 70 kDa protein 1B HSPA1B 3 1.68 3 3.76 5 5.32 6 5.13 6 5.78 
Q08188 Protein-glutamine gamma-glutamyltransferase 
E 
TGM3 7 2.48 4 4.74 4 1.88 8 2.58 5 2.04 
P20930 Filaggrin FLG 4 2.51 7 4.51 4 1.83 4 1.70 3 1.99 
Q9UHX1 Poly(U)-binding-splicing factor PUF60 PUF60 2 0.81 2 1.01 2 1.45 2 1.49 2 1.56 
P28074 Proteasome subunit beta type-5 PSMB5 
  
1 0.87 2 3.19 1 0.54 2 3.42 
P62195 26S protease regulatory subunit 8 PSMC5 
    
1 0.26 
  
2 0.28 
Q9NRR5 Ubiquilin-4 UBQLN4 
    
1 1.89 1 0.52 1 2.02 
O00231 26S proteasome non-ATPase regulatory 
subunit 11 
PSMD11 
    
1 2.98 
  
1 3.15 
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 7 6.52 3 2.23 4 7.43 7 13.14 6 7.82 
Q15006 ER membrane protein complex subunit 2 EMC2 
    
1 0.54 
  
1 0.57 
Q9NQ29 Putative RNA-binding protein Luc7-like 1 LUC7L 
  
1 0.37 1 0.42 1 0.70 1 0.44 
Q9GZT8 NIF3-like protein 1 NIF3L1 
  
1 0.28 2 0.65 2 0.38 1 0.67 
Q96MG8 Protein-L-isoaspartate O-methyltransferase 
domain-containing protein 1 
PCMTD1 1 0.61 1 1.37 2 2.93 2 1.88 1 3.02 
O00767 Acyl-CoA desaturase SCD 
    
1 2.18 1 0.96 1 2.24 
Q96HS1 Serine/threonine-protein phosphatase PGAM5, 
mitochondrial 
PGAM5 
  
1 0.73 1 0.66 1 0.65 1 0.68 
P62241 40S ribosomal protein S8 RPS8 
  
1 0.43 1 0.83 2 0.99 1 0.85 
O75477 Erlin-1 ERLIN1 
    
1 0.94 1 0.39 1 0.95 
P52272 Heterogeneous nuclear ribonucleoprotein M HNRNPM 
    
1 1.78 7 5.04 3 1.79 
Q9UL46 Proteasome activator complex subunit 2 PSME2 
    
1 0.78 
  
1 0.78 
O00232 26S proteasome non-ATPase regulatory 
subunit 12 
PSMD12 
    
3 1.65 
  
3 1.64 
P02545 Prelamin-A/C LMNA 7 2.44 11 3.47 14 3.98 12 3.69 13 3.93 
P35998 26S protease regulatory subunit 7 PSMC2 
    
1 1.02 
  
1 1.00 
O75223 Gamma-glutamylcyclotransferase GGCT 3 2.32 3 3.51 3 2.07 3 1.85 3 2.04 
O43242 26S proteasome non-ATPase regulatory 
subunit 3 
PSMD3 
    
5 2.18 
  
6 2.14 
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Q13347 Eukaryotic translation initiation factor 3 
subunit I 
EIF3I 1 0.56 
  
2 1.16 1 0.74 2 1.14 
Q14498 RNA-binding protein 39 RBM39 1 0.92 1 0.36 1 1.97 1 4.41 1 1.92 
P62753 40S ribosomal protein S6 RPS6 2 0.89 2 1.48 2 2.87 2 3.71 2 2.78 
O75821 Eukaryotic translation initiation factor 3 
subunit G 
EIF3G 
    
2 0.95 3 1.66 1 0.91 
Q9NV79 Protein-L-isoaspartate O-methyltransferase 
domain-containing protein 2 
PCMTD2 1 1.04 1 1.70 3 2.59 3 1.84 2 2.48 
P35613 Basigin BSG 1 0.64 1 1.08 2 1.52 1 1.40 1 1.45 
P04844 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
RPN2 
    
1 1.54 1 0.76 1 1.47 
Q9NZT1 Calmodulin-like protein 5 CALML5 1 0.57 
  
1 0.56 
  
1 0.53 
P11142 Heat shock cognate 71 kDa protein HSPA8 4 3.83 4 6.89 8 10.95 5 9.73 7 10.33 
P01040 Cystatin-A CSTA 7 4.16 3 1.60 5 2.55 5 2.42 6 2.40 
P31689 DnaJ homolog subfamily A member 1 DNAJA1 
    
1 0.67 
  
1 0.63 
O43765 Small glutamine-rich tetratricopeptide repeat-
containing protein alpha 
SGTA 
    
1 1.80 
  
1 1.69 
P46379 Large proline-rich protein BAG6 BAG6 
    
1 2.76 
  
1 2.59 
O15269 Serine palmitoyltransferase 1 SPTLC1 
  
3 1.06 3 1.35 3 1.36 3 1.26 
Q96MT1 RING finger protein 145 RNF145 1 1.68 4 9.74 7 22.87 7 13.39 7 21.14 
P62333 26S protease regulatory subunit 10B PSMC6 
    
1 0.36 
  
1 0.33 
Q9UNM6 26S proteasome non-ATPase regulatory 
subunit 13 
PSMD13 
    
1 1.49 
  
1 1.36 
Q8N163 Cell cycle and apoptosis regulator protein 2 CCAR2 2 2.50 1 2.85 1 3.66 3 3.04 2 3.33 
P55884 Eukaryotic translation initiation factor 3 
subunit B 
EIF3B 5 5.82 3 5.77 6 7.46 6 4.83 6 6.76 
O15371 Eukaryotic translation initiation factor 3 
subunit D 
EIF3D 1 4.09 
  
1 0.36 1 0.32 1 0.32 
Q13263 Transcription intermediary factor 1-beta TRIM28 1 0.63 
  
1 1.39 1 1.77 1 1.25 
O15294 UDP-N-acetylglucosamine--peptide N-
acetylglucosaminyltransferase 110 kDa subunit 
OGT 
  
1 0.45 1 0.66 2 0.59 3 0.59 
Q08170 Serine/arginine-rich splicing factor 4 SRSF4 
    
1 0.81 1 0.85 1 0.73 
Q16850 Lanosterol 14-alpha demethylase CYP51A1 
    
2 0.73 1 0.36 2 0.66 
P63208 S-phase kinase-associated protein 1 SKP1 
    
1 0.45 1 1.04 1 0.41 
Q9Y5K5 Ubiquitin carboxyl-terminal hydrolase isozyme 
L5 
UCHL5 
    
1 0.79 
  
1 0.70 
Q9Y5Z0 Beta-secretase 2 BACE2 
    
1 3.91 
  
1 3.47 
P61626 Lysozyme C LYZ 1 2.96 1 1.95 1 1.79 1 5.04 1 1.56 
Q15149 Plectin PLEC 
  
2 0.59 1 0.86 5 2.07 4 0.75 
P11310 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
ACADM 1 0.67 1 1.32 1 0.94 1 2.14 1 0.82 
Q12907 Vesicular integral-membrane protein VIP36 LMAN2 
  
1 4.94 1 9.84 1 5.32 1 8.54 
Q7L0Y3 Mitochondrial ribonuclease P protein 1 TRMT10C 
    
1 1.19 1 1.15 1 1.03 
P28066 Proteasome subunit alpha type-5 PSMA5 
  
1 0.91 2 5.37 1 0.64 2 4.65 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 HSD17B10 
  
1 0.54 1 0.60 1 0.20 1 0.51 
Q63HN8 E3 ubiquitin-protein ligase RNF213 RNF213 
  
1 
 
1 0.54 
  
2 0.46 
P05023 Sodium/potassium-transporting ATPase 
subunit alpha-1 
ATP1A1 
  
1 0.44 2 0.96 2 0.46 2 0.81 
Q13426 DNA repair protein XRCC4 XRCC4 3 1.93 3 2.13 4 3.48 4 3.03 4 2.91 
Q9Y262 Eukaryotic translation initiation factor 3 
subunit L 
EIF3L 3 1.54 4 1.56 5 3.48 5 3.55 6 2.90 
Q13501 Sequestosome-1 SQSTM1 
    
2 2.95 2 1.95 3 2.40 
Q8NBM4 Ubiquitin-associated domain-containing 
protein 2 
UBAC2 
  
1 2.46 1 5.96 1 3.14 1 4.79 
P60709 Actin, cytoplasmic 1 ACTB 
  
2 1.77 5 1.89 6 1.70 5 1.52 
P08238 Heat shock protein HSP 90-beta HSP90AB1 2 1.83 1 2.45 5 5.56 4 8.22 5 4.42 
Q15843 NEDD8 NEDD8 1 0.54 1 1.00 1 2.63 1 2.14 1 2.08 
Q14165 Malectin MLEC 
    
1 0.85 
  
1 0.66 
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Q02543 60S ribosomal protein L18a RPL18A 
    
1 0.86 1 0.86 1 0.66 
P19338 Nucleolin NCL 2 2.62 3 3.77 5 6.61 5 6.47 3 5.04 
P38646 Stress-70 protein, mitochondrial HSPA9 2 0.51 7 5.01 7 5.33 5 3.46 6 4.03 
Q04837 Single-stranded DNA-binding protein, 
mitochondrial 
SSBP1 1 2.85 1 5.56 1 3.79 1 3.80 1 2.84 
P51648 Fatty aldehyde dehydrogenase ALDH3A2 
    
2 1.47 1 0.81 2 1.10 
Q13310 Polyadenylate-binding protein 4 PABPC4 1 0.43 
  
1 0.69 1 1.34 2 0.51 
P53985 Monocarboxylate transporter 1 SLC16A1 
    
1 0.81 
  
1 0.58 
Q9HCY8 Protein S100-A14 S100A14 1 2.40 1 6.10 1 1.61 1 2.71 1 1.15 
O14818 Proteasome subunit alpha type-7 PSMA7 1 0.94 1 1.93 3 7.24 1 2.09 4 5.12 
Q96SW2 Protein cereblon CRBN 
  
1 0.82 1 1.20 1 1.36 1 0.85 
Q09666 Neuroblast differentiation-associated protein 
AHNAK 
AHNAK 9 1.52 12 3.68 22 5.39 19 4.42 20 3.81 
Q15008 26S proteasome non-ATPase regulatory 
subunit 6 
PSMD6 
    
1 0.49 
  
2 0.34 
P51114 Fragile X mental retardation syndrome-related 
protein 1 
FXR1 2 0.41 1 0.35 3 1.00 3 0.78 2 0.70 
P31025 Lipocalin-1 LCN1 
  
1 1.35 1 1.35 1 2.08 1 0.94 
P21333 Filamin-A FLNA 18 3.40 18 3.16 27 5.92 21 4.20 24 4.11 
P10809 60 kDa heat shock protein, mitochondrial HSPD1 4 4.26 7 5.17 8 6.15 7 6.76 4 4.25 
O75165 DnaJ homolog subfamily C member 13 DNAJC13 
    
1 2.94 
  
1 2.03 
P55036 26S proteasome non-ATPase regulatory 
subunit 4 
PSMD4 
    
2 2.93 
  
2 1.92 
O00264 Membrane-associated progesterone receptor 
component 1 
PGRMC1 
    
1 1.86 1 1.47 1 1.21 
P60900 Proteasome subunit alpha type-6 PSMA6 
    
1 3.35 
  
2 2.15 
Q14254 Flotillin-2 FLOT2 1 0.64 1 0.60 1 0.81 1 0.81 1 0.52 
P27824 Calnexin CANX 3 0.73 4 4.71 6 11.34 4 6.56 5 7.14 
P68871 Hemoglobin subunit beta HBB 4 2.45 3 1.63 2 2.66 4 2.75 2 1.66 
P08195 4F2 cell-surface antigen heavy chain SLC3A2 4 3.09 6 4.66 7 8.71 6 5.39 6 5.43 
Q00839 Heterogeneous nuclear ribonucleoprotein U HNRNPU 
  
1 0.41 3 1.23 3 2.19 2 0.76 
P04843 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
RPN1 
  
1 0.48 2 1.13 1 0.69 1 0.69 
P05089 Arginase-1 ARG1 1 3.86 3 1.03 1 3.97 6 3.53 1 2.39 
P36578 60S ribosomal protein L4 RPL4 1 4.92 1 8.45 1 18.62 1 26.89 1 10.89 
O15427 Monocarboxylate transporter 4 SLC16A3 1 0.46 1 0.60 1 1.50 1 0.78 1 0.88 
Q99460 26S proteasome non-ATPase regulatory 
subunit 1 
PSMD1 
    
1 2.54 
  
2 1.47 
P52597 Heterogeneous nuclear ribonucleoprotein F HNRNPF 
    
1 2.09 1 2.46 1 1.21 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial DLD 1 0.62 1 1.20 1 0.93 
  
1 0.53 
Q01650 Large neutral amino acids transporter small 
subunit 1 
SLC7A5 2 1.94 3 1.75 4 6.71 4 2.96 4 3.86 
P11166 Solute carrier family 2, facilitated glucose 
transporter member 1 
SLC2A1 
  
1 0.34 1 0.49 1 0.16 1 0.28 
P05109 Protein S100-A8 S100A8 6 9.69 8 12.37 4 3.19 6 11.46 3 1.82 
P07355 Annexin A2 ANXA2 5 2.21 3 3.96 7 3.22 7 2.93 4 1.82 
P07339 Cathepsin D CTSD 2 2.91 1 12.31 1 9.14 4 2.20 1 5.13 
P16989 Y-box-binding protein 3 YBX3 1 0.61 1 0.27 1 0.89 1 0.48 1 0.50 
P06702 Protein S100-A9 S100A9 8 17.36 8 17.12 5 11.28 8 15.94 4 6.22 
Q99436 Proteasome subunit beta type-7 PSMB7 
  
1 0.79 1 4.21 1 0.56 2 2.32 
P21796 Voltage-dependent anion-selective channel 
protein 1 
VDAC1 1 1.94 1 1.64 1 4.17 2 4.78 1 2.28 
P31327 Carbamoyl-phosphate synthase [ammonia], 
mitochondrial 
CPS1 1 0.87 3 0.62 2 2.03 6 5.68 3 1.11 
P05388 60S acidic ribosomal protein P0 RPLP0 
  
1 0.54 2 1.68 2 2.08 1 0.92 
Q9UNL2 Translocon-associated protein subunit gamma SSR3 
    
1 0.36 
  
1 0.19 
P49917 DNA ligase 4 LIG4 1 0.65 
  
1 1.13 2 0.51 2 0.60 
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P56537 Eukaryotic translation initiation factor 6 EIF6 
    
1 0.56 1 0.62 1 0.30 
P05187 Alkaline phosphatase, placental type ALPP 1 1.10 1 2.22 1 1.85 1 1.60 1 0.95 
Q13867 Bleomycin hydrolase BLMH 2 1.15 1 0.81 2 0.74 3 0.87 2 0.38 
Q12931 Heat shock protein 75 kDa, mitochondrial TRAP1 1 1.74 
  
1 7.26 
  
2 3.63 
P55072 Transitional endoplasmic reticulum ATPase VCP 
  
2 0.87 4 2.60 3 0.89 4 1.28 
Q07021 Complement component 1 Q subcomponent-
binding protein, mitochondrial 
C1QBP 3 1.00 2 0.77 3 2.18 3 1.52 3 1.07 
P60660 Myosin light polypeptide 6 MYL6 1 1.79 1 8.52 1 16.11 4 38.40 3 7.31 
P40939 Trifunctional enzyme subunit alpha, 
mitochondrial 
HADHA 1 0.88 2 1.22 2 0.97 1 1.22 1 0.44 
P07900 Heat shock protein HSP 90-alpha HSP90AA1 1 0.72 2 0.94 2 2.92 2 2.83 3 1.30 
P51659 Peroxisomal multifunctional enzyme type 2 HSD17B4 2 0.72 2 1.06 1 0.98 2 0.60 2 0.39 
P69905 Hemoglobin subunit alpha HBA1 2 1.58 2 1.16 2 0.90 3 1.27 1 0.36 
Q9HCD6 Protein TANC2 TANC2 
    
1 0.74 
  
2 0.29 
P62979 Ubiquitin-40S ribosomal protein S27a RPS27A 3 3.55 3 5.17 4 68.35 3 11.01 4 26.52 
P25705 ATP synthase subunit alpha, mitochondrial ATP5A1 4 1.15 3 1.49 4 2.15 2 1.69 2 0.82 
P04792 Heat shock protein beta-1 HSPB1 
    
1 0.78 4 1.71 2 0.29 
P22735 Protein-glutamine gamma-glutamyltransferase 
K 
TGM1 2 1.29 3 1.61 1 1.62 1 1.75 1 0.57 
P30044 Peroxiredoxin-5, mitochondrial PRDX5 1 0.54 
  
1 1.35 1 0.92 1 0.47 
P11021 78 kDa glucose-regulated protein HSPA5 3 0.60 3 0.86 6 4.58 6 1.65 6 1.46 
P29508 Serpin B3 SERPINB3 7 2.61 2 1.08 2 2.77 2 0.73 3 0.83 
Q02878 60S ribosomal protein L6 RPL6 
    
2 2.21 2 3.99 1 0.51 
P61604 10 kDa heat shock protein, mitochondrial HSPE1 1 0.53 2 0.70 3 0.68 
  
1 0.11 
A6NDV4 Transmembrane protein 8B TMEM8B 
    
1 10.91 
    
B4DEH9 Acetyl-coenzyme A synthetase, cytoplasmic ACSS2 
    
1 1.26 
    
O14975 Very long-chain acyl-CoA synthetase SLC27A2 
    
1 0.52 
    
O43615 Mitochondrial import inner membrane 
translocase subunit TIM44 
TIMM44 
  
2 0.32 1 0.25 3 0.71 
  
O60884 DnaJ homolog subfamily A member 2 DNAJA2 
    
1 0.09 
    
O75044 SLIT-ROBO Rho GTPase-activating protein 2 SRGAP2 
    
1 0.34 
    
O75190 DnaJ homolog subfamily B member 6 DNAJB6 
    
1 0.21 1 0.20 
  
O75390 Citrate synthase, mitochondrial CS 
    
1 0.95 
    
O75947 ATP synthase subunit d, mitochondrial ATP5H 
    
1 0.18 
    
O95831 Apoptosis-inducing factor 1, mitochondrial AIFM1 1 0.85 1 1.72 1 0.64 1 1.00 
  
O96005 Cleft lip and palate transmembrane protein 1 CLPTM1 
  
1 5.92 1 11.20 1 2.31 
  
P00338 L-lactate dehydrogenase A chain LDHA 
    
1 0.45 2 0.55 
  
P00367 Glutamate dehydrogenase 1, mitochondrial GLUD1 
  
1 0.38 1 0.26 2 0.26 
  
P02671 Fibrinogen alpha chain FGA 
    
1 0.35 
    
P02675 Fibrinogen beta chain FGB 
    
1 3.38 
    
P02679 Fibrinogen gamma chain FGG 
    
1 0.58 
    
P06748 Nucleophosmin NPM1 
    
1 0.46 1 0.57 
  
P07954 Fumarate hydratase, mitochondrial FH 
  
1 0.39 1 0.33 
    
P08670 Vimentin VIM 
    
1 0.49 3 0.71 
  
P08910 Monoacylglycerol lipase ABHD2 ABHD2 
    
1 0.34 
    
P10515 Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial 
DLAT 
  
1 0.53 1 0.44 
    
P11532 Dystrophin DMD 
    
1 0.39 1 0.32 
  
P13073 Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial 
COX4I1 1 1.40 1 2.01 1 2.19 1 1.52 
  
P13804 Electron transfer flavoprotein subunit alpha, 
mitochondrial 
ETFA 1 0.20 1 0.42 1 0.60 
    
P16435 NADPH--cytochrome P450 reductase POR 
    
1 0.22 
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P20700 Lamin-B1 LMNB1 
    
1 0.71 
    
P25789 Proteasome subunit alpha type-4 PSMA4 
    
1 1.31 
    
P30042 ES1 protein homolog, mitochondrial C21orf33 
  
1 0.27 1 0.19 
    
P30048 Thioredoxin-dependent peroxide reductase, 
mitochondrial 
PRDX3 
  
1 1.07 1 0.89 
    
P30084 Enoyl-CoA hydratase, mitochondrial ECHS1 
    
1 0.61 
    
P31040 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
SDHA 
  
1 3.13 1 2.36 1 2.01 
  
P34897 Serine hydroxymethyltransferase, 
mitochondrial 
SHMT2 
    
1 0.44 
    
P43121 Cell surface glycoprotein MUC18 MCAM 
    
1 0.95 1 0.68 
  
P46777 60S ribosomal protein L5 RPL5 
  
1 0.19 1 0.29 1 0.77 
  
P48594 Serpin B4 SERPINB4 
  
1 2.79 1 3.80 1 1.03 
  
P49411 Elongation factor Tu, mitochondrial TUFM 1 3.56 
  
1 3.31 
    
P55809 Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial 
OXCT1 
  
1 0.46 1 0.23 
    
P62266 40S ribosomal protein S23 RPS23 
    
1 0.24 1 0.43 
  
P62899 60S ribosomal protein L31 RPL31 
    
1 0.17 
    
P68371 Tubulin beta-4B chain TUBB4B 1 0.32 2 0.88 2 1.77 
    
Q01469 Fatty acid-binding protein, epidermal FABP5 
  
1 0.35 1 0.26 
    
Q06787 Synaptic functional regulator FMR1 FMR1 
    
1 1.22 1 1.11 
  
Q06830 Peroxiredoxin-1 PRDX1 1 0.95 
  
1 0.76 1 1.26 
  
Q07020 60S ribosomal protein L18 RPL18 
    
1 0.24 
    
Q13835 Plakophilin-1 PKP1 
  
2 1.19 1 0.44 
    
Q14416 Metabotropic glutamate receptor 2 GRM2 
    
1 0.23 
    
Q15165 Serum paraoxonase/arylesterase 2 PON2 
    
1 1.33 
    
Q15392 Delta(24)-sterol reductase DHCR24 
    
1 0.50 
    
Q15758 Neutral amino acid transporter B(0) SLC1A5 
  
1 0.80 1 0.30 1 0.34 
  
Q5J8M3 ER membrane protein complex subunit 4 EMC4 
    
1 0.55 
    
Q5T9A4 ATPase family AAA domain-containing protein 
3B 
ATAD3B 
  
1 0.60 1 1.39 1 2.97 
  
Q7L014 Probable ATP-dependent RNA helicase DDX46 DDX46 
    
1 0.52 1 0.33 
  
Q7L5D6 Golgi to ER traffic protein 4 homolog GET4 
    
1 1.17 
    
Q7Z7M9 Polypeptide N-acetylgalactosaminyltransferase 
5 
GALNT5 
    
1 0.68 
    
Q86WA8 Lon protease homolog 2, peroxisomal LONP2 
    
1 7.00 1 0.51 
  
Q8N490 Probable hydrolase PNKD PNKD 
    
1 0.24 
    
Q8TCJ2 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 
STT3B 
    
1 1.08 1 0.59 
  
Q95604 HLA class I histocompatibility antigen, Cw-17 
alpha chain 
HLA-C 
    
1 1.21 1 1.49 
  
Q96A54 Adiponectin receptor protein 1 ADIPOR1 
    
1 1.51 
    
Q99550 M-phase phosphoprotein 9 MPHOSPH
9 
    
1 0.47 
    
Q99614 Tetratricopeptide repeat protein 1 TTC1 
    
2 0.60 
    
Q9C0I3 Serine-rich coiled-coil domain-containing 
protein 1 
CCSER1 
    
1 0.31 
    
Q9NX63 MICOS complex subunit MIC19 CHCHD3 
    
1 0.61 
    
Q9NYF0 Dapper homolog 1 DACT1 
    
1 0.45 
    
Q9UBX3 Mitochondrial dicarboxylate carrier SLC25A10 
    
1 0.21 
    
Q9UJS0 Calcium-binding mitochondrial carrier protein 
Aralar2 
SLC25A13 
    
1 0.43 
    
Q9UJZ1 Stomatin-like protein 2, mitochondrial STOML2 1 0.77 1 1.17 1 1.11 1 1.19 
  
Q9Y282 Endoplasmic reticulum-Golgi intermediate 
compartment protein 3 
ERGIC3 
    
1 0.35 
    
A0A024RA52 Proteasome subunit alpha type PSMA2 
        
1 1.71 
A0A075B6X0 Protein TRAJ45 (Fragment) TRAJ45 
        
1 0.94 
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A0A0A0MS15 Immunoglobulin heavy variable 3-49 IGHV3-49 
        
1 0.69 
A0A0G2JMW
3 
Cadherin-related family member 5 CDHR5 
        
1 0.38 
A0A1B0GTL5 Rab11 family-interacting protein 5 RAB11FIP5 
        
1 
 
A6NHZ5 Leucine-rich repeat-containing protein 14B LRRC14B 
  
1 
       
A6NIE6 Putative RRN3-like protein RRN3P2 RRN3P2 
  
1 1.54 
      
B5ME19 Eukaryotic translation initiation factor 3 
subunit C-like protein 
EIF3CL 
      
1 0.87 1 1.00 
B9EGA3 SMARCD2 protein SMARCD2 
        
1 
 
F8VWW7 SPRY domain-containing protein 3 SPRYD3 
    
1 
     
F8W7C6 60S ribosomal protein L10 RPL10 
      
1 1.18 
  
H0YI64 Endoplasmic reticulum mannosyl-
oligosaccharide 1,2-alpha-mannosidase 
(Fragment) 
MAN1B1 
        
1 
 
H7BZJ3 Protein disulfide-isomerase A3 (Fragment) PDIA3 
      
1 0.69 1 0.45 
H7C205 Rho GTPase-activating protein 26 (Fragment) ARHGAP26 
        
1 
 
K7EL20 Eukaryotic translation initiation factor 3 
subunit G (Fragment) 
EIF3G 
      
1 2.14 1 2.18 
O00165 HCLS1-associated protein X-1 HAX1 
      
1 1.20 
  
O00410 Importin-5 IPO5 
      
1 0.61 
  
O14617 AP-3 complex subunit delta-1 AP3D1 
        
1 0.39 
O15027 Protein transport protein Sec16A SEC16A 
      
1 0.10 
  
O43175 D-3-phosphoglycerate dehydrogenase PHGDH 
      
1 1.79 2 2.04 
O43399 Tumor protein D54 TPD52L2 
      
1 0.63 
  
O43448 Voltage-gated potassium channel subunit beta-
3 
KCNAB3 
        
1 
 
O43513 Mediator of RNA polymerase II transcription 
subunit 7 
MED7 
    
1 
     
O43707 Alpha-actinin-4 ACTN4 
  
1 0.32 
      
O43776 Asparagine--tRNA ligase, cytoplasmic NARS 
      
1 3.27 
  
O43823 A-kinase anchor protein 8 AKAP8 
      
2 1.37 
  
O60284 Suppression of tumorigenicity 18 protein ST18 
      
1 0.88 
  
O60573 Eukaryotic translation initiation factor 4E type 
2 
EIF4E2 
      
3 1.16 
  
O60716 Catenin delta-1 CTNND1 
      
3 1.42 1 0.92 
O60763 General vesicular transport factor p115 USO1 
        
1 0.43 
O60841 Eukaryotic translation initiation factor 5B EIF5B 
        
2 0.68 
O75342 Arachidonate 12-lipoxygenase, 12R-type ALOX12B 
  
2 0.61 
  
1 0.55 1 0.54 
O75420 PERQ amino acid-rich with GYF domain-
containing protein 1 
GIGYF1 
      
4 1.35 1 0.49 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 
      
1 0.48 
  
O75955 Flotillin-1 FLOT1 
      
1 0.33 
  
O76003 Glutaredoxin-3 GLRX3 
      
2 1.03 2 0.34 
O76031 ATP-dependent Clp protease ATP-binding 
subunit clpX-like, mitochondrial 
CLPX 
      
2 1.14 
  
O76094 Signal recognition particle subunit SRP72 SRP72 
      
1 0.50 
  
O94973 AP-2 complex subunit alpha-2 AP2A2 
    
1 
     
O95232 Luc7-like protein 3 LUC7L3 
      
1 0.21 
  
O95373 Importin-7 IPO7 
        
1 4.05 
O95425 Supervillin SVIL 
      
1 1.33 
  
O95573 Long-chain-fatty-acid--CoA ligase 3 ACSL3 
        
1 0.51 
O95628 CCR4-NOT transcription complex subunit 4 CNOT4 
      
2 0.32 
  
O95684 FGFR1 oncogene partner FGFR1OP 
      
1 0.54 
  
P00966 Argininosuccinate synthase ASS1 
      
2 0.77 
  
P01031 Complement C5 C5 
      
1 0.36 
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P01706 Immunoglobulin lambda variable 2-11 IGLV2-11 
        
1 0.78 
P01876 Ig alpha-1 chain C region IGHA1 2 0.52 
    
3 1.23 2 0.99 
P02647 Apolipoprotein A-I APOA1 
      
1 3.46 
  
P04040 Catalase CAT 
  
1 0.59 
      
P04075 Fructose-bisphosphate aldolase A ALDOA 1 0.38 2 0.39 
  
1 0.47 1 0.41 
P04083 Annexin A1 ANXA1 
      
1 0.25 3 0.69 
P04279 Semenogelin-1 SEMG1 2 0.74 2 0.70 
    
2 0.63 
P04908 Histone H2A type 1-B/E HIST1H2AB 
  
2 2.13 
      
P05141 ADP/ATP translocase 2 SLC25A5 1 0.18 1 0.53 
    
1 0.46 
P05198 Eukaryotic translation initiation factor 2 
subunit 1 
EIF2S1 
        
2 1.16 
P05362 Intercellular adhesion molecule 1 ICAM1 
      
1 0.37 1 0.40 
P06753 Tropomyosin alpha-3 chain TPM3 
  
1 1.88 
      
P07437 Tubulin beta chain TUBB 
      
4 2.86 5 4.39 
P07814 Bifunctional glutamate/proline--tRNA ligase EPRS 
      
1 0.36 
  
P07910 Heterogeneous nuclear ribonucleoproteins 
C1/C2 
HNRNPC 
  
1 0.35 
  
1 0.58 1 0.57 
P08559 Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, mitochondrial 
PDHA1 
      
1 0.50 
  
P08621 U1 small nuclear ribonucleoprotein 70 kDa SNRNP70 
      
1 0.24 
  
P08708 40S ribosomal protein S17 RPS17 
        
1 1.05 
P09525 Annexin A4 ANXA4 
  
1 0.54 
      
P0CW18 Serine protease 56 PRSS56 
      
1 0.33 1 0.61 
P0DME0 Protein SETSIP SETSIP 
      
1 0.16 
  
P11177 Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
PDHB 
      
1 0.87 
  
P11498 Pyruvate carboxylase, mitochondrial PC 
      
1 0.44 
  
P11586 C-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 
  
1 
   
2 2.19 1 2.15 
P11684 Uteroglobin SCGB1A1 
      
1 0.57 
  
P12004 Proliferating cell nuclear antigen PCNA 
      
1 0.88 1 1.15 
P12270 Nucleoprotein TPR TPR 
      
1 0.45 
  
P12956 X-ray repair cross-complementing protein 6 XRCC6 1 0.20 1 
 
1 
 
1 0.50 1 0.27 
P13010 X-ray repair cross-complementing protein 5 XRCC5 
      
1 1.10 
  
P13639 Elongation factor 2 EEF2 
  
2 0.22 
  
1 0.37 
  
P13995 Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial 
MTHFD2 
      
1 0.07 
  
P14625 Endoplasmin HSP90B1 
  
1 0.17 
  
1 0.51 
  
P14735 Insulin-degrading enzyme IDE 
  
1 0.46 
      
P15880 40S ribosomal protein S2 RPS2 
      
1 0.31 
  
P16333 Cytoplasmic protein NCK1 NCK1 
      
1 0.84 1 1.14 
P16402 Histone H1.3 HIST1H1D 
      
2 0.38 3 0.53 
P16615 Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
ATP2A2 
        
1 0.42 
P17661 Desmin DES 
        
1 0.57 
P17812 CTP synthase 1 CTPS1 
      
4 4.43 3 1.96 
P17900 Ganglioside GM2 activator GM2A 1 0.69 
      
1 0.20 
P17980 26S protease regulatory subunit 6A PSMC3 
        
1 0.68 
P17987 T-complex protein 1 subunit alpha TCP1 
      
1 0.83 
  
P18077 60S ribosomal protein L35a RPL35A 
      
1 1.40 
  
P18206 Vinculin VCL 
      
1 0.47 
  
P19971 Thymidine phosphorylase TYMP 
  
1 0.51 
      
P20042 Eukaryotic translation initiation factor 2 
subunit 2 
EIF2S2 
        
2 1.70 
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P20933 N(4)-(beta-N-acetylglucosaminyl)-L-
asparaginase 
AGA 2 0.36 
      
1 0.24 
P22033 Methylmalonyl-CoA mutase, mitochondrial MUT 
      
1 0.23 
  
P22061 Protein-L-isoaspartate(D-aspartate) O-
methyltransferase 
PCMT1 
      
1 0.20 1 0.29 
P22234 Multifunctional protein ADE2 PAICS 
        
1 0.74 
P22732 Solute carrier family 2, facilitated glucose 
transporter member 5 
SLC2A5 
      
1 0.12 
  
P23258 Tubulin gamma-1 chain TUBG1 
      
2 2.07 
  
P23458 Tyrosine-protein kinase JAK1 JAK1 
      
1 0.67 1 0.40 
P23490 Loricrin LOR 1 0.34 1 0.15 
      
P24071 Immunoglobulin alpha Fc receptor FCAR 
  
1 0.84 
      
P25205 DNA replication licensing factor MCM3 MCM3 
      
2 0.92 
  
P25788 Proteasome subunit alpha type-3 PSMA3 
    
1 1.96 
  
1 
 
P28072 Proteasome subunit beta type-6 PSMB6 
        
1 0.34 
P28340 DNA polymerase delta catalytic subunit POLD1 
      
2 1.12 1 0.31 
P29401 Transketolase TKT 
        
1 0.30 
P29590 Protein PML PML 
      
1 1.41 
  
P30153 Serine/threonine-protein phosphatase 2A 65 
kDa regulatory subunit A alpha isoform 
PPP2R1A 
      
1 0.54 
  
P30566 Adenylosuccinate lyase ADSL 
      
1 0.95 
  
P31949 Protein S100-A11 S100A11 1 0.19 
    
1 0.42 
  
P32189 Glycerol kinase GK 
      
1 0.44 
  
P33176 Kinesin-1 heavy chain KIF5B 
      
6 2.02 
  
P35251 Replication factor C subunit 1 RFC1 
      
1 0.69 1 0.76 
P35580 Myosin-10 MYH10 
      
12 2.80 3 0.65 
P35659 Protein DEK DEK 
        
2 1.71 
P36776 Lon protease homolog, mitochondrial LONP1 
  
1 0.28 
      
P37108 Signal recognition particle 14 kDa protein SRP14 
      
1 0.04 2 0.91 
P39748 Flap endonuclease 1 FEN1 
      
1 1.28 
  
P42765 3-ketoacyl-CoA thiolase, mitochondrial ACAA2 
      
1 
 
1 1.11 
P43007 Neutral amino acid transporter A SLC1A4 
        
1 0.23 
P45880 Voltage-dependent anion-selective channel 
protein 2 
VDAC2 1 1.04 
    
1 5.19 1 1.92 
P47929 Galectin-7 LGALS7 
  
1 0.88 
  
1 0.66 1 0.58 
P48643 T-complex protein 1 subunit epsilon CCT5 
      
1 1.32 
  
P49327 Fatty acid synthase FASN 
      
4 1.57 1 0.43 
P49458 Signal recognition particle 9 kDa protein SRP9 
        
1 0.48 
P49750 YLP motif-containing protein 1 YLPM1 
      
1 0.49 
  
P49756 RNA-binding protein 25 RBM25 
        
2 0.41 
P49792 E3 SUMO-protein ligase RanBP2 RANBP2 
      
1 0.57 
  
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 
IDH3A 
      
1 0.81 
  
P50914 60S ribosomal protein L14 RPL14 
      
1 0.10 
  
P50990 T-complex protein 1 subunit theta CCT8 
      
1 0.30 
  
P50991 T-complex protein 1 subunit delta CCT4 
      
3 0.83 2 0.87 
P51531 Probable global transcription activator SNF2L2 SMARCA2 
    
1 
     
P51570 Galactokinase GALK1 
        
1 0.46 
P51993 Alpha-(1,3)-fucosyltransferase 6 FUT6 
    
1 
     
P52701 DNA mismatch repair protein Msh6 MSH6 
      
2 1.17 1 0.43 
P53618 Coatomer subunit beta COPB1 
        
2 0.93 
P53621 Coatomer subunit alpha COPA 
        
1 0.33 
P54709 Sodium/potassium-transporting ATPase 
subunit beta-3 
ATP1B3 1 0.22 1 0.50 
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P54920 Alpha-soluble NSF attachment protein NAPA 
      
1 0.32 
  
P55060 Exportin-2 CSE1L 
        
1 2.21 
P56192 Methionine--tRNA ligase, cytoplasmic MARS 
      
1 0.55 1 0.50 
P60174 Triosephosphate isomerase TPI1 1 0.20 
    
1 0.24 
  
P61026 Ras-related protein Rab-10 RAB10 
  
1 0.26 
      
P61289 Proteasome activator complex subunit 3 PSME3 
      
1 0.91 
  
P61353 60S ribosomal protein L27 RPL27 
      
1 0.63 1 0.45 
P62191 26S protease regulatory subunit 4 PSMC1 
        
1 0.14 
P62244 40S ribosomal protein S15a RPS15A 
      
1 0.27 
  
P62701 40S ribosomal protein S4, X isoform RPS4X 
      
1 0.49 
  
P62736 Actin, aortic smooth muscle ACTA2 4 2.06 1 0.45 
      
P62750 60S ribosomal protein L23a RPL23A 
      
1 0.74 1 1.09 
P62829 60S ribosomal protein L23 RPL23 
      
1 0.48 1 0.50 
P62851 40S ribosomal protein S25 RPS25 
      
1 0.25 
  
P62857 40S ribosomal protein S28 RPS28 
        
1 0.29 
P62861 40S ribosomal protein S30 FAU 
      
1 0.25 
  
P62913 60S ribosomal protein L11 RPL11 
      
1 0.43 1 0.41 
P63173 60S ribosomal protein L38 RPL38 
        
1 0.33 
P67809 Nuclease-sensitive element-binding protein 1 YBX1 
      
1 1.16 
  
P68431 Histone H3.1 HIST1H3A 
      
1 0.75 
  
P80723 Brain acid soluble protein 1 BASP1 
  
1 0.13 
  
1 0.85 
  
P83881 60S ribosomal protein L36a RPL36A 
      
1 0.26 1 0.30 
P84098 60S ribosomal protein L19 RPL19 
      
1 1.10 1 0.72 
Q00325 Phosphate carrier protein, mitochondrial SLC25A3 
  
1 0.55 
    
1 0.15 
Q00610 Clathrin heavy chain 1 CLTC 
      
2 0.58 1 0.50 
Q02388 Collagen alpha-1(VII) chain COL7A1 
        
1 
 
Q05639 Elongation factor 1-alpha 2 EEF1A2 
  
1 0.29 
      
Q05932 Folylpolyglutamate synthase, mitochondrial FPGS 
      
1 0.30 
  
Q06710 Paired box protein Pax-8 PAX8 
        
1 3.67 
Q07866 Kinesin light chain 1 KLC1 
      
1 0.32 
  
Q07955 Serine/arginine-rich splicing factor 1 SRSF1 
  
1 
   
1 0.39 2 0.31 
Q08211 ATP-dependent RNA helicase A DHX9 
    
1 0.56 2 1.24 1 
 
Q08345 Epithelial discoidin domain-containing receptor 
1 
DDR1 
    
1 
     
Q08380 Galectin-3-binding protein LGALS3BP 
      
1 0.20 
  
Q08752 Peptidyl-prolyl cis-trans isomerase D PPID 
      
1 0.81 
  
Q0P6D6 Coiled-coil domain-containing protein 15 CCDC15 
        
1 0.62 
Q12772 Sterol regulatory element-binding protein 2 SREBF2 
        
1 0.43 
Q12864 Cadherin-17 CDH17 
        
1 
 
Q12873 Chromodomain-helicase-DNA-binding protein 
3 
CHD3 
  
1 0.83 
      
Q12965 Unconventional myosin-Ie MYO1E 
      
1 0.50 
  
Q13201 Multimerin-1 MMRN1 
      
1 
   
Q13426-2 Isoform 2 of DNA repair protein XRCC4 XRCC4 
      
2 0.69 
  
Q13428 Treacle protein TCOF1 
      
1 0.51 
  
Q13510 Acid ceramidase ASAH1 2 0.53 1 1.10 
  
2 0.99 1 0.64 
Q14157 Ubiquitin-associated protein 2-like UBAP2L 
      
1 0.89 
  
Q14192 Four and a half LIM domains protein 2 FHL2 
      
2 1.57 1 2.09 
Q14331 Protein FRG1 FRG1 
        
1 0.80 
Q14527 Helicase-like transcription factor HLTF 
      
1 0.82 
  
Q14534 Squalene monooxygenase SQLE 
        
1 0.68 
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Q15084 Protein disulfide-isomerase A6 PDIA6 
      
3 0.58 
  
Q15233 Non-POU domain-containing octamer-binding 
protein 
NONO 
      
1 0.69 
  
Q15365 Poly(rC)-binding protein 1 PCBP1 
      
3 2.12 
  
Q15517 Corneodesmosin CDSN 
  
1 0.45 
  
2 0.68 2 1.25 
Q15831 Serine/threonine-protein kinase STK11 STK11 
        
1 
 
Q16891 MICOS complex subunit MIC60 IMMT 
      
1 0.90 
  
Q27J81 Inverted formin-2 INF2 
        
1 0.30 
Q53GS7 Nucleoporin GLE1 GLE1 
      
1 1.13 
  
Q53RT3 Retroviral-like aspartic protease 1 ASPRV1 
      
1 0.41 
  
Q5MNZ9 WD repeat domain phosphoinositide-
interacting protein 1 
WIPI1 
      
1 0.71 
  
Q5SZL2 Centrosomal protein of 85 kDa-like CEP85L 
      
1 0.40 
  
Q5T3I0 G patch domain-containing protein 4 GPATCH4 
      
1 0.56 1 0.55 
Q68CJ9 Cyclic AMP-responsive element-binding protein 
3-like protein 3 
CREB3L3 
    
1 
     
Q6NUK1 Calcium-binding mitochondrial carrier protein 
SCaMC-1 
SLC25A24 
  
1 1.88 
  
1 1.25 1 0.98 
Q71RC2 La-related protein 4 LARP4 
      
1 0.08 
  
Q71UM5 40S ribosomal protein S27-like RPS27L 
  
1 0.87 
  
1 1.97 1 1.66 
Q76G19 PDZ domain-containing protein 4 PDZD4 
      
1 
   
Q7L3B6 Hsp90 co-chaperone Cdc37-like 1 CDC37L1 
      
1 
   
Q7L5L3 Glycerophosphodiester phosphodiesterase 
domain-containing protein 3 
GDPD3 
  
1 0.41 
      
Q7RTM1 Otopetrin-1 OTOP1 
        
1 10.68 
Q7RTU9 Stereocilin STRC 
    
1 
     
Q7Z2K8 G protein-regulated inducer of neurite 
outgrowth 1 
GPRIN1 
      
1 0.43 
  
Q7Z406 Myosin-14 MYH14 
  
1 0.19 
      
Q7Z4G4 tRNA (guanine(10)-N2)-methyltransferase 
homolog 
TRMT11 
        
1 3.90 
Q7Z4I7 LIM and senescent cell antigen-like-containing 
domain protein 2 
LIMS2 
      
1 0.45 
  
Q86UE4 Protein LYRIC MTDH 
        
1 0.25 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 CAND1 
        
2 0.47 
Q8IUK5 Plexin domain-containing protein 1 PLXDC1 
        
1 
 
Q8IW75 Serpin A12 SERPINA12 
  
1 0.70 
    
1 0.24 
Q8IWT1-3 Isoform 3 of Sodium channel subunit beta-4 SCN4B 
      
1 0.36 
  
Q8IWU4 Zinc transporter 8 SLC30A8 
    
1 
     
Q8IXK2 Polypeptide N-acetylgalactosaminyltransferase 
12 
GALNT12 
      
1 0.32 
  
Q8IY18 Structural maintenance of chromosomes 
protein 5 
SMC5 
      
1 1.56 
  
Q8IY67 Ribonucleoprotein PTB-binding 1 RAVER1 
      
1 1.11 1 0.21 
Q8IYB3 Serine/arginine repetitive matrix protein 1 SRRM1 
        
1 0.56 
Q8N264 Rho GTPase-activating protein 24 ARHGAP24 
        
1 
 
Q8N4Q1 Mitochondrial intermembrane space import 
and assembly protein 40 
CHCHD4 
  
1 0.47 
      
Q8N8S7 Protein enabled homolog ENAH 
      
1 0.81 
  
Q8NE71 ATP-binding cassette sub-family F member 1 ABCF1 
        
6 4.01 
Q8NGZ4 Olfactory receptor 2G3 OR2G3 
      
1 
   
Q8TA86 Retinitis pigmentosa 9 protein RP9 
      
1 0.79 
  
Q8TE49 OTU domain-containing protein 7A OTUD7A 
  
1 
       
Q8WVV4 Protein POF1B POF1B 1 0.22 1 
       
Q8WWI1-3 Isoform 3 of LIM domain only protein 7 LMO7 
      
2 1.05 
  
Q8WY22 BRI3-binding protein BRI3BP 
        
1 0.21 
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Q92804 TATA-binding protein-associated factor 2N TAF15 
  
1 0.95 
      
Q92833 Protein Jumonji JARID2 
      
1 
   
Q92841 Probable ATP-dependent RNA helicase DDX17 DDX17 
        
1 0.57 
Q92945 Far upstream element-binding protein 2 KHSRP 
      
6 1.60 
  
Q92973 Transportin-1 TNPO1 
      
1 0.21 1 0.51 
Q96AE4 Far upstream element-binding protein 1 FUBP1 
      
3 1.23 2 0.63 
Q96D46 60S ribosomal export protein NMD3 NMD3 
        
1 
 
Q96EY7 Pentatricopeptide repeat domain-containing 
protein 3, mitochondrial 
PTCD3 
      
1 
   
Q96F44 E3 ubiquitin-protein ligase TRIM11 TRIM11 
      
1 0.87 
  
Q96J01 THO complex subunit 3 THOC3 
      
1 0.39 
  
Q96KP4 Cytosolic non-specific dipeptidase CNDP2 
      
1 0.70 
  
Q96PK6 RNA-binding protein 14 RBM14 
      
4 0.74 1 0.40 
Q96QA5 Gasdermin-A GSDMA 1 0.14 2 0.37 
  
1 0.24 
  
Q96TA2 ATP-dependent zinc metalloprotease YME1L1 YME1L1 
  
1 0.54 
      
Q99832 T-complex protein 1 subunit eta CCT7 
        
1 0.68 
Q99848 Probable rRNA-processing protein EBP2 EBNA1BP2 
      
1 0.58 
  
Q9BRZ2 E3 ubiquitin-protein ligase TRIM56 TRIM56 
      
1 0.15 
  
Q9BVP2 Guanine nucleotide-binding protein-like 3 GNL3 
        
1 0.42 
Q9BWF3 RNA-binding protein 4 RBM4 
      
4 0.56 
  
Q9BYJ1 Hydroperoxide isomerase ALOXE3 ALOXE3 
  
1 1.07 
    
1 0.35 
Q9BZF3 Oxysterol-binding protein-related protein 6 OSBPL6 
  
1 0.73 
      
Q9H0B6 Kinesin light chain 2 KLC2 
      
2 0.76 
  
Q9H0H5 Rac GTPase-activating protein 1 RACGAP1 
        
1 
 
Q9H222 ATP-binding cassette sub-family G member 5 ABCG5 
      
1 0.30 
  
Q9H2R5 Kallikrein-15 KLK15 
  
1 15.69 
      
Q9H3U1 Protein unc-45 homolog A UNC45A 
      
1 1.09 1 0.61 
Q9H936 Mitochondrial glutamate carrier 1 SLC25A22 
        
1 0.44 
Q9H9J2 39S ribosomal protein L44, mitochondrial MRPL44 
      
1 1.87 
  
Q9HC84 Mucin-5B MUC5B 
      
1 
   
Q9NP64 Nucleolar protein of 40 kDa ZCCHC17 
      
1 0.70 2 0.53 
Q9NQ87 Hairy/enhancer-of-split related with YRPW 
motif-like protein 
HEYL 
      
1 0.45 
  
Q9NQI0 Probable ATP-dependent RNA helicase DDX4 DDX4 
      
1 0.62 1 0.42 
Q9NR30 Nucleolar RNA helicase 2 DDX21 
      
2 0.49 1 0.43 
Q9NWX6 Probable tRNA(His) guanylyltransferase THG1L 
        
1 0.57 
Q9NX58 Cell growth-regulating nucleolar protein LYAR 
      
1 0.54 1 0.64 
Q9NXL9 DNA helicase MCM9 MCM9 
        
1 0.86 
Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 
      
1 0.63 
  
Q9NZ01 Very-long-chain enoyl-CoA reductase TECR 
        
1 0.31 
Q9NZH6 Interleukin-37 IL37 
      
1 0.18 
  
Q9P0K7 Ankycorbin RAI14 
      
1 0.30 
  
Q9P0U4 CXXC-type zinc finger protein 1 CXXC1 
      
2 0.56 
  
Q9P2E9 Ribosome-binding protein 1 RRBP1 
  
1 0.63 
  
1 1.38 1 1.13 
Q9UBG3 Cornulin CRNN 
        
1 0.73 
Q9UEF7 Klotho KL 
      
1 
   
Q9UG63 ATP-binding cassette sub-family F member 2 ABCF2 
      
2 0.78 
  
Q9UHN1 DNA polymerase subunit gamma-2, 
mitochondrial 
POLG2 
    
1 
     
Q9UN30 Sex comb on midleg-like protein 1 SCML1 
        
1 0.49 
Q9UPN3 Microtubule-actin cross-linking factor 1, 
isoforms 1/2/3/5 
MACF1 
        
1 0.47 
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Q9UPQ0 LIM and calponin homology domains-
containing protein 1 
LIMCH1 
      
3 0.77 1 0.31 
Q9UPQ9 Trinucleotide repeat-containing gene 6B 
protein 
TNRC6B 
      
3 1.01 
  
Q9Y263 Phospholipase A-2-activating protein PLAA 
        
3 0.61 
Q9Y285 Phenylalanine--tRNA ligase alpha subunit FARSA 
      
1 0.43 
  
Q9Y2K2 Serine/threonine-protein kinase SIK3 SIK3 
    
1 
     
Q9Y446 Plakophilin-3 PKP3 
      
2 0.86 1 0.46 
Q9Y4W6 AFG3-like protein 2 AFG3L2 
      
1 0.51 
  
Q9Y597 BTB/POZ domain-containing protein KCTD3 KCTD3 
      
1 0.52 1 0.53 
Q9Y5M8 Signal recognition particle receptor subunit 
beta 
SRPRB 
        
1 1.31 
Q9Y696 Chloride intracellular channel protein 4 CLIC4 
      
1 1.00 
  
 
 
